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Abstract 
Multimorbidity, the co-existence of two or more chronic conditions, is common and 
increasing in prevalence. It is associated with poor outcomes for patients and 
increased costs for healthcare providers, so is attracting attention both from 
policymakers and researchers. The use of multiple simultaneous medications 
(polypharmacy) frequently co-occurs with multimorbidity. Multimorbidity including 
physical and mental illnesses has been recognised as important and under-studied. 
It not only poses challenges for patient management but also provides opportunities 
for interventions which could prevent overall clinical decline.  
 
This thesis separates physical and mental illnesses to explore associations between 
multimorbidity and polypharmacy with mental health outcomes and brain health 
biomarkers in ageing cohorts.  
 
Although there are standard published definitions of multimorbidity, understanding the 
concept is difficult due to the numerous ways to measure it. This thesis opens with a 
systematic review of multimorbidity indices. Among 5 560 unique titles identified in a 
literature search, 35 full-text papers were relevant, and are described and evaluated 
in detail.  
 
Data analysis took place in three datasets focused on ageing, with complementary 
designs. These are the PREVENT Dementia and European Prevention of Alzheimer’s 
Dementia (EPAD) study cohorts, and routinely collected data from the National Health 
Service (NHS) Scotland’s Information Services Division (ISD).  
 
In PREVENT Dementia, participants aged 40-59 years are deeply phenotyped, 
allowing exploration of the epidemiological associations between increasing chronic 
conditions and medication use with various clinical and biological outcomes. These 
include self-reported depression, cognitive test results and markers of 
neurodegeneration on magnetic resonance imaging (MRI). From regression analysis 
of 210 participants’ data, each additional condition was associated with increased 
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odds of self-reported depression (adjusted OR=1.41, 95% CI 1.11 to 1.80) and anxiety 
disorder (OR=1.71, 95% CI 1.35 to 2.21). Increasing medication use was associated 
with self-reported depression (adjusted OR per additional medication=1.36, 95% CI 
1.07 to 1.73) but not anxiety disorder (OR=1.24, 95% CI 1.00 to 1.53). There were no 
meaningful associations between multimorbidity or polypharmacy with MRI or 
cognitive test outcomes. 
 
The EPAD cohort permitted a more focused approach in people aged over 50 years, 
specifically examining associations between increasing chronic conditions and 
cerebrospinal fluid (CSF) amyloid-β. In 447 participants, each additional comorbid 
condition carried a decreased likelihood of amyloid positivity (multiply-adjusted 
OR=0.82, 95% CI 0.68 to 0.97). This informs the debate that amyloid may not play a 
part in the pathway between multimorbidity and the development of dementia.  
 
Analyses of NHS data used routinely collected information on prescriptions, 
psychiatric hospital admissions and death certificate diagnoses from 1.23 million 
people aged over 50 years in Scotland. Adjusted hazard ratios for each additional 
drug were 1.03 (95% CI 1.03 to 1.04) for death with any psychiatric cause and 1.04 
(95% CI 1.04 to 1.05) for admission to psychiatric hospital over 8.5 years of follow-
up. In this and the analyses in PREVENT Dementia, the use of antidepressant or 
psychotropic medication attenuated the associations. 
 
The importance of patient and public involvement in research is also discussed, 
including perspectives on this work from a Lay Contributor. 
 
This thesis explores the measurement of multimorbidity in detail and provides further 
evidence that physical multimorbidity and polypharmacy are associated with poor 
mental health. However, the links with biological markers of brain disease such as 
MRI findings and amyloid are less convincing. This leads to a discussion of possible 
mechanisms, clinical implications, and proposed future work.
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Lay summary 
It is becoming more common to have many health conditions at once. This is called 
multimorbidity. People with multiple conditions usually take several medicines too, 
known as polypharmacy. Both multimorbidity and polypharmacy increase as people 
get older. Previous research has found that having multiple conditions is difficult for 
patients and costly for health services. It may also be bad for mental health and linked 
to dementia.  
 
This thesis explores patterns in data to find links between multimorbidity, 
polypharmacy and mental or brain health.  
 
The first part of the thesis focuses on how researchers measure multimorbidity. Some 
choose to count a person’s number of diagnoses or medicines, whereas others use 
tools that assign more importance to some conditions than others. I did a detailed 
search and found 35 such tools, then summarised and appraised them.  
 
I also looked for links between multimorbidity, polypharmacy and mental or brain 
health in three sources. The PREVENT Dementia study included 210 participants 
aged 40-59 years. The European Prevention of Alzheimer’s Dementia (EPAD) study 
had 447 volunteers aged 50 years and over. The third source was routinely collected 
National Health Service (NHS) data from 1.23 million people aged 50 years and over 
in Scotland. 
 
In the PREVENT Dementia study, I found that having more physical conditions or 
taking more medicines increased the risk of depression and anxiety. In the NHS data, 
there were some links between taking more medicines and being admitted to 
psychiatric hospital or having a mental illness recorded at death. However, in both 
PREVENT Dementia and the NHS data, taking a psychiatric medicine (that is, already 
having a psychiatric diagnosis), seemed to explain this link.  
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Participants in PREVENT Dementia and EPAD did not have dementia. They had 
magnetic resonance imaging (MRI) scans and spinal fluid tests that can help predict 
dementia or Alzheimer’s disease. I found that having more conditions was not linked 
with results suggesting a higher risk of dementia. This differs from previous research 
which showed that people with dementia usually have at least two other conditions. 
 
All my results are observations. I cannot suggest that multimorbidity or polypharmacy 
cause mental illness, only that they co-exist. 
 
The final chapter of this thesis includes my reflections on involving a Lay Contributor 
throughout my PhD. 
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Chapter 1 Introduction 
1.1 INTRODUCTION 
There is a saying, “old age doesn’t come alone” – as people age, the number of 
challenges they face increases. Problems can occur in many domains, with health 
being a particularly demanding aspect. When several chronic health conditions co-
exist, the term commonly used is multimorbidity. This thesis explores the associations 
between multimorbidity and polypharmacy (the simultaneous use of several 
medications) with markers of mental disorders and brain health, using an 
epidemiological approach, in three complementary datasets. 
 
1.2 HISTORY AND DEFINITIONS 
1.2.1 Multimorbidity 
Multimorbidity is usually defined as the co-existence of multiple chronic diseases, 
where one is not necessarily more central than the others, within one person.[1] The 
similar concept of comorbidity refers to the co-existence of one or more diseases 
alongside one particular disease, known as an index disease.[2,3] The term 
‘comorbidity’ was first used by Alvan Feinstein in the late 1960s and its use for the 
next thirty years often subsumed what is now called multimorbidity.[2,4] The German 
word Multimorbidität emerged in 1976 and between then and 1990, there were 77 
published articles including this term or ‘multimorbidity’, of which 92% were written in 
German.[5] In 1997 a paper reviewing the use of the terms comorbidity and 
multimorbidity recommended that multimorbidity be used when there was no 
reference to an index disease, and this practice is now usually followed.[2]  
 
Multimorbidity can be understood using the concepts of concordance and 
discordance.[6] In concordant multimorbidity, the co-existing conditions share 
common aetiology and therefore mutually benefit from treatments. For example, 
hypertension increases the risk of both cerebrovascular disease and coronary artery 
disease, and management of hypertension can improve outcomes in both conditions. 
This is also known as causal comorbidity.[2] Discordant multimorbidity (or associative 
comorbidity) describes co-existing conditions that apparently have separate aetiology 
and require different treatments.[2,6,7] These concepts may depend on assumptions 
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about causality and direction of comorbidity, but can be useful when considering 
combinations of diseases within an individual patient. 
 
Two prominent bodies have proposed definitions of multimorbidity that refer to more 
than a dichotomous measure of whether or not an individual has two or more chronic 
diseases. The USA’s National Quality Forum defines ‘multiple chronic conditions’ (its 
preferred term over multimorbidity) as: 
“having two or more concurrent chronic conditions that collectively have an 
adverse effect on health status, function, or quality of life and that require 
complex healthcare management, decision-making, or coordination.” [8] 
Their definition of ‘condition’ includes entities that may be considered risk factors 
elsewhere, such as obesity and harmful use of alcohol. The European General 
Practice Research Network published a comprehensive definition of multimorbidity in 
2013, summarised by the following phrase:  
“Multimorbidity is defined as any combination of chronic disease with at least 
one other disease (acute or chronic) or bio-psychosocial factor (associated or 
not) or somatic risk factor.” [5] 
Including risk factors as conditions introduces heterogeneity within this definition of 
multimorbidity because there is no clear distinction of what constitutes a bio-
psychosocial factor or somatic risk factor. However, risk factors such as smoking 
status are included in some multimorbidity indices.[9,10]  
 
In this thesis, I have focused on chronic conditions, both with continuous counts and 
dichotomous markers of multimorbidity. This is discussed in detail in Chapter 3 
(section 3.5.2). 
 
1.2.2 Chronic conditions 
Although acute conditions can have major impacts on patients’ lives and illness 
burden, multimorbidity definitions usually specify that conditions must be chronic 
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because of their associated long-term consequences.[11] Defining chronicity can be 
challenging. A 2017 article reviewing the overlap between multimorbidity and frailty 
says: 
“a condition is classified as chronic if it is permanent, it is caused by non-
reversible pathologic alterations or requires rehabilitation or a long period of 
care”.[12]  
Given the lack of consensus, when selecting conditions to include in analyses, I opted 
for a definition that captures both duration and impact. I used a combination of 
definitions from the International Classification of Primary Care, version 2,[13] and 
from NHS Scotland Information Services Division [14] to generate the following 
definition: 
Conditions should: 
- last at least six months 
- have an impact on quality of life (either directly or through sequelae) 
- clearly meet diagnostic criteria, and  
- have a pattern of recurrence or deterioration. 
 
Describing what is meant by ‘conditions’ or ‘disease’ is also problematic as there is 
no universally accepted definition. The term disease may refer to either a recognisable 
set of symptoms and signs, or phenomena arising from a specific disorder or other 
cause.[15] For some conditions, such as type I diabetes, there is a clear pathological 
abnormality, physiological consequences and treatment. Other conditions or states 
such as deafness, obesity and addictions may be more contentious, even where 
standard definitions exist. Lay people and doctors differ in their judgement of whether 
these constitute disease.[16] Prevalence of diseases or conditions can also change 
depending on how they are defined, such as cut-offs in ‘normal’ blood pressure or 
using a certain threshold of serum troponin to diagnose myocardial infarction.[17] In 
addition, there is a question of whether a state counts as disease in its own right or 
solely increases the risk of another condition. Hypertension and 
hypercholesterolaemia fall into this category, and emerging labels such as pre-
diabetes further complicate this picture.[17–19] 
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I restricted my definition of chronic conditions to include diagnosable diseases rather 
than symptoms (such as pain) or risk factors (such as hypercholesterolaemia). Using 
existing data means that in many situations, the decision on what counts as a disease 
has already been taken. This could be by the study designers who generated a set 
list of conditions to ask participants about, participants’ own doctors who have 
diagnosed a condition and participants themselves, who declare these conditions 
when asked about their medical history. Throughout this thesis, I use pragmatic 
approaches to this issue, tailored to each dataset, as there is no single accepted list 
of conditions from which to measure multimorbidity.  
 
1.2.3 Terminology 
The concept of multimorbidity suggests a holistic approach to individuals, not starting 
with a particular diagnosis or body system, and this is often most relevant in primary 
care.[20] Some researchers have rejected the term, however, mostly due to its 
unpopularity with patients, and prefer to say ‘multiple chronic conditions’,[8,21] 
‘multiple health conditions’[22] or ‘complex needs’.[23] Although I acknowledge that 
people with multimorbidity have challenging lives including social and environmental 
factors which influence outcomes, my focus in this thesis is on quantifying multiple 
chronic conditions. Therefore, throughout this thesis I use the term multimorbidity. It 
is widely used and understood in the literature, for example gaining its own Medical 
Subject Heading (MeSH) term for indexing in PubMed in January 2018.[24] When I 
use a count of chronic conditions or medicines, I refer to them accordingly, to avoid 
conflating this continuous measure with the implied dichotomy of multimorbidity or 
polypharmacy. Multimorbidity can include any condition, whether classified as 
physical or mental. This thesis explores mental and brain health outcomes so in most 
analyses I separate physical and mental diagnoses in order to examine their interplay.  
 
1.2.4 Polypharmacy  
Polypharmacy is defined as the concurrent prescription of multiple medications.[25] 
Because medication is the primary treatment for most chronic medical conditions, 
polypharmacy commonly co-exists with, or is a direct result of multimorbidity,[26,27] 
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although this association is relatively under-studied.[28,29] As it is usually clear how 
many medications a person is receiving, either from self-report or prescribing records, 
polypharmacy is most often measured by count alone. This does not always reflect 
the number of medications the person actually takes.[30] Unlike for multimorbidity 
where most definitions agree on a cut-off of two or more conditions, there is no 
established number of medications that counts as polypharmacy. The Scottish 
Government, which publishes comprehensive guidance on polypharmacy, defines it 
as two or more medications, in keeping with the word’s Greek origin where poly 
means ‘more than one’.[27,31] However, their reports focus more on situations where 
the use of multiple medications is hazardous and potentially avoidable (known as 
inappropriate polypharmacy) and are less concerned with overall counts.  
 
A 2017 systematic review of polypharmacy definitions found 110 articles, of which 90 
(81.8%) used a numerical distinction, with the remainder using or adding information 
about treatment duration.[32] Of those with a numerical cut-off, the most commonly 
used was five or more drugs (51 studies). Another systematic review of the 
association between polypharmacy and mortality highlighted that many studies 
compare groups using categorical variables, for example 0-4, 5-9 and ≥10 
medications.[33] There has been a recent call to clarify terminology around drug 
prescribing and a proposal of the terms ‘index drug’ and ‘codrug’, but polypharmacy 
is widely used and understood in the literature and is the term I will use in this 
thesis.[34] Some studies use other terms, such as excessive polypharmacy or 
hyperpolypharmacy, to mean polypharmacy including ≥10 drugs.[35,36] These terms 
may imply that this polypharmacy is inappropriate which cannot be proven by count 
alone; I use numerical definitions instead in this thesis. 
 
Although medication use is somewhat useful as a marker for chronic conditions, 
polypharmacy is an issue in its own right, due to the potential adverse effects of each 
drug and interactions between them.[37] Therefore, multimorbidity and polypharmacy 
should be considered separately. In order to capture the full range of medication use, 
in most analyses I use the count of medications as a continuous variable, rather than 
a categorical definition of polypharmacy.  
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1.2.5 Definitions of mental and brain health outcomes 
The exploration of mental health outcomes in this thesis is three-fold, including clinical 
or symptomatic manifestations of mental disorders, cognitive test scores and 
biomarkers of neurodegenerative disease. These outcomes are used depending on 
the specific questions asked and the availability of data. The co-existence of mental 
and physical components within multimorbidity is prevalent, with mild and moderate 
depression particularly important in mid-life and comorbidities with dementia 
prominent in older people.[38,39]   
 
There is current research interest in identifying modifiable risk factors for 
neurodegenerative diseases such as dementia, with the aim of preventing or delaying 
the onset of disease and reducing incidence.[40–42]. Depression and anxiety in mid-
life have been identified as risk factors for dementia,[43–45] although the direction of 
the association remains uncertain.[46] Multimorbidity and polypharmacy also co-exist 
with dementia and cognitive impairment.[39,47,48] If all of these factors were 
managed, theoretically the risk of neurodegenerative diseases could be reduced. In 
addition, if multimorbidity and polypharmacy are risk factors for anxiety, depression 
and other mental disorders, their identification and management (and possibly 
prevention) could have personal benefits to the health of individuals. 
 
I use the term mental disorders to include clinically diagnosed diseases including 
depression, anxiety, and dementia, as the term ‘mental illness’ is not always 
understood to capture dementia. To reflect the diversity of manifestations of mental 
disorders: clinical, pre-clinical and sub-clinical, I explore a variety of outcomes across 
three datasets, as follows: 
1. Mental disorders 
a. Depression and anxiety disorder 
i. Self-reported diagnoses 
ii. Scores on symptom scales 
b. Mental or behavioural disorders recorded on death certificates 
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c. Admission to psychiatric hospital 
2. Cognitive test results 
3. Biomarkers of neurodegenerative disease 
a. Structural magnetic resonance imaging (MRI) measures 
b. Cerebrospinal fluid (CSF) amyloid-β42 
 
1.2.6 Understanding multimorbidity in ageing 
Although multimorbidity is common in older people and has been called in one review 
“the ultimate geriatric syndrome”,[49] there are more people with multiple chronic 
conditions in mid-life due to population demographics.[39] Exploration of 
multimorbidity in mid-life is additionally important given its likely contribution to later 
brain health.  
 
A population study of 138 858 people in Minnesota explored multimorbidity using a 
list of 19 possible conditions, of which five were mental disorders (including 
dementia).[50] The authors separated multimorbidity into general multimorbidity, 
which they defined as two or more of any of the conditions, and somatic-mental 
multimorbidity, where at least one of the conditions was a mental disorder. They found 
that somatic-mental multimorbidity was more common in women and plateaued at 
around 55-75 years, but with a sharp increase after 80 years, as shown in Figure 1-1, 
Panel B. This increase was more marked in participants with somatic-mental 
multimorbidity compared to general multimorbidity (Panel A). This suggests that 
multimorbidity including both physical and mental illness in mid-life and later life may 
not represent the same clinical presentation and may be best examined separately. 
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Figure 1-1: Prevalence of general multimorbidity and somatic (physical)-mental health 
multimorbidity, from Bobo et al., 2016 [50] (note different y-axis limits)1 
 
In this thesis I therefore analyse data from people in a mid-life cohort aged 40-59 
years (PREVENT Dementia, Chapter 4)[42,51]. There is also value in analysing the 
physical and brain health of older people where multimorbidity is almost ubiquitous, 
so the other two analytic chapters include people aged over 50 years. Chapter 5 
features the European Prevention of Alzheimer’s Dementia (EPAD) cohort study, 
comprising volunteers aged over 50 years where the mean age was 66 years 
(standard deviation [SD]=6.6 years).[52] The sample in Chapter 6 includes all 
members of the Scottish population aged 50 years and over at baseline (mean age 
67.4 years, SD=10.8).[53] In all analyses, I pay careful attention to age, both including 
it as a covariate and testing for interactions or stratifying analyses where appropriate.  
 
1.2.7 Frailty 
Multimorbidity is distinct from frailty, a related and similarly pertinent topic in the care 
of older people. Frailty is a dynamic clinical state of decreased resilience which 
manifests as an increased risk of adverse health outcomes or death after a 
stressor.[12,54] There are three main approaches to measuring frailty. Firstly, the 
 
1. Used by permission of the Gerontological Society of America (through Oxford 
University Press) for print and electronic reproduction in PhD thesis: licence 
4716361197415 
 
Panel A Panel B 
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phenotypic approach is concerned with symptoms or biomarkers, including weakness 
or weight loss.[55] Secondly, it is possible to measure the accumulation of deficits, 
such as slow gait and poor grip strength.[56] Frailty can also be considered in terms 
of dimensions, including physical, cognitive and social or quality of life.[57]  
 
Frailty may co-exist with, or be a consequence of, multimorbidity. A systematic review 
and meta-analysis of studies examining this co-occurrence found that the prevalence 
of multimorbidity in people with frailty was 72% (95% CI 63% to 81%) and the 
prevalence of frailty in people with multimorbidity was 16% (95% CI 12% to 21%).[58] 
This highlights the difference between these two states, and perhaps suggests that 
frailty captures more of the clinical functional state compared to multimorbidity’s focus 
on diagnoses. 
 
1.3 IMPORTANCE  
1.3.1 Epidemiology of multimorbidity  
Multimorbidity and polypharmacy are acknowledged as widespread and common, but 
estimates of their prevalence vary. A systematic review of papers published between 
1961 and 2013 found 39 studies on multimorbidity prevalence, with varying age 
ranges and numbers of conditions considered.[59] Most studies were cross-sectional, 
and estimates of multimorbidity (two or more conditions) ranged from 13% when the 
minimum age was 18 years to 95% in those aged 65 years and over. All studies found 
a positive association between increasing age and multimorbidity, with the majority of 
older people having multimorbidity. Socioeconomic deprivation was also universally 
associated with multimorbidity. Another systematic review including only people aged 
over 65 years in high-income countries found 52 articles, of which the majority 
reported prevalence of more than 50% for having two or more concurrent 
conditions.[60] The authors also reported an overall pooled prevalence of 66.1% but 
their methods for pooling such diverse data were not explained. There are fewer 
studies that track rates of multimorbidity longitudinally.[7]  
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The global population is ageing, but evidence from the most recent Global Burden of 
Disease study shows that an increase in life expectancy is not equivalent to adding 
healthy years to life.[61] Therefore, it is assumed that rates of chronic diseases and 
multimorbidity will increase due to population ageing.[62] A study of over 350 000 
patients from GP practices in the Netherlands (using a list of 28 conditions and 
defining multimorbidity as ≥2 conditions) found that rates of multimorbidity increased 
from 12.7% in 2004 to 16.2% in 2011.[63]  Standardising for age still gave an increase 
of 2.7%, suggesting that rates are increasing regardless of the ageing population. 
Danish data have been published stating that the number of patients attending 
multiple outpatient clinics increased from 4.0% in 2004 to 7.7% in 2014.[64] This 
repeated cross-sectional study suggests that multimorbidity may increase over time 
but did not adjust for age; this increase may be explained by population ageing. In 
addition, repeated cross-sectional data from around 70 000 participants of the Survey 
of Health, Ageing and Retirement in Europe (SHARE) across ten countries found that, 
using a list of 14 potential conditions, multimorbidity increased from 38.2% in 2006-7 
to 41.5% in 2015 (multiply-adjusted prevalence ratio 1.05).[65] Multimorbidity is 
therefore common and increasing in prevalence. 
 
In this thesis, I use data from Scotland, England and across Europe. A widely cited 
2012 paper by Barnett and colleagues reported multimorbidity rates from one-third of 
the Scottish population of all ages in 2007, counting from a list of 40 conditions.[39] 
Their overall reported rate of multimorbidity was 23.2%, and among people with at 
least one condition, 54.9% had two or more. A more recent study by Cassell et al. 
used a similar list of 36 conditions in over 400 000 general practice patients aged ≥18 
years in England in 2012.[38] This found that the rate of multimorbidity was 27.2%. 
The difference in patient ages and potential conditions counted between these studies 
means that the prevalence estimates cannot be meaningfully compared. Researchers 
analysing data from SHARE counted multimorbidity from a list of 12 conditions.[66] In 
the 2013 data collection, the overall prevalence of multimorbidity, adjusted for age 
and gender, was 31.4% (95% CI 30.7% to 32.2%). Rates varied by country, with lower 
prevalence in northern Europe and the highest rates in Eastern and Central Europe.  
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Identifying people with multimorbidity can inform care planning that includes the 
person as a whole. For example, this might mean awareness of patients at risk of an 
acute admission in order to prevent one, mobilising community supports rather than 
approaching acute medical care in a health crisis, or even recognising when a 
palliative approach might be the most appropriate action.[67,68] 
 
1.3.2 Adverse consequences of multimorbidity  
By definition, multimorbidity suggests that patients are unwell or experience a greater 
burden of disease than comparable patients without multimorbidity. It is thought that 
conditions are synergistic, with multimorbidity affecting overall health more than the 
addition of each condition separately.[69] Therefore, some outcomes such as higher 
mortality are to be expected. A systematic review of prospective primary care cohort 
studies in multimorbidity reviewed six published papers, finding associations between 
multimorbidity and increased health service use and costs, mortality rates and 
reduced physical function.[70] Another systematic review with a broader focus studied 
41 papers and found that multimorbidity was associated with disability, functional 
decline, high healthcare costs and poor quality of life.[71] It found that some, but not 
all studies showed an association between multimorbidity and an increased risk of 
mortality. However, a further systematic review focusing only on multimorbidity and 
mortality included 26 studies.[72] On meta-analysis, results showed that each 
additional condition had a hazard ratio (HR) for mortality of 1.20 (95% CI 1.10 to 1.30), 
and having two or more conditions compared to zero or one carried a HR of 1.73 (1.41 
to 2.13). However, in all systematic reviews and meta-analyses in this field, it must be 
remembered that the original papers are often heterogeneous, especially when they 
count conditions from lists of different lengths. 
 
Multimorbidity is costly to healthcare services and to individuals. A systematic review 
of cost-of-illness studies in multimorbidity found 26 articles published between 2000 
and 2016, the majority of which were from countries with private healthcare 
systems.[73] The original studies measured multimorbidity in diverse ways, 
precluding meta-analysis, but there was consistent evidence that multimorbidity was 
associated with higher healthcare costs. Cassell and colleagues’ more recent study 
of NHS primary care in England found that people with two or more of a possible list 
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of 36 chronic conditions had 2.58 (95% CI 2.48 to 2.69) times as many hospital 
admissions in four years as patients without multimorbidity, and a similarly increased 
rate of GP visits (2.56, 95% CI 2.48 to 2.64).[38] There is additional evidence from a 
systematic review of 14 studies, that primarily took place in countries without universal 
healthcare, that out-of-pocket expenditure on medicines increases with patients’ 
number of conditions.[74]  
 
Quality of life is also adversely affected for people with multimorbidity. A systematic 
review searched the literature in September 2018 and found 74 studies of 
multimorbidity and quality of life.[75] The majority of included studies used disease 
counts, and on meta-analysis of 19 studies that used the same outcome, the EQ-5D 
scale, each added disease carried an overall decline in health-related quality of life of 
3.9% (95% CI -5.4% to -2.4%). Fifteen studies used the Short Form (SF) instrument 
and meta-analysis showed a steeper decline in its physical health (-3.3% with each 
additional condition) than mental health functioning components (-1.6% per 
condition). In addition, people with multimorbidity have been shown to be excluded 
from clinical trials for single diseases, and are therefore discriminated against in the 
development of new treatments.[76,77] 
 
In summary, multimorbidity is attracting increasing research attention as it is linked 
with outcomes relevant to healthcare services such as costs and mortality, and those 
important to patients such as quality of life. 
 
1.3.3 Epidemiology of polypharmacy 
Polypharmacy is also common, especially among older adults. A Scottish 
Government report using prescribing data from 2014 stated that 13.3% of the whole 
population aged 50 years or over and 26% of those aged over 80 years were 
prescribed ten or more medications simultaneously.[25] A recent Swedish population 
study of over 1.7 million people aged ≥65 years found that 44.0% were taking ≥5 
drugs and 11.7% took ≥10 drugs.[78] This study also quantified the association 
between multimorbidity and polypharmacy, reporting an increase of 0.95 medications 
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(95% CI 0.94 to 0.96) per additional chronic disease. On four-year follow-up of over 
400 000 general practice patients in England, the yearly rate ratio for number of 
prescriptions was 5.91 (95% CI 5.71 to 6.12) for people with multimorbidity (two or 
more conditions) compared to those without.[38] Adverse outcomes associated with 
polypharmacy are explored further in section 6.1. 
 
1.3.4 Epidemiology of mental disorders 
The wide scope of what is meant by mental disorders means that overall, these are 
highly prevalent at population level, particularly in milder states. The majority of 
psychological symptoms are experienced in the community by people who may never 
seek medical attention. Of those who do, most are managed by GPs, a smaller 
number will reach the attention of a community psychiatrist, and fewer still will be 
admitted to psychiatric hospital.  
 
The Adult Psychiatric Morbidity Survey (APMS) is a repeated cross-sectional survey 
of a representative sample of the population in England aged 16 years or over.[79] 
The latest survey wave, conducted in 2014, found that 15.7% (95% CI 14.7% to 
16.7%) of this population had symptoms of mental disorder that would warrant clinical 
attention. This proportion has increased since the 1993 survey when rates using the 
same measure were 14.1%.[80] The rate of self-reported mental disorders in 2014 
was slightly higher than that detected by symptom questionnaires, at 17.0% (16.0% 
to 18.1%). Among people aged over 65 years, rates were lower than in the rest of the 
population: 10.2% of 65 to 74 year olds and 8.1% of those aged 75 years and over 
had symptoms of common mental disorders, excluding cognitive impairment. The 
MentDis_ICF65+ study surveyed older adults across five European countries and 
Israel.[81] Among 3 142 adults with a mean age of 73.7 years, the total point 
prevalence of any mental disorder, according to diagnostic interview, was 23.3% 
(adjusted for age and gender, 95% CI 19.9% to 26.7%). This disparity compared to 
the English data may be explained by MentDis_ICF65+ including cognitive 
impairment. Mental disorders are therefore prevalent in the general population and 
among older people. 
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1.3.5 Importance of physical-mental multimorbidity  
The 2012 Scottish population study by Barnett et al. found that among people with at 
least one condition, 19.8% had multimorbidity including both mental and physical 
conditions.[39] Among all people aged 65-84 years, 17.5% had both physical and 
mental health diagnoses, with this figure rising to 30.8% in those aged over 85 years. 
Cassell and colleagues’ study in England found that 9.5% of all patients had mental 
and physical comorbidity and that this was present in 33.8% of people who had 
multimorbidity.[38] 2  In the previously discussed cross-sectional study of 138 858 
patients in Minnesota, the authors emphasised that in terms of absolute numbers, 
71% of people with physical-mental multimorbidity were aged under 65 years.[50]  
 
In a cohort study of over 252 000 survey participants across the USA, multimorbidity 
(the highest compared to lowest quartile score on a weighted index) was associated 
with a three-fold increased risk of death by suicide on 24-year follow-up.[82] This 
association remained when adjusting for baseline health-related quality of life. 
Measuring factors associated with suicide is difficult due to its low incidence, but a 
study of suicidal ideation among 7 403 participants of the 2007 APMS in England 
found that suicidal thoughts were common in people with physical-mental 
multimorbidity.[83] However, the increased odds were not elevated beyond those 
expected with either having physical conditions or common mental disorders alone. 
Further analyses of a Scottish cohort study by the same group of researchers found 
that having multimorbidity increased the risk of suicidal thoughts and suicide attempts, 
but not any more than having mental illness.[84] 
 
Co-existing physical and mental multimorbidity can increase costs for health services. 
A King’s Fund report into this issue found that having a comorbid mental health 
condition in addition to physical illness increased costs to the healthcare system for 
that individual by at least 45%.[62] It also concluded that these people’s clinical 
outcomes are worse and their ability to manage their own physical symptoms is 
impaired. A study of over 180 000 patients from GP practices in Scotland found that 
 
2 I use the term ‘patients’ throughout this thesis where the people in question are under study 
because of their use of healthcare, and ‘participants’ where they are volunteers in a cohort 
study 
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while multimorbidity increased the risk of unplanned hospital admissions within the 
following year, the risk was exacerbated by having a co-existing mental disorder.[85] 
The co-existence of physical and mental conditions with multimorbidity is therefore 
prevalent, costly and associated with poor outcomes. 
 
The co-existence of physical and mental illnesses within multimorbidity may be due 
to shared biological aetiology, socioeconomic risk factors and other psychosocial 
factors such as health and illness behaviour. 
 
1.4 AREAS OF RESEARCH NEED 
A systematic review reporting a literature search carried out in June 2016 found 
2 864 publications on multimorbidity (and its synonyms) in Web of Science since 
1900.[86] The number rose steeply between 2010-16, as shown in Figure 1-2. This 
study only searched one database, so the total quantity of research in this area may 
be even higher. 
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Figure 1-2: Annual number of publications and citations on multimorbidity worldwide, from Xu 
et al., 2017 [86]3 
 
A similar study, also searching Web of Science in 2016, included ‘comorbidity’ in its 
search terms and found 85 994 papers, of which 76 350 were original research and 
9 644 review articles.[87] This review showed the same rate of increase between 2010 
and 2016, and also noted the prominence of papers on psychiatric comorbidity. A 
further review searched PubMed between 1985 and 2014 with less robust search 
criteria on multimorbidity and comorbidity and found 3 054 papers.[88] The author 
remarked that although all numbers of citations across PubMed had consistently 
increased during that period, the growth in multimorbidity citations was much higher 
than that in the rest of the medical literature.  
 
Despite this striking expansion in multimorbidity research in the last ten years, the 
limited research focus on multimorbidity is still out of proportion with its large 
prevalence, compared to that on single diseases.[86] Multimorbidity is a topical area, 
 
3 Published by Edinburgh University Global Health Society, distributed under the terms of the 
Creative Commons Attribution Licence (CC BY 4.0), which permits unrestricted use, 
distribution, and reproduction in any medium  
https://creativecommons.org/licenses/by/4.0/ No changes made from original material. 
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with policy and research interest highlighted by two recent reports from the Academy 
of Medical Sciences.[7,89] The reports have identified areas of research need, 
including further exploration of the consequences of polypharmacy.[89] Other 
research priorities in this area have been established by the James Lind Alliance and 
National Institute for Health and Care Excellence (NICE).[90,91] The James Lind 
Alliance has patient-focused priorities, two of which relate to the psychological 
wellbeing of patients and carers and the specific questions raised would be best 
answered by trials. NICE recommended research into stopping unnecessary 
medicines and predicting life expectancy, along with improvements to general 
practice structure and management.  
 
1.4.1 Physical-mental multimorbidity  
The need to consider physical and mental health together is currently pertinent. 
Evidence from the APMS in England suggests that common mental disorders 
frequently co-exist with long-term conditions, but when they do, 71.2% of common 
mental disorders are untreated.[92] Recent reports from the Royal College of 
Psychiatrists and Academy of Medical Royal Colleges highlight the importance of 
managing physical health in people with mental disorders,[93,94] but there is 
comparatively little research into the mental health of people with physical 
multimorbidity. For example, research into specific mental health measures such as 
symptom scales in people with polypharmacy is scarce.[95] The authors of a 
systematic review of primary care multimorbidity studies highlighted that mental 
illness in people with multimorbidity was not covered in the papers they reviewed and 
was an important gap.[70] A consensus paper published in 2018 reported a Delphi 
process among 26 expert panellists developing a Core Outcome Set for 
multimorbidity research.[96] Mental health was among the top three highest-rated 
outcomes and was deemed essential.  
 
The World Health Organization (WHO) also ascribes importance to the interactions 
between physical and brain health. In its recent guidelines on preventing cognitive 
decline and dementia, it recommended optimising specific physical conditions.[97] 
There is a small amount of research into associations between multimorbidity and 
specific biomarkers, such as hippocampal volume and cortical thickness.[98,99] 
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There is potential that better understanding of these associations could inform 
strategies to delay or prevent dementia. This is therefore an area where further work 
could provide an impact in advancing the field. 
 
Mental disorders are prevalent, and physical-mental multimorbidity is increasingly 
recognised as important. There is also scope for better understanding of the impact 
of multimorbidity on biomarkers of brain health.  
 
1.5 HYPOTHESES EXPLORED IN THIS THESIS 
In this thesis, I explore mental health outcomes and brain health biomarkers in people 
with multimorbidity, comparing them to those without. Owing to the continued paucity 
of knowledge on broad issues in physical-mental multimorbidity, I use epidemiological 
methods to explore these associations.  
 
1.5.1 Multimorbidity with depression, anxiety and cognitive impairment 
Depressive and anxiety disorders are the commonest mental disorders in adulthood, 
particularly in middle age when multimorbidity is most prevalent.[79] They may reflect 
the everyday burden of psychological distress that has many financial and personal 
costs but does not reach psychiatric attention. As depression and anxiety disorders 
are often included in lists of conditions in multimorbidity studies, it can be difficult to 
extract them to address the overall questions about physical-mental multimorbidity. 
There may be common aetiological factors between multimorbidity and depression or 
anxiety, including biological (for example, vascular) mechanisms and psychosocial 
predispositions. 
 
Cognitive impairment is a manifestation of neurodegenerative disease that can 
emerge early in the disease course, for example in mid-life. Detecting it at this stage 
can improve prospects for possible disease modification or slowing of 
progression.[41] It is therefore of interest when exploring brain health within 
multimorbidity, relating to likely common aetiological factors. 
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1.5.1.1 Hypothesis 1 
Physical multimorbidity (or having a larger number of chronic conditions), will 
be associated with an increased risk of mental disorders. The greater the 
burden of multimorbidity, the higher the individual’s risk of developing a mental 
disorder. These include: 
a. Depression 
b. Anxiety 
c. Cognitive impairment (specific deficits on cognitive testing) 
 
1.5.2 Polypharmacy with depression, anxiety and broader psychiatric 
outcomes  
Polypharmacy commonly co-exists with, but is distinct from, multimorbidity. Its 
relationship to mental health may be explained by biological or psychosocial factors. 
Biologically, psychiatric adverse effects of specific medicines are common and well-
recognised. These can be immediate and short-term such as anxiety when using 
beta-2 agonists,[100] medium-term including depression with beta-blockers or proton 
pump inhibitors,[101] or more chronic such as cognitive impairment with 
benzodiazepines [102] or anticholinergic drugs.[103] The burden of taking multiple 
medications may also be associated with self-reported feelings of stress, anxiety or 
low mood.[104] 
 
Specific quantitative outcomes can be difficult to measure in large scale studies using 
routinely collected data. Broader outcomes such as evidence of psychiatric hospital 
admission or mental disorder on the death certificate provide good specificity but 
limited sensitivity. 
  
1.5.2.1 Hypothesis 2 
Polypharmacy, or using larger numbers of medications (accounting for 
antidepressant or psychotropic drugs), will be associated with poorer mental 
health, and the greater the burden of polypharmacy, the higher a person’s risk 
of developing a mental disorder, including 
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a. Depression, anxiety, cognitive impairment 
b. Mental disorders listed on death certificates 
c. Admission to psychiatric hospital 
 
1.5.3 Multimorbidity or polypharmacy with dementia outcomes on 
neuroimaging 
Neuroimaging and biomarker studies are common in dementia prevention research 
as they help identify markers of neurodegeneration before cognitive manifestations 
emerge.[41] The rationale is that if changes are detected early, disease modification 
may be possible through pharmacological or lifestyle interventions.[40] Neuroimaging 
can also help differentiate between biological and psychological causes of cognitive 
impairment, for example Alzheimer’s disease and functional cognitive disorder.[105] 
Although it is established that multimorbidity and dementia commonly co-exist,[39] 
there is relatively little published neuroimaging research specifically focusing on 
multimorbidity, and none on polypharmacy.[98]  
 
1.5.3.1 Hypothesis 3 
Physical multimorbidity or greater number of conditions, and polypharmacy or 
greater number of medications, will be associated with outcomes linked to 
dementia on structural MRI neuroimaging (periventricular and deep white 
matter hyperintensities, hippocampal volume and microhaemorrhages) 
 
1.5.4 Multimorbidity with CSF amyloid-β 
Of all biomarkers being explored in relation to dementia, amyloid-β is the most studied 
and is of particular interest in drug development.[106] Previous research into 
multimorbidity and neurodegeneration found that the association was independent of 
amyloid,[98] but the evidence is limited and warrants further exploration. 
 
1.5.4.1 Hypothesis 4 
Multimorbidity, or having a larger number of chronic conditions, will be 
associated with lower concentrations of CSF amyloid-β, as a marker of 
Alzheimer’s disease. 
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In keeping with the multimodal nature of these hypotheses, and in the absence of a 
single dataset that would allow me to test all these hypotheses, I use data from 
different sources and tailor my approach to the mental and brain health outcomes 
available in each. The analytical chapters of this thesis use a range of complementary 
methods, in keeping with the complex nature of the questions.  
 
The three datasets I use are two cohort studies focused on brain health and dementia, 
and one population-level dataset of routinely collected NHS data. The latter has the 
volume and variety common to ‘big data’, which are increasingly popular in health 
research for these reasons.[107,108] Other strengths are that the data are real 
healthcare data from patients, and in the NHS this includes almost all of the 
population, regardless of socioeconomic status. However, there are recognised 
limitations, including that routine data do not contain detailed information on 
confounding factors and cannot confirm the accuracy of clinical diagnoses.[109,110] 
The smaller cohort studies offer a degree of detail not available in population-level 
data, for example the ability to examine biomarkers and the presence of both self-
reported diagnoses and screening-positive mental health symptoms. These studies 
carry their own limitations, including selection bias inherent when recruiting relatively 
healthy volunteers. One way of addressing limitations across different sizes of dataset 
is to ‘triangulate’ research by comparing results from two or more different approaches 
to the same research question.[111] As only initial data are available from each cohort 
study, I carried out cross-sectional analyses on these data. Although I could not 
complete exactly the same analyses in each dataset, I address the overall questions 
in differing datasets to add depth to my results.  
 
1.6 EXPLORATION OF MULTIMORBIDITY MEASUREMENT 
IN THIS THESIS 
There are various methods for measuring multimorbidity, the most common of which 
is counting conditions from pre-defined lists that vary in length in breadth.[112] Some 
measures weight individual conditions by their association with outcomes, and others 
add other relevant factors.[113] There have been two major systematic reviews on 
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the measurement of multimorbidity, both of which conducted their searches in 
2009.[112,113] These are now outdated, particularly in the light of the steep increase 
in multimorbidity publications since then and ongoing discussion of using appropriate 
methods for better comparisons.[86,114] There has been a recent narrative review of 
multimorbidity measurement, but this did not involve a systematic literature search 
and an update is required.[11] 
 
Before embarking on data analysis, I begin the thesis with a detailed review of 
available multimorbidity indices in Chapter 2 and a discussion of broad 
methodological issues in measurement, in Chapter 3. 
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Chapter 2 Systematic review of multimorbidity 
indices 
2.1 INTRODUCTION 
When studying multimorbidity, it is important to consider its definition, as outlined in 
Chapter 1, but also how it is measured. In existing multimorbidity research, there is 
relatively little focus on methodology and measurement compared to clinical research 
questions.[113] Two main numerical methods exist for measuring multimorbidity: 
counting diseases and using indices. An index quantifying multimorbidity can be used 
to predict relevant outcomes, to adjust for multimorbidity as a confounding factor or to 
permit its use as a single variable in statistical models.[11] In this chapter, I present a 
systematic review on multimorbidity indices which has been accepted for publication 
in The BMJ, preceded by a general introduction and followed by further discussion. 
Disease counts carry their own methodological issues so are considered separately 
in Chapter 3. 
 
I used the Preferred Reporting Items for Systematic Reviews and Meta-Analyses 
(PRISMA) guidelines to structure and report this work.[115] I consulted an Academic 
Liaison Librarian who assisted me to develop the search strategy, initially by 
combining search terms from previous reviews of multimorbidity measurement with 
additional synonyms. After test runs of my preliminary search strategy revealed over 
42 000 results from one database alone, I refined it under the librarian’s guidance. For 
example, I restricted the search to either titles or titles, abstracts and key words only, 
in the databases where this was possible. This reduced the number of hits owing to 
the large number of published papers that mention multimorbidity somewhere in the 
text but are not specifically focused on the topic. I also added adjacency indicators to 
words such as ‘multiple’ and ‘conditions’, specifying that they should be no more than 
two words apart. 
 
I screened all search results with two co-authors (LGS and DSM). I extracted data 
from all papers and scored their risk of reporting bias; both these tasks were 
duplicated for consistency by DSM. I wrote the first draft of the manuscript and 
prepared all the tables before making amendments following comments from all co-
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authors (the remaining three of whom are my PhD supervisors). I navigated three 
rounds of peer review, conducting a considerable amount of revision before the final 
submission. During this process, we received comments on the manuscript from a 
total of eight unique reviewers, the journal’s Head of Research and two editorial 
committees. Their varied suggestions reflected the heterogeneity of the multimorbidity 
research field, and the additional information they requested led to the paper growing 
beyond a narrative review. I added supplementary files detailing index updates, model 
development and evaluation. We aimed to make the paper more accessible and 
usable as a guide by adding recommendations for index choice. The final paper was 
copy-edited by The BMJ before publication; I approved or changed all amendments. 
 
2.1.1 Background 
There have been several previous systematic reviews of multimorbidity 
measurement, but an updated search is due. In 2003, De Groot and colleagues 
published the first systematic review on this topic, listing 13 methods of measuring 
multimorbidity for both community and hospitalised patients.[116] Another systematic 
review was published by Diederichs et al. in 2011, finding 39 studies from a search in 
August 2009.[113] The most recent systematic review on multimorbidity measures in 
community settings was published by Huntley and colleagues in 2012 after a search 
in December 2009.[112] There have been additional specific reviews since then, such 
as one published in 2015 that focused only on indices for use with administrative 
data.[117]  
 
In 2019, a systematic review of systematic reviews on the definitions and 
measurement of multimorbidity included the reviews mentioned above [118] as well 
as two further studies discussing definitions.[5,119] This review has a broad scope, 
including both measurement and definitions.[118] In addition, it is limited by the search 
dates of the studies included, with the most recent being the review of indices for use 
in administrative data in October 2013.[117] However, research into multimorbidity 
has expanded greatly since 2010.[86] Table 2-1 summarises the characteristics of 
these previous systematic reviews. 
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Table 2-1: Summary of previous systematic reviews on measurement of multimorbidity 




Features of review 
Johnston 
[118] 
2019 6 Systematic review of systematic 
reviews, including both 
measurement and definitions 
Yurkovich 
[117] 
2015 76 Includes development and validation 
studies of comorbidity indices in 
administrative data. Lists Charlson 
Index adaptations [120] 
Huntley  
[112] 
2012 194 Compares use and predictive validity 




2011 39 Among indices, considers lists of 




2003 13 Explores validity and reliability of 
indices. Also includes disease count. 
 
Further to the growth demonstrated in Figure 1-2 on page 16, I ran an up-to-date 
measure of hits in MEDLINE for the term ‘multimorbidity’ as a keyword in December 
2019 (with data only available until 2018). Figure 2-1 shows the results of this search, 
with a continued steep increase after 2015 when the previous bibliographic study 
ended.[121]  
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Figure 2-1: Hits for the term 'multimorbidity' in MEDLINE, per 100 000 papers each year, 1970-
2018 
 
In the context of this rapidly growing field, I conducted a specific and detailed 
systematic review of the available indices for measuring multimorbidity. 
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Methods
No single accepted term describes the methods of 
measuring multimorbidity. In this review we use the 
term “index” to refer to any method of quantifying 
disease burden or predicting specific outcomes that 
includes more than a count of conditions. This could 
be by weighting conditions (for example, by allocating 
a score to each), adding other elements, or exa-
mining other variables such as drug or physiological 
parameters.
Search
To capture all relevant publications we conducted 
a broad search. We included a variety of terms for 
multimorbidity derived from previous systematic 
reviews on this topic! " and other literature discussing 
terminology in this area of research.# We developed 
the search strategy iteratively with the support of an 
Academic Support Librarian. The final search terms 
are listed in the appendix (appendix eTable $) and 
include multimorbidity, comorbidity, polypathology, 
polymorbidity, pluripathology, multi-condition, and 
multiple chronic conditions. The search was restricted 
to adults older than $% years and to English language 
publications.
Eligibility criteria
We planned to summarise reports of novel indices and 
were primarily interested in the original report of each 
index. Therefore we excluded papers that either used 
existing indices or measured multimorbidity using 
only disease counts. In the initial screening process 
we included only the original form of each scale and 
not adaptations or updates; these were found later. 
Records that were not original research papers, such as 
conference abstracts, letters, and systematic reviews, 
were excluded. We defined multimorbidity as multiple 
co-occurring conditions without reference to a specific 
disease, so excluded papers were those that focused on 
comorbidities of an index disease or on comorbidities 
within one disease area (such as the coexistence of 
several psychiatric conditions). As most people with 
multimorbidity are adults living in the community and 
managed in primary care, we excluded articles about 
children, animals, or people admitted to hospital 
or living in residential care. We included studies of 
hospital inpatients when the primary focus was follow-
up after discharge (for example, mortality one year 
later). As resources were limited, we excluded papers 
when full texts were not available in English.
Information sources
On $& October '($% we searched Medline, Web of 
Science Core Collection, Cochrane Library, Embase, 
PsycINFO, Scopus, and CINAHL Plus from inception 
onwards.
Study selection
Two authors used Covidence software independently 
to screen titles against exclusion criteria and the 
subsequent abstracts against the same criteria.% We 
then extracted the full texts of relevant abstracts 
for further screening. Any disagreements at the 
title, abstract, and full text stages were resolved by 
discussion, and a third author mediated unresolved 
conflicts. We excluded papers that referred to an 
existing index, but listed the indices that were used 
when excluding them at the abstract stage. We found the 
original papers describing these indices and returned 
them to the title screening stage. Additional relevant 
titles were found by reviewing previous systematic 
reviews on this topic, searching the bibliographies of 
included full text papers, and tracking their citations 
using Google Scholar. Emerging relevant titles were 
added to the screening process.
Usage, updates, and validation
After the list of included papers had been finalised, we 
searched their citations on Google Scholar for updates, 
revisions, or adaptations as well as validation papers. 
When original indices were adapted and validated 
numerous times, we listed the original performance and 
principal adaptations. We did not include adaptations 
where the original index was translated into another 
language with no other changes made. To assess the 
popularity of each index, we took the total number of 
citations for each original paper from Google Scholar 
on # September '($&, as a proxy for use. We then 
calculated the number of citations for each whole year 
since publication. To retain awareness of the context 
of their initial design and aims, we summarised index 
updates separately from the original papers.
Data collection process
We created a data extraction tool containing specific 
elements of interest for each original index. This tool 
took account of previous reviews on this topic as well 
as additional information relating to mental health. We 
used a broad definition of mental health, comprising any 
mental disorder, including mood disorders, dementia, 
delirium, and addictions as well as relevant symptoms. 
Many papers describe validation of the indices used so 
details on the size and demographic distribution of the 
populations under test was important.
Two authors independently extracted data from all full 
texts. We compared the consistency of extracted items 
and resolved any di)erences by discussion and reference 
to the original paper, with a third author available in case 
of substantially di)ering data extraction.
Data items
The variables of interest during data extraction were 
first author, year of publication, and name of index; 
original purpose of the index; characteristics of the 
population under test, including type of data source 
(eg, cohort study), location, number of participants, sex 
and age distribution, and mean number of concurrent 
medical conditions (when given); components in-
cluded in the index; weighting method (if any) 
and details of model for its development; outcome 
measures; information and resources required to 
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with another index (if applicable); external validation 
and performance compared with another index (if 
applicable); and inclusion of mental health (either in 
comorbidities or as outcomes).
Risk of reporting bias in original studies
We assessed the risk of bias of study design and reporting 
and aimed to develop overall recommendations for 
index choice. The Cochrane Collaboration advises 
against scales that generate total numerical scores, 
preferring emphasis on individual papers’ performance 
on each criterion.! After our search date the Prediction 
model Risk Of Bias ASsessment Tool (PROBAST) was 
published. It focuses on risk of bias and applicability 
in prediction model studies."# As our search was not 
restricted to prediction models, it was not appropriate 
to apply this tool to every paper. We therefore developed 
our own list of criteria having referred to resources 
available for assessing clinical prediction indices.""-"$ 
Our assessment aimed to deal with risk of selection, 
observer, and funding bias. The list contained "# 
questions on the population tested, description of the 
index, statistical methods, validity, and funding. The 
assessment tool is available in the appendix (appendix 
eTable %), including division into domains. We also 
included an overall impression of the papers’ risk of 
bias based on the Scottish Intercollegiate Guidelines 
Network standard, which was scored separately to 
the criteria rather than in an additive fashion."& Two 
reviewers independently assessed each paper and 
resolved disagreements by discussion.
When choosing an index, its predictive ability 
and its use elsewhere are important. We generated 
overall recommendations taking into account 
the generalisability of participants, selection and 
clinical relevance of index components, outcome 
measurement, risk of reporting bias, and model 
evaluation. These were separated into three main 
categories: recommended, potentially useful (usually 
when indices were applicable to certain situations), 
and not recommended.
Synthesis of results
We anticipated finding a wide variety of indices 
covering diverse outcome measures and therefore 
planned to summarise these narratively. Because of 
the range of outcomes included we did not expect to be 
able to perform meta-analysis. We listed performance 
and validity statistics as reported by the original 
papers or validation studies alongside each other, for 
comparison.
We did not expect to find indices specifically 
designed for measuring physical multimorbidity in 
relation to any aspect of mental health. Therefore, for 
separate narrative synthesis we planned to seek those 
indices that mentioned mental illnesses or symptoms, 
either as comorbidities or as outcomes.
Patient and public involvement
An early draft of this paper was discussed with a 
lay contributor who has personal experience of 
multimorbidity. We incorporated her comments into 
the text—for example, noting in the introduction that 
the number of conditions a person has might not reflect 
their experience of health, and in the discussion her 
suggestions about outcomes that could be important to 
patients. The lay contributor also commented on a lay 




The searches yielded '"%( results. A search of 
bibliographies and citations identified &( additional 
relevant titles, and a further ") titles were added from 
the list of indices mentioned in excluded abstracts. The 
total number of titles was therefore '"!". Duplicates 
were removed using EndNote X( and Covidence 
software,( ") leaving ))*# unique records for screening 
(fig ")."* Overall, )%$* titles were excluded at the 
screening stage, leaving $%& abstracts for eligibility 
assessment. Of these, (* full texts were assessed and 
$) papers finally included.
Study characteristics
Twenty articles originated from the United States"'-$*; 
three from Australia$'-$!; two each from the United 
Kingdom,&# &" Taiwan,&% &$ and Italy&& &); and one each 
from Canada,&* Spain,&' Germany,&( New Zealand,&! 
Norway,)# and India.)" They were published between 
"!*( and %#"', with ") (&$%) published since the last 
systematic review on this topic in %##!."'-%# &# &%-)" The 
mean number of participants included in the derivation 
populations of indices developed after %##! was 
$)* !#*, compared with ') &!" before %##!. The newer 
indices primarily required access to medical records in 
"" ('$%) cases,"(-%# &# &%-&) &'-&! and the remainder (&, 
%'%) self-report"' &* )# )"; "# ()#%) indices before %##! 
primarily used medical records%" %$ %* %! $%-$* $! and "# 
()#%) used self-report.%% %& %) %' %( $# $" $' $( &"
The majority of papers described one final 
multimorbidity index, even if they tested various 
models in development, and four papers concluded 
with more than one index or measure.%$ %) $# &* For 
consistency, when articles were summarised and their 
quality assessed we considered each paper as a whole 
and noted when more than one index existed. We did 
not comment on models that used only unweighted 
disease counts, in keeping with our overall exclusion 
criteria.
Index components
Four indices primarily used weighted drug counts 
to quantify multimorbidity,$$ $! &$ &) five used 
diagnostic groups or clusters,%$ %* $& $* &( and %) 
included counts of diseases. Of these, %" were 
weighted"' "! %# %% %& %'-%! $" $% $) $' $( &# &" && &* &' &! )# )" 
and nine incorporated other parameters, demographic 
or otherwise."( "! %% %) %( $# &% &' )" Four papers 
used a combination of weighting and additional 
variables."! %% %( &' One index used physiological 
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relevant)!"-!# $$ $% &' &$ &(-&% &# (' ($ (& () (" (# )! and three 
including mental health markers as an outcome 
only.$( &! && Seven measures included di*erent 
aspects of mental health as both comorbidities and 
outcomes,$' $) $" &" &+ (( (+ and one paper included 
anxiety and depression as both a comorbidity and 
an outcome.(! In appendix eTable +, we summarise 
whether each index dealt with aspects of mental 
health, as either comorbidities or outcomes, and how 
these were measured. Where papers discussed specific 
findings relating to multimorbidity and mental health, 
we present their conclusions.
Risk of reporting bias within studies
Using our quality assessment tool, we classified six 
papers as high quality with little or no risk of bias in 
reporting$$ $( $" &$ &" (# and seven as low quality with 
moderate to high risk of bias.$& $+ &( &) &% (! ($ The 
remaining $$ papers were of satisfactory quality. Of 
the five domains we assessed, the best reported were 
index description and funding source. Validity and 
statistical methods were the least well reported across 
all papers. Table $ shows the scores for all papers 
across each domain. As we had agreed in advance to 
judge the overall impression without summing domain 
scores, the domain scores did not always lead to the 
same overall impression. For example, one study was 
given an overall impression of satisfactory with a total 
domain score of %,(+ whereas another study scored + 
and was also deemed satisfactory.)!
Risk of bias across studies
It was not possible to quantify publication bias owing 
to the variety of methods and outcomes used. It is 
likely that more unpublished methods of measuring 
multimorbidity exist and are used in clinical practice, 
especially tailored to specific patient populations or 
available clinical information.
Usage, performance, and validation
As a proxy for usage, we calculated the number of 
annual citations for each paper. The number of citations 
for each year since publication ranged from three(! to 
#(#,&) with a median of +.+ (interquartile range ).&-
!%.$). This information is listed alongside measures 
of the indices’ performance at predicting outcomes 
and validation in appendix eTables # (indices without 
external validation) and !' (externally validated 
indices). Sixteen original papers described designing 
indices within a derivation cohort and testing their 
ability to predict specific outcomes within a separate 
validation set.$' $$ $+-&' && &) &" &+ (' (& (( () (" (# )'
Fourteen original papers measured an index’s 
performance at predicting outcomes!" $$ $+ &'-&$ &( &%-
&+ (! ($ (% (+ and $' compared an index to an existing 
measure of multimorbidity.!+-$! $&-$" $# && &) &# (' (& (( 
() (" (# )' Fourteen indices were validated elsewhere, 
of which !! were compared with other indices$' $$ 
$% $" &&-&% &# (& (" and three only measured ability to 
predict outcomes.!" $( &$ Among the indices that were 
externally validated, !! were tested at predicting 
di*erent or additional outcomes to those in the original 
index design.$' $( $% &$-&% &# (& (" Some indices were tested 
against other indices that had been developed with 
di*erent original outcomes—for example, the Charlson 
index where the outcome in question was admission to 
hospital(& or health related quality of life.$'
Updates and adaptations
Thirteen (&"%) of the indices had updates or adap-
tations published, by either original or separate 
research teams. These revised versions included 
updated comorbidities or weights, focused on specific 
patient groups, or mapped a clinical index to codes 
for administrative data. Two of the indices are risk 
adjustment methods undergoing regular review and 
updates.$% &( The relevant indices are listed in appendix 
eTable !! alongside a summary of their adaptations 
and updates and any reported performance metrics. 
The older and widely used indices such as Charlson, 
Chronic Disease Score, and Cumulative Illness Rating 
Scale have been adapted and updated many times; we 
include the most cited versions. Most updated indices 
are broadly based on the aim and outcome measures of 
the original, with some exceptions.)"-%'
Of the indices that were not updated, in some cases 
this was because the original index was unsuccessful 
at predicting specific outcomes&" or was not designed 
for use outside of the original study.&'
Discussion
In this review we collated descriptions of &) distinct 
multimorbidity indices. The papers were diverse 
in study design, intended purpose, and variables 
included. Similarities did, however, emerge, such 
as index components concentrating on conditions, 
diagnostic categories, drug classes, or physiological 
measures. Mortality was the most commonly studied 
outcome, with healthcare use, hospital admission, 
functional ability, and health related quality of life as 
other important groups. Those that measure mortality 
will be of most relevance to clinicians and researchers, 
whereas healthcare use and costs are more useful 
to healthcare providers and funders, particularly 
in predominantly private healthcare systems. For 
patients, the most relevant outcomes might be quality 
of life or self-reported health.
Strengths and weaknesses of this study
A major strength of this review was the use of an 
updated search in a rapidly expanding area of re-
search and a focus on multimorbidity measures that 
specifically include mental health.
Although the medical subject heading (MeSH) term 
“comorbidity” has existed since !##', a new MeSH 
term, “multimorbidity,” was introduced in January 
$'!+, after our search had been designed and pre-
registered.! %! We found that the word “indexes” was 
used in some titles when we had used “indices” in 
our search terms. One paper was found by citation 
tracking and had apparently been missed during our 
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Conclusions
At least !" objective measures of multimorbidity are 
available for people living in the community, and each 
of these uses di#erent variables to generate a score or 
index, linked with various or no outcome measures. 
We found no specific index for investigating the 
interplay between mental and physical multimorbidity, 
although this issue is dealt with in a variety of ways 
across the measures. The array of index components 
and outcomes means that a validated measure exists 
for many applications, including clinical, research, 
and cost prediction. It is important when choosing 
an index to consider its original purpose and the 
outcomes for which it is validated. Given the di#ering 
methodologies of multimorbidity research, it would 
not be appropriate to assume that a single index could 
definitively measure multimorbidity in all settings. 
However, with this research area at risk of saturation, 
we propose that anyone measuring multimorbidity 
should study existing indices before developing new 
ones.
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2.3 SUPPLEMENTARY MATERIAL4 
eTable 1: Search strategy by database  
Database Search strategy 




1. TI=(Multimorbidity or multi-morbidity or comorbidit* or co-
morbidit* or polypatholog* or poly-patholog* or polymorbidit* 
or poly-morbidit* or multipatholog* or multi-patholog* or 
multicondition* or multi-condition* or pluripatholog* or pluri-
patholog* or 'multiple chronic condition*' or 'morbidity 
burden') 
2. TI= ((multiple or coexisting or co-existing or concurrent or 
comorbid or co-morbid) NEAR/2 (disease* or illness* or 
condition* or diagnosis or diagnoses or morbid*)) 
3. TI=(((index or indices) not ('body mass' or 'body-mass')) or 
(measure* or tool or instrument or categor* or rating scale* 
or count) or (classif* not 'international classification of 
disease*')) 
4. #2 or #1 
5. #4 AND #3 
6. TI=(Community or outpatient* or ambulatory or ambulant or 
population or generalist* or 'general practi*' or 'primary care' 
or 'primary health*' or 'primary medic*' or 'family practi*' or 
'family physician*' or 'family doctor' or 'family medic*' or 
'medical practice*') 




1.   ((Multimorbidity or multi-morbidity or comorbidity or 
polypathology or polymorbidity or poly-morbidity or 
multipathology or multi-pathology or multicondition or multi-
condition or pluripathology or pluri-pathology or 'multiple 
chronic conditions' or 'morbidity burden') or ((multiple or 
coexisting or co-existing or concurrent or comorbid or co-
morbid) NEAR/2 (disease or illness or condition or 
diagnosis or morbid))) NEAR/5 (((index or indices) not 
('body mass' or 'body-mass')) or (measure or tool or 
instrument or category or rating scale or count) or 
(classification not 'international classification of diseases'))) 
2. (Community or outpatient or ambulatory or ambulant or 
population or generalist or 'general practice' or 'general 
practitioner' or GP or 'primary care' or 'primary health' or 
'primary healthcare' or 'primary medicine' or 'primary 
medical' or 'family practice' or 'family practitioner' or 'family 
physician' or 'family doctor' or 'family medicine' or 'family 
medical' or 'medical practice') 
3. #1 AND #2 
 
4 References for this supplementary material appear in the thesis References on page 321 
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1. ((Multimorbidity or multi-morbidity or comorbidit$ or co-
morbidit$ or polypatholog$ or poly-patholog$ or 
polymorbidit$ or poly-morbidit$ or multipatholog$ or multi-
patholog$ or multicondition$ or multi-condition$ or 
pluripatholog$ or pluri-patholog$ or 'multiple chronic 
condition$' or 'morbidity burden') or ((multiple or coexisting or 
co-existing or concurrent or comorbid or co-morbid) adj2 
(disease$ or illness$ or condition$ or diagnos#s or 
morbid$))) adj5 (((index or indices) not ('body mass' or 'body-
mass')) or (measure$ or tool or instrument or categor$ or 
rating scale$ or count) or (classif$ not 'international 
classification of disease$'))).mp. 
2. (Community or outpatient$ or ambulatory or ambulant or 
population or generalist$ or 'general practi$' or GP$ or 
'primary care' or 'primary health$' or 'primary medic$' or 
'family practi$' or 'family physician$' or 'family doctor' or 
'family medic$' or 'medical practice$').mp  
3. 1 and 2 
4. Animals/ not Humans/ 
5. 3 not 4 





1. ((Multimorbidity or multi-morbidity or comorbidit$ or co-
morbidit$ or polypatholog$ or poly-patholog$ or 
polymorbidit$ or poly-morbidit$ or multipatholog$ or multi-
patholog$ or multicondition$ or multi-condition$ or 
pluripatholog$ or pluri-patholog$ or 'multiple chronic 
condition$' or 'morbidity burden') or ((multiple or coexisting or 
co-existing or concurrent or comorbid or co-morbid) adj2 
(disease$ or illness$ or condition$ or diagnos#s or 
morbid$))) adj5 (((index or indices) not ('body mass' or 'body-
mass')) or (measure$ or tool or instrument or categor$ or 
rating scale$ or count) or (classif$ not 'international 
classification of disease$'))).ti. 
2. (Community or outpatient$ or ambulatory or ambulant or 
population or generalist$ or 'general practi$' or GP$ or 
'primary care' or 'primary health$' or 'primary medic$' or 
'family practi$' or 'family physician$' or 'family doctor' or 
'family medic$' or 'medical practice$').mp  
3. 1 and 2 
4. Animals/ not Humans/ 
5. 3 not 4 
6. limit 5 to english language 
Scopus 
“Advanced” tab 
( ( TITLE ( ( {multiple}  OR  {coexisting}  OR  {co-existing}  OR  
{concurrent}  OR  {comorbid}  OR  {co-morbid} )  W/1  ( disease*  OR  
illness*  OR  condition*  OR  diagnos?s  OR  morbidit* ) ) )  OR  ( 
TITLE ( {multimorbidity}  OR  {multi-morbidity}  OR  comorbidit*  OR  
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Database Search strategy 
co-morbidit*  OR  polypatholog*  OR  poly-patholog*  OR  
polymorbidit*  OR  poly-morbidit*  OR  multipatholog*  OR  multi-
patholog*  OR  multicondition*  OR  multi-condition*  OR  
pluripatholog*  OR  pluri-patholog*  OR  {multiple chronic condition*}  
OR  {morbidity burden} ) ) )  AND  ( TITLE ( ( measure*  OR  "tool"  
OR  "instrument"  OR  category*  OR  rating  AND scale* )  OR  ( 
classif*  AND NOT  {international classification of disease*} )  OR  ( ( 
{index}  OR  {indices} )  AND NOT  ( {body mass index}  OR  {body-
mass index} ) ) ) )  AND  ( TITLE-ABS-KEY ( {community}  OR  
outpatient*  OR  {ambulatory}  OR  {ambulant}  OR  {population}  OR  
generalist*  OR  {general practi*}  OR  gp*  OR  {primary care}  OR  
{primary health*}  OR  {primary medic*}  OR  {family practi*}  OR  
{family physician*}  OR  {family doctor}  OR  {family medic*}  OR  
{medical practice*} ) )  AND  ( LIMIT-TO ( LANGUAGE ,  "English " ) 
) 
CINAHL Plus (TX (((Multimorbidity or multi-morbidity or comorbidit* or co-morbidit* 
or polypatholog* or poly-patholog* or polymorbidit* or poly-morbidit* 
or multipatholog* or multi-patholog* or multicondition* or multi-
condition* or pluripatholog* or pluri-patholog* or 'multiple chronic 
condition*' or 'morbidity burden') or ((multiple or coexisting or co-
existing or concurrent or comorbid or co-morbid) N2 (disease* or 
illness* or condition* or diagnos#s or morbid*))) N5 (((index or 
indices) not ('body mass' or 'body-mass')) or (measure* or tool or 
instrument or category* or rating scale* or count) or (classif* not 
'international classification of disease*')))) AND TX((Community or 
outpatient* or ambulatory or ambulant or population or generalist* or 
'general practi*' or GP* or 'primary care' or 'primary health*' or 
'primary medic*' or 'family practi*' or 'family physician*' or 'family 
doctor' or 'family medic*' or 'medical practice*'))) 
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eTable 2: Risk of bias assessment tool questions, by domain 
Questions 1-9 marked as follows:   Yes +  No or not applicable - 
Participant selection (maximum ++) 
1. Are the patient/population demographics of this study clearly described? 
2. Are the patient/population demographics representative (e.g. Including an 
appropriate proportion of genders, socioeconomic status etc) 
Index description (maximum ++) 
3. Are the variables included in the index clearly defined? 
4. If the index uses a list of diseases, does it describe the selection process for 
this list? 
Statistical methods (maximum ++) 
5. Are the statistical methods used clearly described? 
6. Is a sample size calculation included? 
Validity (maximum +++) 
7. When outcomes were included, were outcome raters blinded to the variables 
used in the index? 
8. Was there a test for inter-rater or test-retest reliability of the index? 
9. Was the index validated, either in this paper or elsewhere? 
Funding source (maximum ++) 
10. Is there a statement of funding or conflicts of interest? 
Yes: no likely conflict ++ 
Yes: possible conflict + 
No statement - 
Overall quality criteria (based on SIGN Guidelines)[122] 
High: Majority of criteria met. Little or no risk of bias 
Satisfactory: Most criteria met. Some flaws in the study with an associated risk of bias 





eTable 3: Data extracted from original papers where weighted conditions are the index components, displayed in chronological order, 
with overall recommendation for use 
Publication 































cohort study of 
people aged 








All aged ≥50 














Weights and list 
of conditions 
given in paper 





































and list of 
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age 55 years, 
80.1% women, 







domain of SF-36 
Self-reported 
diagnoses. 
Weights and list 
of conditions 
given in paper 
None tested in 
this paper 












cohort study of 
all adults aged 



















Weights and list 
of conditions 
given in paper 
Self-reported 









































study of adults 
aged over 65 
years. Canada 
n=16 369, 54.9% 











Index with and 






Weights and list 
of conditions 













Primarily comparison of 
methods; not designed 







































Potentially useful for 
predicting mortality in 
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derivation set 






















































mean age 74.9 
years, 100% 
women, median 2 
chronic conditions. 
Validation: 5,217, 
mean age 74.9 
years, 100% 






















predicting less well 
studied outcomes. 
Needs further 



















median age 76, 
47% women. 
Mean 7 conditions 











survey. List of 
conditions and 
weighting given 





quality of life 
measured using 
SF-36 
Not recommended; as 
authors note, using one 



















over 65 years. 
USA 
n=156, mean age 
75 years, 49.4% 




































































n=170, mean age 
65.3 years, 55% 
women 
13 conditions 
















hospital stay; at 
one-year follow 





Potentially useful for 
predicting HRQL and 
healthcare costs 
through self-report 


















n=524, mean age 
78.7 years, 56% 
women 
Validation: 
n=852, mean age 

















predicting mortality – 
most relevant in 


















all aged ≥65 
years (no other 
details given) 
Validation: n=183, 
median age 78.0 
years, 68.3% 
women, mean 6 
conditions 
22 conditions, 

















28), anxiety and 
depression 
(HAD) 
Potentially useful for 
gathering information 
on symptoms but not 
recommended as index 
due to small sample 


































with type II 
diabetes. USA 
n=1,738, mean 



























Participants all had 
diabetes; list of weights 



















n=414, mean age 
40.5, 58.7% 
women, mean 1.9 
chronic conditions 
All conditions 



















None Potentially useful for 
establishing medical 
history in clinical setting 
but has no limits on 
what constitutes 
conditions so limited 











































predicting mortality due 
to widespread use 
despite possible flaws 
in methods. Original 
weights are outdated; 
recommend using Quan 




























cancer at a 
single hospital. 
USA 





eTable 4: Data extracted from original papers where index components include conditions with additional information 
Publication 
































age 73.4 years, 
50.2% women 
32 codes from 
ICD-9-CM, of 













one, five and 
eight years 
Not recommended: not 
evaluated and is not a 
frailty index as it claims 



















n=103, mean age 
45.0 years, 45% 




























None reported Potentially useful for 
information gathering. 














































Not recommended: not 
usable as information 

























































n=644, mean age 
81.2, 66.4% 





by expert opinion 





List of conditions 










and number of 
eligible quality 
indicators 
Potentially useful in 
older people but needs 
















medicine in 33 
hospitals, 
recruited for 
cohort study at 







































Potentially useful for 
predicting mortality but 
requires specific 
components that may 
























Weighting in this 
paper. 
Lee 2006 [9] * Mortality 
prediction 
One wave of 
cohort study of 
adults aged 








age 67, 56% 
women 





















predicting mortality as 
long as functional 

















age 64, 0% 

























Not recommended: not 
designed as index, 
includes several 
models and some 
methods are unclear 
















age 67.8 years, 
2.6% women, 





















where medical history 

























age 67.8, 2.7% 


















age 42.2 years, 
55.4% women 
(Split in half at 


















One year’s total 
health plan 
expenditure 
Not recommended; as 
authors state it is 
exploratory work and 
do not identify one 
model for external use. 
Useful for comparing 
cost prediction models 
* Indices that have an updated or modified version available 








































age 60.2 years, 
53.7% women 













lists of drugs 








medication data to 

































































and lists of 










































of drugs and 




death within 12 
weeks 
Potentially useful but 





























































records. List of 
drugs and 
weighting given 
in original paper 



















severity and predicting 
mortality and 
hospitalisations using 
drug data. Advise using 
updated version Rx-Risk 
for newer list of drugs 
[55] (see eTable 11) 





eTable 6: Data extracted from original papers where index components are diagnostic groups or physiological measures 
Publication 






























age 74.4 years, 
59.3% women, 
mean 7 chronic 
conditions 
42 diagnostic 








List of conditions 
given in paper 
Health-related 
quality of life 
according to 
EQ-5D 
Potentially useful for 
assigning condition 











taken as part of 
longitudinal 
cohort study of 
people aged ≥
65 years. USA 
n=2,928, mean 

















cohort study but 











requires very specific 
components. Updated 
version Healthy Ageing 
Index more practical 












aged ≥18 years 
who filled a 
n=20 378, mean 




Two separate final 















Not recommended for 
external use, but 
provides evidence 


























counts of 119 
ICD-9-CM 
diagnostic 
clusters. With and 




Pope 2004 [152] 













claims of 5% 
sample of 
population 

















































































and collapsed into 






















Potentially useful for 
predicting costs in USA 
setting but needs 
proprietary software 
Linn 1968 [154] 
Cumulative 
Illness Rating 





Study of adults 
aged over 55 
years. USA 
n=472, no further 
details given 
13 disease areas, 










listed in original 
paper 
Not assessed 










Potentially useful for 
information gathering in 
clinical and research 
settings although 
somewhat subjective 
* Indices that have an updated or modified version available
 
Abbreviations in eTables 3 to 6: 
ADL: Activities of Daily Living 
APR-DRGs: All Patient Refined Diagnosis Related Groups 
BMI: body mass index 




GHQ-28: 28-Item General Health Questionnaire 
GP: General Practitioner 
HAD: Hospital Anxiety and Depression Scale 
HbA1c: (glycated) haemoglobin A1c 
HRQL: Health-related quality of life 
ICD-9-CM: The International Classification of Diseases, Ninth Revision, 
Clinical Modification 
ICU: Intensive Care Unit 
LDL: low-density lipoprotein 
MRC: Medical Research Council [classification of heart failure] 
NEADL: Nottingham Extended Activities of Daily Living Scale 
NYHA: New York Heart Association [classification of heart failure] 
OARS ADL: Older Americans Resources and Services Activities of Daily 
Living Scale 
PHQ-9: Nine-item Patient Health Questionnaire 
PIP-DCG: Principal Inpatient Diagnostic Cost Group Model for Medicare 
Risk Adjustment 
QOF: Quality and Outcomes Framework 
RAND-36: Research And Development Corporation 36-item health survey 
RCT: Randomised controlled trial 
RxRisk model: A revision and expansion of the Chronic Disease Score 
[33,55] 
RxRiskV: Veterans Health Administration Adapted RxRisk 
SCL-90-R: Symptom Checklist-90-Revised 
SF-12: 12-item short-form health survey 
SF-36: Medical Outcomes Study Short Form 






eTable 7: Development of models in original index descriptions 
Publication and name of index 
 
Method of developing model Model details provided Baseline outcomes reported 
Corrao 2017 [123] 
Multisource Comorbidity Score 
Parametric survival models for 
relationship between each 
condition and time to death, then 
least absolute shrinkage and 
selection operator (LASSO) 
method to select predictor 
conditions, then coefficients 
multiplied by 10 and rounded to 
nearest integer 
Regression coefficients of 
survival model for all included 
conditions. No intercepts or 
baseline survival 
No mortality figures reported 
Wen 2017 [138] 
Multimorbidity Frailty Index (mFI) 
Overall index score = number of 
conditions (“deficits”) divided by 
total candidate conditions. No 
weighting 
Not applicable 30,136 deaths (35.0% sample). No 
figures for number of hospitalisations 
or intensive care admissions 
Stanley 2017 [124] 
Measuring multimorbidity (M3) Index 
Conditions weighted by β 
coefficient where β>0. Total score 
= sum of β coefficients 
All coefficients listed. No other 
model details 
28,611 deaths (0.9% sample) in 
derivation and validation sets 
Wei 2016 [125] 
Multimorbidity Weighted Index 
Used mixed models to predict 
physical function (PF) of SF-36 for 
each condition. Pooled coefficients 
from three samples using fixed-
effects meta-analysis to develop 
condition weights 
All coefficients listed. No other 
model details 
PF used for weighting; no clear 
overall outcome. Summary PF scores 
given 
Robusto 2016 [145] 
Drug-Derived Complexity Index 
Weights derived from Cox 
proportional hazard regression 
coefficients for mortality divided by 
0.3, rounded to the nearest integer 
All coefficients listed. No other 
model details 
>213,000 deaths in combined 
samples (10.7%) 
Lorem 2016 [126] 
Health Impact Index 
Weights from ordinal logistic 
regression odds ratios (odds of 
scoring at lower levels of self-rated 
health for those with the disease 
Odds ratios for all components 
given. Full model equation 
given. No intercept 
Summary statistics listed for self-





Publication and name of index 
 
Method of developing model Model details provided Baseline outcomes reported 
compared with those without), 
rounded to nearest integer 
Pati 2016 [139] 
Multimorbidity Assessment 
Questionnaire for Primary Care 
(MAQ-PC) 




Hong 2015 [140] 
estimated Physician Defined 
Complexity (ePDC) 
Logistic regression to identify 
factors predictive of physician-
defined complexity (the odds of 
being defined as complex by 
physician) 
Odds ratios for all components 
given. No intercept or further 
model details 
Figures for all relevant outcome 
events given 
Wister 2015 [127] One model weighted by Health 
Utility Index (HUI3) correlation, one 
weighted by OARS functional 
status scale correlation, one 
weighted by β coefficients 
predicting HUI3 in ordinary least 
squares regression 
All coefficients and 
correlations listed. No 
intercept or further model 
details 
Summary statistics for all outcomes 
given 




EQ-5D summary scores listed 
Min 2013 [141] 
Geriatric CompleXity of Care Index 
(GXI) 
Conditions weighted by physician-
defined severity 
Not applicable Summary values for each outcome 
given 
Carey 2013 [128] 
QOF Comorbidity Score 
Conditions weighted by Cox 
proportional hazard ratios for 
mortality in training set 
No coefficients or other model 
details 
10,595 deaths (3.3% of sample) 
Dong 2013 [146] 
Pharmacy-Based Disease Indicator 
Drugs weighted based on 
coefficients from logistic regression 
for hospitalisation in training set 
All coefficients listed. Equation 
given. No intercepts 
Approximately 60,000 





Publication and name of index 
 
Method of developing model Model details provided Baseline outcomes reported 
Bernabeu-Wittel 2011 [142] 
PROFUND 
 
Cox models for one-year mortality; 
weights generated by β coefficient 
divided by the lowest β coefficient 
and rounded to nearest integer. 
Components included if 
independently associated with 
mortality 
Odds ratios (not coefficients) 
for each included component 
given. No intercepts 
Mortality reported as 35% in 
derivation cohort (n»265) 
Mukherjee 2011 [129] 
Health-Related Quality of Life 
Comorbidity Index (HRQL-CI) 
Predictors selected using LASSO 
method: regression for each 
predictor and either PCS or MCS 
of SF-12. Points generated based 
on coefficients and clinical 
judgement 
All coefficients listed. 
Intercepts given for separate 
physical and mental SF-12 
scores. Tested separately for 
coefficient- or points-based 
models 
Summary statistics for outcomes 
presented 
Newman 2008 [150] 
Physiologic Index of Comorbidity 
Parameters weighted by arbitrary 
abnormality cut-points (tertiles) 
Not applicable No figures listed for number of 
deaths. Method of measuring 
disability not given. Summary scores 
for disability not given 
Tooth 2008 [130] Conditions weighted by regression 
coefficient (scaled and rounded to 
nearest integer) from Cox hazard 
models for mortality, logistic 
regression for healthcare 
outcomes, or multiple regression 
for SF-36. Different weights for 
each outcome 
Hazard ratios and odds ratios 
for mortality and healthcare 
measures. Coefficients for all 
aspects of SF-36 listed. No 
intercept 
14.9% of derivation set died (n»777). 
Summary results given for all other 
outcomes 
George 2006 [147] 
Medication-based Disease Burden 
Index (MDBI) 
Weights based on association with 
disability in previous studies. 
Clinical panel decided on 
medications to include 
None Mortality or hospitalisation within 12 
weeks (77 occurrences of one or 
both) 
Lee 2006 [9] Used backward elimination 
(P<0.05) to choose variables that 
improved predictive value of 
Odds ratios but not 
coefficients given. No 
intercepts 




Publication and name of index 
 
Method of developing model Model details provided Baseline outcomes reported 
model, then further selected using 
Schwarz Bayesian Information 
Criterion (BIC). Weighting 
developed by dividing logistic 
regression β coefficients by the 
lowest coefficient and rounding to 
the nearest integer 
Farley 2006 [151] Addition of various variables (e.g. 
count of physician visits and 
unique prescriptions). No weighting 
Not applicable Summary statistics for specific 
expenditure-related outcomes given 
Byles 2005 [131] Weights generated using hazard 
ratios for mortality and odds ratios 
for admission. Weights with and 
without health self-rating 
Lists of odds and hazard ratios 
given but no coefficients or 
intercepts 
51% admitted to hospital (485 
patients), 7% died (n=59 in derivation 
sample, n=29 validation) 
Bayliss 2005 [132] 
Disease Burden Morbidity 
Assessment 
Conditions weighted by self-
reported severity 
No; correlations between 
overall score and outcomes 
for testing only 
Summary statistics for each outcome 
provided 
Selim 2004 [143] Components chosen by availability 
and expert panel. Weighting was 
not beneficial to model so was not 
used (data not shown in original 
paper) 
Not applicable 77 patients (4%) died. No summary 
statistics for other outcomes 
Pope 2004 [152] 
The Centers for Medicare and 
Medicaid Services’ Hierarchical 
Condition Category (CMS-HCC) 
Developed using weighted least 
squares multiple regression 
Coefficients for all parameters 
included. No intercepts 
Detailed summary statistics of all 
expenditures given 
Sangha 2003 [133] 
Self-Administered Comorbidity 
Questionnaire 
Conditions weighted by patient-
reported severity 
Not applicable Summary statistics given for SF-36, 





Publication and name of index 
 
Method of developing model Model details provided Baseline outcomes reported 
Fan 2002 [10] 
Seattle Index of Co-morbidity 
Conditions weighted by regression 
coefficients from Cox hazard 
models for mortality, multiplied by 
four then rounded to the nearest 
integer 
Hazard ratios and coefficients 
for mortality for each 
parameter listed 
396 (7.2% of sample) deaths, 1,383 
(25.3%) hospitalisations 
Desai 2002 [134] 
High-Risk Diagnoses for the Elderly 
Scale 
Conditions weighted by hazard 
ratio for one-year mortality, 
rounded to the nearest integer 
Hazard ratios listed. No 
coefficients or intercepts 
154 (29%) died within one-year 
follow-up 
Crabtree 2000 [135] 
Comorbidity Symptom Scale (CmSS) 
Conditions weighted by self-
reported severity 
Not applicable Appropriate scales used for each 
outcome but no summary statistics 
given 
Hornbrook 1996 [144] In one model, conditions weighted 
by interaction effects with RAND-
36 
Full model including intercepts 
given 
No summary data given on 
healthcare cost outcomes 
Greenfield 1995 [136] 
Total Illness Burden Index (TIBI) 
Conditions weighted by severity; 
each group's weight calculated by 
summing each condition's 
regression coefficients for 
functioning, combined with clinical 
opinion 
Coefficients for one example 
condition included. No 
intercepts 
Physical function and role functioning 
from SF-36. Summary data given 
Parkerson 1993 [137] 
Duke Severity of Illness Checklist 
(DUSOI) 
Conditions weighted by severity for 
each patient 
Not applicable Not applicable 
Von Korff 1992 [148] 
Chronic Disease Score 
Drugs weighted based on expert 
opinion 
Not applicable Summary data for outcomes in 
population validation cohort. 1,053 
deaths (0.9%), 8,585 hospitalisations 
(8.0%) 
Starfield 1991 [153] 
Ambulatory Care Groups 
Conditions classified into groups 
then treating as counts; no 
weighting 





Publication and name of index 
 
Method of developing model Model details provided Baseline outcomes reported 
Charlson 1987 [120] 
Charlson Index 
Conditions weighted by adjusted 
relative risks for one-year mortality, 
rounded to nearest integer 
Relative risks listed. No 
coefficients or intercepts 
Mortality (in-hospital and at one year) 
figures listed for each condition 
Linn 1968 [154] 
Cumulative Illness Rating Scale 
(CIRS) 
Conditions weighted by physician-
defined severity 
Not applicable None measured in original paper 
 
Abbreviations in eTable 7: 
AUC: Area under the curve 
BIC: Bayesian Information Criterion 
CDS: Chronic Disease Score 
EQ-5D: EuroQol five-dimension measure of health status 
IDI: Integrated discrimination improvement  
LASSO: Least absolute shrinkage and selection operator  
MCS: Mental component summary 
NRI: Net reclassification improvement 
PCS: Physical component summary 
PF: 10-item physical functioning scale of SF-36 
ROC: Receiver operating characteristic 




eTable 8: Original indices that include aspects of mental health as comorbidities or outcome variables 
First author 
and year 
Comorbidities or index components Outcomes Findings, if applicable 
Corrao 2017 
[123] 
Alcohol abuse, psychoses, anxiety and dementia 
included as comorbidities, defined by use of relevant 
medications 
All-cause hospitalisation 
as outcome; no 
separation of admission 
types to include 
psychiatric 
Regression coefficients with time to death: alcohol 
abuse β=0.99 (SE=0.16), psychoses β=0.77 
(SE=0.05), anxiety β=0.52 (SE=0.23), dementia 
β=0.51 (SE=0.06). Weights allocated in model 
accordingly 
Wen 2017 [138] Comorbidities include “senile and presenile organic 
psychotic conditions.” Diagnoses from claims records 
Does not specify 
subtypes of hospital 
admissions (e.g. 
psychiatric) 
Not separately examined 
Stanley 2017 
[155] 
Comorbidity variables: alcohol abuse, anxiety and 
behavioural disorders, dementia, drug abuse, major 
psychiatric disorder, mental and behavioural disorders 
due to brain damage, mental retardation. Diagnoses 
from routinely collected healthcare data 
None β coefficients for one-year mortality (log hazard 
ratios (95%CI)): alcohol abuse=0.58 (0.47 to 0.68), 
anxiety and behavioural disorders=0.12 (0.04 to 
0.21), dementia=1.02 (0.97 to 1.07), drug 
abuse=0.56 (0.38 to 0.74), major psychiatric 
disorder=0.21 (0.13 to 0.29), mental and 
behavioural disorders due to brain damage=0.04 
(−0.17 to 0.24), mental retardation=1.41 (1.21 to 
1.60) 
Wei 2016 [125] Weighted comorbidities include alcohol abuse, 
depression and dementia. Taken from self-reported 
conditions 
None Depression and dementia both significantly 
associated with poorer scores on physical 
functioning subscale of SF-36 
Robusto 2016 
[145] 
Drugs in model include anti-depressants, anti-
psychotics, anti-dementia drugs. Data from record 
linkage 




Hazard ratios (95% CI) for mortality with each class: 
antipsychotics=2.32 (2.24 to 2.40), anti-dementia 
drugs=3.10 (2.92 to 3.29), antidepressants=1.09 
(1.06 to 1.11). Weighted accordingly 
Pati 2016 [139] Comorbidities include dementia (self-report), 
depression (PHQ-9) and mental aspects of HRQL (SF-
12) 
None Self-reported depression did not correlate well with 
PHQ-9 scores, suggesting under-diagnosis (no 
details given) 
Hong 2015 [140] Comorbidities include: anxiety, post-traumatic stress 
disorder, bipolar disorder, dementia, depression, drug 
or alcohol addiction-related conditions, personality 
disorder, schizophrenia or other psychotic disorders, 
chronic pain, eating disorders, or history of domestic 
violence, situational stress/depression/anxiety or 
adjustment reactions, attention deficit disorder, 
None High risk psychiatric and behavioural disorders 
were significantly associated with physician-defined 







Comorbidities or index components Outcomes Findings, if applicable 
dementia, marijuana use, history of drug or alcohol 




Depression, anxiety and somatoform disorders 
included as comorbidities in weighted count. Taken 
from self-report questionnaire. 
(Dementia was an exclusion criterion) 
Anxiety/depression is one 
dimension of EQ-5D 
which was outcome 
Weighted count of morbidities significantly 
associated with all domains of EQ-5D: b=-1.02 (SE 
0.06). No information on weighted count’s 
association with specific dimensions. 
Participants with depression had increased odds of 
poor scores across all EQ-5D domains. Depression, 
anxiety and insomnia were each significantly 
associated with EQ-5D anxiety/depression 
dimension 
Min 2013 [141] Dementia, anxiety and depression as comorbidity 
variables. Taken from medical records, weight 
assigned by expert consensus 
None Not examined separately 
Carey 2013 
[128] 
Dementia, depression and psychotic disorders all 
included as comorbidities. Taken from medical records 
None All included mental disorders were individually 
associated with increased mortality risk in derivation 
set (dementia hazard ratio=2.83 (95% CI 2.63 to 
3.04), depression HR 1.11 (1.05 to 1.18), psychotic 
disorders HR 1.74 (1.49 to 2.04)) 
Dong 2013 [146] Psychiatric medication included as an index 
component 
Does not specify whether 
outcome includes 
psychiatric hospitalisation 
Weights in index: antidepressants=0.23, 
antipsychotics=0.40, lithium=0.85, anxiolytics=0.14. 




Dementia and delirium (in last hospital admission) as 
comorbidities in index. From records or self-report 
None Odds ratio for 12-month mortality with 
dementia=1.89 (95% CI 1.1 to 3.1), P=0.019, for 




Comorbidities include: affective disorders, 
schizophrenia, other psychoses, anxiety, depression. 
Diagnoses from medical records. Cognitive impairment 
codes excluded 
SF-12 mental component 
score, two core health 
status questions 
Mental health diagnoses had strong association 
with worse SF-12 MCS scores, as did asthma, heart 




Depression, anxiety, Alzheimer’s disease (self-
reported) 




reported) as outcome – 
does not specify which 
specialty 
Alzheimer’s disease found to be associated with 
higher risk of mortality, functional dependency and 
poorer social functioning and mental health. 







Comorbidities or index components Outcomes Findings, if applicable 
George 2006 
[147] 
Alzheimer’s and other dementias included as 
comorbidity (identified by prescription of drugs for 
dementia) 
Does not specify whether 
outcome includes 
psychiatric hospitalisation 
MDBI reported as 100% sensitive and 100% 
specific for Alzheimer’s and other dementias when 
measured against medical records 
Lee 2006 [9] Two functional questions (difficulty managing finances 
and personal hygiene) refer to “health or memory 
problems” 
None Difficulty bathing and managing finances each 
assigned two points in overall model 
Byles 2005 
[131] 
Depression and forgetfulness included as 
comorbidities. Self-reported with severity rating 
Mental Component Score 
(MCS) of SF-36 
Increasing scores on all versions of the 
multimorbidity index were associated with worse 
scores on the SF-36 MCS 
Bayliss 2005 
[132] 
None Depression screen from 
Behavioural Risk Factor 
Surveillance System 
Being less depressed was significantly negatively 
correlated with self-reported disease burden 
(P<0.001) and number of conditions (P=0.002) but 
not with Charlson index or RxRisk score 
Selim 2004 
[143] 
Comorbidity variables include self-reported 
schizophrenia, depression, bipolar disorder, anxiety 
disorder, post-traumatic stress disorder, alcohol abuse 
Mental health outpatient 
visits from administrative 
data, SF-36 
Mental disorders on comorbidity index correlated 
better with the mental than physical scale of the SF-
36. 
Comorbidity index including mental disorders was 
not significantly associated with mortality 
Pope 2004 [152] Comorbidity variables: Drug or alcohol psychosis, drug 
or alcohol dependence, schizophrenia, major 
depressive, bipolar, and paranoid disorders. 
Diagnoses taken from claims data 
None Not separately examined 
Sangha 2003 
[133] 
Depression (self-reported diagnosis) included as a 
comorbidity 
Mental Component Score 
(MCS) of SF-36 
Spearman correlation of SF-36 MCS score at one-




Anxiety/depression (self-report) included as one 
comorbidity 
Anxiety/depression 
measured by Hospital 
Anxiety and Depression 
(HAD) scale and GHQ-28 
Overall score on the CmSS correlated with GHQ-28 






Comorbidities or index components Outcomes Findings, if applicable 
Hornbrook 
1996 [144] 
Depression as comorbidity (self-report diagnosis); 
some models included elements of SF-36, which 
includes mental health 
None Depression performed poorly at explaining variance 




Not clearly included as comorbidity (may be counted 
under “neurologic problems”) 
“Mental health index” 
(assume part of SF-36) 
Global severity measure significantly associated 




Any condition could be a comorbidity (Diagnoses from 
medical records, weighted by rater’s clinical 
judgement) 
None Participants with the highest scores were those with 
depression and at least one other condition 
Von Korff 1992 
[148] 
Psychotropic drugs not included Depression, anxiety, 
somatisation as 
outcomes in one test 
(symptoms measured 
with SCL-90-R) 
Chronic Disease Score was not correlated with 
depression and anxiety 
Starfield 1991 
[153] 
Three of 34 listed diagnoses are psychosocial, 
separated into chronic, other and psychophysiologic. 
Taken from health records 
Does not specify subtype 
of outpatient visits (e.g. 
mental health 
Individuals with psychosocial diagnoses, whether 
alone or in combination with other diagnoses, have 
relatively high levels of healthcare use 
Charlson 1987 
[120] 
Dementia, according to medical records, included as 
comorbidity 
None Dementia alone carried relative risk of one-year 
mortality of 1.4 
Linn 1968 [154] Psychiatric disease listed as disease area (severity 
scored by physician) 






eTable 9:  Usage, validation and performance of multimorbidity indices – indices without external validation5 
Publication 

















9 9.0 Tested n or g na  paper 
on one nterna  (sp t-
samp e) and three 
externa  va dat on sets. 
Compared to Char son, 
E xhauser and Chron c 
D sease Score (CDS) 
nd ces 
D scr m nat on: AUC for 
one-year morta ty 
AUCs for one-year morta ty: Mu t source Comorb d ty Score=0.78 
(95% CI 0.77 to 0.79), Char son=0.69 (0.68 to 0.70), 
E xhauser=0.65 (0.64 to 0.66), CDS=0.69 (0.68 to 0.70) 




8 8.0 ROC ana ys s of 
outcomes w th n 
or g na  dataset on y 
D scr m nat on: AUC for 
a  outcomes by 
categor sed mFI scores 
C-stat st cs for: a -cause morta ty=0.67 (95% CI 0.66 to 0.68), 
unp anned hosp ta sat on=0.65 (0.65 to 0.66) and ICU 





12 12.0 Va dated n or g na  
paper on va dat on set 
(random y ass gned 
sp t-samp e). 
Compared w th 
Char son and 
E xhauser nd ces 
D scr m nat on: C-
stat st cs for morta ty and 
hosp ta sat on (a so used 
ntegrated d scr m nat on 
mprovement (IDI) and 
Aka ke nformat on 
cr ter on) 
C-stat st cs for one-year morta ty: M3 + age + gender=0.92 (95% CI 
0.93 to 0.93), Char son + age + gender=0.92 (0.92 to 0.92), 
E xhauser + age + gender=0.92 (0.92 to 0.93); One-year 
hosp ta sat on: M3 + age + gender=0.70 (95% CI 0.70 to 0.71), 
Char son + age + gender=0.68 (0.68 to 0.69), E xhauser + age + 






10 5.0 Va dated w th n or g na  
paper on va dat on 
cohort (random y 
ass gned sp t-samp e). 
Compared w th 
Char son ndex n 
subsamp e of 125,094 
hosp ta sed pat ents 
D scr m nat on and net 
rec ass f cat on 
mprovement (NRI) 
measured for morta ty 
and hosp ta sat on 
C-stat st cs for one-year morta ty: DDCI=0.81 (0.81 to 0.82), age, 
sex and Char son comb ned=0.80 (0.79 to 0.80); overa  morta ty: 
DDCI=0.80 (0.79 to 0.80), age, sex and Char son comb ned=0.79 
(0.78 to 0.79); f rst unp anned hosp ta sat on: DDCI=0.62 (0.62 to 





11 5.5 Va dated n or g na  
paper n separate 
cohort. Compared 
ab ty to pred ct se f-
rated hea th w th 
Char son ndex 
Ca brat on: used 
Spearman s corre at on to 
compare the assoc at on 
of se f-rated hea th to 
both Hea th Impact Index 
and the Char son ndex 
(wh ch was or g na y 
Spearman corre at on (RS) w th se f-rated hea th: HII= -0.36, 
P<0.001, Char son= -0.25, P<0.001 
 
5 Validation of original indices only; validation of index updates not included. Papers marked with * have updates available 

















deve oped to pred ct 
morta ty) 






7 3.5 Tested for nterna  
cons stency w th n 
or g na  cohort. 
Compar son between 
pat ent se f-report of 
d agnoses and 
phys c ans' 
prescr pt ons. Not 
compared w th other 
sca es 
Compared se f-report 
w th d agnoses apparent 
from prescr pt ons 
Overa  Cronbach's a pha=0.69. Concordance (Scott Kappa) 
between se f-report and prescr pt on-based d agnoses ranged from 
0.58 for hear ng prob em to 1.00 for tubercu os s 






15 5.0 Test character st cs 
ca cu ated n va dat on 
set w th n or g na  
paper. Bootstrapp ng n 
random th rd of samp e. 
Compared w th 
outpat ent Char son 
score and propr etary 
commerc a  r sk 
pred ctor, but no 
comparab e pred ct on 
scores g ven 
D scr m nat on: C-
stat st cs for phys c an-
def ned comp ex ty. 
Compared to Char son 
and Commerc a  R sk 
Pred ctor, but no c ear 
compar son resu ts 
ava ab e 
In own va dat on set: Accuracy=0.82, Sens t v ty=0.47, 
Spec f c ty=0.95, Pos t ve Pred ct ve Va ue=0.77, Negat ve Pred ct ve 
Va ue=0.83. C-stat st cs for mode s' pred ct on of phys c an-def ned 
comp ex ty: <45 years=0.82, 45–64 years=0.82 and ≥65 years=0.77 
Wister 2015 
[127] 
15 5.0 Measured construct 
va d ty of s x mode s 
w th each other w th n 
or g na  paper 
None B var ate corre at on coeff c ent for mu t morb d ty add t ve sca e 
(best perform ng mode ) w th fe sat sfact on= -0.23 (compared to 
d chotom sed 0/≥1 cond t ons= -0.10), perce ved hea th= -0.39 (-




85 17.0 None None Ord nary east squares regress on for assoc at on between 
mu t morb d ty measured by we ghted count score w th overa  HRQL 
(EQ VAS), b= -1.02 (SE=0.06) 





26 5.2 In or g na  paper, 
measured corre at on 
and compared 
pred ct ve ab ty w th 
s mp e d sease count, 
mod f ed Char son 
ndex (mCCI) and 
H erarch ca  Cond t on 
D scr m nat on: AUC for 
a  outcomes compared 
to mod f ed Char son 
ndex (mCCI) and 
mod f ed HCC (mHCC) 
Adjusted R2s for pr mary care v s ts: GXI=14.3, mHCC=6.1, 
mCCI=3.8; spec a ty v s ts: GXI=9.1, mHCC=9.9, mCCI=2.9; qua ty 
nd cators (med ca  records on y): GXI=32.8, mHCC=15.8, 
mCCI=19.6. Adjusted AUCs for 5-year morta ty: GXI=76.2, 
mHCC=78.7, mCCI=77.5; 5-year funct ona  dec ne: GXI=83.8, 
mHCC=89.6, mCCI=77.5; Po ypharmacy (≥14 med cat ons): 
























44 8.8 Tested w th n or g na  
paper on va dat on 
cohort (sp t-samp e); 
a so compared 
morta ty pred ct on w th 
Char son ndex 
D scr m nat on: C-
stat st cs for morta ty 
compared to Char son 
ndex 
C-stat st cs for one-year morta ty: standard QOF score=0.83, 







98 9.8 Compared w th age 
a one and s mp e 
cond t on count w th n 
same cohort n or g na  
paper 
D scr m nat on: surv va  
mode s by ndex score 
AUCs for n ne-year morta ty n or g na  paper: age a one=0.67, 
PIC=0.71, PIC adjusted for age, sex, race=0.73 
Tooth 2008 
[130] 
86 8.6 Va dated w th n or g na  
paper on va dat on set 
(random sp t-samp e) 
Exp a ned var at on: 
compared R2 of we ghted 
and unwe ghted scores 
for nd v dua  cond t ons 
across 13 ana yses 
Re at ve d fferences n R2 for we ghted scores: 0.2-1.3% 
(med an=0.9%), unwe ghted scores 4.9%-35.0%, med an=13.3% 
Farley 2006 
[151] 
167 13.9 Compared w th 
Char son-Romano 
ndex, E xhauser ndex 
and RxR sk-V n same 
cohort n or g na  paper 
D scr m nat on: C-stat st c 
for nd v dua s spend ng 
at the 90th percent e for 
each mode  
C-stat st cs for nd v dua s spend ng at 90th percent e on hosp ta  
and phys c an c a ms: Far ey d agnos s c uster ng=0.69 (0.68 to 
0.70), Char son=0.66 (0.65 to 0.67), RxR sk-V 0.64 (0.63 to 0.65), 
E xhauser=0.66 (0.66 to 0.66) 
Byles 2005 [131] 94 7.2 Tested d fferent mode s 
on va dat on cohort 
w th n or g na  paper 
(random sp t-samp e) 
None HRs for two-year morta ty us ng sever ty-we ghted ndex based on 
morta ty=1.3 (P<0.001), sever ty-we ghted ndex based on 
hosp ta sat on=1.1 (P>0.05). ORs for two-year hosp ta sat on us ng 
sever ty-we ghted ndex based on morta ty=1.2 (P>0.05), sever ty-
we ghted ndex based on hosp ta sat on=1.7 (P<0.01). 
Authors adv se that a s ng e ndex cannot pred ct a var ety of 
outcomes 
Selim 2004 [143] 191 13.6 Compared one mode  
to D sease Burden 
Index (DBI) n same 
cohort n or g na  paper 
[156] 
L near regress on for 
var ance n outcomes 
exp a ned by ndex 
mode s. No 
d scr m nat on or 
ca brat on 
Pearson corre at ons: comb ned phys ca /menta  comorb d ty mode  
w th: SF-36 PCS= -0.39, SF-36 MCS= -0.31. Cond t on/symptom 
comorb d ty ndex w th: PCS= -0.50, MCS= -0.39. Hazard rat o for 
35-week surv va  w th each add t ona  un t n phys ca  ndex= 0.14. 
For MCS, a) R2 for regress on mode s: DBI=15%, comb ned phys ca  
+ menta  ndex=33%; b) regress on coeff c ents: DBI= −1.32, 
comb ned phys ca  + menta  ndex= −5.50 (P<0.001). For psych atr c 
outpat ent c n c v s ts, R2: DBI=2.3%, comb ned phys ca  + menta  

















Fan 2002 [10] 
Seattle Index of 
Co-morbidity 
(SIC) 
160 10.0 Tested w th n or g na  
paper on va dat on 
cohort (random sp t-
samp e) 
D scr m nat on: ROC and 
Kap an-Me er curves for 
morta ty and 
hosp ta sat on 
In va dat on set for a) two-year surv va , AUCs: SIC=0.71, comb ned 
PCS+MCS= 0.71; b) two-year hosp ta sat ons, AUCs: SIC=0.61, 
PCS+MCS=0.64 




Scale * (HRDES) 
85 5.3 Va dated w th n or g na  
paper; compared w th 
Char son-Deyo ndex 
and APR-DRGs n 
separate va dat on 
cohort 
D scr m nat on: Kap an-
Me er curves for morta ty 
by score r sk eve  
For one-year morta ty n va dat on cohort, C-stat st cs: 
HRDES=0.69, Char son-Deyo=0.65 (P<0.05 compared to HRDES), 
tota  d agnoses=0.59 (P<0.05 compared to HRDES), APR-






55 3.1 Corre at ons w th 
outcomes tested n 
separate va dat on set 
n or g na  paper. Not 
compared to another 
sca e 
None Spearman's coeff c ent for corre at on between CmSS score and 
act v t es of da y v ng (NEADL)=0.56; perce ved hea th status 




168 7.6 Mode s compared w th 
each other on ha f of 
the samp e n or g na  
paper (random sp t-
samp e). Not compared 
to other sca es 
Ca brat on: regress on of 
pred cted versus actua  
costs 
Grouped R2s for f t of pred cted to actua  costs: D sease count=0.56, 
D sease count + age + gender =0.68, D sease count, age, gender 





133 5.8 Corre at ons w th 
outcomes tested n 
s ng e cohort n or g na  
paper. Not compared 
w th any other sca es 
None Pearson's r for corre at on w th g oba  sever ty measure: phys ca  
funct on= -0.55 (P<0.001); ro e funct on ng due to phys ca  hea th= -
0.54 (P<0.001); og(d sab ty days)=0.43 (P<0.001);  og(phys c an 





eTable 10: Usage, validation and performance of multimorbidity indices – Indices with external validation 
Publication and 













Performance (original outcomes) Additional outcomes 
tested in external 
validation 




22 11.0 Interna y 
va dated through 
bootstrapp ng and 
cross-va dat on to 
test we ght ng. 
Tested for 
spec f c outcomes 
n fo ow-up paper 
by same author 
group. 157] Not 
compared to 
another mode  
None Externa y va dated n 20,509 part c pants of 
the Hea th and Ret rement Survey. Mean (SD) 
age 64.7 (10.7) years, 54.1% women. 
On mu t var ab e regress on, adjusted β for 
each po nt ncrease n MWI: phys ca  
funct on ng score= -3.73 (95% CI -3.84 to -
3.62), gr p strength= -0.27kg (-0.32 to -0.22), 
ga t speed= -0.29m/s (-0.35 to -0.23), TICS-m 
score= -0.06 (-0.07 to -0.04) [157] 
None 




18 3.6 Pred ct on of 
hosp ta sat on 
compared w th 
Char son-Deyo 
ndex n separate 
samp e n or g na  
paper. Compared 
to med cat on and 
cond t on counts 
n subsequent 
paper by d fferent 
authors.[158] 
D scr m nat on: C-
stat st cs and IDI. 
Ca brat on: Br er 
score. Compared 
performance w th 
Char son-Deyo 
us ng net 
rec ass f cat on 
mprovement 
(NRI) 
C-stat st cs for one-year hosp ta sat on: 
a) n or g na  paper: PBDI=0.72 (adjusted for 
age + sex), Char son-Deyo=0.69 (adjusted for 
age + sex).[146] 
b) In va dat on paper (449,715 French workers, 
approx mate y 52% fema e): PBDI=0.68 
(ad usted for age + gender), ad usted cond t on 
count=0.64, a ternat ve med cat on ndex 
(Ind v dua  Chron c Cond t on score)=0.68 [158] 
One-year morta ty. C-
stat st cs for one-morta ty 
PBDI=0.90 (adjusted for 
age + gender), ad usted 
cond t on count=0.90, 
a ternat ve med cat on 
ndex (Ind v dua  Chron c 






133 19.0 Compared w th 
Char son-Deyo 
ndex (w th and 
w thout age 
ad ustment) n 
separate 
va dat on cohort 
n or g na  paper. 
Va dated n four 
subsequent 
Ca brat on: 
compared ndex-
pred cted to 
observed 
morta ty. 
D scr m nat on: 
ROC curves for 
f na  mode  n 
der vat on and 
va dat on sets 
AUCs (95% CI) for one-year morta ty n or g na  
paper: PROFUND=0.73 (0.71 to 0.76), Age-
adjusted Char son-Deyo=0.62 (0.59 to 
0.65).[142] 
AUCs for four-year morta ty: 
a) n 768 peop e w th mu t morb d ty (45.3% 
women, mean (SD) age 78.8 (9.8) years) 
PROFUND=0.71 (0.67 to 0.77), Age-ad usted 
Char son-Deyo=0.61 (0.56 to 0.67) [159] 
Unp anned 
hosp ta sat on. 
In 1,033 card o ogy 
npat ents, mean (SD) 
age 67 (13.1) years 
35.1% women, HR for 
morta ty=1.13 (1.01-1.27) 
and e ther morta ty or 
hosp ta sat on=1.09 
 


















Performance (original outcomes) Additional outcomes 
tested in external 
validation 
papers, three of 
wh ch nc uded an 
or g na  
author.[159–161] 
b) n 441 peop e w th mu t morb d ty (mean (SD) 
age 80.9 (8.7) years, 55.6% women) 160] 
PROFUND n nterna  med c ne=0.75 (0.69-
0.81), Ger atr c med c ne=0.52 (0.37 to 0.67). 
C-stat st c for one-year morta ty n 333 nterna  
med c ne pat ents w th mu t morb d ty (mean 
(SD) age 79.3 (9.0) years, 50.3% women)=0.73 
(0.67 to 0.78), 132 ger atr c med c ne pat ents 
w th mu t morb d ty (mean (SD) age 84.6 (7.1) 
years, 65.0% fema e)=0.55 (0.45 to 0.64) [161] 





Related Quality of 
Life Comorbidity 
Index (HRQL-CI) * 
32 4.6 Interna  va dat on 
w th 10-fo d 
cross-va dat on. 
Compared w th 
Char son ndex n 
separate 
va dat on cohort 
n or g na  paper. 
Va dated n two 
subsequent 
papers, one by 
separate authors 
[163] 
Ca brat on: 
corre at on 
between observed 
and pred cted 
MCS or PCS 
Corre at on between observed and pred cted 
a) PCS: HRQL-CI=0.57, Char son=0.38 b) 
MCS: HRQL-CI=0.37, Char son=0.11. 
D scr m nat on of mu t p e outcomes assessed 
among 9,832 pat ents w th type 2 d abetes 
(mean (SD) age 44.8 (11.6) years, 73.1% 
fema e) n externa  va dat on paper.[164] 
HRQL-CI phys ca =0.66 (0.65 to 0.68), HRQL-
CI menta =0.66 (0.64 to 0.68).  In 13,289 adu ts 
w th d abetes (mean (SD) age 60.5 (13.7) 
years, 49.0% fema e), ad usted R2 for 
pred ct ng a) PCS: HRQL-CI=29.1 (27.5 to 
30.6), Char son=19.1 (17.6 to 20.5), 
E xhauser=21.1 (19.6 to 22.4), CDS=26.3 
(24.7 to 27.7) b) MCS: HRQL-CI=15.0 (14.3 to 
17.4), Char son=5.6 (4.7 to 6.6), 
E xhauser=14.3 (12.8 to 15.8), CDS=14.7 
(13.3 to 16.2) [163] 
Hea thcare costs, 
med cat on adherence, 
hosp ta sat on and 
outpat ent attendance. 
C-stat st cs for hea thcare 
costs: Char son=0.64 
(95% CI 0.62 to 0.66), 
E xhauser=0.70 (0.68 to 
0.71), CDS=0.65 (0.64 to 
-0.67).[164] 




44 3.7 Compared w th 
Chron c D sease 
Score and 
Char son ndex on 
s ng e cohort n 
or g na  paper. 
Later va dat on 
papers by 
d fferent authors 
Tested pred ct ve 
va d ty us ng odds 
rat os for 
outcomes 
At pred ct ng death and hosp ta  readm ss on, 
ORs (95% CI): MDBI=4.7 (1.4 to 15.5), 
CDS=1.13 (1.0 to 1.3), Char son=1.4 (1.2 to 
1.7). 
In externa  va dat on on 212 acute ger atr c 
npat ents, mean (SD) age 81 (7.3) years, 62% 
fema e, pred ct on of three-month morta ty  or 
readm ss on:  MDBI=2.99 (0.99 to 9.03), CIRS-
G=1.2 (1.1 to 1.3), Char son ndex=1.39 (1.12 
Se f-rated hea th. 
Reported as a stat st ca y 
s gn f cant assoc at on 
between MDBI scores 
and decreas ng se f-rated 


















Performance (original outcomes) Additional outcomes 
tested in external 
validation 
compared to 
CIRS-G, Char son 
and cond t on 
count [165] and 
tested assoc at on 
w th morta ty and 
se f-rated hea th 
[166] 
to 1.72), chron c d sease count=1.22 (1.08 to 
1.38).[165] 
In 776 cohort study part c pants (mean age 
83.5 years, 58% fema e), adjusted HR for 
morta ty=3.69 (95% CI 2.26-6.02) [166] 
Lee 2006 [9] * 656 54.7 Tested w th n 
or g na  paper on 
separate 
va dat on cohort 





va dat on by 
d fferent authors 
compared to 
Char son ndex 
[168] 
Ca brat on: 
compared 
pred cted w th 
actua  morta ty n 
der vat on and 
va dat on cohorts. 
D scr m nat on: 
ROC curves n 
der vat on and 
va dat on cohorts 
C-stat st cs for four-year morta ty: deve opment 
cohort=0.84, va dat on cohort=0.82. 
In fo ow-up of or g na  part c pants for pred ct ng 
ten-year morta ty, C-stat st c (va dat on 
cohort)=0.83 (0.82 to 0.84) [167] 
Externa  va dat on tested ten-year morta ty n 
735 pat ents undergo ng rad ca  cystectomy 
(med an age 67 years): HR (95% CI) per un t 
ncrease n nd ces: Lee=1.06 (1.00 to 1.12, 
P=0.04), age-ad usted Char son=1.08 (1.02 to 
1.15, P=0.01).[168] 
None 






200 15.4 Compared survey 
resu ts w th 
Char son and 
RxR sk nd ces n 
s ng e cohort n 
or g na  paper. 
Va d ty tested n 
three subsequent 
papers by 
d fferent authors 
[169–171] 
D scr m nat on: C-
stat st cs for se f-
reported d seases 
on y, not overa  
score 
For overa  hea th status score as outcome n 
or g na  paper, Spearman corre at ons 
DBMA=0.60 (P<0.001), Char son=0.48 
(P<0.001), RxR sk=0.17 (P=0.037). 132] In 
subsequent paper (307 part c pants, mean age 
59 years), Cronbach's a pha for nterna  
cons stency of the tota  DBMA score=0.69.[169] 
Subsequent va d ty paper created a near 
measure n 1,747 adu ts aged over 50 years. 
Spearman's corre at ons w th: phys ca  
funct on ng= −0.48, perce ved hea th=−0.47, 
depress on (score ≥3 on CES-D-10)=0.32, 
qua ty of fe −0.24 [171] 
Morta ty. 
F ve-year morta ty 
va dat on n 625 
commun ty-dwe ng 
adu ts aged ≥65 years for 
h gher compared to ower 
DBMA scores HR=1.07 



















Performance (original outcomes) Additional outcomes 
tested in external 
validation 
Pope 2004 [152] 








731 52.2 In s ng e cohort n 
or g na  paper, 
compared to r sk 
adjustment mode  
PIP-DCG. 
Eva uated 
pred cted versus 
actua  costs n 
subsequent 
papers by 
externa  groups 
172,173] and 
report by or g na  
authors [174] 
Ca brat on: Tests 
of pred cted 
versus actua  
costs; pred ct ve 
rat os g ven 
In or g na  paper, R2 for one-year expend ture: 
age-sex mode  1.0%, PIP-DCG 6.2%, 
DCG/HCC 11.2%.[152] 
 
Among 1,441,247 Med care benef c ar es, rat o 
of pred cted to actua  hea thcare costs n a  age 
and gender groups=1.000 [174] 
Morta ty. 
In 170,342 pat ents 
adm tted to hosp ta  
(mean age 78 years, 60% 
fema e), C-stat st cs for 
s x-month morta ty: CMS-
HCC=0.72 (P>0.05), 
Char son=0.71 (P<0.05), 
E xhauser=0.70 (P<0.05) 
[172] 
Hosp ta sat on 
In 83,187 managed care 
pat ents w th mean age 
46.9 years, 54.6% 
fema e, c-stat st c for 
pred ct ng 
hosp ta sat on=0.67, 
emergency v s ts=0.58 
[173] 





966 64.4 In s ng e samp e 
n or g na  paper, 
tested corre at on 
w th Char son 
ndex. Va dated 
n two ater 
papers by 
d fferent authors 
[175,176] 
None In or g na  paper, Spearman coeff c ents for a) 
corre at on between SCQ and Char son 
ndex=0.32 (0.55 when truncat ng to conta n 
on y comparab e tems); b) number of 
prescr pt ons at one year, SCQ=0.37, 
Char son=0.02; c) frequency of doctor v s ts: 
SCQ=0.15, Char son=0.09.  R2s for a) PCS at 
one year: Char son="non-s gn f cant", 
SCQ=0.22 (69.3% var at on exp a ned by 
comorb d ty); b) MCS: SCQ and Char son both 
"non-s gn f cant". [133] 
In externa  va dat on of 525 pat ents after acute 
coronary syndrome (mean (SD) age 59.7 (12.0) 
years, 36.4% fema e), R2 for EQ-5D scores at 
e ght months: Char son=0.25 (P=0.132), 
SCQ=0.27 (P<0.001); Act v ty Status Index, a 



















Performance (original outcomes) Additional outcomes 
tested in external 
validation 
CCI=0.37 (P<0.001), SCQ=0.36 
(P<0.001).[175] 
In 98 outpat ents w th anky os ng spondy t s 
(mean (SD) age 53.9 (11.4) years, 29.6% 
fema e), Spearman coeff c ents for a) 
corre at on between SCQ and Char son=0.24; 
b) PCS: SCQ= -0.45, Char son= -0.17; b) MCS: 
SCQ= -0.10, Char son=0.09 [176] 
Parkerson 1993 
[137] Duke 
Severity of Illness 
Checklist 
(DUSOI)* 
193 7.7 Compar son 
between 
c n c ans  rat ngs 
and aud tor for 
nter-rater 
re ab ty n s ng e 
samp e n or g na  
paper. Not 
compared to 
another sca e. 
Pred ct on of one-
year hea thcare 
usage tested n 
ater paper by 
same authors 
[177] 
None Intrac ass corre at on coeff c ents (ICC) of 
agreement for prov der-comp eted ana ogue 
sca e of overa  ness sever ty for: DUSOI 
prov der overa  sever ty scores=0.61 
(P<0.001); DUSOI aud t check st scores=0.42 
(P<0.001). 
Externa  va dat on tested nter-rater re ab ty n 
14 sets of records by 33 c n c ans 178]: 
ICC=0.43 (95% CI 0.27 to 0.61). 
 
Hea thcare usage. 
In 1,202 pr mary care 
pat ents (mean (SD) age 
47.6 (16.6) years, 65.0% 
fema e), ad usted R2 
var ance exp a ned by 
DUSOI n a  hea thcare 
v s ts =0.05.[177] 
Von Korff [148] 
Chronic Disease 
Score* 
942 36.2 Compared w th 
phys c an rated 
sever ty sca e n 
p ot samp e and 
separate random 
samp e. 
Compared w th 
ADGs for cost 
pred ct on n ater 
paper by the 
same authors 
[179] 
None In or g na  paper, Pearson corre at on between 
CDS and phys c an-rated phys ca  d sease 
sever ty n p ot samp e (n=219) r=0.57, n 
second samp e (n=722) r=0.46.[148] 
A so used as comparator when deve op ng 
severa  other nd ces [123,129,147] 
Hea thcare costs. 
In ater paper  exam n ng 
254,694 managed care 
enro ees (no 
demograph cs ava ab e), 
ord nary east squares 
regress on R2s exp a n ng 
var ance n s x-month 
tota  cost for age and 
sex=0.02, CDS ad usted 
for age and sex=0.09, 
ADGs ad usted for age 


















Performance (original outcomes) Additional outcomes 
tested in external 
validation 
CDS (d fferent we ght ng 
method) ad usted for age 




574 21.3 In or g na  paper, 
compared 
d str but on of 
d agnost c groups 
n subsamp es 
from across f ve 
hea thcare 
prov ders. Severa  
externa  
va dat ons by 
d fferent authors 
test ng cost 
pred ct on, 
hea thcare use 
and morta ty 
[180] 
None In or g na  paper, for pred ct ng one-year tota  
costs, adjusted R2s: age group + sex=0.04, age 
group, sex, b nary ADG=0.19, 51 
ACGs=0.15.[153] 
Mu t p e externa  rev ews n d fferent sett ngs 
test ts pred ct ve va ue.[180] 
In one cohort of 59,384 Med ca d members (no 
demograph cs g ven), AUC for 90th percent e 
of costs: Chron c ness and d sab ty payment 
system (CDPS)=0.69 (95% CI 0.67 to 0.70), 
d agnost c cost groups (DCG)=0.75 (0.74 to 
0.76), ACG-PM vers on 7.0 (ad usted c n ca  
groups- pred ct ve mode  [an adaptat on])=0.79 
(0.78 to 0.80).[181] 
Morta ty. 
In popu at on of 
10,498,413 adu ts 
(med an age 46 (IQR 34-
59) years, 51% women), 
one-year morta ty C-
stat st cs: age + 
sex=0.88, Char son=0.91, 
32 ADGs=0.87, age, sex 




29408 948.6 Tested w th n 
or g na  paper on 
separate 
va dat on cohort. 
Compared w th 
Kap an-Fe nste n 
method. 
Extens ve y 
va dated and 
used e sewhere 
by d fferent 
authors, often as 
comparator when 
generat ng new 
nd ces 
D scr m nat on: 
Kap an-Me er p ots 
of morta ty w th 
d ffer ng ndex 
eve s compared 
to Kap an-
Fe nste n method 
W th n or g na  paper, RR for one-year morta ty 
for: ncreas ng Char son ndex by 1 po nt=2.3 
(95% CI 1.9-2.8), each decade of age=2.4 (2.0-
2.9) In surv va  ana ys s, var ance exp a ned: 
Char son=0.41, Kap an-Fe nste n=0.41.[120] 
A so used as comparator for many other nd ces 
sted n th s tab e 
[1,3,4,5,7,10,11,32,35,40,41,47,49,60] 
Severa  other outcomes 
tested nc ud ng HRQL, 
med cat on use, ength of 
hosp ta  stay, readm ss on 
[117] 
Linn 1968 [154] 
Cumulative Illness 
1863 37.3 Va dat on br ef y 
ment oned n 
or g na  paper. 
None Or g na  study reports that "tota  scores 
corre ated w th death, v ta  organ nvo vement, 
In study of 181 ger atr c 
npat ents (mean (SD) 


















Performance (original outcomes) Additional outcomes 





va dated n 
severa  p aces by 
d fferent authors 
[183–186] 
number of prev ous nesses at P<0.01" (but 
not age) w th no further deta s.[154] 
 
corre at ons between 
or g na  CIRS and 
act v t es of da y v ng r=-
0.49 (P<0.001), pat ent 
mora e= -0.30 (P<0.001), 
days n hosp ta =0.21 
(P=0.001), number of 
med cat ons=0.31 
(P<0.001).[183] 
In compar son of 238 
adu ts n pr mary care 
(mean (SD) age 59.0 
(14.3) years, 71.0% 
fema e), Pearson 
corre at on coeff c ents for 
PCS: CIRS= -0.54 
(P<0.01), Char son= -
0.31 (P<0.01).[186] 
In 103 npat ents aged 
90-99 years (mean age 
92 years, 71% fema e), 
CIRS corre ated w th 
ength of hosp ta  stay, 
Pearson s r=0.4, 
P<0.05.[185] 
Among 439 res dents of a 
care fac ty w th mean 
(SD) age 84.1 (5.7) 
years, 72.4% fema e, 
CIRS corre ated w th 
funct ona  d sab ty 
accord ng to Phys ca  
Se f-Ma ntenance Sca e 
r=0.322 (P=0.001) and 
tota  number of 






* Indices that have an updated or modified version available 
Abbreviations in eTables 9 and 10:
APR-DRGs: A  Pat ent Ref ned D agnos s Re ated Groups 
AUC: Area under the Curve 
CDS: Chron c D sease Score 
CES-D: Center for Ep dem o og c Stud es Depress on sca e 
CI: Conf dence nterva  
CIRS-G: Cumu at ve I ness Rat ng Sca e – Ger atr c 
EQ 5D: EuroQo  f ve-d mens on measure of hea th status 
EQ VAS: EuroQo -v sua  ana ogue sca e 
HR: Hazard rat o 
HRQL: Hea th-re ated qua ty of fe 
IDI: Integrated d scr m nat on mprovement 
mFI: Mu t morb d ty Fra ty Index 
mHCC: Mod f ed H erarch ca  Cond t on Categor es 
mCCI: Mod f ed Char son Comorb d ty Index  
MCS: Menta  Component Score of SF-36 
NEADL: Nott ngham Extended Act v t es of Da y L v ng Sca e 
NRI: Net rec ass f cat on mprovement  
OR: Odds rat o 
PCS: Phys ca  Component Score of SF-36 
PIP-DCG: Pr nc pa  Inpat ent D agnost c Cost Group Mode  for Med care R sk 
Ad ustment 
QOF: Qua ty and Outcomes Framework 
ROC: Rece ver Operat ng Character st c 
RR: R sk rat o 
RxR sk: A rev s on and expans on of the Chron c D sease Score (w th and w thout 
Veterans  adaptat on) 




eTable 11: Index updates and adaptations  




Aim compared to 
original index 
Details Performance or comparison 
Mukherjee 2011 [129] 
Health-Related Quality of Life 
Comorbidity Index (HRQL-CI) 
Ou 2016 [187] Measur ng hea th-
re ated qua ty of fe 
(same as or g na ) 
Comb nes phys ca  and menta  subsca es of 
or g na  measure nto one sca e 
Regress on coeff c ents for a) genera  hea th: 
ref ned HRQL-CI=0.25, Char son=0.10 b) 
SF-6D: ref ned HRQL-CI=0.25, 
Char son=0.09; c) EQ-5D: ref ned HRQL-
CI=0.28, Char son=0.06 
Newman 2008 [150] 
Physiologic Index of 
Comorbidity 
Mod f ed 
Phys o og c Index 
[188] 
Pred ct ng morta ty 
(same as or g na ) 
Adapted to nc ude more eas y ava ab e 
measures n ep dem o og ca  stud es. 
Parameters: systo c b ood pressure, forced 
v ta  capac ty, D g t Symbo  Subst tut on Test 
score, serum cystat n-C, serum fast ng 
g ucose 
C-stat st cs for morta ty (mean fo ow-up 9.3 
years): Unadjusted ndex=0.66 (95% CI 0.64 
to 0.68), Age a one=0.59 (0.57 to 0.61), 
Index + age=0.67 (0.65 to 0.69) 
Hea thy Ag ng 
Index [189] 
Pred ct ng morta ty 
(same as or g na ) 
Adapted for use n ep dem o og ca  stud es. 
Components nc ude: systo c b ood 
pressure, pu monary v ta  capac ty, 
creat n ne, fast ng g ucose, and Mod f ed 
M n -Menta  Status Exam nat on (MMSE) 
score 
C-stat st cs for morta ty (med an fo ow-up 
12.8 years): ndex a one=0.64 (0.63 to 0.66), 
age a one=0.70 (0.68 to 1.72) 
Lee 2006 [9] Kobayash  2016 
[190] 
Pred ct ng ten-year 
morta ty (compared 
to four n or g na  
ndex) 
We ghted to pred ct ten-year morta ty. 
Ass gns d fferent we ghts to age, nc udes a 
var ab e on ack of phys ca  act v ty. Exc udes 
some var ab es from or g na  ndex (d abetes, 
BMI<25 kg/m2, d ff cu ty bath ng) 
AUC for ten-year morta ty n va dat on 
cohort, w th new ndex=0.84, w th or g na  
ndex=0.81 
Bayliss 2005 [132] 
Disease Burden Morbidity 
Assessment 
Bay ss 2009 [191] Pred ct ng genera  
hea th/d sease 
burden (same as 
or g na ) 
Inc uded 21 cond t ons nstead of or g na  25 
(exc udes ver d sease, k dney d sease, 
a coho sm, nerve cond t ons) 
Corre at on coeff c ents w th Char son-
Quan=0.23 (P<0.001) and CDS=0.26 
(P<0.001) 
Po tras 2012 [192] Pred ct ng genera  
hea th/d sease 
burden (same as 
or g na ) 
Added depress on to 2009 adaptat on 
cond t ons and trans ated nto Canad an 
French 
Compared w th CIRS two weeks after n t a  
assessment, Pearson corre at on 
coeff c ent=0.56 (0.38 to 0.70, P<0.01) 
Pope 2004 [152] 
The Centers for Medicare and 
Medicaid Services’ 
Regu ar updates 
[193] 
Pred ct ng hea thcare 
expend ture (same as 
or g na ) 
Updated annua y w th amended ICD-10 
mapp ngs and software 
Regu ar reports; 2018 report sts deta ed 
pred ct ve expend ture accuracy for 
comb nat ons of cond t ons of CMS-HCC.[69] 








Aim compared to 
original index 
Details Performance or comparison 
Hierarchical Condition 
Category (CMS-HCC) 
expend ture=1.00 (but g ves caveat that th s 
s an average n a very arge group) 





Pred ct ng hea th-
re ated qua ty of fe 
( nc uded n or g na ) 
Adapted for peop e w th system c 
auto mmune d seases: removed rheumato d 
arthr t s from cond t on st 
Kenda s Tau b corre at on between SCQ 
and a) PCS: System c sc eros s= -0.26, 
system c upus= -0.31 b) MCS: System c 
sc eros s= -0.14, system c upus= -0.12 
Sr dharan 2014 
[195] 
Pred ct ng morta ty 
(d fferent from 
or g na ) 
Adapted for pat ents w th end-stage rena  
d sease: added e ght preva ent cond t ons n 
th s group and space for free-text answers; 
removed quest on on k dney d sease 
AUC for 18-month morta ty: mod f ed 
SCQ=0.72 (0.65 to 0.80), Char son=0.75 
(0.68 to 0.82) 
Desai 2002 [134] 
High-Risk Diagnoses for the 
Elderly Scale (HRDES) 
Burden of I ness 
Score for E der y 
Persons (BISEP) 
[196] 
Pred ct ng morta ty 
(same as or g na ) 
Added serum a bum n and creat n ne, 
dement a and wa k ng mpa rment to ten 
we ghted cond t ons from HRDES 
C-stat st cs for one year morta ty n 
va dat on cohort: HRDES=0.59, BISEP=0.77 
Greenfield 1995 [136] 
Total Illness Burden Index 
(TIBI) 
TIBI-P [197] Pred ct ng hea th-
re ated qua ty of fe 
(same as or g na ) 
and morta ty 
(d fferent) 
Mod f ed for men w th prostate cancer. 
Reduced doma ns on some tems, nc uded 
d abetes and non-prostate cancers 
R2 for PCS: ad usted TIBI-P=0.35, 
demograph cs a one=0.16. 3.5-year 
morta ty: adjusted HR for h ghest scor ng 
group compared to owest=13.1 (6.3 to 27.4) 
[198] 
Parkerson 1993 [137] 
Duke Severity of Illness 
Checklist (DUSOI) 
Duke Case-M x 
System (DUMIX) 
[199] 
Pred ct ng hea thcare 
expend ture (d fferent 
from or g na ) 
Adds demograph c nformat on and se f-
reported funct ona  hea th status to DUSOI 
Var ance n future c n c charges exp a ned 
by DUMIX=17.1%, age + gender a one=9.1% 
Von Korff 1992 [148] 
Chronic Disease Score 
Rx-R sk [200] Pred ct ng hea thcare 
expend ture 
(hea thcare use 
nc uded n or g na ) 
We ghted drug groups ncreased to 57 from 
25 n CDS. Inc udes ch dren. W de y used 
and va dated 
In or g na  paper, cost var ance exp a ned 
(R2): RxR sk=8.7%, CMS-HCCs=15.4%, 
ACGs=10.2%. 
In ater va dat on, C-stat st cs for one-year 
morta ty: we ghted RxR sk=0.79 (0.78 to 
0.79) [201] 
Rx-R sk-V [202] Pred ct ng hea thcare 
expend ture 
(hea thcare use 
nc uded n or g na ) 
Adapted for use n veteran popu at on and 
updated to nc ude newer drugs. Inc udes 45 
drug c asses 
Or g na  paper quotes var ance exp a ned 
(R2) for concurrent costs=0.18 and 
prospect ve costs=0.10. Compared to other 









Aim compared to 
original index 
Details Performance or comparison 
McGregor 2006 
[203] 
Pred ct ng spec f c 
d agnoses (d fferent 
from or g na ) 
Adaptat ons for nosocom a  nfect ous 
d seases: MRSA and VRE. Comb ned ndex 
(CDS-ID) conta ns s x cond t ons 
C-stat st cs for pred ct ng MRSA d agnos s: 
CDS-ID=0.57, CDS=0.52; for pred ct ng VRE 
d agnos s: CDS-ID=0.64, CDS=0.57 
Starfield 1991 [153] 
Ambulatory Care Groups 
Regu ar ongo ng 
updates [204] 
Pred ct ng hea thcare 
expend ture (same as 
or g na ) 
Updates to d sease markers, v s t 
c ass f cat ons and software. Vers on 12.0 
re eased March 2019 
See eTab e 10 
Charlson 1987 [120] Deyo 1992 [205] Pred ct ng morta ty 
(same as or g na ) 
and other outcomes 
A gned cond t ons w th ICD-9 codes. 
Comb ned eukaem a/ ymphoma w th other 
ma gnanc es g v ng 17 cond t ons 
Used as comparator n other stud es – see 




Pred ct ng morta ty 
(same as or g na ) 
Adapted for use w th adm n strat ve data 
us ng ICD-9-CM codes; broader def n t ons 
than Deyo 
Compared to other sca es n or g na  Far ey 
paper (see eTab e 9) [151] 
D Hoore 1993 
[207] 
Pred ct ng morta ty 
(same as or g na ) 
Uses f rst three d g ts of ICD-9 In th s paper, C-stat st c for n-hosp ta  
morta ty=0.83 
Gha  1996 [208] Pred ct ng morta ty 
(same as or g na ) 
Ass gns new we ghts to Deyo s system, 
accord ng to study-spec f c morta ty. 
Inc udes on y f ve cond t ons 
In th s paper, C-stat st c for n-hosp ta  
morta ty=0.74, or g na  Char son ndex=0.70 
Quan 2005 [209] Pred ct ng morta ty 
(same as or g na ) 
Adapted for ICD-10, nc udes 12 cond t ons. 
Later rev s on ass gns new we ghts to 
cond t ons [210] 
In th s paper, C-stat st cs d scr m nat ng n-
hosp ta  morta ty n one cohort: Quan=0.83, 
or g na  Char son=0.81 
Linn 1968 [154] 
Cumulative Illness Rating 
Scale (CIRS) 
CIRS-G [211] Pred ct ng overa  
ness sever ty (same 
as or g na ) and 
funct ona  mpa rment 
(d fferent) 
Mod f ed for o der popu at on. Added 
haematopo et c category, c ar f ed where to 
st dement a and breast d sorders. On ne 
ca cu ators ava ab e w th examp es [212] 
W de y used. Th s paper reports Spearman 
corre at on between CIRS-G and a) OARS 
ADL=0.58 (P<0.02) and b) ncreas ng overa  
med ca  mpa rment=0.45 (P=0.002) 
CIRS-SA [213] Pred ct ng overa  
ness sever ty (same 
as or g na ) 
Substance abuse vers on. Has 13 tems 
nc ud ng HIV status and gu dance on where 
to record hepat t s. Removed psych atry 
category 
Cronbach s coeff c ent for nterna  
cons stency=0.57. Kenda s tau for 
agreement between overa  CIRS-SA and 
consu tant assessment of ness 
sever ty=0.58 (P<0.01) 
M stry 2004 [214] Pred ct ng morta ty 
(d fferent from 
or g na ) 
Two subsca es, nc ud ng (CIRS-IP) and 
exc ud ng (CIRS-PH) acute cond t ons 
Cox proport ona  hazards regress on for age-
adjusted days of surv va , standard sed β 
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Abbreviations in eTable 11: 
AUC: Area under the curve 
BMI: Body mass ndex 
EQ-5D: EuroQo  f ve-d mens on measure of hea th status 
ICD-9-CM: Internat ona  C ass f cat on of D seases, N nth Rev s on, C n ca  Mod f cat on 
ICD-10: Internat ona  Stat st ca  C ass f cat on of D seases and Re ated Hea th Prob ems 10th Rev s on 
MCS: Menta  Component Score of SF-36 
MRSA: Meth c n-res stant Staphylococcus aureus 
OARS ADL: O der Amer cans Resources and Serv ces Act v t es of Da y L v ng Sca e 
PCS: Phys ca  Component Score of SF-36 
SF-6D: Shortened rev sed vers on of SF-36 
VRE: Vancomycn-resstant enterococc 
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Appendix lay summary - “Ways of measuring multiple conditions” 
 
Title of research article: Measuring multimorbidity beyond counting diseases: 
systematic review of community and population studies and guide to index choice. 
This research is funded by the Medical Research Foundation and the Medical 
Research Council through a grant to Dr Lucy Stirland. 
 
What is a systematic review? 
A systematic review is a common type of research. It’s a way of finding lots of 
published research articles and summarising them together.  
 
What do we know about this topic already? 
It’s common for people to have two or more chronic conditions at once. This is often 
called multimorbidity. Researchers and clinicians measure multimorbidity in many 
different ways.  
 
What questions does this review ask? 
1. What methods exist for measuring multimorbidity?  
2. How good are they? 
3. Do they include mental health? 
 
How was the search carried out? 
We decided in advance which topics to include. In October 2018, we searched seven 
online medical research databases.  Two researchers separately checked 5,560 
article titles. We discarded irrelevant articles. 
 
What did the review find? 
We ended up with 35 papers, each describing a way to measure multimorbidity. Most 
of them combined the number of chronic conditions with other things like age. Some 
counted people’s prescribed drugs and others included medical test results.  
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Most of the tools aimed to predict health in some way. For example, 18 of them looked 
at death rates, 13 at hospitalisations and six at quality of life. 
Nearly all the papers considered mental health, with 18 counting it as part of 
multimorbidity. Eleven measures aimed to predict some aspect of mental health. 
Only one paper mentioned including patients in their research design. 
 
How good were the papers? 
We graded each paper according to set standards. Six were high quality, 22 were 
satisfactory and seven were low quality. Three of the papers didn’t mention who 
funded their research. Four were funded by drug companies – this might make them 
biased. The other 28 papers had no funding bias. 
 
What does this mean for patients? 
These tools might help make other research more relevant to people with multiple 
conditions. For example, drug trials use very healthy people who are not like most 
patients. Researchers could use these tools to account for multimorbidity in a wider 
range of people. 
Healthcare officials can also use the tools to predict how services will be used and 
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Reprinted from The BMJ, Vol 368: m160. Stirland Lucy E, González-Saavedra Laura, 
Mullin Donncha S, Ritchie Craig W, Muniz-Terrera Graciela, Russ Tom C. Measuring 
multimorbidity beyond counting diseases: systematic review of community and 
population studies and guide to index choice, under the terms of the Creative 
Commons Attribution (CC BY 4.0) license. The publication is available through The 
BMJ at http://dx.doi.org/10.1136/bmj.m160.  
 
2.4 FURTHER DISCUSSION 
Of the 35 indices found, we recommended 12 which would be most relevant for use 
in research. As emphasised in the paper, it is crucial to take into account the 
population in question and the outcomes of interest when employing an index. I detail 




My search strategy included a variety of synonyms for multimorbidity in order to 
capture as many relevant papers as possible. This could have introduced ambiguity, 
however, as there may be nuances of meaning between terms. For example, the term 
‘polypathology’ is linked to the French expression polypathologie en cascade. This 
concept suggests a number of conditions that flow from an original index condition, 
also known as concordant multimorbidity.[2] However, when reviewing the final 
papers this was not an evident issue as they all used the terms multimorbidity, 
comorbidity and polypathology to denote the same state or concept. 
 
Throughout the paper, I used the term ‘multimorbidity’ even when some indices 
referred to themselves as comorbidity 
indices.[120,123,150,151,129,132,133,135,137,141,143,146] I had included 
‘comorbidity’ as a search term as it is sometimes used to mean multimorbidity.[2] In a 
paper published by Dutch primary care researchers in 1996, there was a call to 
differentiate between comorbidity (implying the presence of an index disease) and 
multimorbidity (the general state of having multiple conditions).[2] However, even in 
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papers published since then, there continued to be instances where the word 
comorbidity was used to mean both.[215] In addition, I uniquely used the term ‘index’ 
for consistency, as suggested by a peer reviewer, where some of the papers did not 
technically generate an index and would be better described as a tool, measure or 
model. Four papers compared several models [127,143,144,151] and one was mostly 
designed around information gathering rather than quantifying multimorbidity.[139] 
These dissimilarities in terminology may have led to some papers being considered 
in line with weighted indices when they were not intended to be used in this way. 
 
Another terminology issue is that one index included is titled the Multimorbidity Frailty 
Index, but does not measure frailty.[138] It counts ‘deficits’, which are usually included 
in definitions of frailty, but the ‘deficits’ mentioned are actually conditions, so it 
measures multimorbidity alone. Although the concepts of multimorbidity and frailty 
have some overlap, as explained in section 1.2.7, they measure different states and 
are not equivalent.[216] This is a limitation of that particular paper, rather than my 
work. 
 
2.4.2 Search limitations 
2.4.2.1 Contemporaneity 
As with all systematic reviews, conducting a formal literature search and screening all 
the resulting titles means that research published after the search date is missed. This 
is a particular risk in such a dynamic and growing research field as multimorbidity. I 
originally submitted the paper to The BMJ in July 2018 based on a search conducted 
in August 2017. The first round of editorial board review recommended an updated 
search, so I ran the search again using the same strategy in October 2018. Since 
then, however, there have been at least two papers published presenting new indices, 
despite the field being seemingly saturated already. 
 
In the first of these new papers, Constantinou and colleagues proposed two new 
indices, the Mortality-Related Morbidity Index (MRMI) and the Expenditure-Related 
Morbidity Index (ERMI).[217] These include 16 conditions, gender and age, all 
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weighted based on the outcomes stated in the name of each index. Secondly, 
Quinzler et al. developed a medication-based Chronic Disease Score (medCDS) 
using drugs as markers for common chronic conditions and weighting them according 
to their coefficients for association with mortality.[218]  
 
The Cambridge Multimorbidity Score is another new index.[219] It includes 37 
weighted conditions and was designed around three outcomes: primary care 
consultations, unplanned hospital admissions and mortality. Each of these outcomes 
carries its own weights in the index. The heterogeneity between indices’ derivation 
and use of weighting is further discussed in Chapter 3. 
 
A new solution to the issue of review searches becoming dated quickly is the living 
systematic review approach, which usually involves monthly updated searches and 
combines human paper selection with machine automation.[220] This would not have 
been feasible within the scope of this PhD but is a promising technique for the future 
of systematic reviews. 
 
2.4.2.2 Limitations in search terms 
My search strategy did not find the Multimorbidity Interaction Severity Index, 
published in 2017, which is described as a web-based decision support tool, designed 
for use with individual patients.[221] The search terms referring to community or 
population studies may have obscured this reference from emerging during the 
search, and it was not found in the citation searching. This index could be practical as 
the majority of multimorbidity indices are best used in research or service planning 
rather than with individual patients.[222] In addition, a team of Canadian primary care 
researchers has developed a new questionnaire for gathering information from 
patients which would be useful in practice and was also not found by our search.[223] 
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I used the expression ‘rating scale’ in my search terms so may have missed tools that 
used the word ‘scale’ alone. I also did not include the term ‘score’ in my search 
strategy. This may have led to me missing the Complexity Score, which  includes a 
count of conditions and medications, but it is published in a journal that is not indexed 
in MEDLINE so would probably not have appeared in the search.[224] The article 
does not describe the list of conditions or medications from which the counts were 
derived.  
 
The MeSH term ‘multimorbidity’ was launched in January 2018, after my search 
strategy had been developed and pre-registered, so I did not use it; it should be 
included in future searches.[24] 
 
2.4.2.3 Research published in ‘predatory’ journals 
When reviewing citations, I came across the Institutionalization Comorbidity Index, 
which used prescription data to predict institutionalisation and was derived from a 
population of 61 172 community-dwelling older adults in Québec.[225] Although the 
paper was written by a bona fide group of pharmacy researchers, it was published in 
the Journal of Gerontology & Geriatric Research. This is one of many journals 
published by OMICS International, which is widely understood to be a predatory 
publisher with little to no peer review process.[226] The company has been 
successfully sued for deceptive academic practice by the US Federal Trade 
Commission.[227] I had not considered the possibility of finding predatory journal 
articles when designing my search. In discussion with my co-authors and reference 
to my pre-registered protocol, we agreed to exclude the paper as it did not emerge 
during formal citation tracking.  
 
As the predatory publishing field grows, there have been new recommendations to 
screen included papers for the journal’s quality and exclude those from predatory 
publishers from systematic reviews.[228] While this approach ensures that included 
papers are thoroughly peer-reviewed, it could also lead to the omission of genuine 
research unwittingly submitted to these less rigorous journals. 
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2.4.2.4 Potentially useful excluded indices 
Another commonly used tool is that developed by Gagne and colleagues in 2011, 
which combines elements from the Charlson and Elixhauser indices.[229] The paper 
did not meet our inclusion criteria as it did not include a novel index, and was 
additionally not discussed when reviewing updates as it clearly states its objective 
was to predict mortality by combining the two existing comorbidity indices. However, 
this index was developed to address the outdated list of conditions in the Charlson 
index so could be useful in practice. 
 
2.4.2.5 Limitations in assessing risk of reporting bias  
It is generally preferable to use a validated pre-existing quality or risk of bias 
assessment tool, but when planning the review, I searched the literature and did not 
find one that was suitable. A peer reviewer suggested the comprehensive Prediction 
model Risk Of Bias ASsessment Tool (PROBAST).[230] This is designed specifically 
for diagnostic and prognostic prediction models and was therefore not applicable to 
all the included indices. In addition, it was published after our review was pre-
registered. We therefore developed our own list of quality or reporting bias questions 
based on available resources. We aimed to keep the list relatively concise so that 
readers could refer to it easily. This approach drew criticism from some peer 
reviewers, who pointed out that the list included mostly reported details and was less 
sensitive at detecting bias or assessing quality. We did consider removing mention of 
the tool, but kept it in accordance with PRISMA recommendations that risk of bias 
within and across studies be assessed and reported.[115] Instead of using a new tool 
post-hoc, we included more detail on index development and validation elsewhere in 
the paper. This allowed in-depth comparisons between the indices’ methods and 
application that would not be as clearly captured using a risk of bias tool. 
 
Our overall recommendations for index use, which were an addition requested by 
peer reviewers, drew on the risk of bias assessment, generalisability and validation 
results. However, they had the limitation of being subjective.  
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2.4.2.6 Further limitations 
My search focused only on studies of multimorbidity and excluded those that centred 
on an index condition. A 2016 systematic review of multimorbidity definitions found 
that a small number of studies used comorbidity indices, developed around an index 
disease, that were not designed to measure multimorbidity.[119] When using an index 
disease, for example studying the comorbidities of patients with coronary artery 
disease, these people still have multimorbidity but it has been approached from a 
specific viewpoint. My justification for focusing only on multimorbidity was to include 
all relevant people, not only those selected due to having a particular diagnosis. Two 
of the final included studies in my review were developed in populations of people 
with specific diseases,[136,151] but their focus was on multimorbidity rather than 
comorbidities alongside these conditions. However, we excluded multimorbidity 
indices that were developed in a cohort with a specific disease, even if they were later 
useful for measuring multimorbidity, for example the Index of Co-existent Disease, 
whose original patients were undergoing total hip replacement.[231] This is a 
limitation of the resulting list of indices we generated, but our focus was on the 
methodology and design of original studies, rather than their eventual uses. 
 
We excluded studies that measured multimorbidity within a single disease area. A 
2018 analysis of the use of the term ‘multimorbidity’ within the literature found that it 
was most prevalent within psychiatric publications.[87] Its use there is as a 
replacement for the previous concept ‘dual diagnosis’, usually referring to the co-
existence of substance use disorders with another psychiatric disorder.[232] Using 
multimorbidity in this context reminds psychiatrists that although patients in drug trials 
may only have one mental disorder, in reality this is rarely the case. However, studies 
on multimorbidity within psychiatry usually fail to capture physical comorbidities and 
as such do not fit with the definition of multimorbidity used elsewhere in research and 
in this thesis, which refers to the whole person.[232]    
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It is a limitation common to all systematic reviews that by setting and adhering to 
specific inclusion and exclusion criteria, occasionally important or prominent studies 
will be excluded.[113] 
 
2.4.3 Comparison of indices 
One peer reviewer suggested conducting a direct comparison of the indices’ 
performance at predicting certain outcomes. This would have been difficult due to the 
diversity of index components and predicted outcomes. Numerous studies have 
explored this question, and a systematic review of studies that compared any index 
to either the Charlson or Elixhauser index found 54 titles; this review is discussed 
further in section 3.2.5, page 99.[233] I therefore chose not to compare indices as this 
was not directly linked to my aim of identifying and summarising indices for measuring 
multimorbidity. 
 
2.4.4 Other relevant recent publications 
There have been two recent review articles on measuring multimorbidity, one a 
detailed narrative review [11] and the other documentation of an expert group 
discussion and consensus.[114] In the narrative review, Nicholson and colleagues 
recommended that researchers and clinicians pay attention not only to the original 
outcomes used in developing indices, but also the population in which they were 
derived, for example a cohort study or population-based sample.[11] They also 
highlighted the fact that multimorbidity indices are not usually designed to capture or 
predict multiple outcomes, and that in fact it may be sometimes be useful to use more 
than one index for different purposes in a study.[11,186] They considered the 
measurement of mental health within multimorbidity, which is generally under-
researched. The second review was a report from a meeting and survey of 29 
Canadian experts on ageing and multimorbidity research.[114] They emphasised that 
most indices do not address social factors contributing to outcomes for people with 
multimorbidity, or conditions that vary in severity over time. Similarly to my review, 
they concluded that there is not a single multimorbidity measure that is universally 
suitable and that researchers should find one that fits the study purpose and includes 
an appropriate list of conditions.  
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2.5 CHAPTER CONCLUSIONS 
This chapter has presented a comprehensive review of indices for measuring 
multimorbidity. The commonest, and often most practical, method of measuring 
multimorbidity is counting diagnoses. This, along with other methodological issues, 
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Chapter 3 Methodological issues when measuring 
multimorbidity 
3.1 INTRODUCTION 
Chapter 2 consisted of a review of multimorbidity measurement methods. Most 
papers included in the systematic review used weighted indices, with weights 
generated in diverse ways. This chapter explores the methods of developing indices 
in more detail, including their limitations. There are several other ways to quantify 
multimorbidity. Disease counts are the most commonly used and warrant 
methodological consideration, for example regarding the length and content of lists of 
candidate conditions.[112,119] This chapter also outlines alternative data-driven 
methods such as clustering and network analyses, before concluding with justification 
of the methods I used in data analysis in Chapters 4, 5 and 6. 
 
3.2 ISSUES WITHIN MULTIMORBIDITY INDICES 
3.2.1 Weighting methods 
Among the 35 indices studied in the previous chapter, 29 used some form of weighting 
for the index components, whether they were diseases, drugs or other parameters. 
Twelve of these used relatively subjective ratings of condition severity, either as 
decided by clinicians,[136,137,141,148,149,153,154] or reported by 
patients,[132,133,135] based on previous research,[147] or on abnormality of 
physiological markers.[150] Depending on the outcome of interest, self-report can be 
an appropriate weighting method. For example, the Disease Burden Morbidity 
Assessment (DBMA) asks patients to report which conditions they have from a list of 
25, and their relative interference with daily activities.[132] This is relevant to the 
predicted outcomes, which include self-rated health. Weighting by subjective 
measures of disease severity was commoner in older papers, whereas more recent 
indices tended towards more objective models. One older example is the widely-used 
Chronic Disease Score, developed in 1992 to predict mortality and hospitalisation, 
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The most common method for deriving weights in indices is to attribute a score for 
each condition based on its association with the outcome in question. Among indices 
that used this approach, the majority used regression coefficients for weighting. As 
listed in eTable 7 of section 2.3, these indices summed the coefficients for each 
parameter (either raw or rounded to integers) to generate the overall 
score.[9,10,152,155,123,125,127,129,130,142,145,146] These coefficients were 
primarily from survival analyses, but as noted on page 30, in some indices, the 
weights were generated based on cross-sectional analyses and then used to predict 
longitudinal outcomes.[9,141,147,154] This may limit their validity when used in this 
way.  
 
Table 3-1 shows an example weighting method: that used in the Charlson Index.[120] 
For each condition the patient has, the weight for that condition is added to create an 
overall score. An illustrative patient with dementia, diabetes (with no end-organ 
damage) and a peptic ulcer would receive a score of 3. 
Table 3-1: Weights used in Charlson Index [120] 
Condition Assigned weight 
Myocardial infarct 1 
Congestive heart failure 
Peripheral vascular disease 
Cerebrovascular disease 
Dementia 
Chronic pulmonary disease 
Connective tissue disease 
Ulcer disease 
Mild liver disease 
Diabetes 
Hemiplegia 2 
Moderate or severe renal disease 




Moderate or severe liver disease 3 
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3.2.2 Methodological limitations of the Charlson Index 
In five of the studies included in my systematic review, weights for each index 
component were generated using a hazard ratio, odds ratio or relative 
risk.[120,126,128,131,134] The index developed by Charlson and colleagues is the 
most prominent and commonly applied for measuring multimorbidity and uses this 
approach.[112,120] There has been some dissent about the validity of deriving index 
weights by summing hazard ratios. Charlson and colleagues’ methods were first 
questioned in the Journal of Clinical Epidemiology in 1993, with Romano et al. pointing 
out that relative hazards are multiplicative, not additive, and that adding coefficients 
would better fit the underlying assumptions of the Cox model.[206] Following further 
debate in 1996, Dr Charlson wrote to the journal defending her index, saying that it 
had been able to predict a surprising range of outcomes and that:  
“The original index was never envisioned as the final definitive statement, but 
instead as an important foundation on which to build.” [234] 
 
Mehta and colleagues tested the importance of the limitations in Charlson’s work in 
2016.[235] They studied 766 208 general practice patients, comparing hazard ratio 
weights and coefficients from the original Charlson Index and different adaptations. 
Their own coefficients were from multivariate Cox proportional hazards models for 
one-year mortality. The authors reported that models using regression coefficients 
were slightly better at predicting mortality than those derived from hazard ratios.[235] 
In order to truly test the index’s predictive value, this paper kept Charlson’s original 
list of conditions, even though some of them (such as ulcer disease) were less 
relevant to mortality in 2016 than they were in 1987, when the original paper was 
published.[235,236] In the same 2016 issue of the Journal of Clinical Epidemiology, 
Dr Charlson criticised Mehta and colleagues’ methods and maintained that her 
weighting was valid.[237] The editors’ comment suggested that previous research 
using the Charlson Index should be re-evaluated. They emphasised that “using 
correct algebra is surely not up for debate.”[238] 
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3.2.3 Applicability of indices 
Many index weights were derived in specific populations, for example hospital 
inpatients or survey volunteers, and are less applicable to different groups such as 
population studies. To address this issue, Diederichs and colleagues aimed to 
calculate suitable weighting for ten chronic conditions using individual participant data 
from people aged 65 years and older in five population-based studies in 
Germany.[239] They generated the pooled odds ratios for reporting fair or poor health 
for each condition across all the studies. If there was sufficient similarity across 
studies, they considered that these ratios would be meaningful weights for a 
multimorbidity index. They listed each condition’s weight separately and did not 
propose adding all of them to create an overall score or index. However, this approach 
has two limitations. The first is transforming a Likert scale about self-rated health into 
a dichotomous variable, which not only assumes that a largely subjective measure 
can be split into two outcomes, but also loses statistical power.[240] The second is 
that the authors suggested that researchers sum odds ratios, with the resulting 
limitations discussed earlier.[239] In addition, using self-rated health as the outcome 
limits their usefulness in other studies, for example those predicting mortality, similarly 
to other indices.  
 
All multimorbidity indices are limited by the fact that they usually neglect to capture 
interactions between conditions, treatment effects and functional parameters. One 
commentator has remarked that the indices work based on the assumption that the 
functional decline preceding death is related to the patient’s comorbid conditions 
when in fact these processes may develop in parallel.[241] 
 
3.2.4 Rasch models 
An alternative method of attributing weights or scores to conditions is the Rasch 
model, originally developed for psychometric tests.[242] It is based on the theory that 
an individual’s outcome on a test is dependent on their attributes (for example, ability) 
and the difficulty of the test. It can be used to generate a linear score from categorical 
test items. None of the indices studied in Chapter 2 used this method, although a 
follow-up study of the DBMA tested its validity using Rasch analysis.[132] The authors 
found that according to this method, the index’s reliability was low. However, a linear 
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transformation of the total DBMA score generated using the Rasch model 
discriminated better between age groups than the original raw score.[171] The DBMA 
was designed to calculate disease burden by summing the interference of each 
condition with patients’ lives according to a Likert scale. For this reason, it is suited to 
psychometric test analysis. 
 
Another example of using Rasch models in multimorbidity research is in the 
development of the Multimorbidity Illness Perceptions Scale (MULTIPleS), a scale for 
measuring the perceived impact of multimorbidity.[243]8 The authors’ explanation for 
using Rasch analysis was to allow for comparisons between patients and across 
patients over time. Similarly to the DBMA, MULTIPleS used a Likert scale for each 
item of measurement. The Rasch approach is less likely to be relevant for indices that 
include binary markers for the presence or absence of conditions.  
 
3.2.5 Comparing indices 
Numerous studies have compared the performance of two or more multimorbidity 
indices at predicting specific outcomes (construct validity). The original Charlson 
Index and its later adaptations have been used in studies to illustrate the 
discrepancies between multimorbidity prevalence when using different 
measures.[186,244] They are also used as benchmarks in the development and 
validation of new measures, for example the Measuring Multimorbidity (M3) 
Index.[155,245]  
 
A systematic review published in 2011 found 54 articles that compared at least two 
comorbidity measures in administrative datasets.[233] Its search strategy specified 
that one of these must be the Charlson or Elixhauser Index.[246] The authors found 
that both methods predicted mortality better over longer (>30 days) rather than shorter 
periods, and that the Elixhauser index performed the best.[233] This review was very 
broad and included comorbidity with index diseases in addition to multimorbidity. 
 
8 This paper was not included in my systematic review as it focuses on measuring illness 
perceptions rather than multimorbidity itself. 
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Another systematic review of comorbidity indices for use in administrative data found 
76 papers in 2015.[117] Its search strategy was not limited to specific indices. A total 
of 35 studies used the Charlson Index or its adaptations as comparators and 24 
further studies compared other commonly used indices. This review provided a 
narrative description of the differences between indices rather than meta-analysing 
comparisons. Comparing indices has the benefit not only of testing each one’s validity 
but can also measure the robustness of multimorbidity prevalence estimates within 
large-scale studies. 
 
3.3 DISEASE COUNTS 
Chapter 2 reviewed methods of measuring multimorbidity beyond counting diseases. 
A previous systematic review of all methods of quantifying multimorbidity found that 
among 194 studies, 98 (51%) used disease counts.[112] As the authors observed, 
there is evidence to suggest that counts can perform as well as other measures and 
are often used for practical reasons.[143,151,247] A study comparing five count-
based measures found that continuous disease counts, either of all possible 
conditions or of those on the list from Barnett and colleagues, performed similarly to 
the Charlson Index and RxRisk-V at predicting hospital admissions and functional 
decline.[39,248] The developers of the Functional Comorbidity Index tried weighting 
conditions based on regression coefficients where functional ability was the outcome. 
This method provided similar explanations for variance in physical functioning to 
disease counts, so they chose to use counted conditions for ease.[249]9  
 
Counting conditions does have limitations. If each condition is allocated a count of 
one, i.e. is unweighted, this assumes they all have a similar impact on the patient. For 
example, there are likely to be differences in prognosis and illness experience 
between two patients who each have two conditions: a patient with treated 
hypertension and hypothyroidism may not be comparable to one with heart failure and 
dementia.[250] Disease counts do not capture the severity of individual diseases 
 
9 This index was also excluded from my review as its final model was an unweighted count. 
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either, which differ from person to person.[114]  This is often the rationale for using 
weighted indices as discussed in section 3.2.1.  
 
These limitations are relevant not only in continuous disease counts but also when 
considering a cut-off of two or more conditions to define multimorbidity. However, 
counts are easier to calculate than index scores, especially in large primary care or 
population studies where the impact of each disease on each patient is 
heterogeneous and difficult to measure. Where prevalence of multimorbidity is the 
main research question, or there is no clear defined outcome to guide the choice of 
an index, counts are the most suitable method.[39] In addition, using an index that 
includes weighting based on previous associations may in fact bias the results of a 
new study. As long as the list of conditions is justified, it is therefore appropriate to 
use counts in studies such as mine that examine under-researched areas with diverse 
outcomes. 
 
3.3.1 Justification of candidate conditions 
In all measures of multimorbidity, including weighted indices or unweighted disease 
counts, the list of candidate conditions should be clearly stated. Having a list clearly 
communicates what researchers mean by multimorbidity and permits comparison 
between studies.[251] Decisions on what constitutes multimorbidity and which 
conditions to include may be taken a priori, using a list published elsewhere, or as a 
result of evidence review.[118] 
 
Within the papers reviewed in Chapter 2, only one did not justify its choice of potential 
conditions.[144] This is less than would be expected from previous research; the 2011 
systematic review by Diederichs and colleagues found that among 39 studies using 
disease counts or indices, 59% did not specify the criteria for the selection of 
conditions.[113] The majority of studies reviewed in Chapter 2 used the conditions’ 
associations with their outcomes of interest to refine the list. The others used pre-
existing research, prevalence data, expert and clinician consensus or a combination 
of these approaches. One study considered any condition that each patient 
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reported.[199] Pragmatic reasons were also used, for example which conditions were 
asked about in the medical history of a cohort study or survey.[113,127] Whatever the 
process of list selection, it can always be considered arbitrary; the best approach is 
to give clear justification for which conditions were chosen. 
 
As well as how the list was developed, it is important to understand which conditions 
it includes. For example, ‘heart disease’ in one study may be separated into atrial 
fibrillation, coronary artery disease and arrhythmia in another study, thereby under-
estimating multimorbidity in one list compared to the other. Similarly, cancer may 
count as one condition or be separated by type. When generating a new list, another 
issue to consider is conditions directly caused by another disease, such as 
consequences of diabetes, and whether these should be treated as separate 
conditions.[113] There is no agreed solution to this problem, apart from to decide early 
in the study design process how to account for them.[252]  
 
To improve comparability between studies, Diederichs and colleagues proposed a list 
of eleven conditions to be included as a minimum in future indices.[113] The list was 
based on the use of these conditions in multimorbidity studies of people aged over 65 
years, and prevalence in this age group in Germany. The conditions are: cancer, 
diabetes mellitus, depression, hypertension, myocardial infarction, chronic ischaemic 
heart disease, heart arrhythmias, heart insufficiency [failure], stroke, chronic 
obstructive pulmonary disease, and arthritis. Missing from this list are thyroid 
disorders, any gastrointestinal conditions and common eye diseases such as 
glaucoma. In addition, myocardial infarction and stroke are acute conditions, which 
although may have important sequelae, do not in themselves meet the usual definition 
of chronic diseases. The list is therefore useful as a starting selection of conditions 
but should not be used alone.  
 
3.3.2 Counts using established lists of conditions 
A 2016 systematic review of multimorbidity definitions highlighted that among 163 
articles studied, 115 (71%) generated their own definition of multimorbidity with a 
 
Chapter 3: Methodological issues when measuring multimorbidity  103 
unique list of conditions.[119] This approach introduces heterogeneity between 
studies and using one of the available established lists allows better comparability. 
For example, when counting conditions, several recent studies have used the list of 
40 conditions published in Barnett and colleagues’ major multimorbidity epidemiology 
paper.[39,253,254] These diagnoses were selected based on the 11 conditions 
recommended by Diederichs et al., population prevalence and clinical 
consensus.[113] This list has some limitations, for example that it includes some 
vague conditions such as low vision; these are discussed in more detail in section 
5.5.3 on page 191. Another list of 60 conditions has been more recently developed, 
based on guidance from other studies and application of chronicity criteria to disease 
categories in the International Statistical Classification of Diseases and Related 
Health Problems, 10th revision (ICD-10).[255] This list includes states such as 
obesity, whose definition as a disease is contentious, and allergy, which may vary 
widely in severity. Its advantage over the list produced by Barnett and colleagues is 
that it does not contain symptoms such as ‘painful condition’. There are specific lists 
that have been developed in primary care, such as that published by O’Halloran and 
colleagues in 2004.[13] The authors defined a list of chronic conditions according to 
the International Classification of Primary Care-Version 2 (ICPC-2), which was later 
revised for relevance to include 75 conditions.[256]  
 
When choosing a list, there are practical issues to consider, such as its mapping to 
diagnostic criteria (for example, ICD-10), which can ensure generalisability between 
studies.[255] This is important where definitions of conditions differ between 
classification systems. In addition, condition selection should be justified within the 
age range being studied. For example, if the list was developed according to condition 
prevalence, this can differ between older and younger, often socioeconomically 
deprived, people.[11] The aim of the study that developed the list should also be 
considered, for example whether the conditions were chosen for their association with 
quality of life or mortality. Lists can often be arbitrary or based on practical, rather than 
scientific, reasons. Researchers should therefore be aware of the selection process 
of conditions on pre-defined lists before using them. 
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3.3.3 Length of condition lists 
The number of conditions on a list is important, as the range of possible conditions 
limits comparability, particularly between prevalence studies. The number of 
candidate conditions included in counts has been found to be as high as 147.[257] A 
2012 systematic review compared multimorbidity prevalence across 21 studies.[258] 
The authors found that although various aspects of study design affected prevalence 
rates, the number of conditions was the most important factor. There was minimal 
variation in prevalence between studies that used 12 or more conditions, and the 
authors recommended that this be the minimum number. This was confirmed by a 
population study in Australia that found a list of the 12 most prevalent chronic 
conditions detected 80% of multimorbidity found by using all possible conditions.[259] 
Another systematic review on this topic recommended a list of between 25 and 74 
conditions to optimise estimation of population multimorbidity prevalence.[260] One 
of the indices included in my review accounted for this issue by dividing the number 
of conditions experienced by participants by the total number listed, giving a 
proportion of possible diseases instead of a continuous count.[138] However, this is 
rarely done, so attention should always be paid to the number of conditions listed. 
Alternatively, it can be argued that each condition is so different that a continuous 
count may be less meaningful than an overall dichotomy.  
 
If a list is to be used directly with or by patients or participants, it should be of 
manageable length and in understandable language.[223]  For example, it is relatively 
straightforward to gather data from a list of 40 conditions when using electronic 
medical records, but if they were presented as a list for self-report in an observational 
study, this may be too long for participants. Fortin and colleagues proposed that a 
suitable list length for self-report would be between 12 and 20 conditions.[223] In 
longitudinal studies with several waves, it should be decided in advance how to deal 
with inconsistency of self-report, for example when patients report that they have a 
chronic life-long condition in one wave and then not report it at follow-up.[261] 
 
3.3.4 Cut-offs for defining multimorbidity  
In general, it is most appropriate to analyse a count of any parameter as a pseudo-
continuous variable, i.e. a variable that is discrete, with an upper bound and that only 
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includes integers, but treated as continuous. Dichotomising continuous variables 
loses much of the information available.[262] However, strictly adhering to the 
accepted and most commonly used definition of multimorbidity uses a cut-off of at 
least two conditions.[119] A limitation of this approach is that there is a ceiling effect; 
having two conditions is treated the same as having many more. 
 
A 2014 systematic review of multimorbidity studies found 31 papers that compared 
cut-offs of both two and three conditions for detecting prevalence.[263] Overall, there 
was little difference in prevalence rates whether a cut-off of two or three conditions 
was used. A cross-sectional study of a Canadian cohort of 1 710 individuals found 
that, using a list of 21 conditions, the prevalence of multimorbidity was lower when 
using a cut-off of three rather than two conditions.[264] Prevalence was also lower 
when using a list of six, instead of 21 candidate conditions. The authors also found 
that participants defined as having multimorbidity by the list of six conditions and cut-
off of ≥3 had poorer health-related quality of life than those defined by the list of 21 
conditions and a cut-off of ≥2 conditions. It therefore seems relatively unimportant 
which cut-off is used, but again its use should be justified. 
 
3.4 OTHER MEASUREMENT METHODS 
3.4.1 Cluster analysis 
Newer methods of measuring multimorbidity include clustering and network analyses. 
Clustering uses various methods to identify groups of conditions that co-exist, 
depending on their correlations with each other, within large datasets. The use of 
clustering methods in multimorbidity research is based on the premise that we are 
interested in comorbid conditions that co-exist in a non-random fashion. Given that it 
is a data-driven approach, clustering does not usually use pre-defined information 
about group structure, instead allowing patterns to emerge.[265] This can be with a 
pre-defined number of co-existing conditions (such as two, or ‘disease pairs’),[266] or 
whichever corresponding conditions appear in the data. Alternatively, cluster analysis 
can be used to find groups of people with similar multimorbidity profiles, rather than 
groups of co-existing conditions.[267] The Academy of Medical Sciences’ 2018 report 
on multimorbidity identified outstanding areas of research which included the 
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prevalence, trends and outcomes relating to disease clusters, highlighting their 
current pertinence.[7]  
 
A common method for identifying clusters in multimorbidity is to conduct multiple 
correspondence analysis to detect underlying structures in the data, and derive 
continuous measures from the original binary or categorical variables.[268] The next 
step is to use K-means clustering on these results. This well-established algorithm 
generates groups and allocates each object (or condition) to the group to whose mean 
it was closest. It then iteratively recalculates the group means and re-allocates each 
object.[269,270]  
 
There have been three systematic reviews exploring clustering in multimorbidity. A 
review in 2013 found 19 articles containing 165 combinations of two diseases.[271] 
The authors reported that depression, hypertension and diabetes were the diseases 
that most commonly appeared in clusters. This was due to both their prevalence and 
their co-existence with other conditions. Prados-Torres and colleagues’ systematic 
review focused on associative comorbidity, thereby including 14 articles that 
established the co-existence of conditions was not due to chance.[272]  Among these, 
they found 97 patterns of two or more, and 63 of three or more conditions. These were 
broadly separated into cardiovascular and metabolic conditions, mental disorders and 
musculoskeletal conditions.  
 
3.4.1.1 Hierarchical clustering 
The third systematic review of clustering in multimorbidity, published in 2018, found 
41 studies.[273] The study identified five different analytical methods for identifying 
clusters, with the most common being factor analysis or hierarchical clustering. 
Hierarchical clusters can be represented as dendrograms, which are created by 
algorithms that identify overlapping groups of comorbid conditions and their similarity 
(known as distance between clusters). Highly correlated clusters are near the bottom 
of the dendrogram and those with less correspondence are displayed the furthest 
away from each other.[273,274] Figure 3-1 is an example of this method, presenting 
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25 chronic conditions among 20 788 participants of the Australian National Health 
Survey.[273] Height on the y-axis represents the dissimilarity between clusters and 
the distance at which they diverge.[274] 
 




A population study of the associations between multimorbidity and health-related 
quality of life in 8 841 people compared count-based with hierarchical cluster 
methods, from a list of ten conditions.[275] The authors reported that the hierarchical 
clustering was effective and had the advantage of identifying specific conditions of 
interest contributing to the outcome in question, which is not possible using disease 
counts. Highly prevalent conditions may form part of several clusters, so all clustering 
methods sometimes lead to groups of conditions that are not clinically meaningful. 
The conditions included in the list has an impact on the number and composition of 
clusters. A disadvantage of these methods is therefore that both a large number of 
conditions needs to be included, as well as a large sample size.  
 
10  Used by permission of the International Epidemiological Association (through Oxford 
University Press) for print and electronic reproduction in PhD thesis: licence 4625360146955 
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3.4.2 Network analysis  
Some studies that employ clustering techniques also use network analyses. These 
display the connections between comorbid conditions. Figure 3-2 is an example 
network diagram presenting the same conditions from the Australian National Health 
Survey as in Figure 3-1.[273] It highlights the conditions that most commonly co-exist 
with others by proportional node sizes, with bold connecting lines (edges) 
emphasising the common disease pairs.  
Figure 3-2: Network diagram of co-existing conditions, from Ng et al., 2018.[273] 11 Node size 
is proportional to the condition’s number of comorbid conditions; bold lines highlight the most 
frequently co-occurring pairs 
 
 
It is also possible to map disease clusters onto network diagrams by colour-coding 
conditions.[276] Network analyses have clear applications in visually presenting the 
constituents of multimorbidity within a sample. Clustering and network analyses can 
 
11  Used by permission of the International Epidemiological Association (through Oxford 
University Press) for print and electronic reproduction in PhD thesis: licence 4625300894002  
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present quantitative data on the prevalence of each condition and its co-existence 
with others.  
 
3.4.3 Association Rules 
A method for assessing multimorbidity similar to network analysis is Association 
Rules. This process, used in machine learning, finds combinations of conditions 
based on both prevalence and their co-existence being more likely than chance. It 
can identify relationships between conditions and quantify how often each relationship 
occurs and its likelihood of occurring. A 2016 study used this technique among 1 464 
men aged 70 years and over in Australia.[277] The authors reported that it identified 
predictable clusters such as congestive heart failure co-existing with angina and ‘heart 
attack’, but also a clear association between anxiety and heart failure. A 2018 paper 
using the UK Biobank cohort used a two-step method to map networks of conditions 
with their likely temporality.[278] The authors first used hierarchical clustering to 
generate dendrograms, then used Association Rule Mining to more closely explore 
the links between the conditions, including which ones were likely to be antecedent 
or consequent to each other. They identified three clusters, the first of which contained 
only myocardial infarction and angina. This may not clinically be considered a cluster, 
rather two manifestations of one disease process. The study also found a strong 
association between anxiety and depression which again may represent symptoms 
of one condition rather than two separate ones. The Association Rules method has 
rarely been used in multimorbidity research so far to date but may increase in 
prominence with the rise in the application of machine learning techniques. 
 
3.4.4 Duration of illness 
Another methodological issue to acknowledge when comparing multimorbidity 
prevalence or outcome studies is the length of time over which diagnosis data were 
collected.[20,251] A count-based method can give the same weight to two recently 
diagnosed conditions as two that were diagnosed ten years ago. This is more 
problematic when exploring associations with specific outcomes than in prevalence 
studies. An approach to this is to use a longer retrospective period in which to identify 
diagnoses (for example, in medical records).[279] Alternatively, the cumulative 
duration method has been used recently by Maciejewski and colleagues.[280] This 
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involves summing together the time since diagnosis for all of a patient’s conditions 
from a pre-defined list. For example, a patient with one condition lasting 20 years 
would be assigned 20 patient-years and a patient with three conditions for five, two 
and three years respectively would have a total of 10 patient-years. The authors found 
that there was significant variation in cumulative duration even among people with 
multimorbidity, but that a count of diseases was a better predictor of healthcare 
expenditure than this cumulative count. The time of diagnosis is sensitive to bias, for 
example in that people with better access to healthcare will be diagnosed sooner and 
will have longer duration of illness. In general, it has been identified that there is little 
work addressing whether, and how, to include conditions that are either episodic or of 
short duration within multimorbidity research.[114] 
 
3.4.5 Multimorbidity as a dynamic variable 
Multimorbidity is mostly presented as static, a single count. This may be necessary 
and appropriate in cross-sectional analyses, but multimorbidity can change and 
develop over time. Ageing plays a crucial part in the pathology of conditions, and 
psychosocial factors such as access to healthcare and care-seeking behaviour are 
relevant to the acquisition of diagnoses. In addition, successful treatment of a 
condition may make it less relevant to an individual’s disease burden.  
 
Only a few studies have examined changes in multimorbidity over time and used 
diverse methods. A paper using latent class growth analysis examined primary care 
records of 24 615 people aged over 50 years and identified five clusters depending 
on their multimorbidity status and its trajectory.[281] The authors tested this method 
in a smaller population of 4 532 patients by assigning them to the same clusters. 
Scores on health-related quality of life were worse, as expected, in groups with 
evolving or chronic multimorbidity compared to no or recently diagnosed 
multimorbidity. An 11-year longitudinal study of 335 people with dementia in Utah 
found that the number of comorbidities fluctuated over time and that this number did 
not predict poorer cognitive outcomes.[282] A study of 756 adults aged ≥65 years 
without cognitive impairment in Baltimore counted from a list of 13 conditions and 
used linear mixed models to explore multimorbidity trajectories.[283] The authors 
reported that a faster accumulation of chronic conditions was associated with decline 
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in fluency, but not on memory tests. This study is likely limited by the use of linear 
mixed models with a relatively small number of conditions. An approach that includes 
change in multimorbidity burden is therefore valuable when designing longitudinal 
research. 
 
Network analyses can also be used to monitor changing multimorbidity. For example, 
researchers at Harvard University developed a network of data from all claims in the 
USA’s Medicare system from over 13 million patients.[284] In several stages, they 
explored the relative risk of developing each condition compared to the others, 
generating a phenotypic disease network to track progression from one condition to 
another and to identify mortality risk. These maps currently represent phenotypes but 
could be used in future to identify common molecular or genetic aetiologies between 
conditions or inform new treatments such as by drug repurposing.[285] 
 
3.5 CONCLUSIONS 
3.5.1 Summary of methods of measuring multimorbidity  
Multimorbidity research usually explores the complex co-existence of multiple 
conditions within individuals, and there are methodological factors to consider when 
interpreting existing research and planning analyses.  Table 3-2 briefly outlines these 
issues relating to each method discussed in this chapter. 
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Table 3-2: Summary of measurement methods, their advantages and disadvantages 
Measurement 
method 
Advantages Disadvantages  
Disease 
counts 
- Common, so comparable to other 
studies 
- Easily applicable 
- Produces numerical value 
- Assumes the same 
importance of each condition 
- Dependent on the length and 




- Relatively easy to use if 
appropriate information available 
- Usually produces numerical value 
- Many indices are not well 
validated and have limited 
comparability 
- The most commonly used 
index, the Charlson Index, is 
dated and has possible 
methodological flaws [120] 
Clustering - Provides information on disease 
co-occurrence   
- Hierarchical clustering allows 
visual representation of similarities 
- High prevalence conditions 
can appear in many clusters 
- Clusters are not always 
clinically meaningful   
Network 
analysis 
- Visually displays information 
about relative disease connections  
- Can be used to show temporality 
- Can become difficult to 




- Identifies the prevalence and 
likelihood of diseases co-occurring 
- Requires understanding of 
advanced methods 
- May find associations that are 
not clinically meaningful 
 
3.5.2 Methods used in this thesis 
In Chapter 4, I present the first data analyses in this thesis, exploring the impacts of 
chronic diseases and medication use on varying mental and brain health outcomes. I 
use a pragmatic approach to counting diseases based on which ones were included 
in the PREVENT Dementia study’s Case Report Form, then applying chronicity 
criteria to them.[42] In the European Prevention of Alzheimer’s Disease (EPAD) study 
used in Chapter 5, the medical history collection was limited by there being no marker 
of whether conditions had resolved or were continuing, so I used Barnett and 
colleagues’ list as it defines most conditions based on ever being diagnosed.[39,52] I 
present network analyses in Chapters 4 and 5. This method permits visual 
representation of frequently co-occurring conditions and complement the information 
presented in disease counts. I investigated the possibility of hierarchical and non-
hierarchical cluster analyses in these data, but owing to having ordinal binary 
variables for disease presence or absence, this was not immediately appropriate.  
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The majority of multimorbidity research quantifies multimorbidity by counting diseases 
and uses either a pseudo-continuous count, a dichotomous measure of multimorbidity 
or both.[112] In keeping with this, and accounting for the fact that the PREVENT 
Dementia and EPAD datasets had different lists of conditions, I opted to use disease 
counts and dichotomous multimorbidity measures. When designing my analyses, I 
maintained awareness of important methodological issues, particularly stating a priori 
the content and length of lists of candidate conditions. 
 
Chapter 6 focuses on polypharmacy in NHS routinely collected data. Although some 
indices studied in Chapter 2 use weighted counts of medication to measure 
multimorbidity,[145–148] polypharmacy itself is measured by medication count in the 
vast majority of studies.[32] Therefore, when exploring polypharmacy in Chapters 4 
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Chapter 4 Cross-sectional analyses in the 
PREVENT Dementia Study 
4.1 INTRODUCTION 
As outlined in Chapter 1, population studies have shown that around a third of people 
with multimorbidity have both physical illness and mental disorders.[38,39] These 
mental disorders include depression, anxiety and neurodegenerative diseases such 
as dementia.[39] The co-existence of physical multimorbidity and mental disorders 
results in greater treatment burden for individuals and costs to healthcare 
services.[71] However, understanding of specific mental health outcomes in people 
with multimorbidity remains limited. This chapter will explore associations between 
multimorbidity and polypharmacy with specific mental health, cognitive testing and 
neuroimaging outcomes in a mid-life cohort from the PREVENT Dementia study. 
 
4.1.1 Associations between multimorbidity and depression or anxiety 
Depression has a worldwide prevalence of 2-15% and can lead to substantial 
disability across the life course.[286] There are known links between individual 
physical conditions, such as stroke, and depression,[287] but the relationship 
between multiple chronic conditions and depression, especially in mid-life, is less well 
understood. A 2017 systematic review of multimorbidity and depression including 40 
papers and meta-analysis revealed that people with multimorbidity had a three times 
greater risk of depression than people with no chronic physical conditions.[288] The 
majority (26, 65%) of studies included in this review were undertaken in older adults, 
with only one in a mid-life sample.[289] The review suggested healthcare-related 
explanations for this physical-mental multimorbidity, for example that people with 
chronic conditions may receive better attention to their mental health than people who 
do not regularly attend primary care. It also highlighted previous work on depression 
that found negative cognitions were precipitated by genetic risk, early trauma and 
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The co-occurrence of multimorbidity and anxiety is less frequently studied, but one 
cross-sectional study of 138 858 patients’ medical records in Minnesota has shown 
they do co-exist.[50]  
 
4.1.2 Polypharmacy and mental or brain health 
The associations between polypharmacy and mental or brain health outcomes have 
rarely been studied. A 2014 systematic review of outcomes associated with 
polypharmacy included 58 papers, of which five studied cognitive impairment or 
dementia as outcomes.[291] Two of these showed no convincing associations 
between polypharmacy and these cognitive outcomes. One paper examined 
depression using the Center for Epidemiologic Studies Depression (CES-D) scale and 
found an association between increasing numbers of medication and higher scores 
on the CES-D (β=0.13, P<0.01, adjusted for age, education and physical health).[95] 
This paper, published in 1989, is the only example of work exploring the association 
between polypharmacy and depression to date. It proposed potential explanations for 
their co-existence, including that drug adverse effects can include lethargy and 
depression, that people with depression are likely to seek more care for their physical 
health, and that co-existent multimorbidity physically predisposes patients to 
depression. 
 
4.1.3 Multimorbidity with cognitive impairment and neurodegeneration  
There have been three studies into associations between multimorbidity and 
neuroimaging biomarkers.[98,99,292] One of these studies included 1 449 people 
aged 70-89 years with no cognitive impairment.[98] It found that people with 
multimorbidity (≥2 conditions) had increased odds of fluorodeoxyglucose 
hypometabolism (odds ratio (OR) 2.03, 95% confidence interval (CI) 1.10 to 3.77, 
adjusted for age, sex and education) and reduced MRI cortical thickness (OR=1.53, 
95% CI 1.09 to 2.16 adjusted for age, sex and education), both in regions of interest 
for Alzheimer’s disease. These associations were further increased in people with 
four or more conditions. Another study, of 318 people aged 70-85 years, found an 
association between greater numbers of chronic conditions and decreased 
hippocampal volume (–0.03 ± 0.01cm3; P=0.012).[99] The third study suggested links 
between multimorbidity and combinations of markers of neurodegeneration including 
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amyloid.[292] The importance of amyloid in these papers is discussed in more detail 
in Chapter 5.  
 
The co-existence of multimorbidity and neurodegeneration may be explained by 
common biological aetiology such as inflammatory or vascular pathways.[293] 
Physical conditions contributing to multimorbidity could be either risk factors for 
clinical dementia, such as hypertension or diabetes, or conditions associated with 
dementia in their own right, such as Parkinson’s disease or stroke.[48] 
 
4.1.4 Mid-life approach 
Most research investigating multimorbidity and polypharmacy has been conducted in 
older people, amongst whom they are common.[3] However, the majority of people 
with multimorbidity are middle-aged.[39] Although clinically manifest cognitive 
impairment is more prevalent in older age, there is increasing evidence that 
pathological changes of Alzheimer’s disease are present in mid-life.[41] This is in the 
broader context of a life-course approach to dementia epidemiology, purporting that 
intrauterine and childhood factors, as well as behavioural factors in adulthood, can 
contribute to later dementia risk.[294] Therefore, the focus of dementia prevention 
research is turning towards detailed studies of middle-aged people.[41] In research 
and clinical settings, old age is most commonly defined as being aged over 65 years 
with middle age being between 45-65 years, although it is acknowledged that risk 
factors exist at all ages and that biological age differs between individuals.[40]  
 
Depression and anxiety in mid-life have been identified as risk factors for 
dementia,[43,44] although the direction of the association remains uncertain.[46] 
They are clinically important in this age group due to the potential disability caused in 
working-age adults.[286] Understanding the interplay between multimorbidity and 
polypharmacy with depression and anxiety is therefore not only valuable in its own 
right, but adds to the knowledge on factors leading to poor brain health and dementia. 
This is best explored in a mid-life cohort before substantial cognitive impairment has 
developed. The PREVENT Dementia study offers opportunities to explore the 
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This chapter explores associations between physical multimorbidity and 
polypharmacy with mental disorders and relevant neuroimaging outcomes in a 
middle-aged cohort. The following hypotheses are in keeping with the overall 
hypotheses of this PhD presented in section 1.5 on page 18. 
 
1. Physical multimorbidity (or having a larger number of chronic conditions) will 
be associated with an increased risk of mental disorders. The greater the 
burden of multimorbidity, the higher the individual’s risk of developing a mental 
disorder. These include: 
a. Depression 
b. Anxiety 
c. Cognitive impairment (specific deficits on cognitive testing) 
2. Polypharmacy, or using larger numbers of medications (accounting for 
antidepressant drugs) will be associated with poorer mental health, and the 
greater the burden of polypharmacy, the higher a person’s risk of developing 
a mental disorder as above 
3. Physical multimorbidity (or having more chronic conditions) will be associated 
with outcomes linked to dementia on structural MRI neuroimaging 
(periventricular and deep white matter hyperintensities, hippocampal volume 
and microhaemorrhages) 




4.3.1 The PREVENT Dementia Study 
PREVENT Dementia is a prospective cohort study which was initiated in 2013 with 
the aim of identifying risk factors for dementia in mid-life to inform strategies for 
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secondary prevention.[42] The study population was phenotyped in detail, paying 
particular attention to known risk factors for dementia such as family history and 
APOE e4 status. As well as in-depth medical and lifestyle history, mental health 
questionnaires and rigorous cognitive testing, biomarkers were measured including 
various blood tests and brain MRI and fMRI.  
 
The PREVENT Dementia study was given ethical approval by the NHS Research 
Ethics Committee London Camberwell St Giles, reference 12/LO/1023. My analyses 
did not require separate ethics permissions, as I was not collecting new data or re-
contacting participants. The principal investigators published the study protocol 
prospectively.[51] I submitted an application to the steering group and was granted 
access to the data.  
 
4.3.2 Participants 
Participants were recruited through the dementia register database of West London 
Mental Health NHS Trust, which holds records of people with dementia who have 
consented to be contacted for research and their carers (usually offspring).[295] 
Recruitment was also undertaken through the Join Dementia Research website and 
via publicity online and at public presentations.[296] People were eligible to participate 
if they were aged 40-59 years at baseline and were fluent in English. Exclusion criteria 
were a diagnosis of, or reported cognitive impairment or dementia and known 
contraindication to MRI. 
 
The original pilot study was designed to include three groups of 50 participants each, 
stratified by risk of developing dementia. These included offspring of patients 
diagnosed with Alzheimer’s disease who had an APOE ε4 allele, offspring of patients 
with dementia without an APOE ε4 allele and participants without a parent with 
dementia who had an APOE ε2, but not APOE ε4 allele.[51] Power calculations were 
based on existing studies of biomarkers in mid-life, of which there were few at the 
time of study design.[297,298] The calculations found that with 50 participants per 
group, mean differences in hippocampal volume of 0.327cm3 and mean differences 
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in plasma Aβ42 of 8.07 pg/ml could be detected between groups, with α=0.05 and 0.90 
power in both cases.[51] 
 
There were 210 participants in the initial wave, with a total of 700 currently 
participating across London, Edinburgh, Dublin, Cambridge and Oxford sites. The first 
follow-up visits took place two years after initial assessments and are planned every 
five years thereafter. This chapter contains cross-sectional analysis of quality-
controlled data from the pilot phase in London in 2014-15. 
 
4.3.3 Exposure variables 
4.3.3.1 Chronic conditions  
In keeping with other research into multimorbidity and polypharmacy, I used counts 
of chronic physical conditions and medications for these analyses. Based on a 
combination of definitions from the International Classification of Primary Care, 
version 2,[13] and from NHS Scotland Information Services Division,[14] I developed 
a definition of chronic conditions, as described in section 1.2.2 on page 2. Conditions 
should last at least six months, have an impact on quality of life (either directly or 
through sequelae), clearly meet diagnostic criteria, and have a pattern of recurrence 
or deterioration. I therefore excluded conditions that may have significant impact on 
life but are not chronic such as myocardial infarction, and procedures reported such 
as carotid artery surgery. 
 
The PREVENT Dementia participant case report form names 69 conditions in the 
medical history, with space for other conditions to be entered. These are categorised 
by body system as shown in Table 4-1. I read each free-text ‘other’ entry to decide 
whether the condition fitted the chronicity criteria, and if so, coded it according to body 
system. This created a new ‘other’ category within each body system. The medical 
history in the PREVENT Dementia assessment was collected by a qualified doctor. 
They asked if the participant had ever had each of the conditions, and if so, recorded 
its date of onset, whether it was currently active and whether the participant had 
required hospitalisation. Any uncertainties were clarified by reference to the 
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participant’s medical records, with their consent. I took the outcomes self-reported 
active depression and anxiety disorder from this medical history.  
Table 4-1: Number of conditions by body system 
System Number of conditions in 
full list 
Number of conditions 
included in analyses 
(includes ‘other’)  
Blood 2 2 
Cardiovascular 17 (including 6 procedures) 12 
Gastrointestinal 12 13 
Genitourinary/reproductive 4 4 
Eyes, ears, nose and throat 2 2 
Metabolic 5 4 
Musculoskeletal 5 5 
Neurological/Psychiatric 13 7 
Pulmonary 4 3 
Whole body 4 2 (both immunological) 
Cancer 1 1 
Total 69 55 
 
The focus of multimorbidity in these analyses is physical, with mental disorders the 
outcomes of interest. I therefore excluded psychiatric disorders from my disease 
count. These included ‘alcoholism’ and ‘drug abuse’ which appeared in the ‘whole 
body’ category. I also excluded obesity, as body mass index (BMI) was included as a 
potential covariate in preliminary analyses. In addition, obesity is usually seen as a 
risk factor rather than a disease in itself.[119] Hearing loss is included in some studies 
counting multimorbidity [39] but as its definition can vary widely, as a functional 
impairment rather than physical disease, I excluded it from these analyses. My final 
chronic condition list therefore included 55 diagnoses. 
 
For analyses on depression and anxiety outcomes, I used two measures of 
multimorbidity: pseudo-continuous counts of any chronic conditions the participant 
reported, and binary measures of ≥2 versus 0-1 conditions. This was in anticipation 
that, owing to the overall sample size, there would be few participants reporting each 
number of chronic conditions. It also aligns with other multimorbidity research.[119] I 
did not use the binary variables where the outcomes were cognitive test scores or 
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MRI markers of neurodegeneration after preliminary analyses revealed they had no 
likely associations with the exposure variables. 
 
4.3.3.2 Medication history 
At the initial interview, study doctors collected information on current medication 
according to participant self-report. This included drug name, dose, frequency and 
indication. The reported medications were then coded according to the World Health 
Organization’s (WHO) Anatomical Therapeutic Chemical (ATC) classification.[299] 
This is a hierarchical system of five levels: a letter denoting the anatomical or broad 
pharmacological group, a number for the therapeutic group, two further letters for 
pharmacological subgroups and a final number for the chemical substance. For 
example, fluoxetine has ATC code N06AB03, which consists of the following levels: 
N  Nervous system 
N06  Psychoanaleptics 
N06A  Antidepressants  
N06AB  Selective serotonin reuptake inhibitors 
N06AB03  Fluoxetine. 
 
This system allowed me to find and segregate antidepressants by searching for ATC 
codes starting with the string ‘N06A’. I then created an indicator for whether each 
participant took an antidepressant. I was particularly interested in this as it could 
influence their outcomes regarding depression and anxiety, regardless of the drug 
indication. I used the indicator to account for antidepressant use in these analyses. I 
used the same method to ascertain whether participants took anxiolytics and account 
for this. For both antidepressants and anxiolytics, I reviewed free-text entries stating 
treatment indication as both groups can be used for non-psychiatric indications. 
 
I checked free-text medication entries where there was no ATC code and assigned 
the relevant code as per the ATC online index, where sufficient information 
existed.[299] Most polypharmacy studies use prescribed medication from electronic 
health records.[35] However, the PREVENT Dementia case report form allowed 
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participants to record any medications they took, whether prescribed or not. I therefore 
excluded medications that appeared to be primarily over-the-counter vitamins or 
health supplements, or where insufficient free-text information was recorded to 
generate an ATC code, for example ‘eye drops’. 
 
Similarly to my chronic condition measures, I used two exposure variables for 
quantifying the number of medications. One was a continuous count of any relevant 
medication reported by the participant. I excluded antidepressants from this total 
count as I hypothesised that antidepressant use would be linked to depression and 
anxiety outcomes. I also planned to use antidepressant use as a covariate so 
including them in the exposure would lead to them being counted twice. I used the 
count of medications excluding antidepressants as the medication exposure variable 
in all analyses, regardless of the outcome, for consistency. To further explore the 
concept of polypharmacy, I also used a dichotomous measure of ≥3 versus 0-2 
medications. Although the majority of studies use a cut-off of ≥5,[32] in this cohort of 
mid-life healthy volunteers, I discovered after exploring the data that very few 
participants were taking ≥5 drugs. 
 
4.3.4 Outcome variables 
The primary variables of interest in PREVENT Dementia are the detailed cognitive 
test battery and biomarkers including neuroimaging. Participants also completed 
validated questionnaires on symptoms of depression, anxiety and resilience, with 
these considered risk factors for dementia or cognitive impairment. To complement 
the mental health outcomes used elsewhere in this thesis, I chose to analyse scores 
on the Center for Epidemiologic Studies Depression (CES-D) scale [300] and the 
Spielberger State and Trait Anxiety Inventory (STAI);[301] participants’ self-report of 
depression and anxiety; neuroimaging measures and detailed cognitive outcomes 
from the COGNITO battery.[302] 
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4.3.4.1 Depression measures 
The CES-D is a self-administered scale containing 20 questions about depressive 
symptoms in the past week.[300] The questions cover mood, cognitive and somatic 
symptoms of depressive disorder, and are equally weighted (see Appendix 1, page 
357). Participants answer each question on a scale of zero (rarely or none of the time) 
to three (most of the time, or five to seven days). Four of the questions ask positive 
questions, for example “I am happy”, so their scores are inverted. Overall scores are 
calculated by summing the scores for each answer, giving a maximum total of 60.[300] 
As it was originally designed as a continuous scale to measure symptoms, I treated it 
as such.  
 
The CES-D has been validated in several settings, and a cut-off score of ≥16 is 
generally used to distinguish between people with and without depression.[303] A 
systematic review and meta-analysis of studies using the CES-D found a sensitivity 
of 87% and specificity of 70% using this cut-off.[304] I therefore additionally derived a 
binary measure of scores ≥16 to account for the small sample size. 
 
I also used self-reported medical history of active depression as an outcome, to 
correspond with other datasets which only use diagnoses rather than test outcomes 
and to add further detail beyond test scores. Depression appears on a list of 
conditions in the PREVENT Dementia case report form medical history, which is 
collected by a qualified doctor. The list does not offer further details such as whether 
depression was diagnosed by a doctor or is under treatment, but does specify whether 
this is currently active. 
 
4.3.4.2 Anxiety measures 
The Spielberger State-Trait Anxiety Inventory (STAI) has two sub-tests measuring 
state and trait anxiety.[301] The state sub-test asks about current symptoms at the 
time of inventory completion, and only this was used in PREVENT Dementia. It 
consists of 20 self-report questions on symptoms of anxiety, scored from one to four. 
Ten of the questions are positive statements, such as “I feel at ease” and the other 
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ten are negative, for example, “I am tense”.12 The scale for the positive questions is 
inverted before generating the overall score, so that higher total scores indicate more 
symptoms of anxiety. The maximum possible score is 80. A cut-off of 40 was found 
to have specificity of 75% and sensitivity of 68% in 40 adults aged over 65 years, 
compared to a structured clinical interview conducted by a psychiatrist.[305] Although 
this sample is older than the one used in my analyses, I chose to use the cut-off of 40 
to indicate clinically significant anxiety as it is the most frequently used.[306,307] 
Similarly to CES-D, I used both the continuous score and binary measures for 
comparative analyses. 
 
To strengthen my results, as with depression, I additionally used a dichotomous self-
reported diagnosis of active anxiety disorder from the medical history. 
 
4.3.4.3 Cognitive outcomes 
COGNITO is a computerised neuropsychometric test battery designed for 
epidemiological cognition research.[302] It covers attention, memory, visuospatial 
processing and language. There are 20 tasks which generate detailed results as well 
as an overall score for each task. Due to the relatively small size of this initial phase 
cohort, I chose not to include all COGNITO outcomes. Instead, I referred to those 
previously reported to be significantly associated with risk of dementia. In a 2017 
publication using PREVENT Dementia data, Karen Ritchie and colleagues found an 
association between higher Cardiovascular Risk Factors, Aging, and Incidence of 
Dementia (CAIDE) score and poorer performance on the COGNITO name-face 
associative learning task (OR=1.4, 95% CI 1.04 to 1.26; P=0.008) and phoneme 
comprehension time (β (standard error)=16.7 (7.24); P=0.02).[308] I therefore chose 




12 The Spielberger State-Trait Anxiety Inventory is copyrighted by Mind Garden, who provided 
it under paid licence to PREVENT Dementia; I could not obtain permission to reproduce it here 
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all clinical and genetic study data.[310] The imaging outcome variables of interest 
were hippocampal volume, white matter hyperintensities (quantified by Fazekas 
score) and cerebral microhaemorrhages. Smaller hippocampal volume is associated 
with an increased risk of Alzheimer’s disease, and decreasing hippocampal volume 
can be an early marker of memory deterioration and dementia.[311] The Fazekas 
score was initially proposed in 1987 as a measure of white matter hyperintensities to 
quantify vascular damage. It grades periventricular hyperintensity and deep white-
matter hyperintensity, each on a scale of zero to three based on appearance.[312] 
Risk of dementia and severity of cognitive impairment are associated with more 
periventricular hyperintensities, whereas the risk of mood disorders and their severity 
are associated with deep white-matter hyperintensities.[313] I therefore analysed 
each score as a separate outcome measure. In this study, white matter 
hyperintensities were quantified using specific validated automatic methods.[310] 
 
Cerebral microhaemorrhages, also known as microbleeds, are perivascular deposits 
of haemosiderin that have leaked from small vessels and indicate susceptibility to 
haemorrhage.[314] In general, arteriosclerosis leads to white matter damage and 
deep microbleeds whereas amyloid angiopathy causes white matter damage and 
lobar microbleeds. One study found that overall burden of cerebral microbleeds was 
associated with a higher risk of developing dementia compared to people without 
them, independent of vascular risk factors (hazard ratio 1.74, 95% CI 1.00 to 
3.01).[315] PREVENT Dementia imaging analysis used the Microbleed Anatomical 
Rating Scale (MARS) to evaluate whether each participant had at least one definite 
microbleed in each anatomical area.[310] 
 
The hippocampal volume variable was a mean of left and right grey matter 
hippocampal volume and had already been adjusted for total brain volume.[308] The 
scan images had been processed by a colleague working on imaging within the 
PREVENT Dementia study and I received numerical variables only.  
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4.3.5 Covariates 
I generated an initial list of potentially relevant covariates comprising established risk 
factors for dementia and depression. Age was recorded in whole years and 
participants reported their gender and race.14 Owing to the expected ethnic mix of the 
sample, I used a dichotomous race variable of Caucasian and non-Caucasian for 
analyses.  
 
Data on head injuries were collected using the Brain Injury Screening Questionnaire 
(BISQ). I used a sum variable of the number of self-reported episodes of loss of 
consciousness following a blow to the head.[316] I used separate binary indicators of 
whether the participant was taking at least one antidepressant or anxiolytic for a 
psychiatric indication.  
 
The CAIDE score, as mentioned in section 4.3.4.3, is a validated risk score comprising 
weightings for the following participant characteristics: age, gender, education, 
systolic blood pressure, body mass index (BMI), total cholesterol, physical activity and 
APOE status. Scores vary from 0 to 15, with higher scores conferring a higher risk of 
dementia.[317] I treated the score as a continuous covariate in relevant analyses with 
outcomes relating to cognition or neurodegeneration. The CAIDE score includes age 
and gender so I did not include age and gender when using it as a covariate. 
 
I adjusted appropriate neuroimaging outcomes for total intracranial volume, which 
was calculated as the sum of grey matter, white matter and cerebrospinal fluid. 
 
14  Gender describes a person’s self-representation as male or female, whereas sex is 
determined by biological features including reproductive organs.[591] The PREVENT 
Dementia Participant Case Report Form asks participants their gender. This term is therefore 
used throughout this chapter.  
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4.3.6 Statistical analysis  
I used R version 3.4.3 with RStudio for all analyses.[318] I initially investigated the 
overall characteristics of the sample, including age distribution, prevalence of 
diagnoses and medication use, and generated bar graphs. 
 
4.3.6.1 Network analyses 
In order to investigate the co-occurrence of conditions and prescribed medications, I 
employed network analysis. Firstly, I grouped medications into their ATC therapeutic 
subgroup, giving 39 groups. I used the R package igraph to create adjacency 
matrices of chronic physical conditions and medication subgroups separately.[319] In 
an adjacency matrix, the terms (conditions or medications) appear in both rows and 
columns and each entry represents the co-occurrence of two terms. The igraph 
package then graphs this adjacency matrix. I generated network analysis graphs  
with the Fruchterman-Reingold layout, which aims to produce edges of equal 
length.[320] Some vertices needed manually adjusting to prevent overlap of their 
labels. In keeping with other similar research, I restricted my network analyses to 
participants with at least three conditions or medications, as this allowed exploration 
of their connections.[276] 
 
4.3.6.2 Regression models 
Prior to conducting regression analysis, I tested model assumptions by examining 
diagnostic plots of condition or medication counts against the continuous 
outcomes.[321] These graphical analyses revealed that the appropriate assumptions 
were met. I used linear regression models for continuous outcome variables (raw 
CES-D and STAI scores, phoneme comprehension time, hippocampal volume, 
Fazekas scores and microhaemorrhage count). An illustration of the R code is as 
follows: 
library(tidyverse)  
linear_model = lm(continuous_outcome ~ exposure + 
covariate, data=dataset) 
tidy(linear_model, conf.int = TRUE) 
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For binary outcomes including self-reported depression or anxiety disorder, I used 
logistic regression. I also generated binary variables based on accepted cut scores 
for the COGNITO name-face association test, as well as CES-D and STAI. For these 
binary variables, I anticipated small numbers in each sub-group so used Student’s t-
test to compare the means. On plotting standardised residuals of these models with 
condition and medication counts as exposure variables, there were no influential 
observations. The code used for logistic regression followed the following template: 
library(tidyverse)  
logistic_model = glm(dichotomous_outcome ~ exposure + 
covariate, data=dataset, family=binomial(link=’logit’)) 
tidy(logistic_model, exponentiate = TRUE, conf.int = 
TRUE) 
 
I tested each covariate using logistic or linear regression against all exposure and 
outcome variables. If the variable was associated with both exposure and outcome 
(P<0.05), I included it as a covariate in preliminary analyses. I included age and 
gender in all models, with additional relevant covariates for each group of outcomes. 
 
The analyses were grouped by outcome variable. For each outcome, I ran the 
appropriate regression model with number of chronic conditions and number of 
medications as exposure variables. I conducted the analyses initially unadjusted and 
then included specific combinations of covariates, presenting the adjusted model 
results.  
 
4.3.6.3 Sensitivity analyses 
In analyses with depression and anxiety outcomes, I conducted additional analyses 
in a subsample of participants not taking antidepressants for a psychiatric indication, 
to explore the importance of this variable beyond including it as a covariate. I also 
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tested for interaction effects between the number of chronic conditions and 
antidepressant use. 
 
4.4 RESULTS  
4.4.1 Description of the sample 
The sample consisted of 210 individuals, 148 (70.5%) of whom were women. Self-
reported race was Caucasian for 89.5% of participants with the next largest groups 
being black (n=7, 3.3%) and Indian subcontinent (n=7, 3.3%). Further demographic 
details are listed in Table 4-2. This section focuses on the key exposure and outcome 
variables; further information about the sample has been published 
elsewhere.[308,322] 
Table 4-2: Sample characteristics, n=210 
Variable Missing N (%) Mean (SD) 
Gender (female) 0 148 (70.5%)   
Race (Caucasian) 0 188 (89.5%)   
Currently have depression 
(self-report) 
0 16 (7.6%)  
Currently taking antidepressant 0 26 (12.4%)  
Taking antidepressant for 
psychiatric indication 
0 18 (8.6%)  
Currently taking anxiolytic 0 1 (0.5%)  
Current anxiety disorder (self-
report) 
0 21 (10.0%)  
Head injuries leading to loss of 
consciousness 
0 0 = 129 (61.4%) 
1-2 = 70 (33.3%) 
3 or more = 11 
(5.2%) 
 
≥2 chronic conditions 0 119 (56.7%)  
Taking ≥3 medications 
(excluding antidepressants) 
0 39 (18.6%)  
Age in years 0  52.0 (5.47) 
Women: 51.7 
(5.42) 
Men: 52.7 (5.56) 
Years of education 0  15.9 (3.44) 
Number of chronic physical 
conditions 
0  2.17 (1.86) 
Women: 2.34 
(1.97) 
Men: 1.76 (1.50) 
Number of current medications 0  1.65 (2.15) 
Number of current medications 
excluding antidepressants 
0  1.52 (2.00) 
Women: 1.47 
(1.89) 
Men: 1.66 (2.25) 
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Variable Missing N (%) Mean (SD) 
CES-D total score 0  9.2 (8.15) 
STAI total score 0  30.4 (9.40) 
Mean time for correct response 
on phoneme comprehension 
test (milliseconds) 
0  1585.7 (304.24) 
Number of names correctly 
recalled on name-face 
association (maximum 9) 
  5.34 (2.21) 
CAIDE Dementia risk score 2  5.9 (2.81) 
Total intracranial volume / cm3 17  1389 (131.1) 
Periventricular Fazekas score 17  1.1 (0.42) 
Deep white matter Fazekas 
score 
17  0.68 (0.57) 
Hippocampal volume / cm3 17  73.72 (0.34) 
Cerebral microhaemorrhages 17  0.28 (1.22) 
 
4.4.1.1 Chronic conditions 
After excluding conditions not deemed to be chronic, I calculated the prevalence of 
each listed condition, as shown in Table 4-3 and displayed in Figure 4-2 on page 134. 
Of these 55 conditions, 14 were not reported by any participants. It is apparent that 
eye disease is the most prevalent condition. This may be due to the method of 
information gathering, which did not allow any sub-categories of eye disease and 
therefore may include a variety of conditions such as glaucoma or presbyopia.  
 
Table 4-3: Prevalence of all conditions. Total n=210 
Body system Condition Active prevalence 
Blood Anaemia 12 (5.7%) 
 Other haematological 3 (1.4%) 
Cardiovascular Angina 2 (1.0%) 
 Congestive heart failure 0 
 Hypertension 22 (10.5%) 
 Cardiac arrhythmia 14 (6.7%) 
 Peripheral vascular disease – arterial  0 
 Peripheral vascular disease – venous 6 (2.9%) 
 Congenital heart disease 0 
 Valvular heart disease 1 (0.5%) 
 Coronary artery disease 1 (0.5%) 
 Aortic aneurysm (surgery) 0 
 Pacemaker 0 
 Other cardiovascular 2 (1.0%) 
Gastrointestinal Peptic ulcer disease 2 (1.0%) 
 Gastro-oesophageal reflux disease 23 (11.0%) 
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Body system Condition Active prevalence 
 Liver disease (excluding hepatitis) 2 (1.0%) 
 Hepatitis 0 
 Pancreatitis 0 
 Gastrointestinal bleed 1 (0.5%) 
 Cholelithiasis (gallstones) 3 (1.4%) 
 Cholecystitis  0 
 Inflammatory bowel disease 4 (1.9%) 
 Diverticulitis 3 (1.4%) 
 Irritable bowel syndrome 17 (8.1%) 
 Chronic constipation 12 (5.7%) 
 Other gastrointestinal 5 (2.4%) 
Genitourinary or 
reproductive  
Kidney disorder 0 
Benign prostatic hyperplasia 1 (0.5%) 
 Nephrolithiasis 1 (0.5%) 
 Other genitourinary/reproductive 4 (1.9%) 
Ears, eyes, nose, 
throat 
Eye disease 113 (53.8%) 
Other eye disease 2 (1.0%) 
Metabolic Diabetes 7 (3.3%) 
 Hyperthyroidism 1 (0.5%) 
 Hypothyroidism 11 (5.2%) 
 Other metabolic 1 (0.5%) 
Musculoskeletal Gout 2 (1.0%) 
 Osteoarthritis 26 (12.4) 
 Collagen vascular disease 0 
 Degenerative disc disease 13 (6.2%) 
 Other musculoskeletal 17 (8.1%) 
Neurological Seizure/convulsion disorder 0 
 Migraine 27 (12.9%) 
 Stroke (ever) 2 (1.0%) 
 Parkinson’s disease 0 
 Peripheral nerve disorder 3 (1.4%) 
 Sleep disorder 25 (11.9%) 
 Other neurological disorder 2 (1.0%) 
Immunological Immune deficiency 1 (0.5%) 
 Other immunological 1 (0.5%) 
Cancer Cancer (ever) 14 (6.7%) 
Pulmonary Chronic obstructive pulmonary disease 0 
 Asthma 28 (13.3%) 





Figure 4-2: Prevalence of chronic conditions 
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The mean number of chronic physical conditions was 2.17 (SD=1.86), with a range of 
0-9 and median 2. Women reported more physical conditions than men; a Student’s 
t-test identified a difference in the means (µmen=1.76 [SDmen=1.50]; µwomen=2.34 
[SDwomen=1.97],  t= -2.34, P=0.020). Table 4-4 shows the prevalence of multimorbidity 
using different cut-offs. 
Table 4-4: Prevalence of multimorbidity 
Number of conditions n (%)  
0 34 (16.2%) 
1 57 (27.1%) 
≥2 119 (56.7%) 
≥3 71 (33.8%) 
≥4 40 (19.0%) 
 
Figure 4-3 shows the distribution of participants’ total number of chronic conditions.  




The mean number of medications reported was 1.65 (SD=2.15), median 1 and 
range 0-12, and the distribution is displayed in Figure 4-4.  
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Figure 4-4: Distribution of total number of current medications  
 
Twenty-six (12.4%) participants took antidepressants, with indications as follows: ten 
for depression, eight for anxiety, obsessive-compulsive disorder or bipolar disorder 
and eight for other diverse indications including pain relief, pre-menstrual tension and 
hot flushes.  
 
When adding an interaction term to the model, there was no statistically significant 
interaction between chronic condition count and antidepressant use. After excluding 
antidepressants, the mean number of medications was 1.52 (SD=2.0), median 1 and 
range 0-11. The distribution is shown in Figure 4-5. On Student’s t-test, there was no 
difference between the mean medication use, excluding antidepressants, for men and 
women (µmen=1.66 [SDmen=2.25]; µwomen=1.47 [SDwomen=1.89] ,  t=0.60, P=0.551). 
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Figure 4-5: Distribution of number of current medications, excluding antidepressants 
 
Figure 4-6 shows the number of medications, excluding antidepressants, compared 
to the total number of chronic physical conditions. For those participants with at least 
one chronic condition, the mean number of medications per condition was 0.72 (SD 
0.85), median 0.5 and range 0.2-5.0. 
Figure 4-6: Number of medications by chronic physical conditions 
 
Only one participant was taking an anxiolytic medication, and not for a psychiatric 
indication, so this was abandoned as a covariate. 
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4.4.2 Network analyses  
Seventy-one participants had three or more conditions and 48 people took three or 
more medications (including antidepressants). I only included participants with at least 
three conditions or medications in the network analyses in keeping with similar 
published research.[276] 
 
Among the participants with three or more concurrent conditions, 38 conditions were 
reported by at least one participant. Figure 4-7 is a network analysis diagram of the 
interaction between the conditions. The label size of each node reflects its number of 
connections to other conditions, whereas the node size represents the prevalence of 
that condition. The thickness of lines between nodes displays the relative frequency 
of that connection. 
 
Due the disproportionately high prevalence of eye disease and therefore its high rates 
of comorbidity, I generated another sample of people with three or more conditions, 
excluding all eye disease from the condition list. This sample included 48 participants. 
I produced another network analysis diagram of this sample, seen in Figure 4-8. 
Figure 4-9 is a network graph of the medications used by participants who took at 
least three medications. It shows that psychoanaleptics (the ATC term that includes 
antidepressants, stimulants and anti-dementia drugs, but in this sample only 
antidepressants were relevant) were the most connected group. Acid-related drugs 
and antihypertensives were the most prevalent but were relatively less frequently co-
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4.4.3 Depression outcomes 
The mean score on the CES-D was 9.2 (SD 8.1), median 7 and range 0-52. Figure 
4-10 shows the distribution of the scores, with clear right skew. A total of 35 (16.7%) 
participants scored 16 or over. 
Figure 4-10: Distribution of CES-D scores  
I adjusted for age and gender in all models. Other variables that were associated 
(P<0.05) with at least one outcome and at least one exposure variable were number 
of head injuries, antidepressant use and any reported history of depression. I did not 
include any history of depression in these analyses, as there was too much overlap 
with self-reported history of current depression. In order to minimise the number of 
covariates used in this relatively small sample, I did not include head injuries as it was 
less clinically relevant. I added race as a covariate in order to harmonise with the 
anxiety outcomes, where it was significantly associated with the exposure variables. 
I used the same covariates across all exposure variables for both CES-D and self-
reported depression outcomes. 
 
In all the results for depression and anxiety outcomes, I list three models: Model 1 
with age, gender and race as covariates, Model 2 with the addition of antidepressant 
use and Model 3 as the sensitivity analyses in participants not taking antidepressants 
for a psychiatric indication (adjusted for age, gender and race).  
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4.4.3.1 Chronic conditions and CES-D score 
There were relatively few participants with each number of chronic physical conditions 
according to binary CES-D score, as shown in Table 4-5.  
Table 4-5: Number of participants with each number of conditions, by CES-D score 
Number of conditions CES-D <16  CES-D ≥16  CES-D <16  CES-D ≥16  
0 29 5 75 16 
1 46 11 
2 41 7 100 19 
3 27 4 
≥4 32 8 
 
On linear regression, there was an association between continuous condition count 
and continuous CES-D score that met conventional statistical significance when 
adjusted for demographics, as shown in Table 4-6. This suggested an increase in 
CES-D score by 0.62 points (95% CI 0.04 to 1.20) with each additional chronic 
condition. However, the association was no longer significant when additionally 
adjusting for antidepressant use or in a subsample not taking antidepressants. In 
addition, the positive associations had wide confidence intervals, likely due to small 
numbers of people attaining each score on the CES-D (all results are shown in Table 
4-6). To address this, I also used a binary outcome variable of ≥16, which showed no 
significant associations with continuous conditions. Multimorbidity (≥2 conditions) was 




Table 4-6: Results of regression models for depression outcomes dependent on chronic physical conditions 
 
Model 1: Adjusted for 
age, gender, race 
Model 2: Adjusted for 
age, gender, race, 
antidepressant use for 
psychiatric indication 
Model 3: Adjusted for 
age, gender, race in 






a Odds ratio per unit increase in number of chronic conditions 
    Exposure 
 
Outcome 
Model Chronic physical conditions Multimorbidity  
(≥2 compared to 0-1 conditions) 












Model 1 0.62  
(0.04 to 1.20) 
 0.035 1.72  
(-0.44 to 3.89) 
 0.118 
Model 2 0.46  
(-0.13 to 1.05) 
 0.126 1.26 
(-1.02 to 3.54) 
 0.278 
Model 3  0.37  
(-0.26 to 1.00) 
 0.250 0.91  
(-1.31 to 3.14) 
 0.420 
CES-D ≥16 Model 1  1.06  
(0.86 to 1.29) 
0.573  0.86  
(0.39 to 1.88) 
0.698 
Model 2  1.01  
(0.81 to 1.24) 
0.904  0.75  
(0.36 to 1.68) 
0.486 
Model 3   0.94  
(0.72 to 1.19) 
0.629  0.63  




Model 1  1.41  
(1.11 to 1.80) 
0.005  2.38  
(0.77 to 9.02) 
0.159 
Model 2  1.25  
(0.82 to 1.90) 
0.295  0.81 
(0.10 to 5.72) 
0.833 
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4.4.3.2 Chronic conditions and self-reported depression  
Sixteen (7.6%) people reported a current diagnosis of depression, and of those, seven 
(43.7%) scored 16 or more on the CES-D (Table 4-7).  
Table 4-7: CES-D scores compared to self-report 
Self-reported depression CES-D <16 CES-D ≥16 
Current depression 9 7 
No current depression 166 28 
 
I calculated the mean of each exposure variable according to participants’ self-
reported depression status, and used a Student’s t-test to examine the differences 
between the means, as shown in Table 4-8. There was a difference between the mean 
number of chronic physical conditions among people with and without self-reported 
depression (P=0.025), but not their number of medications. 
Table 4-8: Mean chronic conditions and medications according to depression status 
 Mean (SD) in 
participants with self-
reported depression 






Number of chronic 
conditions 
3.63 (2.50) 2.05 (1.75) 0.025 
Number of 
medications 
2.69 (3.20) 1.43 (1.85) 0.140 
 
Again, the numbers of people with each number of chronic conditions and depression 
were small, as shown in Table 4-9.  
Table 4-9: Number of conditions by self-reported depression status 
 No depression Depression 
0 conditions 34 0 
1 condition 53 4 
2 conditions 45 3 
3 conditions 29 2 
≥4 conditions 33 7 
 
I carried out logistic regression of continuous number of physical conditions as the 
exposure variable to predict self-reported depression. There was an association 
between these two, shown in Table 4-6, which remained when adjusting for 
demographic covariates (OR for depression with each additional condition=1.41, 95% 
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CI 1.11 to 1.80, P=0.005) but not for antidepressant use (OR=1.25, 95% CI 0.82 to 
1.90, P=0.295). However, the numbers in each group were small. When treating 
multimorbidity as dichotomous, there was no significant association with self-reported 
depression. 
 
I did not conduct analyses in the subsample of people not taking antidepressants for 
psychiatric indication with the outcome of self-reported depression, as the overlap 
between this outcome and taking antidepressants was high, and numbers of 
participants were small. 
 
4.4.3.3 Medication use and CES-D score  
In these analyses, the count of medications excludes antidepressants. Similarly to 
chronic conditions, the number of people with individual numbers of medications 
according to CES-D score was relatively small, as shown in Table 4-10.  
Table 4-10: Number of participants with each number of medications (excluding 
antidepressants), by CES-D score 
Number of medications CES-D <16  CES-D ≥16  
0 67 14 
1 48 6 
2 32 4 
3 5 3 
4 13 2 
≥5 10 6 
 
With each additional medication, the CES-D score increased by 0.66 points (95% CI 
0.12 to 1.21, P=0.017), until adjusted for antidepressant use (β=0.52, 95% CI -0.03 
to 1.07, P=0.062), as shown in Table 4-11. The association between continuous 
conditions and scoring ≥16 on CES-D was only significant in the unadjusted model 
(OR with each additional medication=1.20, 95% CI 1.02 to 1.40, P=0.022).  
 
Polypharmacy (≥3 medications) was only associated with continuous and binary CES-
D scores in unadjusted models (continuous: β=3.52, 95% CI 0.71 to 6.34 and binary: 




Table 4-11: Results of regression models for depression outcomes dependent on medication use 
 
Model 1: Adjusted 
for age, gender, 
race 
Model 2: Adjusted 
for age, gender, 
race, antidepressant 
use for psychiatric 
indication 
Model 3: Adjusted 
for age, gender, 





a Odds ratio per unit increase in number of medications 
    Exposure 
 
Outcome 
Model Medications  
excluding antidepressants 
Polypharmacy 













Model 1 0.66  
(0.12 to 1.21) 
 0.017 2.59 
(-0.22 to 5.40) 
 0.071 
Model 2 0.52  
(-0.03 to 1.07) 
 0.062 2.30  
(-0.48 to 5.08) 
 0.104 
Model 3  0.38  
(-0.23 to 0.99) 
 0.220 1.60  
(-1.33 to 4.53) 
 0.283 
CES-D ≥16 Model 1  1.17  
(0.98 to 1.39) 
0.078  2.13 
(0.83 to 5.24) 
0.106 
Model 2  1.14  
(0.94 to 1.36) 
0.169  2.02  
(0.77 to 5.03) 
0.139 
Model 3   1.05  
(0.84 to 1.29) 
0.651  1.42  





Model 1  1.36  
(1.07 to 1.73) 
0.010  1.80 
(0.42 to 6.55) 
0.392 
Model 2  1.11  
(0.76 to 1.71) 
0.621  1.21  
(0.12 to 10.3) 
0.865 
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4.4.3.4 Medication use and self-reported depression 
On logistic regression, there was an association between number of medications and 
self-reported depression (OR with each additional medication=1.36 (95% CI 1.07 to 
1.73, P=0.010), except when adjusting for antidepressant use (OR=1.11, 95% CI 0.76 
to 1.71, P=0.621). These results are shown in Table 4-11 and, along with the models 
where conditions were an exposure, are displayed in Figure 4-11.  
 
Owing to the small number of people with self-reported depression, I used a binary 
polypharmacy exposure variable of ≥3 compared to 0-2 medications. There was no 
significant association between this and the occurrence of self-reported depression. 
 
In summary, increasing conditions and medications were associated with self-
reported depression. Increasing numbers of conditions and medications were 
associated with increasing scores on CES-D. These associations were attenuated 
when accounting for antidepressant use. 
 
Figure 4-11: Odds ratio for reporting depression in medical history with larger (continuous) 
numbers of conditions or medications 
 
Model 1: Adjusted for age, gender, race 
Model 2: Adjusted for age, gender, race, antidepressant use for psychiatric indication 
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4.4.4 Anxiety outcomes 
The range of possible scores on the STAI is 20-80. The mean score in the PREVENT 
Dementia cohort was 30.4 (SD 9.4), median 28 and range 20-60. I used the 
continuous measure to better understand symptoms, as well as a dichotomous 
outcome. Figure 4-12 shows the distribution of scores, again with right skew. 
 
In preliminary analyses with the outcomes of the Spielberger State-Trait Anxiety 
Inventory (STAI) (state questions only) and self-reported anxiety disorder, I tested 
control variables using linear regression. Race, antidepressant use and head injuries 
were associated (P<0.05) with at least one of the two anxiety outcomes and at least 
one of the exposure variables (number of chronic conditions and medications). I 
included age, gender and race as covariates, for consistency with the depression 
outcome analyses.  
 
Figure 4-12: Distribution of STAI scores in PREVENT 
 
4.4.4.1 Chronic conditions and Spielberger State Anxiety Inventory score 
Using linear regression, I examined the association between numbers of chronic 
physical conditions (continuous and dichotomous) and STAI scores (both continuous 
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and dichotomised). None of the models attained conventional statistical significance; 
all results are shown in Table 4-13. 
 
4.4.4.2 Chronic conditions and self-reported anxiety disorder 
Due to the relatively small numbers of people reporting an anxiety disorder diagnosis, 
I present the characteristics of each exposure variable between the groups in Table 
4-12. A Student’s t-test showed a difference between the means of chronic conditions 
(P<0.001) in people with and without an anxiety disorder, whereas the mean numbers 
of medication were not significantly different. 
 
 
Table 4-12: Exposure variable characteristics by anxiety disorder diagnosis 




Mean (SD) in 
participants 




Number of chronic 
conditions 
4.2 (2.44) 1.95 (1.65) <0.001 
Number of medications 2.24 (2.51)  1.44 (1.93) 0.174 
 
Logistic regression of continuous chronic conditions showed an association between 
increasing morbidity and self-reported anxiety disorder, which remained when 
adjusting for all relevant covariates, including antidepressant use (OR with each 




Table 4-13: Results of regression models for anxiety outcomes dependent on chronic conditions 
Model 1: Adjusted 
for age, gender, race 
Model 2: Adjusted 
for age, gender, 
race, antidepressant 
use for psychiatric 
indication 
Model 3: Adjusted 
for age, gender, race 




a Odds ratio per unit increase in number of chronic conditions
    Exposure 
 
Outcome 
Model Chronic physical conditions Multimorbidity  













Model 1 0.06  
(-0.64 to 0.76) 
 0.860 1.20  
(-1.39 to 3.79) 
 0.361 
Model 2 -0.07  
(-0.78 to 0.65) 
 0.855 0.92  
(-1.70 to 3.53) 
 0.490 
Model 3  0.02  
(-0.75 to 0.78) 
 0.963 0.62  
(-2.08 to 3.32) 
 0.651 
STAI ≥40 Model 1  0.69  
(0.22 to 1.84) 
0.485  0.74 
(0.33 to 1.64) 
0.451 
Model 2  0.72 
(0.23 to 1.92) 
0.532  0.77  
(0.34 to 1.72) 
0.517 
Model 3   0.68 
(0.21 to 1.89) 
0.487  0.73 





Model 1  1.71  
(1.35 to 2.21) 
<0.001  5.35 
(1.68 to 23.9) 
0.011 
Model 2  1.74  
(1.31 to 2.39) 
<0.001  4.50 
(1.13 to 24.9) 
0.051 
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4.4.4.3 Medication use and Spielberger State Anxiety Inventory score 
Twenty-one (10.0%) participants reported a diagnosis of anxiety disorder in the 
medical history. Of these, seven (33.3%) scored ≥40 on the STAI and 12 (46.2%) took 
antidepressants, as displayed in Table 4-14. 
Table 4-14: Characteristics of participants reporting anxiety disorder 
 Self-reported anxiety 
disorder 
No anxiety disorder 
STAI <40 14 164 




Taking antidepressants 12 14 
 
On linear regression analyses, there were no significant associations between 
medications, either continuous or dichotomised, and continuous or dichotomised 
STAI scores. These results are listed in Table 4-15. 
 
4.4.4.4 Medication use and self-reported anxiety disorder 
Results of logistic regression with self-reported anxiety as the outcome and 
medications, both continuous and binary, as exposure variables, are shown in Table 
4-15. Although there was a marginal association in the model adjusted for age and 
gender, there was overall no association to suggest rejecting the null hypothesis in 
these analyses. The results of the odds ratios for self-reported anxiety disorder with 
chronic conditions and medication use are represented in Figure 4-13 on page 154. 
 
In summary, increasing numbers of chronic physical conditions and multimorbidity 
were associated with self-reported anxiety, although absolute numbers were small. 






Table 4-15: Results of regression models for anxiety outcomes dependent on medication use 
 
Model 1: Adjusted for 
age, gender, race 
Model 2: Adjusted for 




Model 3: Adjusted for 
age, gender, race in 





a Odds ratio per unit increase in number of medications 
 
    Exposure 
 
Outcome 
Model Medications  
excluding antidepressants 
Polypharmacy 













Model 1 0.10  
(-0.56 to 0.75) 
 0.766 0.62 
(-2.75 to 3.98) 
 0.717 
Model 2 -0.01  
(-0.68 to 0.66) 
 0.973 0.42 
(-2.94 to 3.79) 
 0.805 
Model 3  0.08  
(-0.65 to 0.82) 
 0.823 0.61 
(-2.95 to 4.17) 
 0.737 
STAI ≥40 Model 1  0.92 
(0.73 to 1.12) 
0.452  0.69  
(0.22 to 1.84) 
0.485 
Model 2  0.94 
(0.74 to 1.14) 
0.547  0.72 
(0.23 to 1.92) 
0.532 
Model 3   0.91  
(0.70 to 1.14) 
0.447  0.68 





Model 1  1.24  
(1.00 to 1.53) 
0.043  1.76 
(0.50 to 5.53) 
0.350 
Model 2  1.05  
(0.78 to 1.40) 
0.760  1.41  
(0.28 to 6.05) 
0.656 
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Figure 4-13: Odds ratios for reporting anxiety disorder in medical history with increasing 
numbers of conditions and medications 
 
Model 1: Adjusted for age, gender, race 
Model 2: Adjusted for age, gender, race, antidepressant use for psychiatric indication 
 
4.4.5 Cognitive test outcomes 
When choosing covariates for the cognitive test outcomes, I found that age, gender, 
race, years of education and CAIDE score were each associated with at least one 
outcome and at least one exposure variable.  
 
4.4.5.1 Chronic conditions and phoneme comprehension time 
The range of mean times on the phoneme comprehension test was 1000-2654 
milliseconds, with a median of 1527. On linear regression with this as a continuous 
outcome and continuous chronic conditions as the exposure, the results (shown in 
Table 4-16) showed no support for rejecting the null hypothesis. Anticipating no further 














Model 1: Adjusted for age, gender 
Model 2: Adjusted for age, gender, race, years of education 
Model 3: Adjusted for CAIDE score 
 
a Odds ratio per unit increase in number of conditions 
b Odds ratio per unit increase in number of medications 
 
 
      Exposure 
 
Outcome 














Model 1 -0.08 
(-22.4 to 22.3) 
 0.994 -4.62 
(-25.3 to 16.1) 
 0.661 
Model 2 -0.87  
(-23.7 to 21.9) 
 0.940 -5.50 
(-26.8 to 15.8) 
 0.611 
Model 3  -0.93 
(-23.3 to 31.5) 
 0.935 -3.31 





Model 1  1.01  
(0.86 to 1.17) 
0.948  1.06  
(0.92 to 1.23) 
0.419 
Model 2  0.99  
(0.84 to 1.16) 
0.873  1.09 
(0.93 to 1.28) 
0.277 
Model 3   1.03  
(0.89 to 1.20) 
0.664  1.07  
(0.93 to 1.23) 
0.375 
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4.4.5.2 Medication use and phoneme comprehension time 
There was no significant association between continuous number of medications and 
phoneme comprehension time, as shown in Table 4-16 on page 155. I therefore did 
not pursue using a dichotomous polypharmacy variable. 
 
4.4.5.3 Chronic conditions and name-face association 
The median score on name-face associative learning was six out of a maximum of 
nine. Using a binary variable around this median, in keeping with previously published 
research using this measure, I performed logistic regression according to continuous 
number of chronic conditions.[308] I found no significant associations. (Table 4-16). 
 
4.4.5.4 Medication use and name-face association  
Using continuous number of medications (excluding antidepressants) as the exposure 
variable, I found no association with binary name-face association scores on logistic 
regression, as shown in Table 4-16.  
 
In summary, there was no suggestion of any associations between increasing 
conditions or medications and either of the cognitive test outcomes.  
 
4.4.6 MRI Outcomes 
Seventeen (8.1%) participants did not have an MRI, so all the following results apply 
to the 193 (91.9%) participants that did. The following covariates were associated 
(P<0.05) with at least one exposure variable and at least one outcome: age, gender, 
race, CAIDE score, and total intracranial volume (except for hippocampal volume, 
which had already been adjusted for total brain volume). To avoid including too many 
covariates in this small sample, I did not include race. 
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4.4.6.1 Chronic conditions and hippocampal volume  
On linear regression analyses, a negative coefficient would suggest that increasing 
chronic conditions was associated with smaller hippocampal volume (which is in turn 
associated with cognitive impairment and dementia). Table 4-17 shows the results, 
which include only a marginal association between the two when adjusting for CAIDE 
score (β= -0.03, 95% CI -0.05 to 0.00, P=0.040). 
 
4.4.6.2 Medication use and hippocampal volume  
In keeping with previous analyses, the medication variable excluded antidepressants, 
although this is less likely to affect MRI outcomes than depression or anxiety. I used 
linear regression to model the association between increasing medications and 
increasing hippocampal volume, and found no significant association, as shown in 
Table 4-17. 
 
In summary, there was only weak evidence in support of an association between 




Table 4-17: Regression results for MRI findings in relation to conditions and medication use 
Model 1: Adjusted for age, gender 
Model 2: Adjusted for CAIDE score 
Model 3: Adjusted for age, gender, total intracranial volume 
 
            Exposure 
 
Outcome 
Model Chronic physical conditions Medications 
(excluding antidepressants) 
Coefficient  (95% CI) P-value Coefficient  (95% CI) P-value  
Hippocampal volume Model 1 -0.01 (-0.04 to 0.01) 0.294 -0.01 (-0.04 to 0.01) 0.230 
Model 2 -0.03 (-0.05 to 0.00) 0.040 -0.02 (-0.05 to 0.01) 0.167 
Periventricular Fazekas 
score 
Model 1 -0.04 (-0.07 to 0.00) 0.027 -0.02 (-0.06 to 0.01) 0.175 
Model 2 -0.03 (-0.06 to 0.01) 0.112 -0.02 (-0.06 to 0.01) 0.112 
Model 3  -0.02 (-0.06 to 0.01) 0.184 -0.02 (-0.06 to 0.01) 0.184 
Deep white matter Fazekas 
score 
Model 1 -0.02 (-0.07 to 0.02) 0.360 0.02 (-0.03 to 0.06) 0.458 
Model 2 -0.02 (-0.06 to 0.03) 0.486 0.02 (-0.03 to 0.06) 0.479 
Model 3  -0.02 (-0.07 to 0.02) 0.300 0.01 (-0.03 to 0.06) 0.534 
Microhaemorrhage count Model 1 0.03 (-0.07 to 0.12) 0.596 -0.02 (-0.12 to 0.08) 0.716 
Model 2 0.03 (-0.07 to 0.13) 0.555 -0.01 (-0.11 to 0.09) 0.825 
Model 3  0.03 (-0.07 to 0.13) 0.539 -0.01 (-0.12 to 0.09) 0.780 
 
Chapter 4: Cross-sectional analyses in the PREVENT Dementia cohort  159 
 
 
4.4.6.3 Chronic physical conditions and Fazekas scores 
I analysed each sub-test of the Fazekas score separately, firstly using the 
periventricular hyperintensity scale as the outcome. The results of linear regression 
analysis with chronic conditions as the exposure showed a marginal association 
between increasing chronic conditions and decreased score on the periventricular 
Fazekas score when adjusted for age and gender only (β= -0.04, 95% CI -0.07 to 
0.00, P=0.027). Again, this association was attenuated when adjusted for CAIDE 
score or intracranial volume. The results are listed in Table 4-17 on page 158.  
 
On linear regression with deep white matter Fazekas subscore as the outcome, there 
was no evidence to suggest an association with total chronic conditions (Table 4-17). 
 
4.4.6.4 Medication use and Fazekas scores  
I used linear regression of continuous number of medications with periventricular 
Fazekas score, and then deep white matter Fazekas score, as the outcomes. Neither 
of these analyses revealed a significant association, as seen in Table 4-17. 
 
4.4.6.5 Chronic conditions and microhaemorrhage count  
The mean number of cerebral microhaemorrhages was 0.28 (SD 1.22), with a range 
of 0-15. In linear regression analyses with continuous chronic conditions as the 
exposure variable, there was no evidence to support an association between these 
variables (see Table 4-17). 
 
4.4.6.6 Medication use and microhaemorrhage count 
With continuous medications as the exposure variable, I used linear regression with 
microhaemorrhage count as the outcome. There was no apparent association, as 
shown in Table 4-17. 
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In summary, there was no convincing evidence for associations between increasing 




4.5.1 Summary of main findings 
Findings from this initial wave of the PREVENT Dementia study show that participants 
had a mean of 2.2 (SD 1.9) chronic physical conditions. It is difficult to compare 
multimorbidity between studies, as the lists used to generate condition counts vary 
considerably.[264] A recent English primary care cohort study found that people aged 
45-54 years had a mean of 0.8 (SD 1.2) chronic conditions,[38] and Scottish data 
showed 45-64 year-olds had a mean of 1.2 conditions (SD 1.5).[39] The apparently 
above-average prevalence of multimorbidity in PREVENT Dementia participants may 
reflect the high number of conditions enquired about and the method of self-report at 
a detailed interview by a doctor. 
 
The majority of PREVENT Dementia participants (n=132, 62.9%) were taking at least 
one medication, and among those, the mean medications taken was 2.6 (SD 2.2). 
This compares to a study of all adults in one area of Scotland aged over 20 years 
which found 58.2% of the population were prescribed any drugs, and of those, the 
mean of drugs dispensed was 4.4.[323] PREVENT Dementia participants therefore 
take on average fewer medications than the general population, which is likely due to 
the mid-life age range and that participants are healthy volunteers. 
 
As discussed in section 4.4.1.2 on page 137, the mean number of medications per 
condition was 0.72, which is less than figures reported in the literature. For example, 
a 2018 Swedish register-based population study of adults aged over 75 years found 
a mean of 2.4 chronic conditions and 4.6 medications, that is a mean of 1.92 
medications per condition.[78] The discrepancy may be explained in PREVENT 
Dementia by the detailed medical history interview revealing more conditions than 
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would be found in medical records, but the number of medications remaining the 
same. 
 
4.5.1.1 Hypotheses addressed  
1. a) There was an association between increasing chronic conditions and self-
reported depression (adjusted OR with each additional condition=1.41, 95% 
CI 1.11 to 1.80, P=0.005) and increasing CES-D scores (adjusted model 
β=0.62, 95% CI 0.04 to 1.20, P=0.035). Dichotomous multimorbidity was not 
associated with these outcomes. In all cases, the associations were 
attenuated when accounting for use of antidepressants for psychiatric 
indications. 
b) An increasing number of chronic conditions was associated with self-reported 
anxiety disorder, which was maintained when adjusting for antidepressant use 
(adjusted OR=1.74, 95% CI 1.31 to 2.39, P<0.001). There was no association 
between chronic conditions and increasing scores on the STAI. 
c) There were no associations between multimorbidity and cognitive test scores. 
 
2. a) There was an association between increasing numbers of medication 
increasing scores on the CES-D (adjusted β for each additional 
medication=0.66 (95% CI 0.12 to 1.12, P=0.017). The association was not 
convincing when adjusted for antidepressant use. Increasing numbers of 
medication were also associated with self-reported depression (OR=1.36, 
95% CI 1.07 to 1.73, P=0.010), but not when adjusting for antidepressant use. 
A dichotomous marker of polypharmacy was not significantly associated with 
depression outcomes in adjusted models. 
b) There were no associations between medication use and either self-reported 
anxiety disorder or increasing scores on STAI. 
c) I found no associations between medication use and cognitive impairment 
according to COGNITO test scores. 
3. There was no association between increasing numbers of chronic conditions and 
decreasing hippocampal volume, cerebral microhaemorrhages or increasing Fazekas 
score.  
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4. There were no associations between increasing medication use and MRI outcomes 
linked to dementia and cognitive impairment. 
 
4.5.2 Comparison with other literature 
A systematic review and meta-analysis of 40 papers studying multimorbidity and 
depression found that people with multimorbidity were at over twice the risk (risk ratio 
2.13 (95% CI 1.62 to 2.80)) of developing depression compared to those without.[288] 
My findings support this result, albeit with a smaller odds ratio and treating chronic 
conditions as continuous (OR with each condition for self-reported depression=1.41, 
95% CI 1.11 to 1.80, P=0.005).  
 
There was an association between increasing number of medications and scores on 
the CES-D, which supports previously published findings using this measure.[95] 
However, the results differed when I dichotomised medications into a polypharmacy 
variable. I am aware of the dangers of over-analysing data, particularly in a relatively 
small dataset. I consider that if changing the parameters could substantially alter the 
strength of an association, the association should be considered modest at best. 
There is little in the literature about polypharmacy and specific anxiety outcomes so 
my positive findings in this area are new. 
 
Previous work reported from a longitudinal study has also found that people with 
multimorbidity are at increased risk of having increased anxiety symptoms (OR=2.30, 
95% CI 1.44 to 4.01).[324] I did not find a similar association on testing for anxiety 
symptoms, but did find an association between increasing physical conditions and 
reporting a diagnosis of anxiety disorder (fully adjusted OR=1.74 95% CI 1.31 to 2.39, 
P<0.001). This difference between reported diagnosis and objective measurement 
may reflect the fact that those who report a diagnosis are likely to be receiving 
treatment and therefore report fewer active symptoms.  
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There is little published literature on multimorbidity and neuroimaging outcomes and 
none on polypharmacy.[98,99] Either this is a novel area for exploration, or my 
negative findings in this area may suggest publication bias, in that other researchers 
have found no associations and therefore have not published their results. There is 
more evidence of a link between multimorbidity and cognitive decline,[47] and the co-
existence of dementia with multiple physical conditions.[39] The only findings of 
interest on neuroimaging were marginal associations between chronic conditions with 
decreased hippocampal volume and decreased periventricular Fazekas scores. 
These contradict each other, as smaller hippocampal volume and higher Fazekas 
scores are markers of neurodegeneration. Previous research has established a link 
between multimorbidity and lower hippocampal volumes.[99] 
 
Other research has examined links between polypharmacy and worsening cognition, 
with variation between studies on whether they found an association or not.[291,325] 
There is no single agreed definition of a cut-off for polypharmacy, and many of these 
studies use different parameters. In addition, my analyses did not support an 
association between chronic condition count and poorer performance on cognitive 
testing. This may be due to the mid-life age profile of the PREVENT Dementia cohort. 
Its design aims to detect subtle longitudinal changes in cognition, which is outside the 
scope of this cross-sectional work.  
 
4.5.3 Strengths  
This chapter investigates the risk factors of chronic conditions and medications in a 
thoroughly phenotyped ageing cohort. The outcomes examined include not only 
validated rating scales and cognitive tests but also MRI measures and participant-
reported clinical diagnoses. This selection of measures therefore adds considerable 
breadth compared to existing research in this area. In addition, most previous studies 
only measure continuous or dichotomous measures of chronic conditions or 
medications, whereas this chapter includes both.[288] 
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In all but one analysis, apparent associations between multimorbidity or 
polypharmacy and depression or anxiety outcomes ceased when including 
antidepressant use as a control variable. This implies that taking antidepressants, 
perhaps as a marker for mental disorders (fully or partially treated), is an important 
explanation in the pathway between chronic conditions, medication use and anxiety 
and depression. This overlap between physical and mental illness is complex and 
difficult to capture but I attempted to understand it by approaching it from several 
different angles. To my knowledge, no previous research on these topics has 
attempted to account for this example of confounding by indication; this is a strength 
of my work.[95,288,324,326] 
 
4.5.4 Limitations 
4.5.4.1 Study characteristics 
The data available were collected in the baseline pilot phase of the PREVENT 
Dementia study, so allow only cross-sectional analyses of 210 participants. The 
cohort was designed as a longitudinal study. Cross-sectional analysis leaves 
questions about direction of causality unclear. It is known, for example, that all mental 
disorders are associated with later physical health consequences, so the findings from 
this study may reflect people who were originally depressed experiencing physical 
health deterioration.[286] Although relevant covariates were considered, the 
possibility of residual confounding remains. 
 
With such a sample size, groups within the dataset can be small, for example only 26 
participants reported current use of antidepressant medication. There are also more 
women (148, 70.5%) than men in the sample, so when groups are subdivided by 
gender they can become very small. For example, only seven men took 
antidepressants. It is important to recognise the role of chance in analyses on these 
numbers, and effect size could be over-estimated.  
 
The cohort in general is relatively young and consists of healthy volunteers. I expected 
an under-estimation of levels of multimorbidity and polypharmacy through selection 
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bias. However, following up a young cohort allows investigation of the theory that the 
genesis of later-life depression associated with polypharmacy may originate in mid-
life. The results compared to other published data suggest that under-estimation is 
unlikely.  
 
There was a high prevalence of previous head injuries within the cohort, with 81 
(38.6%) participants reporting at least one head injury that led to loss of 
consciousness. This may have been relevant to cognitive or neuroimaging outcomes, 
but was deemed less important than other confounding factors when selecting 
covariates. 
 
Seventeen (8.1%) of the sample did not have an MRI, for reasons unknown. This is 
another potential source of selection bias for the MRI outcome variables. My analysis 
with cerebral microhaemorrhages as an outcome looked only at total load rather than 
presence in specific regions. When analysing future waves I will include a breakdown 
of lobar versus deep microbleeds, which could differentiate between microvascular 
and Alzheimer’s pathology.[314] 
 
4.5.4.2 Medical history 
The nature of the PREVENT Dementia initial visit is that all the medical history and 
medications are self-reported at interview with a doctor. This can lead to several types 
of bias including recall bias and social desirability bias.[327] Self-reported depression 
may be more sensitive than CES-D for identifying people with a clinical diagnosis who 
have received treatment and therefore perform better on testing than they might have 
done untreated. However, participants may also report depression that has not been 
clinically diagnosed, more so perhaps than a physical condition. Previous studies 
comparing self-report with diagnostic or screening tests for depression have remarked 
upon this complex relationship.[328] Self-reported antidepressant use in cohort 
studies, however, has been found to correlate strongly with prescription records.[329] 
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Some of the medical history obtained in PREVENT Dementia is rather ambiguous; for 
example, there is no differentiation between type I and type II diabetes, which differ 
pathologically and prognostically. There were incidences where significant conditions 
were only included in the free-text ‘other’ section, such as rheumatoid arthritis and 
sarcoidosis. There is potential for overlap between some listed conditions, such as 
irritable bowel syndrome and chronic constipation. 
 
There is only one option for recording any eye disease, with no possibility of adding 
free text. Therefore, the relatively high proportion of people reporting ‘eye 
disease/disorder’ may be explained by myopia or presbyopia. There is no way of 
establishing whether this is the case, though, and the category would also include 
common ophthalmic conditions such as glaucoma and age-related macular 
degeneration. A systematic review and meta-analysis on the prevalence of 
depression among people with eye disease found a pooled odds ratio of depression 
of 1.59 (95% CI 1.40 to 1.81) compared to healthy controls, across 13 studies.[330] 
The study also found that the eye condition with the highest prevalence of depression 
was dry eye disease, which could be considered a relatively minor diagnosis. This 
highlights that mental health implications of common conditions may not correlate with 
clinicians’ perceived severity of illness. Owing to these associations, I chose not to 
exclude all eye disease from the main analyses, as doing so would make assumptions 
that what was recorded was not important. I did remove eye diseases from some of 
my network analyses. 
 
The inclusion of eye diseases which had unexpectedly high prevalence is likely to 
have artificially increased the mean number of conditions and the prevalence of 
multimorbidity. It may have led to over-estimated associations between chronic 
condition count and the mental health outcomes. If future similar analyses are 
performed in this dataset, I will advise conducting sensitivity analyses to assess the 
importance of eye diseases. 
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For these analyses, I included all conditions listed in the PREVENT Dementia 
participant case report form that I deemed chronic. There have been numerous 
publications discussing how many and which conditions should be included when 
investigating multimorbidity, as discussed in detail in Chapter 2. Previous research 
has recommended using a list of between 25-75 conditions, so the 55 I included is 
likely to be an appropriate number.[260] My selection could be seen to be subjective. 
Future work on this dataset may benefit from redefining the list of conditions based 
on previous publications, although it would not possible to fully harmonise the list used 
in PREVENT Dementia with that of Barnett et al.[39] For example, the lack of free text 
options means that conditions like glaucoma included in Barnett and colleagues’ list 
could not be separated. 
 
I applied my definition of chronic disease broadly to each diagnosis. No information 
on individual participants’ disease severity was collected so this process may have 
over- or under-estimated the impact on each individual. I excluded conditions that are 
nonetheless important risk factors for significant disease, such as hyperlipidaemia, 
based on this definition. There is no separate category for gynaecological disorders 
so these were recorded under ‘other genitourinary/reproductive’. There is no space 
on the participant case report form to record ‘other pulmonary disease’. I excluded all 
dermatological conditions recorded in ‘other’ categories as none of them met the 
criteria above. I list prevalence for all conditions in Table 4-3 on page 132, even those 
where no participants reported the condition, to allow harmonisation with analysis of 
future waves of the PREVENT Dementia study. 
 
4.5.4.3 Sample size 
The most obvious limitation of this work compared to that in other datasets is its 
relatively small size. I chose to conduct these analyses partly to inform further the 
questions I would ask in bigger datasets, and to prepare the practicalities of doing so. 
PREVENT Dementia contains detail on many measured parameters that may be 
confounding factors, and this level of information is not available in extremely large 
datasets such as the linked NHS prescribing data presented in Chapter 6. In addition, 
the cognitive tests used in PREVENT Dementia are rigorous and well validated. 
 
Chapter 4: Cross-sectional analyses in the PREVENT Dementia cohort  168 
 
 
The pilot phase of PREVENT Dementia was powered to detect changes in 
hippocampal volume and plasma Aβ42, not the other outcomes examined. However, 
where I did see results suggesting statistical significance, I reported raw P-values to 
allow cautious interpretation rather than relying upon an arbitrary cut-off. 
 
4.5.4.4 Other measurements and analyses 
I included all medication that had a WHO ATC code. This included all regularly taken 
prescription medicines, but also included some that may be less relevant, such as 
three-monthly depot progesterone injection and an adrenaline EpiPen that would only 
be used infrequently as required. This does not match with my analyses in Chapter 6 
and could be reconsidered in future work with these data.  
 
PREVENT Dementia used the original CES-D, as opposed to the 2004 revised 
version, in order to harmonise with other similar cohort studies. The revised version 
replaces the inverted questions (for example “I was happy”) with their opposites 
(“nothing made me happy”). It also includes questions on somatic and psychomotor 
symptoms of depression and thoughts of self-harm and death. Nine of the twenty 
questions were replaced with completely different ones, so the scales are not 
interchangeable. The total scores are comparable, but there is an additional option 
for answering ‘nearly every day for two weeks’ as a symptom measure for use when 
making a diagnosis.[331] This limits the comparability of some of my findings to other 
research using the revised CES-D. 
 
Owing to the small sample size, I only used outcomes of two subtests of the 
COGNITO battery that had previously been found to be of interest in this cohort.[308] 
The phoneme comprehension task tested semantic memory and name-face 
associative learning tested episodic memory.[332] Changes in episodic and semantic 
memory have been identified as early markers of prodromal Alzheimer’s 
disease.[333,334] However, restricting my analyses to these tests neglected other 
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important cognitive domains for detecting preclinical disease including psychomotor 
speed and verbal fluency.[334] 
 
Network analysis has limitations depending on the specific methods used, and in this 
chapter I present the graphs only for description of the sample rather than to infer the 
existence of statistical networks.[335] 
 
4.5.5 Implications 
The presence of associations between condition count and medication use with 
depression, and condition count with anxiety, lends support to my overall thesis 
hypotheses of the important influence of physical health and resulting medication 
burden on mental health. The modest nature of these results in a small sample size 
limits the certainty with which conclusions can be drawn, but reinforces the need to 
corroborate them in much larger datasets. A particular strength of completing this 
work in a pilot wave of an ongoing longitudinal study is the opportunity to revisit the 
analyses when data from future waves are available. 
 
4.6 CONCLUSIONS 
In this cross-sectional study of a middle-aged cohort of healthy volunteers, I found 
associations between increasing chronic conditions and both self-reported depression 
and self-reported anxiety disorder. In addition, there were associations between 
medication use and depression (both self-reported and according to a screening 
scale).  
 
I found evidence of a marginal association between multimorbidity and decreasing 
periventricular Fazekas score. I found these associations in the context of numerous 
other calculations, the remainder of which suggested no association. The findings 
should therefore be interpreted with caution. This work is not able to support the idea 
that mechanisms leading to late-life depression or dementia may appear in the 
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decades before clinical concern arises, but follow-up of these same participants may 
be able to examine this link. 
 
The work on depression and anxiety outcomes in this chapter has been published in 
the Journal of Comorbidity and is presented in Appendix 2. 
 
In Chapter 5, I focus in more depth on a specific biomarker of Alzheimer’s disease, 
amyloid-β, as measured in cerebrospinal fluid in a different cohort optimised for 
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Chapter 5 Cross-sectional analyses in the EPAD 
cohort 
5.1 INTRODUCTION 
In Chapter 4, I explored the relationship between multimorbidity and clinical mental 
health outcomes including self-reported diagnoses and scores on cognitive and 
psychological tests. I also assessed some imaging outcomes, finding no strong 
associations between multimorbidity, polypharmacy and markers of 
neurodegeneration. In this chapter, I build on that biological investigation by focusing 
in depth on one biomarker of Alzheimer’s disease in the European Prevention of 
Alzheimer’s Dementia (EPAD) longitudinal cohort study.  
 
This work has been published in the Journal of Alzheimer’s Disease and is presented 
below after a general introduction, then followed by further discussion. I prepared and 
analysed the data, created the figures, wrote the first draft of the manuscript and made 




Dementia is a common mental disorder, with an estimated prevalence of 7.1% in 
people aged 65 and over in the UK.[336] It is associated with adverse outcomes for 
individuals including reduced independence and increased mortality. There are 
economic costs to health and social care providers as well as personal costs to unpaid 
carers.[40] Diagnoses of dementia are made clinically and in most patients cannot 
currently be confirmed by imaging or biomarker investigations. Estimates suggest that 
clinically overt Alzheimer’s disease accounts for 62% of dementia in the UK.[336]  
 
 
15 A reviewer from the Journal of Alzheimer’s Disease pointed out the difference between the 
terms sex and gender. The EPAD participant case report form used the word ‘sex’ so I have 
used this term throughout the chapter. 
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5.1.1.1 Amyloid hypothesis 
Alzheimer’s disease pathology is defined as the presence of plaques formed of 
extracellular amyloid-β (Aβ) deposits, neurofibrillary tangles of abnormal tau filaments 
and evidence of neurodegeneration.[337] Around 95% of cerebral Aβ is Aβ40 (the 
peptide terminating at carboxyl 40), but Aβ42 is believed to initiate the formation of 
plaques.[338] The amyloid cascade hypothesis states that an increase in Aβ leads to 
its aggregation, impaired synaptic function and resulting neuronal damage.[337] Aβ42 
is secreted into cerebrospinal fluid (CSF), so is accessible in clinical and research 
settings. Low CSF amyloid β42 is a marker of brain Aβ deposition and is used to 
identify preclinical Alzheimer’s disease that is present before the emergence of 
cognitive symptoms.[339,340] Cerebral amyloid is also important as a therapeutic 
target, and there have been several trials of drugs, for example that decrease Aβ 
production or aggregation, or act as immunotherapy against Aβ.[341] Some of these 
trials, for example of aducanumab, have shown promising results but there is as yet 
little evidence that they will be clinically or cost effective.[342] 
 
5.1.1.2 Amyloid and vascular disease 
It has previously been established that systemic vascular disease is associated with 
cerebral amyloid angiopathy, where amyloid is deposited in arterial walls, increasing 
arterial stiffness.[343] This in turn reduces amyloid clearance and further increases 
deposition within both brain vasculature and parenchyma.[344] Epidemiological 
studies have found associations between mid-life hypertension and Alzheimer’s 
disease.[345] While this relationship between vascular and amyloid processes has 
been thoroughly studied both in fundamental science and at population level, there 
has to date been very little research into the biological mechanisms between 
multimorbidity and neurodegeneration. 
 
5.1.1.3 Existing evidence 
To inform my analysis, I first conducted a literature search in MEDLINE for relevant 
papers on amyloid and multimorbidity (updated 16th January 2020), then checked their 
bibliographies. There are three publications, reflecting two unique studies, on 
multimorbidity and amyloid neuroimaging biomarkers, all published since 
2016.[98,99,292] They all report no association between numbers of chronic 
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conditions and amyloid status, and are explored in more detail in the paper’s 
Discussion. I found no published research investigating multimorbidity and CSF Aβ.  
 
The majority of people with dementia have at least one other comorbid condition. A 
cross-sectional study carried out in 291 169 adults aged over 65 years in Scottish 
primary care found that 10 258 (3.5%) had a recorded diagnosis of dementia.[346] 
Using a list of 32 possible physical conditions, the authors found that people with 
dementia were more likely to have five or more physical conditions than people 
without (age and sex adjusted OR=1.42, 95% CI 1.35 to 1.50; P<0.001) and had 
increased levels of polypharmacy. Data from 21 917 patients in The Health 
Improvement Network (THIN) in England, albeit with a shorter list of ten conditions, 
showed that 77% of people with dementia had at least one other condition.[48] A 
cross-sectional Spanish study of 72 815 people aged over 64 years explored the 
comorbidities of dementia in detail. The authors reported that the most common 
comorbidity was hypertension but that comorbidities differed by gender, with a 
prominence of comorbid anxiety disorders in women.[347] In addition, a cross-
sectional examination of the World Health Organization Study on Global Ageing and 
Adult Health included six low and middle income countries and found an association 
between multimorbidity (≥2 conditions) and mild cognitive impairment in these 
settings (multiply-adjusted OR=1.40, 95% CI 1.23 to 1.58).[348] 
 
Up to 35% of risk factors for dementia are thought to be potentially modifiable.[40] A 
major report on this topic in 2017 estimated that hypertension contributes 2% and 
diabetes 1% to a person’s lifetime risk of dementia.[40] Optimal management of these 
conditions, whether existing alone or as aspects of multimorbidity, could prevent or 
delay progression to dementia. It is therefore worthwhile exploring the area of chronic 
illnesses as a potential candidate for dementia prevention. This fits with one of the 
stated aims of the European Prevention of Alzheimer’s Dementia (EPAD) Consortium, 
“to improve the understanding of the early stages of Alzheimer’s disease”.[349] 
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The relationship between multimorbidity and dementia is clinically relevant, but 
mechanisms are unclear. There is a particular gap in the literature on multimorbidity 




Multimorbidity, or having a larger number of chronic 
conditions, will be associated with lower concentrations of 
CSF amyloid-β, as a marker of Alzheimer’s disease. 
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Abstract.
Background: Multimorbidity (the co-occurrence of multiple chronic conditions) is increasingly common, especially among
people with dementia. Few neuroimaging studies have explored amyloid biomarkers in people with multimorbidity.
Objective: We aimed to conduct the first study of the association between multimorbidity and cerebrospinal fluid amyloid-!42
(CSF A!).
Method: The European Prevention of Alzheimer’s Dementia (EPAD) Longitudinal Cohort Study V500.0 dataset includes
volunteers aged "50 years from 12 sites. Participants undergo detailed phenotyping, including CSF measures and a self-
reported medical history. Using logistic and linear regression analyses, we explored the association between multimorbidity
and continuous chronic condition count with CSF A! positivity (A!42 <1000pg/ml) and continuous CSF A! concentration.
All models were adjusted for age, sex, APOE status, education, and family history of dementia.
Results: Among 447 eligible participants without dementia, the mean (SD) age was 66.6 (6.6) years, 234 (52.3%) were
women, and 157 (35.1%) were amyloid positive. With chronic conditions regarded as pseudo-continuous, each additional
condition carried a decreased likelihood of amyloid positivity (OR = 0.82, 95%CI: 0.68–0.97; p = 0.026). With CSF A! as a
continuous variable, each additional condition was associated with an increase of 54.2 pg/ml (95%CI: 9.9–98.5, p = 0.017).
Having "2 conditions was inversely associated with amyloid positivity (OR 0.59, 95%CI: 0.37–0.95, p = 0.030) compared
to one or none.
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Conclusion: Our findings suggest that the established association between multimorbidity and dementia may be due to a
pathway other than amyloid. However, this cross-sectional study does not allow us to make causal inferences. Longitudinal
work is required to confirm the inverse association found.
Keywords: Alzheimer’s disease, amyloid, dementia, multimorbidity
INTRODUCTION
Multimorbidity, the co-occurrence of multiple
chronic diseases within one individual, is increas-
ing in prevalence. It is costly to health services and
has been shown to be associated with poor quality of
life in adults of all ages [1, 2]. A recent report high-
lighted its importance and identified it as a priority
for research [3].
The literature on multimorbidity and dementia
is limited. For example, a cross-sectional study of
the Scottish population found that 82% of people
with dementia had two or more comorbid conditions
[4]. Investigators from the longitudinal Mayo Clinic
Study of Aging (MCSA) reported that people with
!2 conditions were at increased risk of cognitive
impairment or dementia compared to individuals with
0–1 conditions (hazard ratio, 95% confidence inter-
val [CI] 1.38, 1.05–1.82) [5]. However, three recent
papers, describing cross-sectional analyses of two
cohort studies, reported no association between the
total number of conditions and amyloid deposition
on neuroimaging [6–8].
Cerebrospinal fluid (CSF) amyloid-!1-42 (A!) is a
biomarker that represents soluble amyloid. Low lev-
els of CSF A! may reflect plaque deposition under
the peripheral sink hypothesis and are associated with
Alzheimer’s disease and dementia [9, 10]. Cerebral
amyloid is of interest both for use in clinical diagno-
sis and as a focus for stratification into Alzheimer’s
disease drug trials [11, 12]. We found no published
research into multimorbidity and amyloid status as
determined using CSF. Consequently, we present the
first study investigating associations between multi-
morbidity and CSF A!42.
METHODS
Study participants
The European Prevention of Alzheimer’s Demen-
tia (EPAD) study is a pan-European multi-site project
consisting of a cohort without dementia (ClinicalTri-
als.gov #NCT02804789). It allows both longitudinal
research into potential preventative strategies for
neurodegeneration and a cohort prepared for clin-
ical trials of dementia drugs [13, 14]. Participants
aged over 50 years were recruited from parent cohorts
across twelve trial delivery centers in Europe. To be
eligible, they had to have at least seven years of for-
mal education and have a study partner willing to
provide collateral information. Potential participants
were excluded if they fulfilled diagnostic criteria for
dementia, had a known genetic mutation associated
with autosomal dominant Alzheimer’s disease, had
active cancer within the last five years (except basal or
squamous skin carcinoma or localized prostate can-
cer), had a significant unstable physical or mental
illness or were unable to consent. All participants
provided informed consent and ethical approval
was obtained from ethics committees local to each
study site. Numerous biological, psychometric, and
imaging measures were taken to allow detailed phe-
notyping. In this study, we used the EPAD V500.0
data release, which contains initial visit data from
the first 500 participants across all twelve sites. The
sample characteristics were described in detail in a
previous publication [15].
Study variables
Each EPAD study visit included a detailed medical
and medication history, collected by a study doctor.
Participants reported their own diagnosed conditions
and current medications. To define chronic condi-
tions for these analyses, we adapted a list from a
previous multimorbidity publication (Supplementary
Table 1 lists the 39 possible conditions and their rele-
vant definitions in this dataset) [4]. This list has been
used in other epidemiological multimorbidity stud-
ies so we chose to use it to improve comparability
with other research [16–20]. We calculated a count
of the total number of conditions on this list for each
participant and used this as a pseudo-continuous vari-
able. In keeping with the commonly used definition
of multimorbidity being two or more concurrent con-
ditions, we also generated a dichotomous variable for
multimorbidity (!2 versus 0–1 conditions).
Participants reported their own number of years
of education, and age in years at initial interview
 




L.E. Stirland et al. / Multimorbidity and CSF Amyloid in EPAD Cohort 705
Table 1
Sample characteristics according to CSF amyloid ! status
Variable Total N missing A! positive A! negative p for difference
(<1000 pg/ml) (!1000 pg/ml) between A! groups
Total sample (%) 447 NA 157 (35.1) 290 (64.9) –
Mean age in years (SD) 66.6 (6.58) 0 67.8 (6.96) 65.9 (6.31) 0.005
Female (%) 234 (52.3%) 0 73 (46.5) 161 (55.5) 0.085
Mean years of education (SD) 14.1 (3.68) 0 13.9 (3.80) 14.1 (3.62) 0.506
Mean chronic conditions (SD) 1.1 (1.27) 0 0.94 (1.27) 1.15 (1.26) 0.102
!2 chronic conditions (%) 128 (28.6) 0 37 (23.6) 91 (31.4) 0.102
Carrier of !1 APOE "4 allele (%) 178 (39.8) 5 80 (51.6) 98 (34.2) 0.001
!1 first-degree relative with dementia (%) 265 (59.3) 0 96 (61.1) 169 (58.3) 0.625
was calculated from their date of birth. We treated
both of these as continuous variables. Sex was self-
reported and treated as dichotomous. Participants also
reported any family history of dementia, which we
converted into a dichotomous variable of having at
least one first-degree relative (sibling or parent) with
dementia. Blood was taken for APOE genotyping and
we generated a dichotomous variable for having at
least one APOE "4 allele.
At the initial visit, doctors at each EPAD site
carried out lumbar punctures on all participants
and the CSF samples collected were analyzed cen-
trally at the University of Gothenburg, Sweden, with
the automated Elecsys immunoassay [21]. Previ-
ous research examining multimorbidity and amyloid
on neuroimaging has used dichotomous variables
to represent amyloid abnormality [8], and the com-
monly used A/T/N (amyloid, tau, neurodegeneration)
system for classifying biomarkers also relies on “pos-
itive” and “negative” results for each parameter [22].
We therefore used a dichotomous variable for CSF
A!42 to allow comparison between groups, and as
the outcome in our primary analyses. There is no uni-
versally agreed cut-off for CSF A!42 as assays vary
[23], but other studies using the same assay have used
a cut-off of 1092 pg/ml [24] and 1100 pg/ml [25,26].
The EPAD Consortium agreed to lower the cut-off
to 1000 pg/ml to balance sensitivity and specificity,
giving a dichotomous variable for CSF A!42: <1000
pg/ml (amyloid positive) or !1000 pg/ml (amyloid
negative). To assess the robustness of our results to
decisions made regarding the CSF cut-off points, we
conducted sensitivity analyses excluding participants
whose A! was between 1000 pg/ml and the high-
est previously published cut-off using this assay of
1100 pg/ml [26]. Concentrations between these val-
ues are the most relevant in comparing the difference
in performance between our cut-off and that used
by others. To investigate the association further, tak-
ing into account the continuum of possible amyloid
concentrations, we also used a continuous amyloid
outcome measure.
Statistical analysis
We used Student’s t-test to compare the means
of demographic variables between A! groups, and
Chi-squared test to compare proportions of binary
variables (for example, sex). We used logistic regres-
sion analyses to model the association between the
number of chronic conditions, both as a pseudo-
continuous variable and dichotomized as 0–1 versus
!2 conditions, with dichotomous CSF A!42. We
further adjusted for age, sex, carriage of at least
one APOE "4 allele, family history of dementia (at
least one first-degree relative) and years of education.
We used linear regression to explore the association
between chronic conditions, multimorbidity and con-
tinuous CSF A!42.
In all models, when analyzing continuous number
of chronic conditions, we added number of condi-
tions squared to the model to explore a possible
non-linear association between the number of condi-
tions and amyloid positivity. This would test whether
any association between chronic conditions and amy-
loid changes at extreme numbers of conditions. We
also tested for an interaction effect between age
and chronic conditions. All analyses were performed
using R version 3.4.3 [27].
Finally, given the complexity of counting combina-
tions of conditions, we employed network analyses,
an increasingly important method for data visu-
alization, to represent combinations of conditions
graphically [28]. We used the R package igraph
to generate network graphs for chronic conditions
present in amyloid positive and negative participants
separately, in circular and alphabetical layout to allow
visual comparisons [29]. Participants with fewer
than two conditions were excluded from the net-
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Fig. 3. Network analyses of self-reported chronic conditions according to amyloid status, in participants with !2 chronic conditions Amyloid
negative participants (CSF A!42 !1000 pg/ml), n = 91 Amyloid-positive participants (CSF A!42 <1000 pg/ml), n = 37 COPD, chronic
obstructive pulmonary disease; TIA, transient ischemic attack Node sizes represent relative prevalence of each condition and text size the
relative number of connections for that condition.
These associations were present when adjusting for
age, sex, years of education, APOE status, and fam-
ily history of dementia. There was no significant
association between categorical multimorbidity (0–
1 versus !2 conditions) and continuously measured
A!. This may reflect the fact that using a con-
tinuous count of conditions is more robust than
choosing an arbitrary number of conditions to define
multimorbidity.
Comparison with other literature
Previous research found no association between
multimorbidity and brain amyloid deposition in
people without cognitive impairment [6, 7]. Cross-
sectional analysis of the Mayo Clinic Study of Aging
(MCSA), where participants had a mean age of 79
years and 85% had two or more chronic conditions,
found an association between multimorbidity and
other imaging biomarkers of brain pathology but
not amyloid [6]. The authors concluded that mul-
timorbidity’s association with brain pathology was
independent of amyloid deposition. Our findings tend
to support this, albeit in a younger sample. In further
work on MCSA, the same team found that multimor-
bidity was only associated with amyloid positivity
when there was other imaging evidence of neurode-
generation [8].
It is challenging to compare multimorbidity across
studies that use different methods to record and count
conditions.[30] For example, the MCSA studies used
medical records for chronic condition diagnoses, and
counted from a list of 19 possible conditions [6]. The
INSIGHT-PreAD study, however, used self-reported
diagnoses from a list of 14 conditions [7]. Our chosen
list of 39 chronic conditions has been used in other
multimorbidity research [16–20], but we may have
over-estimated multimorbidity compared to the stud-
ies with shorter lists. The list of chronic conditions
we chose has several limitations. For example, it does
not include hyperlipidemia, which is the most preva-
lent condition in similar studies [8]. It also includes
the term “painful condition” which could represent
a number of diagnoses, and other conditions which
could be better classified as symptoms, such as “low
vision”. Discrepancy between potential conditions
is another recognized disadvantage of using disease
counts for multimorbidity research and limits our
ability to meaningfully compare the prevalence of
conditions with other studies [31].
Potential mechanisms
Given the previously discussed association
between multimorbidity and dementia [4,5], it seems
unlikely that multimorbidity is protective against
amyloid positivity. Our study, although examining a
biomarker rather than a clinical outcome, supports
the suggestion that this association may not be
driven by amyloid [6]. Instead, it is likely that the
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impact of multimorbidity on brain health in general
is multifactorial.
Using an overall disease count groups all condi-
tions (and therefore biological mechanisms) together,
when in fact they may each be risks, neutral or
even protective for cerebral amyloid deposition. For
example, hypertension, a key vascular risk factor,
was highly prevalent in both amyloid groups and
may have influenced amyloid burden regardless of
whether or not the participant had multimorbidity.
Vascular pathology has an important contribution to
the development of Alzheimer’s disease, and hyper-
tension has been shown to be separately associated
with low CSF A! [32, 33]. There is evidence that
cognitive function declines faster in people with amy-
loid positivity in midlife if they have hypertension
or obesity [34]. Therefore, it is difficult to elucidate
mechanisms when measuring multimorbidity purely
by disease counts.
An alternative explanation for the contrast between
our findings and previous research that found an asso-
ciation between multimorbidity and dementia may be
age differences (for example, a mean age of 78.5 years
in the MCSA, compared to 66.6 years in our sample).
In addition, Vassilaki et al.’s outcome was clinically
diagnosed dementia or mild cognitive impairment,
suggesting a more advanced neurodegenerative pro-
cess than amyloid positivity in our population [5].
Given that the prevalence of both multimorbidity and
amyloid positivity increase with age [4, 10], it may
be that age is the most important factor driving both
variables.
Strengths and limitations
To our knowledge, this is the first exploration of
the association between multimorbidity and a CSF
marker of Alzheimer’s disease. We tested the associ-
ation for both categorically-defined multimorbidity
and a pseudo-continuous count of chronic condi-
tions with both dichotomous and continuous amyloid
measures.
Given the research participants’ age and that
they are volunteers, EPAD is a generally healthy
cohort. Relatively few participants had two or more
conditions in each amyloid status group compared
to population-based estimates of multimorbidity in
similar age groups [4]. This reflects the ongoing
under-representation of people with multimorbid-
ity in clinical trials.[35] EPAD participants reported
a mean of 1.1 chronic conditions. A population-
based study using the same list of conditions found
a mean of 1.0 conditions across all ages, with this
rising to 2.6 in people aged 65 to 84 years and 3.6
in those aged 85 years and over [4]. Our study’s
exclusion criteria mean that the reported conditions
are less severe than might occur in a population-
based sample. Potential research participants with
a diagnosis of cancer (except non-melanoma skin
cancer and localized prostate cancer) within the last
five years were excluded, meaning that a cancer
diagnosis reported by EPAD research participants
is most likely historical. The selection of EPAD
participants limits this study’s generalizability and
may not reflect associations in the general popu-
lation. One aim of EPAD is to investigate people
without dementia who may go on to develop it.
This means that the cohort was relatively young,
so amyloid evidence of neurodegeneration, whether
related to multimorbidity or not, may not yet be
apparent.
People with dementia were excluded from this
study, meaning our findings are only applicable to
people with amyloid positivity who have not devel-
oped dementia. In addition, we did not examine
cognitive outcomes in these analyses, focusing only
on biomarkers.
The Elecsys immunoassay’s performance has not
been formally established at A! concentrations above
1700 pg/ml [36]. Similarly to other studies using
this assay, we have cautiously included values in this
range to allow treatment of A! as a continuous vari-
able, as they clearly represent A! negativity [25].
However, when using continuous A! as the outcome
for linear regression models, higher concentrations
are likely to be less accurate. We accounted for this
by using both continuous and dichotomous A! as
separate outcomes.
The medical history collected did not include
timing of diagnoses, meaning that any recorded diag-
nosis may not reflect a current or recent one. We
managed this by choosing the list of chronic con-
ditions based on a paper which originally defined
most conditions according to whether they had ever
been recorded [4]. Furthermore, using self-reported
conditions, although a commonly used method, has
limitations, especially in a cohort at risk of cogni-
tive impairment where recall bias may be a particular
problem. This may lead to the under-estimation of
multimorbidity. The sample size of this initial release
of EPAD data, which is smaller than some com-
parable studies [6,8], may also mean that a true
association was missed because of limited statistical
power.
 




710 L.E. Stirland et al. / Multimorbidity and CSF Amyloid in EPAD Cohort
Conclusions
Our finding that multimorbidity is inversely associ-
ated with amyloid positivity in a cross-sectional study
is novel, so needs to be replicated longitudinally. The
lack of association between a dichotomous measure
of multimorbidity and continuous amyloid suggests
this result needs further exploration.
EPAD’s longitudinal cohort study design will
allow us to replicate these analyses in future, and
confirm whether the inverse association found per-
sists on follow-up as the participants age. In addition,
this cross-sectional study does not allow us to make
causal inferences, so further research could explore
the mechanisms explaining the inverse association
between multimorbidity and amyloid positivity. An
upcoming release of the larger dataset V1500.0 by
the end of 2019 will also permit more detailed anal-
ysis of the associations between specific clusters of
conditions, amyloid and cognitive change.
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Kulczyńska A, Molinuevo JL, Mroczko B, Nordberg A,
Oliveira CR, Otto M, Rinne JO, Rot U, Saka E, Soininen
H, Struyfs H, Suardi S, Visser PJ, Winblad B, Zetter-
berg H, Waldemar G (2017) Recommendations for CSF
AD biomarkers in the diagnostic evaluation of dementia.
Alzheimers Dement 13, 274-284.
[12] Cummings J (2019) The National Institute on Aging-
Alzheimer’s Association Framework on Alzheimer’s
disease: Application to clinical trials. Alzheimers Dement
15, 172-178.
[13] Ritchie CW, Molinuevo JL, Truyen L, Satlin A, Van der
Geyten S, Lovestone S (2016) Development of interven-
tions for the secondary prevention of Alzheimer’s dementia:
The European Prevention of Alzheimer’s Dementia (EPAD)
project. Lancet Psychiatry 3, 179-186.
[14] Solomon A, Kivipelto M, Molinuevo JL, Tom B, Ritchie
CW, EPAD Consortium (2018) European Prevention of
Alzheimer’s Dementia Longitudinal Cohort Study (EPAD
LCS): Study protocol. BMJ Open 8, e021017.
[15] Ritchie CW, Muniz-Terrera G, Kivipelto M, Solomon A,
Tom B, Molinuevo JL, EPAD Consortium (2019) The
 
Chapter 5: Cross-sectional analyses in the EPAD cohort  183 
 
 
Reprinted from Journal of Alzheimer’s Disease, Vol 71, No 2. Stirland Lucy E, Russ 
Tom C, Ritchie Craig W, Muniz-Terrera Graciela, EPAD Consortium. Associations 
Between Multimorbidity and Cerebrospinal Fluid Amyloid: A Cross-Sectional Analysis 
of the European Prevention of Alzheimer’s Dementia (EPAD) V500.0 Cohort, Pages 
703-711, Copyright (2019) with permission from IOS Press. 
The publication is available through IOS Press at http://dx.doi.org/10.3233/JAD-
190222   
L.E. Stirland et al. / Multimorbidity and CSF Amyloid in EPAD Cohort 711
European Prevention of Alzheimer’s Dementia (EPAD)
longitudinal cohort study: data release V500.0. J Prev
Alzheimers Dis, in press.
[16] Jani BD, Hanlon P, Nicholl BI, McQueenie R, Gallacher
KI, Lee D, Mair FS (2019) Relationship between multimor-
bidity, demographic factors and mortality: findings from the
UK Biobank cohort. BMC Med 17, 74.
[17] Hanlon P, Nicholl BI, Jani BD, Lee D, McQueenie R, Mair
FS (2018) Frailty and pre-frailty in middle-aged and older
adults and its association with multimorbidity and mortality:
A prospective analysis of 493 737 UK Biobank participants.
Lancet Public Health 3, e323-e332.
[18] Nicholl BI, Mackay D, Cullen B, Martin DJ, Ul-Haq Z, Mair
FS, Evans J, McIntosh AM, Gallagher J, Roberts B (2014)
Chronic multisite pain in major depression and bipolar dis-
order: Cross-sectional study of 149,611 participants in UK
Biobank. BMC Psychiatry 14, 350.
[19] Gallacher KI, Batty GD, McLean G, Mercer SW, Guthrie
B, May CR, Langhorne P, Mair FS (2014) Stroke, multi-
morbidity and polypharmacy in a nationally representative
sample of 1,424,378 patients in Scotland: Implications for
treatment burden. BMC Med 12, 151.
[20] Payne RA, Avery AJ, Duerden M, Saunders CL, Simp-
son CR, Abel GA (2014) Prevalence of polypharmacy in
a Scottish primary care population. Eur J Clin Pharmacol
70, 575-581.
[21] Bittner T, Zetterberg H, Teunissen CE, Ostlund RE,
Militello M, Andreasson U, Hubeek I, Gibson D, Chu DC,
Eichenlaub U, Heiss P, Kobold U, Leinenbach A, Madin
K, Manuilova E, Rabe C, Blennow K (2016) Technical
performance of a novel, fully automated electrochemilumi-
nescence immunoassay for the quantitation of !-amyloid
(1–42) in human cerebrospinal fluid. Alzheimers Dement
12, 517-526.
[22] Jack CR, Bennett DA, Blennow K, Carrillo MC, Feldman
HH, Frisoni GB, Hampel H, Jagust WJ, Johnson KA, Knop-
man DS, Petersen RC, Scheltens P, Sperling RA, Dubois
B (2016) A/T/N: An unbiased descriptive classification
scheme for Alzheimer disease biomarkers. Neurology 87,
539-547.
[23] Kuhlmann J, Andreasson U, Pannee J, Bjerke M, Portelius
E, Leinenbach A, Bittner T, Korecka M, Jenkins RG, Van-
derstichele H, Stoops E, Lewczuk P, Shaw LM, Zegers
I, Schimmel H, Zetterberg H, Blennow K (2017) CSF
A!1–42 – an excellent but complicated Alzheimer’s
biomarker – a route to standardisation. Clin Chim Acta 467,
27-33.
[24] Willemse EAJ, van Maurik IS, Tijms BM, Bouwman FH,
Franke A, Hubeek I, Boelaarts L, Claus JJ, Korf ESC,
van Marum RJ, Roks G, Schoonenboom N, Verwey N,
Zwan MD, Wahl S, van der Flier WM, Teunissen CE
(2018) Diagnostic performance of Elecsys immunoassays
for cerebrospinal fluid Alzheimer’s disease biomarkers
in a nonacademic, multicenter memory clinic cohort:
The ABIDE project. Alzheimers Dement (Amst) 10,
563-572.
[25] Shaw LM, Waligorska T, Fields L, Korecka M, Figurski
M, Trojanowski JQ, Eichenlaub U, Wahl S, Quan M, Pon-
tecorvo MJ, Lachno DR, Talbot JA, Andersen SW, Siemers
ER, Dean RA (2018) Derivation of cutoffs for the Elecsys®
amyloid ! (1–42) assay in Alzheimer’s disease. Alzheimers
Dement (Amst) 10, 698-705.
[26] Hansson O, Seibyl J, Stomrud E, Zetterberg H, Trojanowski
JQ, Bittner T, Lifke V, Corradini V, Eichenlaub U, Batrla R,
Buck K, Zink K, Rabe C, Blennow K, Shaw LM (2018) CSF
biomarkers of Alzheimer’s disease concord with amyloid-!
PET and predict clinical progression: A study of fully auto-
mated immunoassays in BioFINDER and ADNI cohorts.
Alzheimers Dement 14, 1470-1481.
[27] R Core Team (2017) R: A language and environment for
statistical computing.
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5.3 SUPPLEMENTARY MATERIAL 
Supplementary Table 1. List of chronic conditions and definitions, adapted from 
Barnett et al., Lancet 380, 37–43, 2012. 
 
Condition Definition 
Hypertension Recorded diagnosis 
Depression Recorded diagnosis and current prescription of 
antidepressant 
Painful condition Prescription-only analgesic 
Asthma Recorded diagnosis and current prescription of 
asthma medication  
Coronary heart disease Recorded diagnosis 
Dyspepsia Recorded diagnosis and current prescription of acid-
reducing medication except for antacids 
Diabetes Recorded diagnosis 
Thyroid disorders Recorded diagnosis 
Inflammatory joint or connective tissue 
disorders 
Recorded diagnosis 
Hearing loss Recorded diagnosis 
COPD Recorded diagnosis 
Anxiety & other neurotic, stress-related & 
somatoform disorders 
Recorded diagnosis and current anxiolytic or 
antidepressant medication 
Irritable bowel syndrome Recorded diagnosis 
Cancer Recorded diagnosis 
Constipation Current prescription of laxatives 
Stroke or transient ischemic attack Recorded diagnosis 
Chronic kidney disease Recorded diagnosis 
Diverticulitis Recorded diagnosis 
Atrial fibrillation Recorded diagnosis 
Prostate disorders Recorded diagnosis 
Glaucoma Recorded diagnosis 
Schizophrenia, non-organic psychosis or 
bipolar disorder 
Recorded diagnosis  
Psoriasis or eczema Recorded diagnosis and related prescription 
(excluding emollients) 
Inflammatory bowel disease Recorded diagnosis 
Migraine Prescription-only migraine medication 
Low vision Recorded diagnosis 
Eating disorder Recorded diagnosis 
Bronchiectasis Recorded diagnosis 
Viral hepatitis Recorded diagnosis 
Chronic liver disease Recorded diagnosis 
Alcohol problems Recorded diagnosis 
Other psychoactive substance misuse Recorded diagnosis 
Peripheral vascular disease Recorded diagnosis 
Heart failure Recorded diagnosis 
Epilepsy (currently treated) Recorded diagnosis and prescription of anti-epileptic 
medication  
Chronic sinusitis Recorded diagnosis 
Learning disability Recorded diagnosis 
Parkinson's disease Recorded diagnosis 
Multiple sclerosis Recorded diagnosis 
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5.4 ADDITIONAL ANALYSES  
5.4.1 Cut-offs for defining categorical multimorbidity  
As stated in the paper’s Results, the relationship between multimorbidity (0-1 versus 
≥2 conditions) and continuously measured Aβ concentration did not meet 
conventional statistical significance. I hypothesised that this may be because using 
an arbitrary cut-off for the number of conditions is less sensitive than a continuous 
count. However, the continuous count includes the increase from 0 to 1 condition, 
which does not fall under the usual definition of multimorbidity. To explore the 
importance of where the cut-off for multimorbidity lies in this case, I performed 
additional analyses, presented in Table 5-1 on page 186. These show that the 
strength of association and significance levels vary depending on the number of 
conditions chosen to define multimorbidity. Of note, where ≥2 conditions was used, 
splitting 0 and 1 conditions into separate levels gave a result that did not meet 
conventional statistical significance when continuous Aβ concentration was the 
outcome. This suggests that in the continuous count, the difference between 0 and 1 
conditions was unlikely to be important in the overall results.  
 
It has been shown that there is little difference in the sensitivity of detecting 
multimorbidity between using cut-offs of ≥2 or ≥3 conditions, as discussed in Chapter 
3 (section 3.3.1.4, page 104).[263] As in other analyses in this thesis, and the most 
commonly used approach, the cut-off of 0-1 and ≥2 seems most appropriate for binary 
multimorbidity, especially alongside complementary continuous measures.[119] 
Using a binary exposure variable has lower statistical power than continuous 
measures owing to the information lost.[240] There is also a risk of over-analysing 
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Table 5-1: Results of logistic and linear regression when using different definitions of 
categorically-defined multimorbidity 
  Outcome 
Number of 
conditions   n (%) Continuous Aβ concentration 
Dichotomous Aβ 
positivity (<1000pg/ml) 









(-7.7 to 239.0)  
0.066 
0.59  










(-0.40 to 264.7) 
0.051 
0.54  






(36.3 to 306.4)  
0.013  
0.46  










(16.2 to 253.1)  
0.026  
0.49  






(33.4 to 392.5)  
0.020  
0.51  










(-27.2 to 310.9) 
0.100 
0.74  
(0.39 to 1.38) 
0.352 
All models adjusted for age, sex, APOE status, family history of dementia and years 
of education  
 
5.4.2 Rates of amyloid positivity 
In the EPAD v500.0 sample, 157 (35.1%) participants were amyloid-β positive using 
the cut-off of 1000pg/ml. Reported rates of amyloid positivity in the general population 
without cognitive impairment vary from 0% to 47%, with most estimates between 10-
30%.[350] The variation is likely due to differing methods and cut-offs used, and the 
age ranges of participants. EPAD aimed to recruit participants across a range of 
dementia risk profiles, so the amyloid positive prevalence of 35.1% is relatively high 
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given its age range.[52] A positron emission tomography (PET) imaging study of 1 671 
participants in the population-based Mayo Clinic Study of Aging, where the mean age 
was 71.3 (SD=9.8) years at baseline, explored amyloid positivity in relation to age and 
cognitive impairment status.[351] The authors reported that the prevalence of amyloid 
positivity in participants without cognitive impairment was 2.7% (95% CI 0.5% to 
4.9%) in those aged 50 to 59 years compared to 41.3% (95% CI 33.4% to 49.2%) in 
those aged 80 to 89 years. This study emphasises the importance of age when 
studying amyloid positivity. 
 
5.4.3 Importance of age in the association between multimorbidity and 
amyloid 
Although my analyses were adjusted for age, a possible explanation for the 
association between chronic conditions and Aβ could be that age is the main factor 
driving both variables. In univariate analysis of age as a predictor for continuous Aβ, 
age explained a minimal amount of the variance in Aβ (multiple R2= 0.05%, adjusted 
R2= -1.79%). A moderation analysis is therefore useful in this instance to investigate 
the impact of age on each of the variables. 
 
The Johnson-Neyman technique calculates the value of the moderator variable (in 
this case, age) for which the effect of the exposure (chronic conditions) on the 
outcome (Aβ) are significant.[352,353] Figure 5-1 shows the Johnson-Neyman plot 
for the slope of continuous chronic conditions predicting continuous Aβ by age. With 
α=0.05, the region of significance of the simple slope is between 60.0 and 66.2 years. 
This suggests that age could explain the relationship between chronic conditions and 
Aβ between these ages, but not in the rest of the sample, where the overall range is 
51.1 to 88.7 years. It is counterintuitive that age should explain this association, as 
increasing age would be expected to be associated with both increasing number of 
conditions and decreasing CSF Aβ.[354] The relatively young age of my sample is a 
limitation in this regard, and it is possible that there could be a positive association 
between chronic conditions and amyloid positivity in older people. There also may be 






Figure 5-2: Network analyses of self-reported chronic conditions according to CSF Aβ status 
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The node sizes and text size represent the relative number of connections for each 
condition, and line thickness the relative frequency of that connection. A limitation of 
conducting network analyses in this dataset is the small size of the groups analysed 
(n=37 and n=91), meaning that some connections may appear prominent but that this 
can be explained by chance. In addition, the small sample means the line thickness 
on the amyloid positive graph is less informative. Conducting these analyses was 
valuable preparation for me to both understand similar analyses in other publications 
and to familiarise myself further with techniques to apply in larger datasets. 
 
5.5 FURTHER DISCUSSION 
5.5.1 Hypothesis addressed 
There was an inverse association between multimorbidity or having a larger number 
of chronic conditions and a lower concentration of CSF amyloid-β, a marker of 
Alzheimer’s disease. 
 
5.5.2 Potential mechanisms 
In the context of previous research reporting associations between multimorbidity and 
dementia, the finding that a larger number of chronic conditions is inversely 
associated with amyloid positivity was unexpected. An explanation for this may be 
that amyloid is less important in the development of dementia in people with 
multimorbidity than those without. There is evidence from post-mortem and positron-
emission tomography (PET) imaging studies that people with pathological features of 
Alzheimer’s disease may not all have cognitive impairment.[355–359] Additionally, 
those with a clinical diagnosis of Alzheimer’s dementia have evidence of 
neurodegeneration with multiple pathologies, for example vascular. People with 
multimorbidity are likely to have multiple cerebral pathologies that contribute to 
neurodegeneration and clinical manifestations of dementia.[98] 
 
Cerebral amyloid load does not correlate with clinical dementia or severity.[360] There 
have been clinical trials of drugs that successfully reduced amyloid plaques and 
neurofibrillary tangles on neuroimaging.[361] However, the majority of these studies 
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have failed to show evidence of improvement in participants’ cognitive and functional 
abilities.[362,363] Cerebral amyloid deposition may be a marker of a process, for 
example attempts at brain repair, rather than the pathological cause of 
neurodegeneration.[364] This would explain why its removal does not tend to improve 
clinical outcomes in people with cognitive impairment. There are ongoing studies 
exploring the hypothesis that clearing amyloid before the onset of symptoms may be 
effective, rather than after cognitive impairment has manifested clinically.[363] My 
findings, although only from cross-sectional analyses, may support the understanding 
that clinical dementia is multifactorial and not solely related to amyloid.[365–367] 
 
5.5.3 Additional limitations 
People with a contraindication to lumbar puncture or MRI scan were excluded from 
the EPAD cohort, as is the case in similar CSF studies. This would include participants 
taking anticoagulant medication for conditions such as atrial fibrillation, adding to the 
limitation of only including healthy volunteers. In addition, CSF Aβ concentrations can 
be useful in clinical practice but are not diagnostic when used in isolation. These 
results should therefore be viewed in the context of adding specific knowledge to a 
defined area of dementia research, and not extrapolated beyond this. 
 
In these analyses, I used the list of conditions from the influential 2012 primary care 
multimorbidity epidemiology paper by Barnett and colleagues.[39] As highlighted in 
section 3.3.1 on page 101, it is important to have a clear definition of multimorbidity, 
and when counting conditions the list of potential diagnoses should be clearly justified 
and contain a robust number of conditions. Using an established list improves 
comparability with other similar studies. Unlike in the PREVENT Dementia study, 
where participants reported their medical history according to a pre-defined list in the 
Case Report Form, EPAD participants reported any medical conditions without 
guidance. They thereby self-selected what counted as a condition. The EPAD Case 
Report Form did not include any indication of whether a condition was current or 
previously diagnosed. I therefore chose to count the conditions from the list in Barnett 
and colleagues’ paper.[39] The list specifies the criteria for recording each condition, 
and this is often ‘ever recorded’. I amended the list to remove dementia, as people 
with pre-existing dementia were excluded from the study, and to adapt some of the 
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disease definitions to a cohort study case report rather than its original design for 
primary care records. This list includes some mental disorders, namely depression, 
schizophrenia or bipolar disorder, eating disorders, learning disability and anxiety or 
other neurotic and somatoform disorders. I chose to include these conditions to 
preserve the list’s comparability with other studies. However, these inclusions should 
be taken into account when comparing results in this chapter with those of Chapter 4, 
where mental disorders were specifically excluded. I made this decision because 
Chapter 4 examined a range of mental and brain health outcomes, whereas in this 
chapter the outcome of interest was a specific biomarker related to Alzheimer’s 
disease. 
 
The sample size was too small to conduct analyses accounting for specific disease 
groups with multimorbidity. Future work could explore the contribution of vascular 
disease, for example, to any effect seen between multimorbidity and CSF amyloid 
concentration. 
 
5.5.4 Longitudinal comparisons 
The theory that amyloid is a marker, rather than cause, of neurodegeneration may fit 
with my results,[368] and leads to the hypothesis that longitudinal follow-up may 
reveal more association between multimorbidity and clinical dementia than with 
Alzheimer’s pathology. A systematic review of multimorbidity and progression of 
dementia found six longitudinal studies.[369] The authors concluded that the 
association between increasing multimorbidity and cognitive decline was dynamic and 
less likely to be detected in cross-sectional analyses. This is a possible explanation 
for the results seen in my work. A more recent longitudinal study of 14 265 people 
without dementia found that increasing scores on the Multimorbidity Weighted Index 
were associated with worse scores on global cognition and recall.[370] Two studies 
have longitudinally explored not only cognitive outcomes but also varying levels of 
multimorbidity.[282,283] This approach is a strength over studies that artificially treat 
multimorbidity as a static state. Future investigations into multimorbidity and amyloid 
in the EPAD Cohort could explore the association longitudinally, possibly with the 
addition of measures of cognitive function. 
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5.5.5 Outcomes of multimorbidity that includes dementia 
There is clear evidence that multimorbidity is common in people with dementia.[39] A 
recent study of quality of life in people with dementia captured 23 chronic conditions 
using an adapted Charlson Index through an interview with the person with dementia 
and a carer.[371] The median number of conditions was one. Increasing numbers of 
conditions was associated with worse scores on mobility, self-care, functioning, pain 
and anxiety and depression scores within the EuroQol five-dimension measure of 
health status (EQ-5D). Having dementia alongside other comorbidities is also 
associated with increased use of health services and costs.[372,373] Multimorbidity 
in people with dementia is therefore associated with adverse outcomes for the patient, 
regardless of the underlying mechanisms. 
 
5.5.6 Implications 
High quality healthcare should integrate both physical and mental health and account 
for their complex interactions.[374] My cross-sectional findings should be understood 
in the context of previous research reporting high levels of comorbidity in people with 
dementia. They are insufficient to confirm a mechanism or suggest changes in 
practice. The paper will form a valuable part of the body of research exploring 
biomarkers in this area, and could direct longitudinal investigation in a larger, or older 
group. Replicating the analyses in the same participants, especially as some begin to 
develop dementia, will inform this further. Perhaps biomarkers are of less importance 
in older people with multimorbidity and this should be taken into account when 
designing memory or brain health clinics.[375] If amyloid is confirmed not to be 
important in the relationship between multimorbidity and dementia, this should only 
reinforce the need for person-centred healthcare that acknowledges the importance 
of both physical and brain health.  
 
5.6 CHAPTER CONCLUSIONS 
This chapter has focused closely on multimorbidity in relation to one biomarker of 
brain health, CSF amyloid-β. These cross-sectional results show that there is an 
inverse relationship between having multiple chronic conditions and lower CSF 
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amyloid concentrations, which are linked to Alzheimer’s disease. Chapter 6 will 
explore longitudinal associations between medication use (a marker of multimorbidity) 
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6.1.1 Associations between polypharmacy and mortality 
A 2017 systematic review and meta-analysis of polypharmacy as a risk factor for 
mortality found 47 studies on this topic.[33] Polypharmacy was measured in five main 
ways and overall, meta-analysed results showed an increased risk of death with 
increasing medication use. The largest of these studies included 1 917 646 people 
aged 65 to 94 years in Italy.[378] It found that with chronic use of ≥5 compared to 0-
4 drugs, the hazard ratio for death within one year was 1.11 (95% CI 1.08 to 1.14, 
adjusted for year, sex, age and raw number of drugs). However, a 2017 longitudinal 
German study of 2 687 people aged 58-82 years found the opposite, with an adjusted 
hazard ratio for non-cancer mortality in those taking ≥10 drugs of 1.42 (95% CI 0.57 
to 3.57) in participants without multimorbidity, and 0.51 (0.11 to 2.27) in people with 
multimorbidity.[379] The authors reported a significant interaction between taking ≥10 
medications and having multimorbidity, defined as severe or very severe disease in 
more than one organ system (P=0.019). The size of the Italian study and the meta-
analysis findings suggest there is an association between polypharmacy and 
mortality, but none of these studies examined specific causes of death. 
 
This observational association is likely due to the co-existence of polypharmacy and 
multimorbidity, in that polypharmacy is a marker of severity of comorbid illnesses, 
which in itself increase the risk of death.[379] There may also be specific adverse 
effects from individual drugs or an increased risk of drug interactions, each of which 
is associated with increased mortality.[291] 
 
6.1.2 Polypharmacy and cognitive impairment or dementia 
There is some evidence to suggest that polypharmacy is associated with worse 
cognitive outcomes and poorer mental health in older age. As discussed in Chapter 4 
(section 4.1.2 on page 116), a 2014 systematic review of outcomes associated with 
polypharmacy found 58 papers, of which the most common outcomes were those 
relating to falls (23 studies), adverse drug events (14 studies) and hospitalisation or 
mortality (10 studies).[291] Six included papers investigated mental health outcomes, 
of which five explored cognitive impairment or dementia and one depressive 
symptoms. This reflects the fact that research into polypharmacy rarely investigates 
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mental or brain health outcomes, and of studies that do, most focus on cognitive 
impairment or dementia. 
 
A systematic review exploring polypharmacy and dementia published in 2019 found 
seven studies, a relatively small number compared to the 47 included in the review 
on polypharmacy and mortality.[33,35] Polypharmacy did appear to be a risk factor 
for dementia in most of the studies, with an adjusted risk ratio of 1.30 (95% CI 1.16 to 
1.46) on meta-analysis. However, the meta-analysis included papers that used 
different cut-offs for polypharmacy so this figure should be interpreted with caution. It 
is clearer that polypharmacy is common among people with existing dementia, with 
one cross-sectional Scottish population study finding that people with dementia were 
more likely to be prescribed 5-9 medications (OR=1.46 (1.40 to 1.52, P<0.001)) and 
≥10 medications (OR=2.01, 1.90 to 2.12; P<0.001) compared to people without 
dementia.[346] 
 
At least two relevant studies have been published since this systematic review’s 
search date. A cross-sectional study of 2 122 people aged 69 years found a difference 
of -2.0 points (95% CI -2.8 to -1.1) on the Addenbrooke’s Cognitive Examination 
version III in those taking 5-8 medications compared to 0-4, and -2.9 points (95% CI 
-4.4 to -1.4) in those taking ≥9 medications.[325] However, a study of over 15 000 
people with dementia in London found no statistically significant difference in the rate 
of cognitive decline as measured on the Mini-Mental State Examination (MMSE) 
between those taking 0-4, 5-9 or ≥10 medications.[380] Limitations of this study were 
that it used the MMSE, which has a known ceiling effect, and that 21.3% of the original 
sample was excluded due to insufficient MMSE data.[381] In addition, a recent review 
of 12 studies found that the prevalence of potentially inappropriate prescribing for 
people with dementia was 31% (95% CI 9 to 52%) in the community and 42% (95% 
CI 30 to 55%) in residential care settings.[382] 
 
Along with evidence of harms associated with polypharmacy, specific medications 
have been associated with cognitive decline and dementia, including 
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benzodiazepines,[102] anticholinergics [383–385] and anti-convulsants.[386] The use 
of these drug groups may explain a large proportion of the association apparently 
seen with polypharmacy. 
 
6.1.3 Polypharmacy and delirium 
A Spanish study of 457 patients with multimorbidity admitted to medical wards, with a 
mean age of 81 years, found that patients were prescribed a mean number of 8.2 
drugs (standard deviation 3.4).[387] The researchers found no significant difference 
in one-year survival between patients on 0-4, 5-9 or ≥10 drugs. They also found that 
people on ≥10 medications were less likely to have been diagnosed with delirium on 
a previous hospital admission (13.1% v 24.0%, Student’s t-test P=0.006), with 
adjusted OR=0.48 (95% CI 0.25 to 0.91). They postulated that this may be because 
delirium and cognitive impairment are signs of advanced disease and less intensive 
treatment regimes. This could also be due to patients undergoing medication reviews 
as a result of developing delirium on a previous admission. A systematic review of 
risk factors for in-hospital delirium, however, identified that polypharmacy carried a 
relative risk of 2.9 (95% CI 1.6 to 5.4) or OR=1.9 (95% CI 1.1 to 3.2).[388] The authors 
suggested that these positive associations may be due to confounding factors such 
as the presence of dementia, long hospital stay and severity of physical illness, which 
are all associated with both polypharmacy and delirium. Individual drugs’ mechanism 
of action, adverse effects and interactions may also be an explanatory factor.[389] 
Some research exists linking polypharmacy with in-hospital delirium,[388,389] but no 
research exists exploring broader mental health outcomes in people with 
polypharmacy at a population level.  
 
6.1.4 Associations between polypharmacy and mental disorders 
A cross-sectional study of 5 502 women aged 76 to 81 years in Australia linked 
prescribing records to mental health scores on the Medical Outcomes Study 36-item 
Short-Form Health Survey (SF-36).[390] The authors reported that compared to 
taking no medications, people taking 1-3 medicines had better mental health scores 
(adjusted β=1.53, 95% CI 0.02 to 3.09, P=0.05), people taking ≥10 medications had 
worse mental health scores (adjusted β= -2.89, 95% CI -5.05 to -0.73, P<0.009) and 
there was no statistically significant difference for those taking 4-9 medications. This 
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longitudinal cohort study had the advantage of including detailed phenotypes, but may 
have limited generalisability to the population. 
 
A general practice records study of 4 506 people aged ≥50 years in England linked 
prescribing data to physical and psychological scores on the Short-Form 12 (SF-12) 
questionnaire at three year follow-up.[391] The author reported that with increasing 
drug use between four categories (1-4, 5-7, 8-11 and ≥12 drugs), there was a 
significant association towards poor physical health (P for trend=0.025) but no 
significant association with psychological scores. However, this single-author paper 
reports unusual methods, for example using logistic regression to test for longitudinal 
changes between dichotomised SF-12 scores, so is of limited value.  
 
A 2016 systematic review of seven papers on polypharmacy and medication 
adherence found an association between taking increasing numbers of drugs and 
worse medication adherence.[392] It has been suggested that this in turn could 
contribute to the development of mental disorders, due to the under-treatment of a 
physical or mental illness.[35]  
 
6.1.5 Scottish context 
There have been no population-level studies of polypharmacy in Scotland with 
longitudinal outcomes. A repeated cross-sectional study exploring the dispensed 
community prescriptions of over 300 000 patients aged over 20 years in Tayside found 
that 50.6% of people were dispensed one or more drugs in the previous 84 days in 
1995, compared to 58.9% in 2010.[37] The proportion of people dispensed 5-9 drugs 
rose from 9.7% to 16.3% and 10-14 drugs from 1.5% to 4.7% in the same period. A 
study of electronic primary care records of 180 815 adults aged over 20 years using 
data from 2006 found 16.9% of adults were prescribed 4-9 medications and 4.6% ten 
or more.[393] These data were from 40 demographically representative GP practices 
in Scotland. A cross-sectional study of 1 424 378 people aged over 18 years, also 
from representative primary care practices using 2007 data, compared people with 
and without a history of stroke, so does not allow population-level estimates for the 
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number of medications used.[394] There is therefore an opportunity for research 
investigating polypharmacy in Scotland longitudinally, at population level and with a 
particular focus on psychiatric outcomes. 
 
Scotland has arguably the most complete and best quality healthcare data in the 
UK.[395] Every person registered with a GP in Scotland has a unique ten-digit 
identifier, the Community Health Index (CHI) number. The CHI number can also be 
generated following other healthcare contacts such as hospital admissions.[22] It 
identifies the patient at any healthcare contact and its ubiquitous use allows for linkage 
between the datasets held by the NHS as well as by other agencies, such as National 
Records of Scotland (NRS) death certificate information.[107,396] The data are 
collected and managed by NHS Information Services Division (ISD) and, at the time 
I accessed the data, were hosted within the Farr Institute of Health Informatics 
Research.17 
 
The use of unconsented routinely collected healthcare data for research is common, 
but public perception of this practice varies. In general, attitudes are positive as long 
as data are carefully stored with restrictions to prevent inadvertent identification of 
individuals.[397,398] In Scotland, unconsented data are stored in Safe Havens, which 
are secure environments for data linkage and analysis.[399] They are covered by 
strict governance procedures and robust security. All researchers wishing to access 
these data must apply by submitting a research proposal to the Public Benefit and 
Privacy Panel for Health and Social Care. 
 
Given that the evidence for associations between polypharmacy and mental health 
outcomes is mixed, this chapter explores these links. It takes advantage of the very 
large sets of routinely collected data available in Scotland to address the lack of 
longitudinal population-wide studies in this area. 
 
17 The Farr Institute was named after William Farr (1807-1883) who set up the first system for 
routinely recording causes of death. It closed in 2018 and has been replaced by Health Data 
Research UK 
 
Chapter 6: Longitudinal analyses of routinely collected NHS data  201 
 
6.2 HYPOTHESES 
In keeping with the overall hypotheses of this thesis presented in Chapter 1 (section 
1.5, page 18), this chapter addresses the following hypotheses: 
1. Using larger numbers of medications (accounting for psychotropic 
prescriptions) will be associated with poorer mental health, as demonstrated 
by  
a. Presence of a mental disorder on death certificate  
b. Admission to psychiatric hospital 
In order to understand mental disorders on death certificates in context, I will also 
approach the following hypothesis: 
2. Using larger numbers of medications (accounting for psychotropic 
prescriptions) will be associated with increased all-cause mortality. 
 
6.3 METHODS 
In this chapter, I describe analyses of routinely collected data provided by NHS 
National Services Scotland Information Services Division (ISD). I aimed to follow up 
members of the population dependent on their medication use at baseline. I therefore 
accessed data from the Prescribing Information System (PIS), NRS death certificate 
data and hospital records from the Scottish Morbidity Record for psychiatric hospital 
admissions (SMR04). Demographic data were also required and available via the CHI 
database. 
 
6.3.1 Access application and procedures 
I prepared an application to the Public Benefit and Privacy Panel for Health and Social 
Care (PBPP), outlining my proposal and plans for data analysis and management. 
Prior to submitting the application, I presented my plans to lay members of the Farr 
Institute Scotland Public Panel, who gave positive feedback. I then applied to the 
PBPP with the proposal and plans presented in Appendix 3. After revisions, my 
proposal was approved on 22nd June 2017. Ethical approval has previously been 
granted for the broader electronic Data Research and Innovation Service (eDRIS) by 
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the East of Scotland NHS Research Ethics Service (reference 16/ES/0112), so an 
individual ethics application was not required. 
 
6.3.2 Dataset 
6.3.2.1 Prescribing Information System 
The NHS ISD Prescribing Information System (PIS) collects information on every 
prescription dispensed in the community and claimed for payment by pharmacies in 
Scotland. This does not include medication dispensed in hospital or those dispensed 
but not reimbursed (numbers of which are likely to be very small).[53,400]  
 
6.3.2.2 Death certificate data 
National Records of Scotland (NRS) is responsible for registering all deaths that occur 
in Scotland. ISD’s eDRIS provided a linked dataset featuring all deaths in the study 
period. For every death, a doctor records the causes of death on the Medical 
Certification of Cause of Death (hereafter referred to as death certificate). NRS then 
codes the diagnoses according to the International Statistical Classification of 
Diseases and Related Health Problems 10th Revision (ICD-10). This is initially done 
by specialist software, then checked by a medical coder.[401] The first field on the 
death certificate is primary or underlying cause of death, which is the diagnosis 
considered primarily responsible for the death. Secondary causes of death are those 
that did not primarily cause the death but are considered relevant to it. Other comorbid 
diagnoses that are not deemed relevant to the death are not included on the death 
certificate. 
 
6.3.2.3 Scottish Morbidity Record 
The Scottish Morbidity Record (SMR) captures healthcare data for individual patients 
and reporting of episodes by health boards is mandatory.[402] SMR04 contains data 
on psychiatric inpatient and day case care. Data have been recorded in SMR04 since 
the 1960s and are routinely available from 1981 onwards. 
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6.3.2.4 CHI database 
The CHI database holds basic demographic details of registered people, including 
their address, from which Scottish Index of Multiple Deprivation (SIMD) and care 
home status are generated. My data extract included these variables at the beginning 
of each quarter. It also allowed identification of individuals with a CHI number who 
were not prescribed medication in the final quarter of financial year 2008-2009. This 
dataset allowed for an overall mean of drugs used to be calculated, but since other 
essential variables including age were only included in the PIS extract, analyses were 
only possible among those receiving one or more medications.  
 
6.3.2.5 Data linkage 
The data from these four databases (PIS, SMR04, NRS death certificates and CHI) 
were linked by an eDRIS analyst. Patients’ CHI numbers had been removed and 
replaced with a unique pseudonymised identifier before being made available to me. 
Table 6-1 summarises the raw variables extracted from each database. The raw data 
were only available for viewing and analysis via remote access to the Farr Institute 
Safe Haven, to which access is strictly controlled. Results, including descriptive 
statistics, outputs of statistical tests and data visualisation, were only released after 
approval by an eDRIS Information Analyst and data controller.  
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Table 6-1: List of variables from each ISD dataset 
Linked dataset Variables Time period 
Prescribing Information 
System (PIS) 
Age at start  
Gender 
Count of unique medicines 
dispensed 
List of all unique medicines 
1st January 2009 
1st January 2009 
First quarter of 2009 
 
First quarter of 2009 
Community Health 
Index (CHI) 
Care home residency status 
Scottish Index of Multiple 
Deprivation (SIMD) 
1st January 2009 
National Records of 
Scotland (NRS) deaths 
Age at death 
Causes of death 
January 2009 to June 
2017 
Scottish Morbidity 
Record for psychiatric 
hospital admissions 
(SMR04) 
Age at admission to psychiatric 
hospital 





From the PIS data extract, I received two main drug variables, a count of unique drugs 
and a concatenated variable of all unique drug names reimbursed between 1st 
January and 31st March 2009. The inclusion of only unique medications meant that 
repeat prescription items would not be counted more than once. In keeping with a 
previous similar study that examined prescriptions over 84 days, my data were 
extracted by quarter. Guthrie and colleagues stated that the most common 
prescription length for repeat drugs is 56 days (usual range 28-84 days).[37] They 
justified using a longer window to capture routinely collected data as the interval 
between a patient requesting prescriptions does not match exactly with the length of 
the prescription.  
 
I chose to request dispensing, rather than prescribing, information in order to minimise 
over-estimation occurring with prescriptions that are not filled. I received access to all 
prescriptions where a CHI number was present, which is estimated to be almost 100% 
of dispensed prescriptions.[53] PIS data are organised by the financial quarter in 
which the dispensing pharmacy was reimbursed for the prescription. Reimbursement 
usually takes place around two months after dispensing, meaning that for example, 
medication appearing in a quarter from 1st January to 31st March 2009 would have 
been prescribed and dispensed between 1st November 2008 and 31st January 
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2009.[53] Until April 2011, flat-rate prescription charges of £5 per item were applicable 
in Scotland for people aged under 60 years who did not have an exemption due to 
certain chronic illnesses or low income. Medication was free for all other patients.[403] 
 
In keeping with a previous similar study, I excluded devices that did not actually deliver 
drugs, and any other preparations that were prescribable but did not constitute active 
medications.[37] I addressed this in two ways. Firstly, I reviewed the NHS Scotland 
Prescription Cost Analysis which lists all items dispensed in Scotland, to find specific 
formulations that could be considered irrelevant.[404] I then requested the following 
formulations be excluded: aerosols, cleansing agents, crystals, flour, gum, jelly, 
mouthwash, oil, paint, paste, rinses, rubs, scrubs, soup, tinctures, vaccines, washes, 
water and wax. Secondly, I examined the structure of the British National Formulary 
(BNF) and excluded chapters 14 (immunological products and vaccines) and 18 to 
23, sometimes called appendices and indices, which include for example dressings 
and appliances for incontinence.[405] 18  Then at paragraph level, which mostly 
represents drug classes, I excluded items which were either not medications (such as 
foods for special diets) or had little pharmacological action (for example, emollients, 
throat lozenges, artificial saliva and aromatic inhalations). I included prescribed 
oxygen as it is a drug and its use is likely to represent significant illness.[406] 
 
The primary exposure variable was the count of unique medications dispensed within 
one quarter. This is a continuous variable so I primarily treated it as such. However, 
anticipating a wide range, when comparing hazard ratios for each level of medication 
use I collapsed the categories at ≥20. When comparing groups of patients by their 
level of medication use, for example to allow clearer visual comparison on a Kaplan-
Meier graph, I used the groups 1-4, 5-9 and ≥10 medications. These cut-offs have 
been used in several similar studies.[32] 
 
 
18 The BNF structure changed in 2017; I referred to the original chapter structure as in BNF 69 
(September 2015), now called BNF Legacy  
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6.3.3.2 Outcome variables 
6.3.3.2.1 Deaths 
From the NRS linked extract, I received data on any person who was aged over 50 
years on 1st January 2009 and died between then and 30th June 2017. The variables 
included their age at death in months, their primary cause of death and any listed 
secondary causes of death (of a possible maximum of ten). From these data, I used 
two time variables, age at death and time to death (age at death minus age at 1st 
January 2009). I generated a binary variable for mortality to allow analyses on all-
cause mortality, and inform and contextualise specific examination of psychiatric 
causes. I then created a concatenated variable of all causes of death and searched 
this and the primary cause of death variable separately for psychiatric codes.  
 
I reviewed ICD-10 Chapter V, Mental and Behavioural Disorders, for relevant 
diagnosis codes.[407] In keeping with my hypotheses that polypharmacy might 
increase mental disorders, I was interested in those mental disorders that can develop 
or worsen in ageing. Therefore I excluded intellectual disabilities (“mental retardation” 
in ICD-10) and other neurodevelopmental disorders, and all disorders of adult 
personality and behaviour (F60-69). This includes specific personality disorders and 
gender identity disorders, which are by definition lifelong. The disorders included are 
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Table 6-2: Mental and behavioural disorders included in definition of psychiatric causes of 
death 
Overall group of 
disorders 
Disorders included ICD-10 codes 
Dementia or mild 
cognitive impairment 
All subtypes of dementia (including 
unspecified), mild cognitive disorder 
F00, F01, F02, 
F03, F67, G30 
Delirium Delirium not induced by alcohol and 
other psychoactive substances 
F05 
Other organic disorders Organic amnesic syndrome, mental, 
personality or behavioural disorders 
due to brain damage and dysfunction 
or physical disease, unspecified 
organic mental disorder 
F04, F06, F07, 
F09 
Mental and behavioural 
disorders due to use of 
alcohol 
Includes harmful use, dependence 
syndrome, acute intoxication, 
withdrawal state, amnesic syndrome 
F10 
Mental and behavioural 
disorders due to other 
psychoactive substance 
use 
Includes harmful use, dependence 
syndrome, acute intoxication, 
withdrawal state, amnesic syndrome 
F1, excluding 
F10 
Schizophrenia and other 
non-organic psychotic 
disorders  
Schizophrenia, persistent delusional 
disorder, acute and transient psychotic 
disorder, schizoaffective disorder, 
other or unspecified nonorganic 
psychosis. 
Not schizotypal disorder 
F20, F22, F23, 
F25, F28, F29 
Depression and other 
mood (affective) 
disorders 
Depressive episode, recurrent 
depressive disorder, other or 
unspecified mood disorders 
F32, F33, F34, 
F38, F39 
Bipolar affective disorder 
and mania 
Bipolar affective disorder, manic 
episode 
F30, F31 
Anxiety and adjustment 
disorders 
Obsessive-compulsive disorder, 
adjustment disorder, phobic and other 
anxiety disorders 
F40, F41, F42, 
F43 
Somatoform, 
dissociative and other 
neurotic disorders 
Dissociative disorder, somatoform 
disorder, other neurotic disorders 
F44, F45, F48 
Eating disorders Anorexia nervosa, bulimia nervosa, 
other psychogenic eating disorders 
F50 
Other disorders  Unspecified mental disorder, 
psychological and behavioural factors 




I created two binary variables, one for death where the primary cause was a mental 
disorder and another for death with a mental disorder listed as any (including primary) 
cause of death. For each of these variables, a psychiatric cause of death was coded 
as 1 and either survival or death without a psychiatric cause was 0.  
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6.3.3.2.2 Psychiatric admissions 
Using the SMR04 dataset, which records all admissions to psychiatric hospital in 
Scotland, I made a binary variable of whether all linked patients were admitted to 
psychiatric hospital within the study period. For people with multiple admissions, I took 




The follow-up begins on 1st January 2009, which was when Scotland’s prescribing 
records were linked to other health datasets. This is an arbitrary time point in relation 
to the exposure and outcome variables, so time in follow-up is therefore irrelevant for 
most analyses. Patients’ ages are more relevant to mortality and hospital admission 
in this age group. The most appropriate metric of time is therefore age at event (death 
or hospital admission), with age at entry to the cohort (on 1st January 2009 in all cases) 
as a covariate.[408–410] This starting age, in months, was taken from the PIS extract. 
 
I generated a time at censoring variable where those who did not die or have a hospital 
admission were allocated 102 months (the length of follow-up duration). For hospital 
admission analyses, I used informative censoring with death as a competing event, 
in that patients who died were censored at their death and did not continue 
contributing to the hazards of hospital admission. Age was treated as a continuous 
variable in most analyses, but age groups were used to stratify analyses where 
appropriate.  
 
6.3.3.3.2 Psychotropic drug use 
Medication is the primary form of treatment for most people who seek medical 
attention for mental disorders.[79] In the UK, psychotropic medication is only 
prescribed where it has an evidence base for clinical effectiveness, so in theory, taking 
psychotropic medication should reduce the incidence of mental health outcomes if it 
effectively treats them. In any case, in this dataset where diagnoses are not available, 
psychotropic medication use can act as a marker for a pre-existing psychiatric 
diagnosis. It was therefore important to account for psychotropic drug use in analyses. 
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I used the concatenated variable of all dispensed drug names to find specific 
psychotropic medications for descriptive analyses, for use as a covariate and to create 
a subsample of people not taking psychotropic drugs. I defined drugs as psychotropic 
if they appeared in the following sections of the British National Formulary (BNF): 
 4.1 Hypnotics and anxiolytics 
4.2 Drugs used in psychoses and related disorders (includes those used in   
mania) 
 4.3 Antidepressant drugs 
 4.11 Drugs for dementia [405] 
 
I did not include any of section 4.10, drugs used in substance dependence (which 
includes methadone and nicotine replacement), as their effects are not primarily 
psychotropic. I considered including stimulants used for attention deficit disorder such 
as atomoxetine, dexamfetamine and methylphenidate, but preliminary analyses 
showed these to be negligibly small in number, given the age population studied. 
Table 6-3 lists the drugs included within the psychotropic drug marker. I used the R 
function grepl to include the strings below and any surrounding letters; asterisks in 
the table represent possible truncations. 
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Table 6-3: Drugs counted in psychotropic variable 
Overall group Class Drugs 
Antidepressants Tricyclics and 
related drugs 
Amitriptyline, clomipramine, dosulepin, 
doxepin, imipramine, lofepramine, 




*citalopram (includes escitalopram), 






Other Mirtazapine, venlafaxine, agomelatine, 
duloxetine, reboxetine 
Antipsychotics First generation Benperidol, flupentixol, haloperidol, 
levomepromazine, pericyazine, 
trifluoperazine, perphenazine, pimozide, 
prochlorperazine, *promazine, sulpiride, 
zuclopentixol 
Second generation Amisulpride, aripiprazole, clozapine, 
lurasidone, olanzapine, paliperidone, 





Benzodiazepines *azepam, *azolam, chlordiazepoxide 





Other sedatives Chloral hydrate, clomethiazole, 
meprobamate, buspirone, phenobarbital 
Mood stabilisers Lithium, asenapine, carbamazepine, 
valpro*, lamotrigine 
Drugs for dementia Donepezil, galantamine, rivastigmine, 
memantine 
 
For use as a covariate, I generated a binary variable of whether a patient received 
one or more of any of these psychotropic medicines. Anticipating that this 
psychotropic drug use marker might be informative in its own right, I conducted 
secondary analyses with dichotomous psychotropic drug use as the exposure 
variable for all outcomes as below and adjusted for the number of unique drugs as 
well as the other covariates.  
 
6.3.3.3.3 Other covariates 
Average life expectancy at birth in Scotland in 2016 was 77.0 years for men and 81.1 
years for women, so gender is relevant to these analyses and was included as a 
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covariate.[411] Gender were taken from the PIS extract and recorded as at 1st January 
2009.19  
 
I had intended to include ethnic group as this is relevant to multimorbidity prevalence 
and by extension polypharmacy,[278] but this is only recorded in SMR from hospital 
contacts, and even then is not recorded well. There was a large proportion of missing 
data for this variable in exploratory work so I excluded it from further analyses. 
 
Socioeconomic status is strongly associated with multimorbidity, and with mortality 
relating to this. A seminal multimorbidity paper studying a cross-section of Scotland 
in 2007 found around a ten-year gap in prevalence of multimorbidity in younger ages 
between the most and least deprived deciles of deprivation.[39] This has recently 
been replicated in an English study, which found a ten-year gap in middle age which 
decreased with increasing age.[412] Polypharmacy has also been shown to be 
associated with socioeconomic deprivation in Scotland, with people in the most 
deprived quintile at over twice the risk of being prescribed ≥10 drugs than those in the 
least deprived quintile (adjusted OR=2.36 (95% CI 2.22 to 2.51).[27,37] The 
prescription charge of £5 that was applicable to some included patients in 2009 may 
have reduced medication uptake in people on low incomes who had not met the 
criteria for exemption due to low income. 
 
The Scottish Index of Multiple Deprivation (SIMD) is a relative measure of deprivation 
calculated across seven domains: income, employment, health, education, skills and 
training, housing, geographic access and crime.[413] Scotland is split into 6976 data 
zones of approximately equal population (around 760 people) which are then ranked 
according to these domains. The SIMD therefore allows comparison of deprivation in 
different areas, but relates to the area of residence rather than circumstances of an 
individual. My CHI extract included the 2016 SIMD decile of each individual, thus 
representing their deprivation based on their postcode, relative to other places in 
 
19 The variable provided by ISD was called gender, and as it is possible to request a change 
to the gender code in a CHI number,[592] I have used this term throughout this chapter 
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Scotland, with 1 the most deprived and 10 the least deprived. Specific SIMD rank or 
postcode would have included too much identifiable information. Deciles of other 
similar scores (for example, Carstairs) have been used in similar population-level 
studies.[39] The Scottish Government’s latest polypharmacy guidance document 
used SIMD quintiles to demonstrate the disparities in polypharmacy by 
socioeconomic group.[27]  
 
I also included care home residency as a covariate because people living in care 
homes or institutions have higher rates of polypharmacy than the general population. 
For example, a Scottish polypharmacy study found that compared to people living in 
their own home, the odds ratio of being prescribed ≥10 medications for those living in 
care homes was 2.88 (95% CI 2.65 to 3.13).[37] A Swedish population-based study 
of people who died aged 65 years or over found that 37.2% of people living in 
institutions were taking ≥10 drugs.[414] People living in care homes also have high 
rates of multimorbidity and frailty so it is important to take this group into account.[415] 
A care home residency flag was included in the CHI extract. This marker has been 
found to have 97-99% positive predictive value and sensitivity of 55-89%.[416]  
 
6.3.4 Statistical analysis 
The primary methods in this chapter are survival analyses of mortality (all-cause and 
with mental or behavioural disorders on the death certificate, either as primary or any 
cause of death) and psychiatric admission, according to the number of medications 
dispensed. 
 
6.3.4.1  Descriptive statistics 
All analyses were conducted within the Farr Institute Safe Haven remote desktop, in 
R version 3.5.1.[417] For descriptive cross-sectional analyses at the study start date, 
I used linear regression, using the same template code as detailed in section 4.3.6.2, 
for example to assess the relationship between age and number of drugs dispensed. 
I used Student’s t-test to compare means and c2 tests to compare proportions 
between groups, for example when describing the characteristics of participants 
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receiving and not receiving psychotropic drugs. To prevent the inadvertent 
identification of individuals, outliers on graphs at extreme old age were removed. 
Where there were fewer than ten patients in a group of patient characteristics, this 
was presented as only ‘<10’.  
 
6.3.4.2 Survival analyses 
The longitudinal analysis approaches used were Cox proportional hazards regression 
and the Kaplan-Meier method. The follow up period for longitudinal analyses was 1st 
January 2009 to 30th June 2017: 8.5 years or 102 months. Ages were given in months, 
so I used months as my time scale.  
 
6.3.4.2.1 Cox proportional hazards models 
Survival analyses are concerned with whether participants met an outcome event 
(including death) or not, and if they did, the time taken to reach that event. They also 
account for censoring, that is whether the participant’s time to outcome is unknown 
because it did not occur during the study period. A hazard is the risk of reaching an 
outcome at a certain time, given that it has not been reached already.[418] Cox 
proportional hazard ratios, first developed in 1972, are a version of survival models 
used to investigate the simultaneous effects of multiple explanatory variables on the 
hazard.[419] The assumption is that the ratio of hazards remains constant over time, 
and Cox regression coefficients are exponentiated to generate a hazard ratio. 
 
After checking model assumptions graphically using Schoenfeld residuals, I used the 
R package survival to conduct Cox proportional hazards regression models, with 
right censoring applied.[420] Right censoring means that although patients’ starting 
age was known, if they survived the study period, their age when the outcome 
occurred was unknown. An example of the code used was as follows: 
 library(survival) 
summary(coxph(Surv(censor_time, outcome==1, 
type=“right”) ~ exposure_continuous + covariate, 
data=dataset)) 
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Included covariates were starting age, gender, care home status and SIMD in all 
models. The psychotropic medication marker was an additional covariate.  
 
6.3.4.2.2 Kaplan-Meier method 
The Kaplan-Meier method, originally described in 1958, represents the estimated 
probability of survival (or an event not occurring) for a member of the population at 
that age or time.[421] The method estimates conditional probabilities: the probability 
of surviving to the end of a time interval given that the participant has already survived 
to the beginning of it. Survival probability is then calculated as the product of the 
conditional probabilities of surviving that time interval.[422] Plotting a Kaplan-Meier 
estimate of the survivor function shows the crude association between the exposure 
variable at baseline and cumulative probability of the outcome during the follow-up 
period. The survival probability only changes when an event occurs, which appears 
as a step on the graph. The step height relates to the remaining sample at risk of the 
event. In large sample sizes such as mine, the large number of steps makes the curve 
appear smooth. A disadvantage of using the Kaplan-Meier method is that covariates 
cannot be included.[418] 
 
I used the R packages survival and survminer to generate and plot Kaplan-Meier 
curves as follows:[420,423]  
 library(survival) 
 library(survminer) 
fit = survfit(Surv(censor_time, outcome==1, type=“right”) 
~ exposure_category, data=dataset) 
ggsurvplot(fit, censor=FALSE) # with additional details 
for adjusting size, colours, guides and legends 
 
I did not include censoring ticks on the curves as there were too many events to be 
meaningfully visible. I separated the sample into subsets of age bands, 50-64 years, 
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65-79 years and ≥80 years. These age groups are commonly used in longitudinal 
studies of ageing where the minimum age is 50 years,[424] and have the benefit of 
including a cut-point at 65 years, which is when older adult healthcare provision 
begins in much of the UK. This approach allowed some comparison between the age 
groups.  
 
I used both age at event and time to event (age at event minus age at start) as time 
variables for comparison, given that it was not possible to adjust for starting age. The 
explanatory variable was number of drugs categorised into 1-4, 5-9 and ≥10 for ease 
of interpretation. 
 
6.3.5 Treatment of missing data 
Patients whose age at death or admission was less than their starting age were 
excluded. If the difference between age at death or admission and the starting age 
was greater than 102 months, these patients were also excluded. Patients with a 
starting age of less than 50 years were excluded. There were small numbers of these 
patients and these anomalies were assumed due to errors in either data entry or 
during the linkage process. 
 
SIMD was the only included variable which contained missing data. Patient 
characteristics between the groups of those with SIMD available and missing were 
calculated and compared using c2 and t-tests. This preliminary analysis suggested 
SIMD was missing at random; I excluded those with missing SIMD from the main 
analyses and conducted sensitivity analyses as follows: 
i) Including people with missing SIMD but excluding SIMD as a covariate 
ii) Generating estimated SIMD by multiple imputation  
 
Multiple imputation was performed using the R package mice (Multivariate Imputation 
by Chained Equations).[425] The imputation process generates multiple copies of the 
dataset, simulating possible options for the missing data based on regression models 
using the non-missing variables. Residual error is added via the regression model’s 
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parameter estimates to create imputed values.[426] The convention is to generate 
three to five imputations, but White and colleagues suggest the fraction of missing 
information is often lower than the percentage of missing cases, so the number of 
imputations should be at least equal to the percentage of missing cases.[427] As 
8.96% of the total sample had SIMD missing, I generated nine imputations twice, 
based on the cumulative hazard for each all-cause mortality and psychiatric 
admission. For each of these imputations I used five iterations, where the first 
generates random possible values for the missing data and each iteration refines 
these using regression coefficients and residual error. The final iteration generates 
the first imputed dataset and the process is repeated in the next imputation. 
 
The following code is an example of how I generated the imputation: 
 library(mice) 
 d = data.frame(dataset) 
 cumulative_hazard = nelsonaalen(d, censor_time, outcome) 
 d2 = data.frame(d, cumulative_hazard) 
 imputation1 = mice(d2, m=1, maxit=0, seed=100) 
 Pred = imputation1$predictorMatrix 
Pred[2, “censor_time”] = 0 # the variable to impute is 
in column 2 
Full_imputation = mice(d2, m=9, maxit=5, seed=100, 
predictorMatrix = Pred) 
 
The analysis, in this case Cox proportional hazards, is conducted in each of the 
imputed datasets as normal.[428] It generates an estimate for each parameter for 
each imputation. The pool function of the mice package then calculates the mean 
of these estimates (in this case, Cox regression coefficients), along with the total 
variance over the repeated analysis according to Rubin’s rules, giving one point 
estimate.[425,429,430] An example of the code used to do this is as follows: 
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 library(mice) 
 library(survival) 
cox_model = with(data = Full_imputation, 
exp=coxph(Surv(censor_time, outcome) ~ 
exposure_continuous + covariate)) 
pool_cox_model = summary(pool(cox_model, dfcom = 
1346595)) 
pool_hr = exp(cbind(pool_cox_model[,1], 
(pool_cox_model[,1] - 1.96*(pool_cox_model[,2])), 
(pool_cox+model[,1] + 1.96*(pool_cox_model[,2])))) 
 
6.4 RESULTS 
6.4.1 Sample overview 
There were 2 007 825 people aged 50 years and over with a CHI number in the study 
period. Of these, 661 109 did not have a prescription processed in the first quarter of 
2009 so were excluded from further analyses. After removing those in the remaining 
sample with ages either NA or under 50 years (n=2), 1 346 714 people were in the 
whole sample for descriptive analyses. After removing 118 patients whose age at 
death or admission was either less than their starting age or >102 months and the 
120 706 with missing SIMD (four people met both these exclusion criteria), the 
analytic sample comprised 1 225 894 individuals. Figure 6-2 displays the number of 
participants included and excluded at each stage.  
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Table 6-4: Characteristics of whole sample (including those with missing SIMD), and analytic 
sample (complete cases) during study period January 2009 to June 2017  
Whole sample Analytic sample 
Mean 
(SD) 





1 346 714  1 225 894 






















757 552 (56.25)  687 431 (56.08) 








 332 954 (24.72)  303 743 (24.78) 
Dispensed antidepressant 
 
217 546 (16.15)  198 213 (16.17) 
Dispensed anxiolytic or 
hypnotic 
 
119 291 (8.86)  108 950 (8.89) 
Dispensed antipsychotic 
 
45 779 (3.40)  42 154 (3.44) 
Dispensed dementia drugs 
 




26 627 (1.98)  24 261 (1.98) 
Care home resident  46 095 (3.42)  45 925 (3.75) 
SIMD missing 
 
120 706 (8.96)  0 
Died 
 
363 743 (27.01)  336 244 (27.43) 




















Died with mental disorder 
as primary cause 
 35 543 (9.77)  32 737 (9.74) 
Died with mental disorder 
as any cause 
 69 569 (19.13)  63 974 (19.03) 
Admitted to psychiatric 
hospital 
 26 688 (1.98)  23 747 (1.94) 






Figure 6-3 shows the distribution of age by gender of the whole sample of people 
aged ≥50 years as at 1st January 2009 (n=1 346 714). The peak at aged around 62 
years reflects people born immediately after the Second World War in 1946-7. There 
is another marked step in both genders around age 89 years, showing fewer people 
alive who were born before 1920. This may reflect either high maternal and infant 
mortality or miscarriage rate in 1918-20 due to the Spanish influenza pandemic, a 
peak in births after the end the First World War, or a combination of the two.[431] 
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The mean number of medications dispensed within one quarter in the analytic sample 
(who all received at least one drug) was 4.99 (SD=3.65). The median number of drugs 
was 4, and interquartile range 2-7. Table 6-5 shows the breakdown of the drugs 
dispensed according to the groups used for survival analyses. 
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Table 6-5: Number of unique drugs dispensed in analytic sample 
Total number of unique drugs N (%) N (%) of grouped 
number of drugs  
1 196 313 (16.01)  661 030 (53.92) 
2 171 951 (14.03) 
3 156 431 (12.76) 
4 136 335 (11.12) 
5 119 136 (9.72) 421 000 (34.34) 
6 101 776 (8.30) 
7 82 825 (6.76) 
8 65 581 (5.35) 
9 51 682 (4.22) 
10 39 484 (3.22) 143 864 (11.74) 
11 29 490 (2.41)  
12 22 008 (1.80) 
13 15 939 (1.30) 
14 11 150 (0.91) 
15 8 019 (0.65) 
16 5 526 (0.45) 
17 3 890 (0.32) 
18 2 716 (0.22) 
19 1 796 (0.15) 
≥20 3 846 (0.31) 
 
I used linear regression for a cross-sectional analysis of age and number of 
medications in the first quarter of 2009. In an unadjusted model, increase in age by 
one year was associated with an increase in total drugs by 0.090 (95% CI 0.090 to 
0.091, P<0.001).20  When adjusted for gender, SIMD and care home status, this 
reduced to 0.087 (95% CI 0.087 to 0.088, P<0.001). The distribution of continuous 





20 Throughout this chapter, I give regression results to three decimal places to provide a level 




Figure 6-4: Heat map showing distribution of unique drugs by age (outliers at extreme old age removed to avoid identification) 
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The mean age for patients taking each number of unique drugs is displayed in Figure 
6-5. This shows that although mean age increases steeply for people receiving 1-5 
drugs, the increase does not remain linear. The mean age peaks at 71.9 (SD=10.6) 
years for people taking 11 drugs, then decreases to 68.4 (SD=10.1) years for people 
receiving ≥20 drugs. 
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Figure 6-6 is a bar chart of the mean unique drugs dispensed according to ten-year 
age bands, showing an increase in mean number of drugs with age. 
Figure 6-6: Mean unique drugs dispensed according to age in January 2009, in 10-year bands 
 
For stratified analyses using both Cox regression and Kaplan-Meier analyses, I split 
the sample into age groups and bands by number of medications. Table 6-6 shows 
the characteristics of the analytic sample as divided by age group. 
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Table 6-6: Characteristics of analytic sample by age group 
 
N (%) or mean (SD) 
50-64 years 65-79 years ≥80 years 
All 562 889 (45.92) 484 311 (39.51) 178 694 (14.58) 
Female gender 302 401 (53.72) 267 101 (55.15) 117 929 (65.99) 
Care home resident 2 223 (0.39) 13 411 (2.77) 30 291 (16.95) 
Mean number of 
medications (SD) 
4.04 (3.33) 5.58 (3.70) 6.41 (3.67) 
1-4 medications 377 071 (66.99) 222 728 (45.99) 61 231 (34.27) 
5-9 medications 144 681 (25.70) 192 634 (39.77) 83 685 (46.83) 
³10 medications 41 137 (7.31) 68 949 (14.24) 33 778 (18.90) 
Dispensed any 
psychotropic medication 
143 107 (25.42) 107 929 (22.29) 52 707 (29.50) 
Dispensed 
antidepressant 
104 369 (18.54) 65 891 (13.61) 27 953 (15.64) 
Dispensed anxiolytic or 
hypnotic 
44 247 (7.86) 42 219 (8.72) 22 484 (12.58) 
Dispensed antipsychotic 17 155 (3.05) 15 106 (3.12) 9 893 (5.54) 
Dispensed dementia 
drugs 
340 (0.06) 3 528 (0.73) 4 686 (2.62) 
Dispensed mood 
stabilisers 
12 933 (2.30) 8 477 (1.75) 2 851 (1.60) 
Died 54 478 (9.68) 149 514 (30.87) 132 252 (74.01) 
Died with mental 
disorder as primary 
cause 
1 306 (2.40) 10 751 (7.19) 20 680 (15.64) 
Died with mental 
disorder as any cause 
4 155 (7.63) 22 912 (15.32) 36 907 (27.91) 
Admitted to psychiatric 
hospital 
8 618 (1.53) 10 384 (2.14) 4 745 (2.66) 
 
6.4.1.1 Psychotropic drug use 
Characteristics of the analytic sample according to psychotropic drug use status are 
in Table 6-7. People receiving psychotropic drugs were older, more likely to be female 
and be resident in a care home. They were more likely to die, especially with 
psychiatric causes, at younger ages than people not receiving psychotropic drugs. A 
higher proportion of them were admitted to psychiatric hospital, at younger ages, than 
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Table 6-7: Characteristics of analytic sample by psychotropic drug status 
 








P for difference 
All 922 151 303 743  
Starting age in years 67.31 (10.55) 67.55 (11.53) <0.001 (t=10.15) 
50-64 years 419 782 (45.52) 143 107 (47.11) 
 
65-79 years 376 382 (40.82) 107 929 (35.53) 
 
≥80 years 125 987 (13.66) 52 707 (17.35) 
 
Female gender 484 207 (52.51) 203 224 (66.91) <0.001  
(c2= 19 230) 
Care home resident 20 700 (2.24) 25 225 (8.30) <0.001  
(c2= 23 268) 
Number of medications 4.31 (3.11) 7.07 (4.32) <0.001 (t=326.39) 
Died 227 675 (24.69) 108 569 (35.74) <0.001  
(c2= 14 026) 
Died with mental 
disorder as primary 
cause 
17 571 (1.91) 15 166 (4.99) <0.001  
(c2= 8 379.3) 
Died with mental 
disorder as any cause 
35 252 (3.82) 28 722 (9.46) <0.001  
(c2= 14 658) 
Admitted to psychiatric 
hospital 
10 322 (1.12) 13 425 (4.42) <0.001  
(c2= 13 101) 
Age at death in years 80.53 (10.00) 79.59 (10.78) <0.001 (t=24.3) 
Age at admission in 
years 
76.23 (10.47) 70.38 (11.22) <0.001 (t=41.32) 
 
Figure 6-7 is a bar graph representing the proportion of each age group receiving 
psychotropic medication, with a breakdown of medication types as listed in Table 6-3 
(page 210). Antidepressants were the most commonly received psychotropic drug in 
all age groups.  
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Figure 6-7: Proportion of each age group dispensed psychotropic drugs 
 
 
Figure 6-8 shows the proportion of patients in each SIMD decile that received at least 
one psychotropic drug, suggesting decreasing use of psychotropic drugs with 
decreasing deprivation. 
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Because previous research has found an association between increasing deprivation 
and increasing levels of polypharmacy, I used linear regression to explore the 
association between increasing SIMD decile at 1st January 2009 and unique drugs 
dispensed in that quarter. In an unadjusted model, increasing SIMD decile by one 
(that is, decreasing deprivation) had an associated decrease in total number of drugs 
(β= -0.200, 95% CI -0.202 to -0.197, P<0.001). In a model adjusted for age, gender 
and care home status, this reduced further to -0.203 (95% CI -0.205 to -0.201, 
P<0.001). 
 
I plotted the mean number of dispensed drugs according to SIMD decile, where 1 is 
the most and 10 the least deprived decile, in Figure 6-9. This shows a decrease in the 
mean number of drugs as deprivation decreases. The mean number of drugs for 
people in SIMD decile 1 was 5.96 (SD=4.06) and in decile 10, 4.11 (SD=3.11). On 
Student’s t-test, there was a difference between these two deciles, with t=124.21 and 
P<0.001. 
Figure 6-9: Mean drugs dispensed according to deprivation decile 
 
Dementia was the most common mental or behavioural disorder listed on death 
certificates, with alcohol and substance use second. Table 6-8 lists the breakdown of 
the types of mental disorders listed on death certificates. The definitions of each group 
of disorders are in Table 6-2 on page 207.  
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Table 6-8: Deaths with mental disorder on the death certificate 
Group of disorders Primary cause of 
death  
(% of all deaths) 
In any cause of death 
field (including primary) 
(% of all deaths) 
Dementia or mild cognitive 
impairment 
31 503 (9.37) 57 241 (17.02) 
Delirium 118 (0.04) 689 (0.20) 
Other organic disorders <10  27 (0.01) 
Mental and behavioural disorders 
due to use of alcohol 
908 (0.27) 3 156 (0.94) 
Other psychoactive substance 
use 
32 (0.01) 1 974 (0.59) 
Schizophrenia and other non-
organic psychotic disorders  
33 (0.01) 529 (0.16) 
Depression and other mood 
(affective) disorders 
106 (0.03) 792 (0.24) 
Bipolar affective disorder and 
mania 
21 (0.01) 239 (0.07) 
Anxiety and adjustment 
disorders 
<10 114 (0.03) 
Somatoform, dissociative and 
other neurotic disorders 
0 <10 
Eating disorders <10 15 (0.00) 
Other disorders  0 <10 
 
6.4.2 Survival analysis: all-cause mortality 
6.4.2.1 Cox proportional hazards models  
To contextualise explorations of mental disorders as causes of death, the first 
analyses were of mortality with any cause. Preliminary graphical analysis of 
Schoenfeld residuals for mortality confirmed that the proportional hazards assumption 
had not been violated. On Cox regression, the hazard ratio (HR) for mortality with 
medications increasing by one was 1.089 (95% CI 1.088 to 1.090, P<0.001), adjusted 
for starting age, gender, SIMD and care home status. With psychotropic drug use as 
an additional covariate, the HR was 1.080 (95% CI 1.079 to 1.081, P<0.001). In a 
subsample excluding patients receiving psychotropic drugs (n=922 151), the HR for 
mortality with each additional medication was 1.087 (95% CI 1.086 to 1.088, 
P<0.001), adjusted for starting age, gender, SIMD and care home status. Receiving 
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I also conducted Cox regression models with each number of medications used as a 
categorical exposure, collapsing this at ≥20 drugs. The results of these analyses are 
listed in Table 6-9 and displayed in Figure 6-10.  
 
Table 6-9: Cox proportional hazards ratios for all-cause mortality with number of unique drugs 
Number of unique drugs Model 1: HR (95% CI) Model 2: HR (95% CI) 
1 Reference Reference 
2 1.118 (1.098 to 1.137) * 1.106 (1.087 to 0.126) * 
3 1.246 (1.225 to 1.267) * 1.224 (1.203 to 1.245) * 
4 1.352 (1.330 to 1.375) * 1.317 (1.295 to 1.339) * 
5 1.503 (1.478 to 1.528) * 1.452 (1.428 to 1.477) * 
6 1.652 (1.624 to 1.680) * 1.584 (1.557 to 1.611) * 
7 1.791 (1.760 to 1.822) * 1.699 (1.670 to 1.729) * 
8 2.007 (1.972 to 2.043) * 1.883 (1.850 to 1.918) * 
9 2.166 (2.216 to 2.206) * 2.013 (1.976 to 2.051) * 
10 2.318 (2.273 to 2.364) * 2.133 (2.091 to 2.176) * 
11 2.502 (2.450 to 2.555) * 2.282 (2.234 to 2.331) * 
12 2.759 (2.697 to 2.822) * 2.495 (2.439 to 2.553) * 
13 2.887 (2.815 to 2.960) * 2.591 (2.526 to 2.658) * 
14 3.180 (3.092 to 3.271) * 2.824 (2.744 to 2.905) * 
15 3.484 (3.375 to 3.596) * 3.069 (2.972 to 3.168) * 
16 3.666 (3.532 to 3.804) * 3.207 (3.089 to 3.329) * 
17 3.822 (3.661 to 3.990) * 3.338 (3.196 to 3.485) * 
18 4.020 (3.822 to 4.229) * 3.477 (3.305 to 3.658) * 
19 4.452 (4.192 to 4.727) * 3.846 (3.621 to 4.085) * 
≥20 5.308 (5.088 to 5.536) * 4.516 (4.328 to 4.713) * 
* P<0.001 in all analyses 
Model 1: Adjusted for starting age, gender, SIMD, care home status 
Model 2: Adjusted for starting age, gender, SIMD, care home status and psychotropic 
medication use 
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Although these analyses were adjusted for starting age, to further investigate the 
importance of age in these associations, I conducted stratified analyses in three age 
groups, 50-64, 65-79 and ≥80 years. The results for an increase in drugs by one are 
listed in Table 6-10 and with specific medication numbers shown in Figure 6-11. 
Table 6-10: Hazard ratios for all-cause mortality with increase in drugs by one, stratified by 
age 
Age group Covariates HR (95% CI) P-value 
50-64 years Starting age, gender, care home 
status, SIMD 
1.123 (1.121 to 1.125) <0.001 
Starting age, gender, care home 
status, SIMD, psychotropic drug 
use 
1.111 (1.109 to 1.113) <0.001 
65-79 years Starting age, gender, care home 
status, SIMD 
1.095 (1.094 to 1.096) <0.001 
Starting age, gender, care home 
status, SIMD, psychotropic drug 
use 
1.085 (1.084 to 1.087) <0.001 
≥80 years Starting age, gender, care home 
status, SIMD 
1.058 (1.056 to 1.059) <0.001 
Starting age, gender, care home 
status, SIMD, psychotropic drug 
use 
1.051 (1.049 to 1.052) <0.001 
  
Figure 6-10: Forest plot of hazard ratios for mortality with medication use in adults aged ≥50 
years 
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Figure 6-11: Hazard ratios for all-cause mortality with medication use by age group 
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These age-stratified analyses demonstrate that the association between increasing 
medication use and mortality was present at all ages, but was less pronounced as 
age increased. 
 
6.4.2.2 Sensitivity analyses  
To account for the missing data in SIMD, I performed sensitivity analyses with two 
methods: including all patients but not using SIMD as a covariate, and imputing SIMD 
and including it as a covariate. The results, in Table 6-11, show minimal change in 
effect size compared to analyses in the sample excluding those with missing SIMD. 
These results are of Cox regression models for all-cause mortality with a continuous 
increase in unique drugs. 
 
Table 6-11: Sensitivity analyses for continuous increase in drug use with all-cause mortality 
Sample Covariates HR (95% CI) P-value 
All receiving ≥1 
drug, including 
those with 
missing SIMD  
(n=1 346 714) 
Starting age, gender, care 
home status 
1.094 
(1.093 to 1.095) 
<0.001 
Starting age, gender, care 
home status, 
psychotropic drug use 
1.085  
(1.084 to 1.086) 
<0.001 
All receiving ≥1 
drug, with imputed 
SIMD  
(n=1 346 714) 
Starting age, gender, care 
home status, SIMD 
1.089  
(1.088 to 1.089) 
<0.001 
Starting age, gender, care 
home status, 
psychotropic drug use, 
SIMD 
1.079  
(1.078 to 1.080) 
<0.001 
 
6.4.2.3 Cox proportional hazards models with psychotropic medication as the 
exposure 
Following the confirmation that psychotropic drug use did attenuate the associations 
between overall drug use and mortality, I conducted secondary analyses of 
psychotropic drug use as the exposure variable in the sample of complete cases 
(n=1 225 894). The hazard ratio for mortality in those taking any psychotropic drug 
compared to those who did not was 1.262 (1.252 to 1.271, P<0.001), adjusted for total 
number of drugs, starting age, gender, care home status and SIMD. 
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6.4.2.4 Kaplan-Meier curves 
Using the survival models in the Cox models above, I plotted Kaplan-Meier curves for 
all-cause mortality with medication use categorised into 1-4, 5-9 and ≥10 concurrent 
drugs. In order to account for age, I analysed the three age groups separately, with 
age at death as the outcome, as shown in Figure 6-12. Within these age groups, there 
is a 15-year range in the starting age, so I also plotted these curves with time to death 
as the time variable, out of the maximum 102 months (Figure 6-13). In both these sets 
of plots and in all age groups, increasing categories of medication were associated 
with earlier age at or faster time to death. The differences between drug groupings 
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6.4.3 Survival analysis: mortality with mental or behavioural disorder as 
primary cause of death 
6.4.3.1 Cox proportional hazards models 
The hazard ratio for mortality with a mental disorder as the primary cause of death 
with continuous drug count increasing by one was 1.011 (95% CI 1.008 to 1.014, 
P<0.001), adjusted for starting age, gender, SIMD and care home status. When 
psychotropic medication use was an additional covariate, the association’s direction 
reversed, with HR=0.979 (95% CI 0.976 to 0.982, P<0.001). In the subsample of only 
patients not receiving psychotropic drugs (n=922 151), the HR for primary psychiatric 
cause of death with each additional medication was 0.993 (95% CI 0.988 to 0.998, 
P=0.004), adjusted for starting age, gender, SIMD and care home status. Table 6-12 
lists the results of analyses treating each number of drugs separately and they are 
represented in Figure 6-14 on page 239. These show that when adjusting for 
psychotropic drug use, increases in medication use were not statistically significantly 
associated with a primary psychiatric cause of death from 2 to 6 medications, and for 
≥7 medications, higher levels of medication use were inversely associated with dying 
and having a mental disorder as primary cause of death. 
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Table 6-12: Cox proportional hazards ratios for mortality with primary psychiatric cause of 





Model 1 Model 2 
HR (95% CI) P-value HR (95% CI) P-value 
1 Reference  Reference  
2 1.023 (0.968 to 1.080) 0.422 0.980 (0.928 to 1.035) 0.464 
3 1.070 (1.015 to 1.127) 0.012 0.991 (0.940 to 1.044) 0.722 
4 1.061 (1.007 to 1.118) 0.026 0.943 (0.894 to 0.993) 0.027 
5 1.105 (1.049 to 1.164) <0.001 0.953 (0.904 to 1.004) 0.069 
6 1.172 (1.112 to 1.234) <0.001 0.979 (0.929 to 1.032) 0.424 
7 1.165 (1.104 to 1.229) <0.001 0.934 (0.885 to 0.986) 0.014 
8 1.203 (1.137 to 1.272) <0.001 0.926 (0.875 to 0.980) 0.008 
9 1.183 (1.115 to 1.255) <0.001 0.886 (0.835 to 0.941) <0.001 
10 1.211 (1.137 to 1.291) <0.001 0.875 (0.821 to 0.934) <0.001 
11 1.186 (1.107 to 1.272) <0.001 0.840 (0.783 to 0.902) <0.001 
12 1.164 (1.076 to 1.259) <0.001 0.805 (0.744 to 0.872) <0.001 
13 1.100 (1.003 to 1.205) 0.043 0.748 (0.682 to 0.821) <0.001 
14 1.126 (1.012 to 1.253) 0.029 0.737 (0.661 to 0.820) <0.001 
15 1.130 (0.992 to 1.287) 0.066 0.727 (0.638 to 0.828) <0.001 
16 1.072 (0.913 to 1.260) 0.397 0.683 (0.581 to 0.790) <0.001 
17 1.025 (0.841 to 1.249) 0.806 0.648 (0.531 to 0.790) <0.001 
18 1.118 (0.891 to 1.403) 0.337 0.689 (0.549 to 0.865) 0.001 
19 1.166 (0.876 to 1.552) 0.293 0.729 (0.548 to 0.971) 0.031 
≥20 0.890 (0.691 to 1.145) 0.364 0.522 (0.406 to 0.673) <0.001 
Model 1: Adjusted for starting age, gender, SIMD, care home status 
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Figure 6-14: Forest plot of hazard ratios for mental disorder as primary cause of death with 
increasing medications in adults aged ≥50 years 
 
I then carried out stratified analyses by age group. The results are listed in Table 6-13 
and displayed in Figure 6-15 on page 240. 
 
Table 6-13: Hazard ratios for mental disorder as primary cause of death with increase in drugs 
by one, stratified by age 
Age group Covariates HR (95% CI) P-value 
50-64 years Starting age, gender, care home 
status, SIMD 
1.048  
(1.033 to 1.063) 
<0.001 
Starting age, gender, care home 
status, SIMD, psychotropic drug use 
0.998  
(0.983 to 1.014) 
0.809 
65-79 years Starting age, gender, care home 
status, SIMD 
1.024  
(1.019 to 1.029) 
<0.001 
Starting age, gender, care home 
status, SIMD, psychotropic drug use 
0.988  
(0.983 to 0.994) 
<0.001 
≥80 years Starting age, gender, care home 
status, SIMD 
0.996  
(0.992 to 1.000) 
0.051 
Starting age, gender, care home 
status, SIMD, psychotropic drug use 
0.974  
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Figure 6-15: Forest plot of hazard ratios for mortality with mental disorder as primary cause by 
medication use, by age group 
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In people aged 50-79 years, increasing medication use was associated with an 
increase in mortality with a mental disorder as the primary cause, but adding 
psychotropic medication as a covariate removed the association’s statistical 
significance. In people aged ≥80 years, increasing medication use was inversely 
associated with mortality where a mental disorder was the primary cause of death, 
when adjusting for psychotropic medication use only. 
 
6.4.3.2 Sensitivity analysis 
To account for the missing SIMD values, I performed sensitivity analyses with the 
same methods as for all-cause mortality. Table 6-14 shows the hazard ratios for 
primary psychiatric mortality with an increase in drug use by one. The results were 
robust to the sensitivity analyses. 
Table 6-14: Sensitivity analyses for continuous increase in drug use for mortality with a mental 
disorder as the primary cause 
Sample Covariates HR (95% CI) P-value 
All receiving ≥1 
drug, including 
those with missing 
SIMD  
(n=1 346 714) 
Starting age, gender, care 
home status 
1.014  
(1.011 to 1.017) 
<0.001 
Starting age, gender, care 
home status, psychotropic 
drug use 
0.982  
(0.979 to 0.985) 
<0.001 
All receiving ≥1 
drug, with imputed 
SIMD  
(n=1 346 714) 
Starting age, gender, care 
home status, SIMD 
1.012  
(1.009 to 1.015) 
<0.001 
Starting age, gender, care 
home status, psychotropic 
drug use, SIMD 
0.980  
(0.977 to 0.983) 
<0.001 
 
6.4.3.3 Cox proportional hazards models with psychotropic medication as the 
exposure 
In the sample of complete cases (n=1 225 894), the hazard ratio for mortality where 
there was a mental disorder as primary cause of death in those taking any 
psychotropic drug compared to those who did not was 2.182 (95% CI 2.130 to 2.235, 
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6.4.3.4 Kaplan-Meier curves 
I plotted Kaplan-Meier curves for mortality with a mental disorder as the primary cause 
of death, in three age groups, with time to death and age at death as the time 
variables. These are shown in Figure 6-16 on page 243 and Figure 6-17 on page 244. 
There was little difference in mortality rates between drug groups in the 50-64 years 
age group with either time metric. People taking 5-9 drugs had the highest increased 
probability of mortality with mental disorders as a primary cause where time to death 
was the time metric, followed by those on ≥10 and 1-4 medications. Regarding age at 
death, the same pattern is seen in those aged 65-79 years and in those aged ≥80 
years and there is little difference between the groups with some overlap at extreme 
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6.4.4 Survival analysis: mortality with mental or behavioural disorder in 
any field on death certificate 
6.4.4.1 Cox proportional hazards models  
Using Cox regression models for mortality with a mental disorder in any field on the 
death certificate (including as the primary cause), each additional medication had an 
HR of 1.033 (95% CI 1.031 to 1.035, P<0.001) when adjusting for age, gender, SIMD 
and care home status. With psychotropic medication as an additional covariate, the 
HR reduced to 1.002 (95% CI 1.000 to 1.005, P=0.033). When excluding those 
receiving psychotropic medication, the HR was 1.016 (1.013 to 1.020, P<0.001). The 
HRs for each number of medications are listed in Table 6-15 and displayed in Figure 
6-18. They show only slight cumulative increases in HR with increasing medication, 
with smaller effect sizes (and results not meeting conventional statistical significance) 
with higher numbers of drugs received. 
 
Table 6-15: Cox proportional hazards ratios for mortality with any psychiatric cause of death 





Model 1 Model 2 
HR (95% CI) P-value HR (95% CI) P-value 
1 Reference  Reference  
2 1.076 (1.033 to 1.120) <0.001 1.034 (0.993 to 1.077) 0.102 
3 1.149 (1.105 to 1.194) <0.001 1.071 (1.030 to 1.113) 0.001 
4 1.181 (1.137 to 1.227) <0.001 1.061 (1.021 to 1.103) 0.002 
5 1.253 (1.206 to 1.302) <0.001 1.095 (1.054 to 1.138) <0.001 
6 1.349 (1.298 to 1.401) <0.001 1.144 (1.101 to 1.189) <0.001 
7 1.368 (1.315 to 1.422) <0.001 1.117 (1.074 to 1.162) <0.001 
8 1.426 (1.369 to 1.485) <0.001 1.120 (1.075 to 1.167) <0.001 
9 1.443 (1.383 to 1.506) <0.001 1.104 (1.057 to 1.153) <0.001 
10 1.490 (1.423 to 1.559) <0.001 1.102 (1.052 to 1.154) <0.001 
11 1.494 (1.421 to 1.570) <0.001 1.082 (1.029 to 1.138) 0.002 
12 1.556 (1.473 to 1.643) <0.001 1.101 (1.042 to 1.164) 0.001 
13 1.495 (1.404 to 1.593) <0.001 1.039 (0.975 to 1.108) 0.234 
14 1.512 (1.405 to 1.626) <0.001 1.014 (0.942 to 1.091) 0.720 
15 1.590 (1.458 to 1.733) <0.001 1.047 (0.960 to 1.142) 0.295 
16 1.670 (1.508 to 1.848) <0.001 1.088 (0.982 to 1.205) 0.106 
17 1.585 (1.400 to 1.795) <0.001 1.026 (0.906 to 1.162) 0.687 
18 1.463 (1.253 to 1.709) <0.001 0.923 (0.790 to 1.079) 0.315 
19 1.567 (1.293 to 1.898) <0.001 0.999 (0.824 to 1.211) 0.991 
≥20 1.599 (1.382 to 1.851) <0.001 0.963 (0.832 to 1.116) 0.618 
Model 1: Adjusted for starting age, gender, SIMD, care home status 
Model 2: Adjusted for starting age, gender, SIMD, care home status and psychotropic 
medication use 
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Figure 6-18: Forest plot of hazard ratios for mortality with mental disorder as any cause of 
death by medication use, adults aged ≥50 years  
 
Results of the Cox regression stratified by age group for an increase in medication by 
one are shown in Table 6-16.  
 
Table 6-16: Hazard ratios for mental disorder as any cause of death with increase in drugs by 
one, stratified by age 
Age group Covariates HR (95% CI) P-value 
50-64 years Starting age, gender, care home 
status, SIMD 
1.086  
(1.078 to 1.094) 
<0.001 
Starting age, gender, care home 
status, SIMD, psychotropic drug use 
1.042  
(1.033 to 1.050) 
<0.001  
65-79 years Starting age, gender, care home 
status, SIMD 
1.047  
(1.043 to 1.050) 
<0.001 
Starting age, gender, care home 
status, SIMD, psychotropic drug use 
1.014  
(1.011 to 1.018) 
<0.001 
≥80 years Starting age, gender, care home 
status, SIMD 
1.010  
(1.007 to 1.013)  
<0.001 
Starting age, gender, care home 
status, SIMD, psychotropic drug use 
0.984  
(0.981 to 0.987) 
<0.001 
 
In people aged 50-79 years, there was a positive association between increasing 
number of drugs and increased mortality with any mental disorder. This association 
persisted when adjusting for psychotropic medication use. The associations were 
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weaker in the 65-79 year age group than 50-64 years. Plots of individual drug 
numbers show that the association is not significant with all numbers of drugs (see 
Figure 6-19). In people aged ≥80 years, there was a positive association between 
increasing number of drugs and mortality but this became an inverse relationship 
when adjusting for psychotropic medication use. Figure 6-19 shows the hazard ratios 
for individual drug numbers in this age group and shows that this inverse association 
only meets conventional statistical significance at ≥4 drugs. 
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Figure 6-19: Forest plot of hazard ratios for mortality with mental disorder as any cause of 
death by medication use, by age group 
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6.4.4.2 Sensitivity analysis  
Sensitivity analyses accounting for the missing data in the SIMD variable generated 
similar results to the main analyses, as shown in Table 6-17, suggesting that 
conducting the main analysis in complete cases only was reasonable. 
Table 6-17: Sensitivity analyses for continuous increase in drug use for mortality with a mental 
disorder as any cause 
Sample Covariates HR (95% CI) P-value 
All receiving ≥1 
drug, including 
those with missing 
SIMD  
(n=1 346 714) 
Starting age, gender, care 
home status 
1.037  
(1.035 to 1.039) 
<0.001 
Starting age, gender, care 
home status, psychotropic 
drug use 
1.007  
(1.004 to 1.009) 
<0.001 
All receiving ≥1 
drug, with imputed 
SIMD  
(n=1 346 714) 
Starting age, gender, care 
home status, SIMD 
1.033  
(1.031 to 1.035) 
<0.001 
Starting age, gender, care 
home status, psychotropic 
drug use, SIMD 
1.003  
(1.001 to 1.005) 
0.007 
 
6.4.4.3 Cox proportional hazards models with psychotropic medication as the 
exposure 
I conducted secondary analyses of psychotropic drug use as the exposure variable in 
the sample of complete cases (n=1 225 894). On Cox regression, the hazard ratio for 
mortality where there was a mental disorder as any cause of death in those taking 
any psychotropic drug compared to those who did not was 2.099 (95% CI 2.063 to 
2.136, P<0.001), adjusted for total number of drugs, starting age, gender, care home 
status and SIMD. 
 
6.4.4.4 Kaplan-Meier curves  
Using the Cox regression models above, I generated Kaplan-Meier curves for survival 
probability where there was a mental or behavioural disorder in any field on the death 
certificate, as shown in Figure 6-20 and Figure 6-21. I again conducted separate 
analyses stratified by age group. Similarly to the analyses looking at primary cause of 
death, these show that the 5-9 drugs group had the lowest survival probability in 
people aged 50-79 years, with the greatest difference between drug groups visible in 
the 65-79 year age group. For people aged over 100 years, where age at death was 
the time variable, the drug group curves cross over which may reflect the smaller 










Figure 6-21: Kaplan-Meier curves for mortality with mental disorder as any cause of death and time to death 
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6.4.5 Survival analysis: psychiatric admission 
6.4.5.1 Cox proportional hazards models  
The final survival analyses in this cohort explored first episode of psychiatric 
admission as the outcome, with age at admission as the time variable. On preliminary 
graphical analysis of Schoenfeld residuals for psychiatric admission, I determined that 
the proportional hazards assumption had not been violated. On Cox regression, the 
hazard ratio for psychiatric admission with each additional continuous medication was 
1.064 (95% CI 1.061 to 1.068, P<0.001), adjusted for starting age, gender, SIMD and 
care home status. When psychotropic drugs were an additional covariate, the hazard 
ratio reduced to 1.002 (95% CI 0.999 to 1.006, P=0.246). In a subsample of patients 
not taking psychotropic drugs (among which there were 10 322 admissions to 
psychiatric hospital), the hazard ratio per additional drug was 1.002 (95% CI 0.995 to 
1.008, P=0.623). The results for individual drugs between 1 and ≥20 are shown in 
Table 6-18 and plotted in Figure 6-22. 
Table 6-18: Cox proportional hazards ratios for first admission to psychiatric hospital with 




Model 1  Model 2 
HR (95% CI) P-value HR (95% CI) P-value 
1 Reference  Reference  
2 1.203 (1.137 to 1.273) <0.001 1.078 (1.019 to 1.140) 0.009 
3 1.370 (1.296 to 1.449) <0.001 1.136 (1.074 to 1.201) <0.001 
4 1.475 (1.394 to 1.561) <0.001 1.134 (1.071 to 1.200) <0.001 
5 1.524 (1.438 to 1.615) <0.001 1.101 (1.039 to 1.168) 0.001 
6 1.656 (1.561 to 1.757) <0.001 1.121 (1.056 to 1.190) <0.001 
7 1.825 (1.717 to 1.939) <0.001 1.151 (1.082 to 1.224) <0.001 
8 1.852 (1.736 to 1.977) <0.001 1.087 (1.017 to 1.161) 0.014 
9 1.980 (1.849 to 2.120) <0.001 1.093 (1.020 to 1.172) 0.012 
10 2.026 (1.880 to 2.182) <0.001 1.056 (0.979 to 1.140) 0.155 
11 2.089 (1.925 to 2.267) <0.001 1.037 (0.955 to 1.127) 0.389 
12 2.100 (1.915 to 2.303) <0.001 0.995 (0.907 to 1.093) 0.924 
13 2.443 (2.212 to 2.697) <0.001 1.113 (1.007 to 1.231) 0.036 
14 2.564 (2.289 to 2.872) <0.001 1.115 (0.994 to 1.251) 0.063 
15 2.640 (2.315 to 3.011) <0.001 1.105 (0.968 to 1.262) 0.139 
16 3.154 (2.730 to 3.643) <0.001 1.296 (1.121 to 1.498) <0.001 
17 2.901 (2.425 to 3.470) <0.001 1.167 (0.975 to 1.397) 0.093 
18 2.555 (2.038 to 3.203) <0.001 0.993 (0.792 to 1.246) 0.951 
19 2.938 (2.258 to 3.823) <0.001 1.136 (0.873 to 1.479) 0.344 
≥20 3.391 (2.844 to 4.043) <0.001 1.245 (1.043 to 1.485) 0.015 
Model 1: Adjusted for starting age, gender, SIMD, care home status 




Chapter 6: Longitudinal analyses of routinely collected NHS data 253 
Figure 6-22: Forest plot of hazard ratios for first psychiatric admission with increasing 
medications in adults aged ≥50 years 
 
As there was a relatively high mean age of those admitted to psychiatric hospital, I 
analysed the sample stratified by age group, with the results for increasing drugs by 
one listed in Table 6-19. 
Table 6-19: Hazard ratios for admission to psychiatric hospital with increase in drugs by one, 
stratified by age 
Age group Covariates HR (95% CI) P-value 
50-64 years Starting age, gender, care home 
status, SIMD 
1.104  
(1.098 to 1.109) 
<0.001 
Starting age, gender, care home 
status, SIMD, psychotropic drug 
use 
1.025  
(1.020 to 1.031) 
<0.001 
65-79 years Starting age, gender, care home 
status, SIMD 
1.041  
(1.036 to 1.047) 
<0.001 
Starting age, gender, care home 
status, SIMD, psychotropic drug 
use 
0.987  
(0.982 to 0.993) 
<0.001 
≥80 years Starting age, gender, care home 
status, SIMD 
1.009  
(1.001 to 1.018) 
0.022 
Starting age, gender, care home 
status, SIMD, psychotropic drug 
use 
0.973  
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Plots of the hazard ratios for individual drugs are shown in Figure 6-23. In the 
youngest group, increasing medications were associated with higher risk of 
psychiatric admission regardless of covariates and only at 17 medications did the 
association not meet conventional statistical significance. Adjusting for psychotropic 
drug use in this group reduced the association. When adjusting for psychotropic drug 
use in the older age groups, taking 4-14 (for 65-79 years) or 3-15 (for ≥80 years) 
medications was inversely associated with being admitted to psychiatric hospital. 
Psychotropic drug use therefore appears to be a particularly important factor when 
assessing this outcome, perhaps because it represents that patients taking 
psychotropic drugs had a pre-existing psychiatric diagnosis. 
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Figure 6-23: Forest plot of hazard ratios for first psychiatric admission with increasing 
medications, by age group 
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6.4.5.2 Sensitivity analysis  
To explore if removing or imputing SIMD changed the strength of association, I 
performed sensitivity analyses as for the other outcomes. The results, in Table 6-20, 
show little difference from the hazard ratios of analyses in the sample of complete 
cases. 
Table 6-20: Sensitivity analyses for first psychiatric admission with continuous increase in drug 
use 
Sample Covariates HR (95% CI) P-value 
All receiving ≥1 
drug, including 
those with missing 
SIMD  
(n=1 346 714) 
Starting age, gender, care 
home status 
1.071  
(1.067 to 1.074) 
 
<0.001 
Starting age, gender, care 
home status, psychotropic 
drug use 
1.007  
(1.004 to 1.010) 
<0.001 
All receiving ≥1 
drug, with imputed 
SIMD  
(n=1 346 714) 
Starting age, gender, care 
home status, SIMD 
1.064  
(1.061 to 1.067) 
 
<0.001 
Starting age, gender, care 
home status, psychotropic 
drug use, SIMD 
1.002 
(0.999 to 1.005) 
0.272 
 
6.4.5.3 Cox proportional hazards models with psychotropic medication as the 
exposure 
I conducted secondary analyses of psychotropic drug use as the exposure variable in 
the sample of complete cases (n=1 225 894). On Cox regression, the hazard ratio for 
psychiatric admission in those taking any psychotropic drug compared to those who 
did not was 4.217 (95% CI 4.100 to 4.337, P<0.001), adjusted for total number of 
drugs, starting age, gender, care home status and SIMD. 
 
6.4.5.4 Kaplan-Meier curves   
Using the same Cox models as above, I plotted Kaplan-Meier curves of survival 
probability, where survival meant not being admitted to psychiatric hospital in the 
study period. I compared age groups, and performed separate analyses for age at 
admission and time to admission as the time variable, in Figure 6-24 on page 258 and 
Figure 6-25 on page 259. In all patients, those taking 5-9 medications had the highest 
survival probability followed by those on ≥10 and 1-4 medications, although the overall 
differences in probability were small. The difference between drug use groups was 
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more defined in the youngest group. These graphs are limited by not accounting for 
covariates; this is particularly important here where psychotropic drug use is an 
important factor. Of note, in these graphs only, I truncated the y-axis to show clearer 
visual definition between the groups; the main point here is that the differences 




Figure 6-24:Kaplan-Meier curves for admission to psychiatric hospital and age at admission 




Figure 6-25: Kaplan-Meier curves for admission to psychiatric hospital and time to admission 
 
NB. Y-axis truncated to allow clearer differentiation between groups for ease of visual interpretation 
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6.5 DISCUSSION 
6.5.1 Summary of main findings 
Polypharmacy is common in Scotland, with 46% of this sample of adults aged 50 
years and over receiving five or more different medications during a three-month 
period in 2009. In keeping with previous research, I found that increasing medication 
use correlated with older age and increasing levels of socioeconomic deprivation.[37] 
Receiving more medication was associated with all-cause mortality and remained 
significant when adjusting for all covariates, but the association was less pronounced 
with increasing age.  
 
Increasing medication count was marginally associated with mortality where there 
was a mental disorder anywhere on the death certificate, and was strongly associated 
at the highest levels of medication use, especially in the youngest age group. The 
association persisted but was attenuated when psychotropic drug use was added as 
a covariate, except in those aged ≥80 years where adding psychotropic drugs as a 
covariate reversed the direction of association. Total medication count was 
associated with mortality where a mental disorder was the primary cause of death 
when adjusted for age, gender, care home status and SIMD but inversely so when 
psychotropic drug use was added as a covariate. 
 
The association between larger numbers of medication and mortality with mental 
disorders was weaker than that with all-cause mortality, especially when adjusting for 
psychotropic drug use.  
 
Receiving larger numbers of medication did increase the risk of admission to 
psychiatric hospital, but when adjusting for psychotropic drug use, the association 
was attenuated. Given that psychotropic drug use is very relevant in people admitted 
to psychiatric hospital, it should be accounted for and the null hypothesis cannot be 
rejected in this case.  
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These findings suggest that polypharmacy is likely to be less negatively associated 
with the measured mental health outcomes than it is to overall mortality rates. Along 
with the noticeable difference made by adjusting for psychotropic medication, I 
surmise that the medication taken by people with psychiatric conditions (that become 
evident in the data either at death or by psychiatric admission) are of overall benefit. 
The findings may also be explained by the mental health outcomes being relatively 
crude. Future work could explore a more clinically precise outcome such as diagnosis 
on psychiatric outpatient contact.  
 
6.5.2 Hypotheses addressed 
1. Using larger numbers of medications, accounting for psychotropic 
prescriptions, was: 
a. Not convincingly associated with presence of a mental disorder 
anywhere on death certificates (fully adjusted HR=1.002 (95% CI 
1.000 to 1.005, P=0.033) 
b. Not associated with admission to psychiatric hospital (adjusted HR 
with each additional medication=1.002 (95% CI 0.999 to 1.006, 
P=0.246). 
2. Using larger numbers of medications was associated with increased all-cause 
mortality, with HR for increase in medication by one of 1.080 (95% CI 1.079 to 
1.081, P<0.001), adjusted for age, gender, SIMD, care home status and 
psychotropic drug use. 
 
The positive association between psychotropic drug use and all the outcomes is of 
interest, particularly that being dispensed a psychotropic drug carried a 26% 
increased risk of dying from any cause. I included these analyses for completeness 
when its relevance as a covariate was clear. It would be worthwhile exploring this 
further, perhaps examining each psychotropic drug group separately. However, this 
would mean using psychiatric conditions as exposures and would move away from 
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6.5.3 Comparison with other literature 
In my analyses, 7.3% of the population aged ≥50 years and 18.9% of those aged ≥80 
years received ≥10 unique drugs. This is lower than that reported by the Scottish 
Government using 2014 figures, which showed that 13.3% of over 50 year-olds and 
26% of over 80 year-olds took ≥10 drugs.[25] Differences between this report and my 
results could be explained by the fact their data included all the population, whereas 
my analytic sample was only of those receiving at least one medication. However, if I 
had been able to include those taking no medication, my estimate would be smaller 
as the total sample size would increase. In addition, where I looked at individual drugs, 
they used BNF paragraphs (approximately equating to drug class) over six months 
instead of my three, and included a criterion specifying that at least one drug they had 
defined as ‘high risk’. They did not specify whether this included all prescribable items 
or only chemically active drugs. My prescribing data are from 2009 so there may have 
been an increase between then and 2014, which would be supported from other 
evidence suggesting an increase in polypharmacy, perhaps related to population 
ageing.[37,377] A cross-sectional Scottish study of over 1.4m adults reported that 
1.75% of the population were taking eleven or more repeat medications in 2007, but 
this figure is for all adults aged 18 years and over.[394] Similarly, a separate Scottish 
study using 2006 primary care data found that 4.6% of 180 815 patients aged ≥20 
years were prescribed ≥10 medications on repeat prescription.[393] As my data were 
from all patients aged ≥50 years in Scotland, they are more representative of this age 
group. 
 
Previous population-based research from Sweden, retrospectively assessing the 
records of deceased people, has found an increase in polypharmacy in the last year 
of life.[414] The proportion of people exposed to ≥10 medications increased from 
30.3% to 47.2% in that year. This was due not only to symptomatic treatments but 
also long-term preventive medication. The reasons for this may be that people nearing 
the end of life had more symptoms or new conditions requiring treatment, whether or 
not it was expected that they would die. In any case, this increase in the last year of 
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Psychotropic drug use, particularly of antipsychotics, has been extensively 
investigated in relation to adverse outcomes. A population-based study from Finland 
that adjusted for relevant comorbidities gives a hazard ratio for nine-year mortality of 
2.07 (95% 1.73 to 2.47) for people taking any antipsychotics compared to those taking 
none.[432]  A Swedish register study of 1 288 875 people aged ≥65 years found that 
people taking one psychotropic drug were at increased risk of death in one year 
compared to those on none (adjusted HR=1.42 (95% CI 1.39 to 1.45)), and that this 
increased with the number of concurrently prescribed psychotropic medicines.[433] 
These results are in line with my results in section 6.4.2.3, where the HR for all-cause 
mortality for patients taking any psychotropic drug compared to those not taking a 
psychotropic drug was 1.262 (95% CI 1.252 to 1.271, P<0.001), albeit with a smaller 
estimate. This may be due to the younger age of my sample.  
 
A 2016 systematic review of the use of mental health diagnoses from administrative 
data explored 39 studies on this topic, with a wide variety in the quality of 
publications.[434] The authors concluded that psychotic disorders were more 
accurately recorded than anxiety disorders. Although the outcome of psychiatric 
admission in my analyses was broad, it is robust; details on admission dates are 
subject to less error than those of diagnoses.[395]  
 
6.5.4 Strengths 
This is the largest UK-based longitudinal study of polypharmacy to date and the first 
to consider psychiatric outcomes at such scale. Using routine data in a universal 
healthcare system offers insights into the outcomes and experiences of real patients, 
rather than volunteers in cohort studies. For example, cross-sectional work exploring 
polypharmacy and multimorbidity in people with chronic obstructive pulmonary 
disease has been undertaken in the UK Biobank cohort,[254] but the response rate 
to UK Biobank invitations was 5.5%.[435] The dataset used in this chapter uses 
population-level data from everyone who uses the NHS. 
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6.5.5 Limitations 
It was not possible to control for multimorbidity in this dataset, as the main exposure 
variable was routinely collected prescription information. This is not currently linked to 
primary care diagnosis lists in this cohort. In some recent polypharmacy studies, there 
has been a move towards accounting for number of diagnoses to address 
confounding by indication.[377,379] However, a systematic review of polypharmacy 
outcome studies found this was done in only 20 out of 58 included studies (receiving 
‘good’ or ‘fair’ rating).[291] Other work using NHS Scotland prescribing data has 
inferred multimorbidity from the number of body systems addressed by prescriptions; 
cautiously used, this could be an approach for future research.[436] 
 
Previous research found that the strength of association between the number of drugs 
prescribed and potentially avoidable hospitalisation was reduced when the number of 
conditions was added as a covariate.[437] Another study reported that the main factor 
associated with polypharmacy in Scotland is multimorbidity, although the impact of 
increasing conditions is less when they are concordant comorbidities (conditions 
within a disease group, such as cardiovascular, that require similar pharmacological 
treatment).[393] However, when choosing between counting diagnoses and 
medications to measure burden of disease, an advantage of medication use is that it 
may better represent the patient’s overall severity. For example, a severe form of one 
illness such as chronic obstructive pulmonary disease would require multiple 
medications but only count as one diagnosis.  
 
6.5.5.1 Medication appropriateness 
It was not possible with the data available to measure whether medication was 
prescribed appropriately. There are two widely used methods of assessing potential 
medication appropriateness in older people, the American Geriatrics Society’s Beers 
Criteria for Potentially Inappropriate Medication Use in Older Adults [438] and the 
Screening Tool of Older People's Prescriptions and Screening Tool to Alert to Right 
Treatment (STOPP/START) criteria.[439,440] These tools were developed for clinical 
use, on the premise that adverse drug reactions in older people are common and 
avoidable. They both require information beyond medication prescribed, such as drug 
indication, comorbid conditions or physiological parameters such as blood test results. 
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The availability of a large quantity of data that lacks in detail is a recognised limitation 
of this sort of ‘big data’ research.[441] One study of over 38 000 primary care patients 
examined prescriptions using only applicable elements of the STOPP/START 
criteria.[442] This would be a possible way to address inappropriateness in future 
work using my prescribing data. In addition, current Scottish Government 
polypharmacy guidance specifies that patients’ preferences and priorities should be 
considered.[27] This emphasises that for clinical application, decisions should be 
taken at an individual patient level, which again cannot be accounted for in population-
based studies.  
 
Many of the people receiving multiple medications in my sample probably had several 
conditions, for which multiple medications managed their symptoms or disease 
progression or were appropriate secondary prevention. Reviews and consensus 
statements on polypharmacy in recent years have advised against assuming that all 
polypharmacy is negative and unnecessary, and instead treating it as “potentially 
problematic rather than always inappropriate”.[37,443,444] Furthermore, it can be 
simultaneously appropriate and problematic even within one individual.[445] In this 
chapter I have therefore reported only the total medication use per person in relation 
to the outcomes of interest, rather than assuming polypharmacy is inherently 
negative. In fact, my results show that receiving larger numbers of medication 
decreased the likelihood of psychiatric admission. 
 
The PIS extract did not include dosage or frequency regimens, so I could not establish 
indication for medications where there are more than one possible indication. This is 
particularly relevant when I generated my psychotropic drug variable, for example, 
low-dose tricyclic antidepressants are used for pain or night-time sedation; 
levomepromazine for nausea and carbamazepine or valproate for epilepsy. The 
inclusion of these drugs is a limitation, but it could be argued that, if given at a 
therapeutic dose, their psychotropic action persists regardless of their indication. 
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6.5.5.2 Prescribing Information System extract limitations 
Examining unique drugs from one quarter in 2009 means that patients may have 
received a high number within that quarter because of an acute process. For example, 
in an acute exacerbation of COPD, numerous drugs are required and several 
antibiotics may be tried. This capture of drugs may reflect more acute scenarios than 
the chronic ones that are intended to fit in with my overall perspective on 
polypharmacy. In addition, looking at an isolated quarter does not allow the elucidation 
of whether or not drugs are prescribed for long-term use. 
 
Using the CHI system to identify people on no medications for whole population 
estimates misses people who do not have a CHI number, such as recent migrants, 
and may include also people who have migrated out of Scotland. Among people 
without a CHI number, people from disadvantaged and vulnerable groups such as 
homeless people or prisoners (who did not have CHI numbers prior to 2012) are likely 
to be over-represented.[446]  
 
Due to the nature of data availability and access through eDRIS, I did not have 
sufficient information on people who were not prescribed any medication to include 
them in survival analyses. According to the CHI system, there were 661 109 people 
who received no medications during the quarter in question. These people did not 
appear in the PIS extract from which starting age was taken, so I had to exclude them 
from survival analyses. Using one as the reference number of drugs for regression 
models may have led to under-estimates of the effect size, if we are to extrapolate 
results and assume that people on no medication have an even smaller likelihood of 
the relevant outcomes than those on one medication. However, it is possible that 
some people taking no medication are less healthy than those on a small number; 
they may have chronic undiagnosed and untreated illnesses and do not seek medical 
care. They could also have been hospital inpatients for the whole initial study period 
in 2009. I plan to obtain comparable data on people taking no medication, so I can 
revisit my analyses and test whether the associations remain.  
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PIS does not record over-the-counter medication or those dispensed by hospitals. 
Hospitals dispense medication to inpatients (who are arguably the most unwell people 
in a community) during an admission or for short-term use after discharge. They also 
provide specialist medication such as biologics, clozapine and some long-acting 
injectable antipsychotics.[53] These are important, but probably relatively rarely 
prescribed treatments. In early 2009, drugs for dementia would have been initiated by 
specialists (usually psychiatrists). It is impossible to know how many of these were 
prescribed on community prescription pads and processed by community 
pharmacies, and therefore appear in this dataset, and how many were dispensed by 
hospital pharmacies. In future work I could combine medication over a longer initial 
period or compare changes over time, which would account for some of the hospital 
dispensing issues.  
 
Continuous Positive Airways Pressure (CPAP) is the mainstay of treatment for one 
particular chronic condition, obstructive sleep apnoea. The supply of these machines 
is also not captured in PIS. This is one disease area where medication does not act 
as a marker for the condition and where using a list of diagnoses seems preferable. 
 
Adherence to prescribed medication or treatment is recognised as a problematic area, 
with estimates for treatment adherence stable around 50%.[30,447,448] However, 
these estimates in large-scale health records are calculated by comparing prescribed 
with dispensed medications. At such a scale, it would be impossible to know the true 
adherence to prescribed medication once it has been dispensed. A small study of 84 
patients with multimorbidity using self-reported actual adherence found rates of 
94.7%, but this was likely affected by recall and self-presentation biases.[449] A study 
of the Generation Scotland cohort found an adherence rate of 84.9% to 
antidepressants, as measured by the more reliable Proportion of Days Covered 
method.[450] My data are therefore conservative estimates of the total medication 
actually consumed by each person. However, using dispensed, rather than 
prescribed, medication is a strength over some previous similar studies.[378,393,394]  
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Memantine was first approved by the European Medicines Agency in 2002, 
Galantamine in 2000, Rivastigmine in 1998 and Donepezil in 1997.[451] They are 
therefore relatively new drugs and are restricted to specialist use.[100] In addition, 
National Institute for Health and Clinical Excellence (NICE) guidance in 2005 changed 
the criteria for which patients would be eligible, with this later revised in 
2011.[452,453] This may explain the relatively low numbers of dementia drugs 
dispensed in 2009 (2.6% of people aged ≥80 years) and more recent data would 
better reflect current usage. 
 
My psychotropic medication covariate was a simple binary variable in these analyses; 
future work could explore types of medication, combinations and the number of 
psychotropic medications taken. The differences in hazard ratios when including 
psychotropic drug use as a covariate are probably due to it being a marker of pre-
existing psychiatric diagnosis. This could explain the disparities in hazard ratios for 
psychiatric hospital admission, for example.  
 
There is an increasing body of evidence that anti-hypertensive medication is 
associated with a decreased risk of developing dementia. A German primary care 
study of 12 400 people with dementia and 12 400 matched controls found a decrease 
in dementia incidence with most antihypertensive medication subtypes (excluding 
diuretics).[89] This could be one explanation for the lower rates of mental disorders 
than overall mortality in people with polypharmacy. Investigating individual drugs or 
using a trial emulation design is a potential avenue for further exploration. 
 
6.5.5.3 Confounding factors 
There are likely to be numerous confounding factors that may explain the associations 
found between polypharmacy, death and psychiatric admission. These include 
lifestyle factors such as smoking status and alcohol or substance intake, other 
physical issues such as underweight or obesity and environmental issues. This 
information is not available from the routinely collected data process, such as when 
generating a prescription or recording a death. These are accepted limitations that 
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must be considered when balancing the benefits of a very large dataset such as 
this.[109,110] In addition, I did not account for the month or year of death, therefore 
neglecting any seasonal influences on mortality rates. It is possible, therefore, that 
residual confounding exists and my results over-estimate the associations found. 
 
Owing to variation in multimorbidity prevalence by ethnic group, I had originally 
intended to include ethnicity as a covariate in my analyses.[278] However, ethnicity is 
not recorded on prescriptions or death certificates and is only available from hospital 
admission or outpatient records. Even in people who did have a linked hospital record, 
the majority had ‘not known’ or ‘not provided’ codes, meaning this became 
uninformative. The 2011 census found that in Scotland, 4% of people reported non-
white ethnicity.[454] The poor quality of ethnicity recording in health records is a 
recognised problem, and the Scottish Health and Ethnicity Linkage Study was set up 
to address this, linking census information to health records.[455] This information 
was also linked to psychiatric admissions and Mental Welfare Commission for 
Scotland’s records on detentions under the Mental Health (Care and Treatment) 
(Scotland) Act 2003. The study found that people from all ethnic minorities were at 
increased risk of being detained and that there were significant variations in the rates 
of psychiatric disorders and admissions between groups, that remained when 
adjusting for socioeconomic markers.[456] A representative population survey, the 
Health Survey for England, found that although ethnic minority respondents were not 
less likely to use primary care than white participants, there were inequalities in their 
access to hospital services.[457] This suggests that ethnicity is important when 
exploring mental health outcomes and that this is a limitation of my analyses. 
 
6.5.5.4 Accuracy of death records 
The death record is complete for all deaths registered in Scotland for the study period. 
However, it does not capture deaths that occurred outside of Scotland, meaning that 
an individual appearing in the study sample in 2009 who later moved away from 
Scotland and died elsewhere would not be recorded as having died. The assumption 
that these people survived the study period could lead to an under-estimation of the 
probability of dying. The NRS official estimates for migration, broken down by age, 
are only publicly available for 2015-17.[458] In this example period, 20 637 people 
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aged 57 and over (who would have been aged ≥50 years at the start of my study 
period) emigrated from Scotland, either elsewhere in the UK or the world. During the 
same time, 21 699 people migrated into Scotland, raising the possibility that perhaps 
some of the emigrants had previously moved into Scotland and would not have 
appeared in my 2009 prescribing sample. My linked dataset did not allow for tracking 
of individuals’ migration.  
 
The software used to code causes of death in Scotland was updated in 2011 and 
replaced in 2017.[459,460] These changes implemented updates to the WHO ICD-
10 rules and resulted in increased prevalence of dementia as a primary cause of 
death. For example, the 2017 change increased the number of deaths where 
dementia was the primary cause by 7.5%, because people who died with respiratory 
infections and dementia were now classified as having died primarily of dementia in 
most cases.[460] In addition, the Certification of Death (Scotland) Act 2011 was 
implemented in 2015, mandating accuracy checks on at least 10% of Medical 
Certifications of Cause of Death.[461] The changes may mean that my survival 
analyses for mental disorders as causes of death may be less comparable between 
individuals, depending on when they died. However, the relevance is limited, as I did 
not track trends in specific diagnoses as causes of death over time. My analyses with 
the outcome of a mental and behavioural disorder as any cause of death, rather than 
the primary one, would capture dementia in scenarios both before and after the 
change. 
 
The way the death certificate is completed is open to some subjectivity on the part of 
the completing doctor as to which conditions are relevant to the death. This is a 
particular issue for many mental disorders and means it is likely the prevalence on 
death certificates is much lower than in the general population. Although it would be 
very unusual to list a depressive disorder as a primary cause of death, it was only 
listed anywhere on 792 (0.24%) death certificates in my dataset. This is lower than 
the estimated population lifetime prevalence, which has been calculated as 
6.4%,[462] although this figure varies depending on how depression is screened for 
or measured.[463] This would suggest it is either considered irrelevant to death even 
as a contributory factor or is underreported on death certificates. 
 
Chapter 6: Longitudinal analyses of routinely collected NHS data  271 
 
I may have over-estimated the extent of psychiatric disorders on death certificates by 
including alcohol and substance use disorders, as at death these may have primarily 
physical consequences. However, I used only the codes from Chapter V of ICD-10, 
and cirrhosis, for example, would be recorded under liver diseases in Chapter XI as 
K70.3. This area may be one example of where creating a dichotomy between mental 
and physical disorders is artificial and does not fit with patient experience.  
 
6.5.5.5 Dementia on death certificates 
Dementia was by far the most prevalent mental disorder coded on death certificates, 
contributing 88.4% of all mentions of mental disorders in any field. For practical 
reasons, I did not include analyses with each mental disorder as an outcome in this 
chapter, but aim to do this, specifically for dementia and depression, in future work. 
This will have the benefit of informing policy more specifically, with reference to 
individual outcomes. It is likely that dementia accounted for most of the associations 
found in the included analyses, and separating the other conditions would have 
reduced the statistical power of those observations.  
 
The recording of dementia has come under scrutiny on death certificate diagnoses 
elsewhere. A recent cohort study of 7 115 people with clinically diagnosed dementia 
in London aged ≥65 years found that frequency of dementia recording increased from 
39.9% in 2006 to 63.0% in 2013.[464] The rates in the Edinburgh area were higher, 
with a study using 2010 data from 502 deceased individuals with dementia finding 
71.5% had dementia listed on their death certificate.[465] The prevalence of dementia 
or mild cognitive impairment on death certificates in my sample of adults aged ≥50 
years was 17%. This compares to UK-wide prevalence figures published by 
Alzheimer’s Research UK of 16.3% for women and 8.7% for men, with a significant 
increase in prevalence on death certificates from around 2011 onwards.[466] Using 
data from 24 506 deceased participants of the Cognitive Function and Ageing Study 
(CFAS) in England and Wales, the proportion of death certificates including a 
diagnosis of dementia rose from 11.6% in 1990-2008 to 20.3% in 2008-2018.[467] 
This study also compared death certificates with study visit diagnoses and found an 
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The presence of polypharmacy implies that an individual is in poor health and, as has 
been demonstrated in this chapter and in previous research, at increased risk of death 
from any cause. This chapter has explored mental health outcomes linked to 
polypharmacy. The findings do not convincingly support the overall hypotheses of this 
thesis that multimorbidity and polypharmacy are associated with mental disorders.  
 
6.6 CONCLUSIONS 
In this large population-based cohort, receiving a larger number of medications was 
associated with mortality, even after adjusting for starting age and other relevant 
demographics. There was a weaker association between polypharmacy and death 
with psychiatric diagnoses and psychiatric admissions, and adjustment for 
psychotropic drug use further attenuated these associations. It is likely that 
polypharmacy acted here as a marker for multimorbidity or overall poor health, but 
may also have contributed independently to mortality. My analyses are observational 
and cannot infer causality or temporality.  
 
Chapter 7 presents an overview of all the findings in this thesis and their relevance to 
existing research. It also considers future directions possible using this dataset, for 
example using a medication-based index of multimorbidity such as the Chronic 
Disease Score or Medication-Based Disease Burden Index, as identified in my 
systematic review.[147,148] 
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Chapter 7 Discussion 
7.1 INTRODUCTION 
In this thesis, I have explored in detail the measurement of multimorbidity and the 
relationship between multimorbidity and polypharmacy with mental disorders and 
brain health outcomes. In this chapter, I summarise my main findings and discuss 
their limitations, application and the conclusions I have drawn. 
 
7.2 SUMMARY OF FINDINGS 
7.2.1 Measurement and methodology 
I conducted a systematic search of the literature on multimorbidity measures for use 
in the community or population, and a detailed review of the resulting 35 articles. The 
main conclusions from this work were that it is important to understand the original 
design of a multimorbidity index before applying it. The development and publication 
of new indices since my search suggests that there continues to be appetite for novel 
measurement tools despite there already being an abundance of them 
available.[217,218,468] In Chapter 3, I explored the overall limitations of indices and 
the process of measuring multimorbidity using robust disease counts instead of an 
index. This method is especially relevant where the outcomes examined in a study do 
not clearly match an existing index design. For the data analysis chapters, I therefore 
used the commonest method of measuring multimorbidity and polypharmacy, namely 
counts of diseases or medication.[112] 
 
7.2.2 Hypotheses addressed using data analysis 
The main question posed by this thesis was whether physical multimorbidity and 
polypharmacy are associated with an increased risk of mental disorders or markers 
of poor brain health. I addressed the hypotheses as stated below. 
 
7.2.2.1 Hypothesis 1 
Physical multimorbidity (or having a larger number of chronic 
conditions) will be associated with an increased risk of mental 
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disorders. The greater the burden of multimorbidity, the higher 
the individual’s risk of developing a mental disorder. 
In cross-sectional analyses of data from the PREVENT Dementia study (Chapter 4), 
I found that having a larger number of chronic conditions was associated with self-
reported depression and anxiety disorder and increasing Center for Epidemiologic 
Studies Depression (CES-D) scores but not increasing Spielberger State-Trait 
Anxiety Inventory (STAI) scores. Antidepressant use was an important covariate in 
these analyses. Multimorbidity as a binary measure was only associated with self-
reported anxiety and not self-reported depression, continuous CES-D or STAI scores. 
There were no associations between increasing chronic conditions and scores on 
COGNITO cognitive tests. 
 
7.2.2.2 Hypothesis 2 
Polypharmacy, or using larger numbers of medications 
(adjusting for antidepressant or psychotropic drugs), will be 
associated with poorer mental health, and the greater the 
burden of polypharmacy, the higher a person’s risk of 
developing a mental disorder. 
In Chapter 4, analysing cross-sectional data from the PREVENT Dementia study 
showed that higher use of medications was associated with self-reported depression 
and increasing CES-D scores, although antidepressant use attenuated these 
associations. Increasing medication use was not associated with self-reported 
anxiety, STAI scores or COGNITO subtests. Dichotomous measures of polypharmacy 
were only associated with self-reported anxiety (with wide confidence intervals) and 
not with any other mental disorder outcomes. 
 
Chapter 6 included longitudinal analyses of routinely collected NHS data. When 
adjusting for psychotropic drug use, I found no convincing association between higher 
medication use and mental disorders on death certificates. In this case, there was 
also an inverse association between increasing drug use and mortality where there 
was a mental disorder anywhere on the death certificate in people aged over 80 years. 
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There was no association between increasing medication use and admission to 
psychiatric hospital when adjusting for psychotropic drug use. 
 
7.2.2.3 Hypothesis 3 
Physical multimorbidity or greater number of conditions, and 
polypharmacy or greater number of medications, will be 
associated with outcomes linked to dementia on structural 
MRI neuroimaging.  
In the PREVENT Dementia study explored in Chapter 4, I found no significant 
associations between having a larger number of chronic conditions or using more 
medications with hippocampal volume, cerebral microhaemorrhages or either deep 
white matter or periventricular Fazekas scores. 
 
7.2.2.4 Hypothesis 4 
Multimorbidity, or having a larger number of chronic 
conditions, will be associated with lower concentrations of 
cerebrospinal fluid (CSF) amyloid-β, as a marker of 
Alzheimer’s disease. 
In Chapter 5, when analysing data from the EPAD longitudinal cohort study I found 
that multimorbidity, or an increased number of chronic conditions, was inversely 
associated with lower concentrations of CSF amyloid-β, as a marker of Alzheimer’s 
disease. This directly opposed the stated hypothesis. 
 
7.2.3 Comparison between results across datasets 
Overall, I did not observe the expected associations between multimorbidity or 
polypharmacy and mental disorders or brain health. I conducted complementary 
analyses in diverse datasets and interrogated each in an approach tailored to its 
components and study design. It is therefore not possible to compare the outcomes 
from each chapter directly. 
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However, in general, having multiple chronic physical conditions was associated with 
depression and anxiety, was inversely associated with CSF amyloid positivity and was 
not associated with any cognitive or imaging measures of neurodegeneration. It is 
notable that associations existed between multimorbidity or polypharmacy and the 
clinical or patient-reported outcomes such as depression but not with the biomarkers. 
Age is an important contributor, as many of the biomarkers were taken from middle-
aged study participants. These findings could suggest that multimorbidity is more 
important to mental health outcomes as experienced by individuals, rather than in 
specific biological pathways. This may be explained by psychological or personality 
factors related to having multiple physical symptoms. 
 
Using a larger number of medications was associated with having a self-reported 
diagnosis of depression. It was not associated with anxiety disorders, and when 
adjusting for psychotropic drug use was not associated with psychiatric admissions 
or mental disorders listed on death certificates. This was unexpected, especially in 
the context of a clear relationship between polypharmacy and increased mortality. 
The lack of association may reflect the fact that the count of medications and method 
for adjusting for psychotropic drug use were relatively crude. Polypharmacy where 
the patient is taking several psychotropic medications, for example, is likely to 
represent more severe mental illness, in comparison to a patient taking the same 
number of drugs which comprise numerous treatments for physical conditions and 




7.3.1 Study design 
Chapters 4 and 5 used cross-sectional designs in cohort studies of healthy mid-life 
volunteers. Both studies were designed to investigate factors contributing to 
neurodegeneration. While multimorbidity and polypharmacy are relevant to 
neurodegenerative diseases, the populations are not best designed to explore other 
mental health outcomes. For example, they were not powered to identify a proportion 
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of people with a diagnosis of depression. However, multimorbidity and polypharmacy 
in mid-life are under-researched and as they are emerging as important risk factors 
for neurodegeneration, my work provides valuable insights in this area. 
 
7.3.2 Causal inference in observational studies 
Observational studies of this type cannot infer causality, regardless of whether they 
are longitudinal or cross-sectional.[469] Causality implies that a specific state or risk 
factor is truly significant and becomes important when considering public health or 
policy interventions. In 1965, Sir Austin Bradford Hill listed his suggestions for 
additional evidence needed to interpret association as causation, in the historical 
context of the recently established association between smoking and lung 
cancer.[470] His viewpoints were that the following characteristics of an association 
should be considered: 
a. Strength  
b. Consistency (or replicability),  
c. Specificity  
d. Biological gradient (or dose-response) 
e. Plausibility 
f. Coherence (that the findings fit with other known facts about the disease) 
g. Experiment (i.e. translation into a randomised trial) 
h. Analogy (for example, pre-existing evidence of an association in a similar 
condition) 
i. Temporality.[470]  
Hill’s original paper listed these as general viewpoints and did not propose they were 
criteria or provide methods for testing each one. Nor did he suggest that all his 
viewpoints must be met; temporality is the only requisite criterion.[471] My analyses 
in Chapters 4 and 5 were cross-sectional, so cannot provide evidence of temporality. 
My longitudinal analyses in Chapter 6 did not produce convincing results of any new 
associations (except for the established link between polypharmacy and mortality). 
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7.3.3 Temporality 
Cross-sectional analyses cannot explore the order in which events occur, or in this 
case, diseases accumulate. Temporality is a relevant consideration in multimorbidity 
research, particularly when studying physical and mental disorders together. For 
example, in a cross-sectional study, a patient diagnosed with diabetes who later 
developed depression and one with chronic depression who later developed diabetes 
would both be counted as having two conditions.[20] There may be shared 
predisposing or aetiological factors for these conditions.  
 
People with chronic mental disorders are known to have poor physical health, and 
relevant research and interventions usually assume that the mental disorder came 
first. Analysis of data from 47 609 participants in the World Mental Health Surveys 
between 2001-2011 revealed strong associations between the onset of mental 
disorders with later physical conditions and that having multiple mental disorders 
increased the risk of physical conditions.[286] An American study of 664 838 patients’ 
records found that mental disorders preceded cancer diagnoses in both sexes and in 
all age groups.[472] These associations may be explained by confounding factors 
such as smoking. The temporality of physical-mental multimorbidity onset in general 
may also be important. A Danish population study of 27 262 people who had died by 
suicide with 468 007 matched controls found that physical and mental illnesses both 
increased the risk of suicide independently.[473] The adjusted incident rate ratio for 
suicide in patients with a mental disorder diagnosed after a physical illness was 1.54 
(95% CI 1.46 to 1.63) and mental disorder diagnosed before physical illness was 0.90 
(0.85 to 0.95), both compared to those with only a psychiatric diagnosis. Mental illness 
occurring after the onset of physical illness increased the risk of suicide beyond that 
of physical or mental illness alone. My analyses in Chapters 4 and 5 therefore cannot 
show which comes first of multimorbidity and mental health symptoms or diagnoses. 
 
7.3.4 Dynamicity 
As discussed in Chapter 3, multimorbidity is usually treated as a one-dimensional 
construct although it is constantly changing within an individual. There is evidence 
from repeated survey data that changes in an individual’s number of conditions have 
varying associations with depressive symptoms, for example.[474] Even within one 
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chronic condition, intensity and severity can fluctuate depending on whether it is 
currently active or causing symptoms.[114] A limitation of all my analyses is that I did 
not measure trajectories of multimorbidity or polypharmacy, although this is in keeping 
with most similar research.[114] 
 
7.3.5 Sample size and statistical power 
The sample size used in Chapter 4 (n=210) is relatively small for some of the 
questions examined. For example, a 2017 systematic review of observational studies 
exploring the association of multimorbidity with depression found 40 papers, of which 
6 (15%) had a sample size of less than 210.[288] Using this dataset did have the 
benefit of allowing the inclusion of detailed measures of symptoms and markers of 
neurodegeneration. The EPAD dataset used in Chapter 5 is of a reasonable size 
compared to similar studies (n=447). A systematic review of dementia biomarkers 
found that of 37 studies examining amyloid-β in CSF or plasma, 29 (92%) had a 
sample size of less than 500.[106]  
 
Because I used existing datasets, the sample size was fixed. The PREVENT 
Dementia study’s initial planned sample size was 150, based on genetic and 
biomarker studies, with development of dementia as the primary outcome, so the 
sample I used exceeded this.[51] EPAD aims to have several thousand participants 
in readiness for clinical trials of disease-modifying drugs for dementia that will require 
stratification by amyloid status. The number in the first data release (n=500) was 
powered to contain sufficient amyloid positive participants for this purpose.[52,475] 
 
There is potential for some overlap between participants in EPAD (Chapter 5) and the 
NHS cohort (Chapter 6). Among my EPAD sample, 65 of the 447 eligible participants 
(14.5%) were recruited from study sites in Scotland. These individuals would have to 
have been aged 50 years or over on 1st January 2009 in order to also appear in the 
NHS sample. EPAD started recruiting people aged 50 years and over in 2016. Even 
if all 65 EPAD participants were aged at least 50 years in January 2009, this is 0.005% 
of the overall NHS sample size. In addition, the exposure and outcome variables were 
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different between Chapters 5 and 6 so any overlap is unlikely to have affected the 
results. 
 
7.3.6 Measurement of chronic conditions and medications 
The comparability between chapters is further limited because I used different 
measures of multimorbidity in Chapters 4 and 5 depending on the data available and 
on the research questions. For example, in Chapter 4 I excluded psychiatric 
diagnoses from the condition count as I used specific mental disorder outcomes, 
whereas the list of conditions used in Chapter 5 included mental disorders (except 
dementia) as the outcome was a biomarker of Alzheimer’s disease. Clinical mental 
disorders were less relevant to this biological outcome. Despite Chapter 2 revealing 
numerous potential multimorbidity indices, I used disease counts in my analyses. This 
was for pragmatic reasons and I clearly justified my choices of candidate condition 
lists in Chapters 4 and 5. In order to strengthen my results and allow comparability 
with other studies, I also included dichotomous measures of multimorbidity. Using 
counts of conditions has advantages, such as practicality and preventing the possible 
bias associated with using an index weighted on a particular outcome. However, as 
discussed in Chapters 2 and 3, counts are limited by assuming the same importance 
for each condition and not representing patients’ burden of disease well.[118] 
 
I was unable to harmonise the lists of conditions between Chapters 4 and 5 because 
the medical history in PREVENT Dementia was taken from a set list of conditions 
within the Case Report Form. These conditions did not provide the requisite 
information to either map onto the list of conditions from Barnett and colleagues [39] 
or onto the free-text style medical history collected in the EPAD study. In order to 
maximise the sensitivity of each list at detecting meaningful conditions and burden of 
disease, I aimed to include between 25 and 75 conditions per list as recommended 
by previous research.[260] If I had used one list of only the conditions that could be 
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In Chapter 6, I used counts of simultaneous drugs received from among all 
prescribable active substances. This, along with categorising the number of 
medications, is the most frequent method of measuring polypharmacy.[32] My 
systematic review in Chapter 2 revealed that there are at least four weighted drug 
indices, designed to measure multimorbidity through medication use rather than to 
measure polypharmacy itself.[145–148] In the NHS dataset where diagnoses were 
not available, I chose to refer to medication counts rather than attempt to infer 
multimorbidity from them. In PREVENT Dementia, where both diagnoses and 
medications were available, I handled each separately.  
 
Simple drug counts have limitations similar to disease counts. In clinical practice, they 
have limited significance when treated without consideration of the individual’s level 
of multimorbidity.[32] Drug counts do not account for differences between 
medications, such as in side effects or interactions.[37] Measuring medication use at 
one time point does not reflect the patient’s true intake of drugs over time.[476] In 
contrast with the lists of eligible conditions available for measuring multimorbidity, 
drugs are usually counted from any prescriptions the patient receives.[260] A 2017 
systematic review of polypharmacy definitions did not comment on whether 
medications were counted from lists, implying that they included all possible 
medication.[32] It was also not possible to assess concordance with prescriptions 
using any of the included datasets, in keeping with most other polypharmacy 
research.[30,447] There are overall limitations inherent in counting diseases or drugs 
throughout this thesis, which are common to other studies with similar 
methods.[11,114] 
 
7.3.7 Generalisability of results  
Chapters 4 and 5 included relatively healthy volunteers and are therefore not 
generalisable to the whole population or clinical practice due to selection bias. In 
addition, they relied upon self-reported medical and medication history which were 
both subject to recall bias and are likely to over-estimate the level of multimorbidity. A 
Dutch study found that the prevalence of multimorbidity (≥2 conditions) in 2011 was 
16.2% according to the GP records of 359 682 people and 17.5% on health survey 
self-reports from around 15 000 community inhabitants.[63] This discrepancy was 
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present despite the list of conditions being longer (28 conditions) in the GP sample 
than the survey (11 conditions). Another study of 1 625 people aged over 65 years in 
Québec found poor agreement between self-report and health records for a list of 17 
conditions.[477] Hyperlipidaemia and gastrointestinal diseases had the lowest 
agreement between the two sources (Kappa 0.05 and 0.11 respectively). One 
approach which aims to improve the accuracy of self-reports, particularly in people 
with low health literacy, is a new multimorbidity questionnaire developed in 2017.[223] 
It asks patients about conditions including clear diagnoses such as diabetes but also 
groups of symptoms, such as ‘musculoskeletal conditions causing pain or limitation’.  
 
I chose the PREVENT Dementia and EPAD datasets for their depth of phenotyping, 
and complemented them with a population-based study in Chapter 6. A limitation of 
most multimorbidity studies that use survey data is that they miss the population of 
younger, more deprived people whose multimorbidity often includes substance use 
and associated conditions.[39,478] These patients would only have appeared in my 
NHS dataset if they were aged 50 years or over and engaging with primary care 
sufficiently to receive prescribed drugs. They would be unlikely to participate in 
voluntary cohort studies either, so my work has limited generalisability to this group.  
 
7.3.8 Sociocultural homogeneity 
The populations studied in this thesis were all from high-income countries in Europe. 
Multimorbidity is increasing in prevalence worldwide, and in low and middle income 
countries (LMICs) there is disparity between patients’ burden of disease and available 
treatments.[89] Data from the 2003 World Health Surveys showed that the prevalence 
of multimorbidity (the co-existence of two chronic diseases from a list of six, including 
depression and psychotic illness) in people aged over 65 years was 30.2% in Nepal 
and 27.1% in Georgia.[479] Further work from the same World Health Surveys found 
increased odds of multimorbidity (≥2 of a possible nine conditions) in people with any 
depressive episode, with a pooled OR of 3.26 (95% CI 2.98 to 3.57).[480] This was 
the case in 42 out of the 43 LMICs included and confirms that physical-mental 
multimorbidity is also prevalent in these countries. 
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My systematic review included relevant papers from any country, but of 35 original 
papers, only one came from an LMIC, India.[139] Our search strategy was limited to 
English language, which may have reinforced this restriction. Within Europe, there are 
varying figures for estimates of multimorbidity prevalence.[59] In the Survey of Health, 
Ageing and Retirement in Europe (a study of people aged ≥50 years in 14 European 
countries and Israel), multimorbidity was defined as the co-existence of ≥2 self-
reported conditions from a possible list of 12.[66] This study showed that the 
prevalence of multimorbidity, adjusted for age and gender, was 26.2% in northern 
Europe compared to 35.2% in Eastern European countries. This may be due to 
socioeconomic and cultural differences, for example relating to access to and use of 
healthcare.  
 
The imbalance in multimorbidity studies in LMICs compared to high-income countries 
has been recognised before, and is also reflected in the fact that integration of care 
interventions have only been implemented in high-income countries.[481,482] This is 
pertinent when LMICs have comparatively little mental health policy and legislation, 
in addition to their funding being even more limited for mental than physical 
healthcare.[481,483] Studying only high-income countries could therefore perpetuate 
the inequalities in research.  
 
7.3.9 Confounding factors 
As in other observational studies, confounding is a potential explanation for the results 
found in my analyses. I adjusted for variables that were clinically relevant, available, 
and which emerged as statistically significant in preliminary analyses. However, there 
is likely to be residual confounding.[484] This could be from relevant known factors 
such as alcohol use and smoking history which were either not available in the NHS 
data or did not emerge as significant in PREVENT Dementia and EPAD. There could 
also be unknown confounders. For example, a study on 2 002 individuals from 
Canada, Albania, Brazil and Colombia explored multimorbidity and depression.[485] 
The authors found no association between the two, but the incidence of depression 
varied across study regions, suggesting that geographical factors may play an 
important role.  
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Chapter 5 used EPAD data from 12 sites across Europe, where the prevalence of 
each chronic disease could vary. The variation could relate not only to the aetiology 
of conditions but also their likelihood of being diagnosed. CSF amyloid positivity may 
also differ due to environmental factors. In addition, the sites used different 
recruitment methods, for example from memory clinics or population-based 
studies.[52] Owing to the varied number of participants between sites, where some 
had small numbers, I did not adjust for site in my analyses, but this could be seen as 
a limitation. People with multimorbidity have complex clinical presentations and social 
circumstances, which were not captured by my methods of quantifying chronic 
conditions. There may be relevant, more nuanced, factors here that are difficult to 
measure.  
 
7.3.10 Accounting for pre-existing psychotropic drug use 
In Chapters 4 and 6, it was challenging to account for pre-existing psychiatric 
diagnoses when mental disorders were the outcome of interest. As an attempt to do 
so, I included antidepressant use as a covariate in relevant analyses in Chapter 4, 
and any psychotropic drug use in Chapter 6. In Chapter 6, where the sample size was 
large enough, I additionally conducted sensitivity analyses excluding those patients 
taking psychotropic drugs. The two main areas of uncertainty are temporality (whether 
the mental disorder pre-dated the multimorbidity or polypharmacy) and partial 
treatment (patients or participants taking psychotropic drugs might be expected to 
have treated or resolved mental disorders).  
 
The main findings of this thesis depend on whether psychotropic drug use was 
included as a covariate. Any associations found were attenuated when it was, 
suggesting that these factors (as markers for pre-existing mental disorders) explain 
the associations found. Previous research has already established that physical 
multimorbidity is common in people with chronic mental disorders but there is still 
limited evidence on whether multimorbidity increases the risk of mental 
disorders.[486] Future work could address this by exploring temporality in more detail. 
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7.3.11 Mind-body dualism 
The broad research question of physical conditions as the exposure and mental 
disorders as outcomes creates a dichotomy between physical and mental health. For 
example, in Chapter 4, I excluded psychiatric conditions from counts of conditions 
when depression was the outcome. This separation has been used in clinical 
medicine for centuries and remains evident in the organisation of most health 
services. However, humans are embodied beings; this dichotomy has no scientific 
basis.[487] In addition, multimorbidity in its truest sense includes both physical and 
mental disorders.[7] By disentangling them and specifying physical multimorbidity in 
Chapter 4, perhaps I was not studying true multimorbidity. However, only by 
separating physical and mental illnesses can we understand the links between the 
two and strengthen the case for integration and parity.[488] 
 
7.4 POTENTIAL MECHANISMS 
Interactions between physical multimorbidity and poor mental or brain health may be 
due to a range of biological, psychological and social mechanisms. There are multiple 
factors at play and any causality is likely to be bi-directional.[489] Conditions could 
have common predisposing and perpetuating factors. In clinical practice, the 
symptoms of physical and mental disorders often overlap. It can be difficult to 
disentangle their chronology and attribute symptoms to conditions.[490] Longitudinal 
approaches allow the exploration of whether physical multimorbidity or mental 
disorders precede the other. Figure 7-1 shows the possible explanatory mechanisms 
which are explored in this chapter. 
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Figure 7-1: Spider diagram of potential mechanisms for associations between multimorbidity 
and mental illness or neurodegeneration 
 
7.4.1 Importance of individual conditions 
It may be that individual conditions are more important than overall multimorbidity at 
influencing mental health. It is known that stroke and myocardial infarction, for 
example, are commonly followed by depressive episodes [491,492] and that 
depression commonly co-exists with each of diabetes, hypertension and arthritis.[271] 
Some physical and mental disorders have risk factors in common, for example 
hypertension and hypercholesterolaemia being linked with both cardiovascular 
disease and Alzheimer’s dementia.[493]  
 
There is a complex relationship between blood pressure, depression, and cognitive 
impairment or dementia, the direction of which is uncertain.[494] Hypertension in mid-
life is an established risk factor for both vascular and Alzheimer subtypes of 
dementia.[40] Hypotension, particularly low diastolic blood pressure, in later life may 
also be associated with increased rates of dementia.[495] Other vascular risk factors, 
particularly those related to lifestyle, commonly co-exist with depression. Some 
evidence suggests that depressive symptoms may be a prodromal feature of 
dementia, with another explanation being that depression and dementia share 
common aetiology.[496] It is also useful here to examine these interactions across 
age groups. Changes in blood pressure over time may lead to different trajectories, 
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particularly of cognitive profile.[497] It is therefore worthwhile considering this risk 
factor in the overall context of physical health relating to various mental health 
outcomes. These contributions of specific conditions or risk factors may explain why 
my broader approach to multimorbidity did not capture convincing associations with 
mental disorders; perhaps certain conditions are more relevant than overall disease 
burden. 
 
7.4.2 Early life predictors 
This thesis has taken a life-course approach to multimorbidity, including mid-life, 
ageing and later life samples. There is some evidence to suggest that early life factors 
are also associated with later multimorbidity. A longitudinal study of children born in 
Hertfordshire, England between 1931 and 1939 found that, among the 2 299 who 
survived to follow-up in 2007-8, higher rates of childhood illnesses were associated 
with multimorbidity (from a list of 11 conditions and free-text) at age 69-76 years.[498] 
These associations persisted when adjusting for childhood factors including 
socioeconomic status. A similar study of 10 584 participants of the US Health and 
Retirement Study also found that poor childhood health was associated with adult 
multimorbidity, even when adjusted for adult socioeconomic status.[499] The 
Hertfordshire study captured information from the participants’ child health records 
and found no significant associations with other childhood factors such as birth weight 
and method of feeding.[498]  It did not include adverse childhood experiences. A 
recent review suggested that the established link between childhood adversity and 
schizophrenia may be explained by the increased inflammation that appears after 
childhood adversity; neuroinflammation has been associated with psychosis.[500] 
Peripheral inflammation is also associated with a number of physical conditions 
including cardiovascular disease and type II diabetes.[500] Therefore, both physical 
and mental illnesses could share life-course aetiology whatever the mechanism, and 
this association warrants further exploration. 
 
7.4.3 Psychosocial explanations 
For individual people, there may be psychological or social explanations for the co-
existence of their physical multimorbidity and mental illness. For example, someone 
who is aware of having multiple conditions and the burden of managing them may 
 
Chapter 7: Discussion  288 
identify that this makes them more anxious or depressed.[478,501] Polypharmacy, as 
a consequence and daily reminder of multimorbidity, can reinforce this phenomenon, 
and patients may worry about making mistakes with their medication.[502] 
Furthermore, the symptoms of chronic conditions often include pain and fatigue, 
which can contribute to low mood and anxiety.[503] Chronic physical conditions can 
be linked to functional impairment and social isolation;[504] these too are risk factors 
for anxiety and depression [505] and cognitive impairment.[47] They may also limit 
patients’ ability to seek or access mental health care or treatment when required, or 
in some cases impede the recognition of depression.[486,506]  
 
Research has been conducted on the relationship between health perceptions and 
multimorbidity in a Swedish population-based longitudinal study of 2 293 people aged 
60 years and over.[507] Health perceptions and life satisfaction were measured using 
self-report questionnaires, and participants were followed up for a mean of nine years, 
reporting new diagnoses from a list of 60 possible conditions.[255] Regardless of 
whether or not participants had multimorbidity at baseline, high life satisfaction and 
positive health outlook were associated with a lower rate of accumulating 
conditions.[507] Personality factors may therefore influence people’s likelihood of 
reporting symptoms and their threshold for impacting on daily life. Again, there may 
be common underlying factors acting as residual confounders, such as early life 
experience, that lead to low life satisfaction and multimorbidity, but objective research 
in this area is limited. I discussed these psychosocial issues with my Lay Contributor, 
as summarised in Chapter 8 (8.3.1, page 311). 
 
7.4.4 Socioeconomic factors 
Previous research has found that the prevalence of multimorbidity increases with 
socioeconomic deprivation.[39,504] A systematic review of 24 cross-sectional studies 
on this topic confirmed the association, and found that low, compared to high 
educational attainment was associated with increased odds of multimorbidity 
(OR=1.64, 95% CI 1.41 to 1.91).[508] Barnett and colleagues’ Scottish primary care 
epidemiology study of all ages found that multimorbidity including both physical and 
mental illnesses was almost twice as prevalent in the most, versus the least deprived 
areas (11.0% versus 5.9% respectively).[39]  In addition, patients in the most deprived 
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decile were over twice as likely to have any mental disorder. Socioeconomic status is 
therefore highly relevant and should always be considered when exploring physical-
mental multimorbidity. It is also potentially important in polypharmacy, particularly 
where patients have to pay for prescriptions. I adjusted for deprivation index in 
Chapter 6, and used educational level as a covariate in Chapters 4 and 5 as it is both 
a marker of socioeconomic status and relevant to brain health.[40] In future studies 
using NHS data, it could be useful to stratify by deprivation decile to explore this issue 
further. 
 
7.4.5 Lifestyle factors 
People with chronic mental disorders may have poorer physical health due to 
difficulties accessing healthcare, side effects of medication and lifestyle factors such 
as higher rates of smoking and physical inactivity.[489] These factors may contribute 
to the life expectancy of people with serious mental illness being 12-13 years shorter 
at birth than that of those without.[509] Lifestyle factors may also partly explain the 
relevance of socioeconomic status to the associations between chronic physical and 
mental conditions. A mediation analysis of 10 693 participants aged 50 years and over 
across six waves of the English Longitudinal Study of Ageing explored physical health 
(as measured by the six-item Katz Activities of Daily Living (ADL) score) and mental 
health (CES-D score) separately as both exposures and outcomes.[510] The authors 
suggested that there may be both direct and indirect effects of physical health on 
mental health and vice versa. They found that the indirect effects of past mental health 
on current physical health included social interactions, lifestyle choices including 
physical activity and smoking, socioeconomic status and biological factors. However, 
the relationship between past physical health and current mental health was mediated 
only by physical activity. This paper studied mediating factors in depth, but is limited 
by extrapolating functional ability (Katz ADL score) to represent overall physical health 
and CES-D, a specific depression scale, to general mental health. However, other 
studies have confirmed this association between physical inactivity and 
multimorbidity.[511]  
 
A report on multimorbidity from the Global Alliance for Chronic Disease has stated 
that public health interventions to address lifestyle factors such as diet and exercise 
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should be prioritised to address multimorbidity.[512] The intervention of the Finnish 
Geriatric Intervention Study to Prevent Cognitive Impairment and Disability (FINGER) 
trial included advice on diet, exercise, cognitive training and optimising vascular risk 
factors.[513] Its primary aim was to prevent cognitive decline but secondary analyses 
showed a reduction in participants developing new chronic diseases after two 
years.[514] This suggests that holistic interventions focusing on lifestyle factors could 
improve both cognitive outcomes and the prevalence of multimorbidity. 
 
7.4.6 Biological mechanisms 
7.4.6.1 Vascular mechanisms 
The co-existence of physical multimorbidity and mental disorders may be due to 
common aetiological or predisposing factors. This is clearer in some conditions than 
others. As introduced in section 7.4.1 on page 286, there is robust evidence that 
vascular pathology is present in the brains of people with dementia, both of vascular 
and Alzheimer’s subtypes.[343] In addition, according to Alexopolous:  
 “cerebrovascular disease may predispose, precipitate or 
perpetuate some geriatric depressive syndromes.”[515] 
This is known as the vascular hypothesis of depression. Current theories are that this 
may be due to focal vascular damage and white matter lesions disrupting neural 
connectivity or causing hypoperfusion and inflammation.[516]  
 
A cross-sectional study within the Irish Longitudinal Study on Ageing examined 2 616 
participants’ frontal lobe perfusion, orthostatic blood pressure and depressive 
symptoms according to the eight-item CES-D.[517] Participants with significant 
depressive symptoms had significantly lower frontal perfusion but this was likely 
mediated by having lower blood pressure. A systematic review of mortality in late-life 
depression meta-analysed longitudinal data from nearly 200 000 individuals across 
61 studies.[518] Depression was associated with an increased risk of cardiovascular 
mortality (risk ratio 1.31, 95% CI 1.20 to 1.43) but this was not different from its 
association with all-cause mortality (risk ratio 1.34, 95% CI 1.27 to 1.42). Like most 
mental disorders, depression is a multifactorial condition with relevant biological, 
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psychological and social factors.[290] Its causes and manifestations are 
heterogeneous and research is underway exploring whether it in fact represents 
several conditions.[519] In addition to vascular contributions, other mechanisms that 
may co-exist with physical conditions include monoamine neurotransmitter 
disturbance and hypothalamic-pituitary-adrenal axis dysregulation.[490] 
 
7.4.6.2 Genetic components 
There may be some common genetic aetiology between physical and mental 
disorders. For example, there are known shared single nucleotide polymorphisms for 
schizophrenia and cardiovascular disease.[520] This could be applicable to the co-
existence of multimorbidity and mental disorders, although there is little research into 
the genetics of multimorbidity. A 2018 paper aiming to create an atlas of multimorbidity 
genetics listed disease phenotypes linked by findings from Genome-Wide Association 
Studies (GWAS).[521] The authors reported the existence of clusters of conditions 
with related underlying pathology, such as fat metabolism. A limitation of this paper is 
that the disease traits they included are not compatible with the lists of conditions in 
clinical multimorbidity research. For example, they included Crohn’s disease and 
colorectal cancer alongside measurements such as muscle strength and body height. 
It is therefore not applicable to the clinically orientated understanding of 
multimorbidity. A more relevant study conducted a network analysis of chronic 
conditions among 1 749 722 people with at least two chronic conditions in Catalonia, 
using primary care records.[522] Diseases were listed from the clinical chapters of 
ICD-10. Using the emergent patterns in this network analysis as a guide, the authors 
then explored genetic associations in a different cohort, identifying that the most 
common diseases shared 20 associated variants with each other. Smoking was also 
associated with the conditions in question, which the authors remarked was likely an 
important causal factor. 
 
A Swedish study examining the associations between subjective cognitive impairment 
or Cognitive Impairment No Dementia (CIND) and multimorbidity investigated 11 379 
twin individuals without dementia.[523] The authors found a stronger relationship 
between chronic diseases and both types of cognitive impairment when there was 
multimorbidity. Including familial confounders attenuated the association between 
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most disease clusters and CIND, suggesting genetic and early life environmental 
factors are important in this relationship. However, the association between chronic 
diseases and subjective cognitive impairment was not attenuated by these familial 
factors. It may be that subjective cognitive impairment is more related to issues at the 
time of testing, such as mood symptoms, rather than genetic or early life factors.[105] 
In addition, these findings have some parallels with my results in Chapter 4, that 
condition and medication counts were more strongly associated with self-reported 
depression and anxiety disorders than with scores on symptom scales. 
 
Two studies have examined associations between specific psychological traits and 
genetic predisposition to physical and mental illness in the UK Biobank cohort, even 
among participants with no physical or mental diagnoses.[524,525] One study of 
108 038 participants explored associations between neuroticism and polygenic risk 
scores from GWAS consortia.[524] The authors reported associations between 
neuroticism and the polygenic risk scores for coronary artery disease and several 
mental disorders including major depressive disorder. However, the analysis also 
showed significant associations with physical risk factors for coronary artery disease, 
namely body mass index and smoking status. A further study of 112 151 UK Biobank 
participants revealed an association between scores on specific cognitive tests 
(verbal-numerical reasoning) with the polygenic risk scores for ischaemic stroke and 
coronary artery disease, as well as Alzheimer’s disease and schizophrenia.[525] 
There has been no research conducted into associations between each of these 
psychological traits and multimorbidity. It could be argued that rather than relying on 
polygenic risk scores, epidemiological research examining these traits in people with 
extant diagnoses would be just as valuable, although would not elucidate causal 
factors. 
 
Genomic instability, including defective DNA repair and accumulation of mutations, is 
a hallmark of ageing.[526] It is also associated with multimorbidity and 
inflammation.[504] Telomeres are sequences of nucleotides at the end of 
chromosomes. They protect the genome from damage and are shortened by cell 
division; short telomeres induce cell senescence.[527] Shorter telomeres are 
associated with both physical and mental chronic conditions.[528,529] Recent 
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research explored whether telomere length could be a biomarker for multimorbidity 
but found it was not clearly related to multimorbidity and was therefore 
unsuitable.[530] Ageing is also associated with epigenetic alterations, for example 
changes in DNA methylation, which may play a role in the development of 
multimorbidity as additional conditions accumulate.[526,531] Overall, there has been 
a range of genetics research relevant to interactions between physical and mental 
health, but none has found a convincing genetic signature of multimorbidity. With the 
increasing interest in epigenetics in relation to brain health, this is likely to become an 
important area of future study.[532] 
 
7.4.6.3 Ageing and inflammation 
The prevalence of both multimorbidity and mental disorders (including dementia and 
depression) increases with age.[39,59,533–535] This can be understood at a cellular 
level. Hallmarks of cellular ageing not yet discussed include deregulated nutrient 
sensing, mitochondrial dysfunction, cellular senescence and stem cell 
exhaustion.[526] Inflammation increases with age, probably partly due to the 
accumulation of tissue damage and senescent cells releasing pro-inflammatory 
cytokines, both of which perpetuate the inflammatory process. Over time, the immune 
system also becomes less adept at clearing pathogens and dysfunctional host 
cells.[526] As discussed in section 7.4.2 (page 287), inflammation is implicated in the 
pathogenesis of type II diabetes, one of the commonest conditions contributing to 
multimorbidity,[536] and atherosclerosis, a cause of vascular conditions.[537] 
 
The link between inflammation and multimorbidity has been specifically examined in 
a longitudinal study of 1 018 people aged 60 years and over, with a list of 15 candidate 
conditions.[538] This study identified that higher baseline levels and steeper increase 
of the inflammatory cytokine interleukin-6 was associated with an increased rate of 
developing multimorbidity, adjusted for age, sex and education. The authors also 
discovered that this link was not associated with individual conditions. Inflammation 
has established links with schizophrenia, depression and Alzheimer’s 
disease,[539,540] so inflammation could explain the co-existence of physical 
multimorbidity and mental disorders. It is being investigated as a potential treatment 
target in depression.[541] Potential aetiological overlap could inform future treatment 
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and preventative interventions for multimorbidity, both regarding lifestyle factors and 
pharmacological management.[542] 
 
More clinically apparent age-related changes, such as differing length and depth of 
sleep, may predispose to or perpetuate mental disorders in older people.[490] 
Multimorbidity does not appear exclusively in older people, and the majority of people 
with multimorbidity are aged under 65 years.[39] It may therefore be more 
representative of biological, rather than chronological age, although its presence in 
younger adults can display a different combination of diseases, for example including 
those related to substance use disorders. In summary, as discussed in section 7.2.3 
(page 275), my findings suggest that multimorbidity and polypharmacy are more 
connected with clinical mental disorders than the biological processes linked to 
dementia. 
 
7.4.7 Healthcare factors 
People with one condition are more likely to acquire another by virtue of the fact that 
they attend healthcare.[20] For example, when consulting a GP about one condition 
they may have their blood pressure checked and gain a diagnosis of hypertension. 
This can introduce a form of selection bias, even to population studies.  
 
A systematic review of polypharmacy in multimorbidity found five studies that reported 
low recognition and suboptimal treatment of depression in people with chronic 
conditions.[29] Mental disorders in people with multimorbidity may therefore be under-
treated. In contrast, there is some evidence that people with multimorbidity experience 
better overall healthcare than those without,[543] and for example their attendance at 
healthcare means their vaccine uptake is higher.[544] A systematic review on 
depression recognition in primary care found that among 13 studies, only four found 
that higher physical multimorbidity burden reduced rates of depression recognition, 
two papers found physical multimorbidity increased recognition and the remaining 
seven were equivocal.[506] The review found that the quality of treatment for 
depression was not convincingly different between people with and without physical 
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multimorbidity. Conversely, a systematic review of the literature on the medical care 
received by people with comorbid mental and substance use disorders found that they 
had more contacts with physical healthcare services than people with no mental 
disorders, but that these contacts were of lower quality.[545]  
 
People with more conditions perhaps have more insight into their physical symptoms 
compared to those with fewer diagnosed conditions who may not have sought 
healthcare. A patient with well-managed hypertension and COPD, for example, might 
have better overall health than someone who has symptoms of both conditions but 
has not been diagnosed; the patient with diagnoses would score higher on a disease 
count than the one with none. This phenomenon is particularly relevant in studies of 
volunteers, given that likely participants have been shown to be more health 
conscious than non-responders.[546] It reduces the generalisability of these results 
as people with higher disease counts in cohort studies may actually be healthier than 
non-responders. It seems unlikely to explain the inverse relationship between 
multimorbidity and amyloid positivity presented in Chapter 5, as this was measured 
by biomarkers which are not influenced by personality or self-report. However, there 
has been some research suggesting that personality factors may play an indirect role 
in the development of clinical dementia, probably through lifestyle and social 
engagement factors.[547]  
 
There may be a tendency against intervention, for example prescribing, in people with 
pre-existing multimorbidity and polypharmacy. For example, Soysal and colleagues 
found that, among 12 148 patients with dementia, those taking ≥10 medications were 
less likely to be prescribed an acetylcholinesterase inhibitor for dementia symptoms 
(20.5% of this group) than people on 0-4 (25.8%) or 5-9 (27.5%) medications 
(P<0.001 for both comparisons).[380] This may reflect clinicians’ judgement, tailored 
to each individual, that people with multimorbidity and polypharmacy are likely to be 
more frail and gain less benefit from adding another medication. They may also have 
lower tolerance for medication adverse effects. However, there is evidence that 
acetylcholinesterase inhibitors are effective at managing cognitive symptoms in 
people with dementia.[548] This could mean that clinicians do not initiate psychotropic 
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medication in people with multimorbidity even when it might benefit their mental 
health.[380]  
 
7.4.7.1 Medication adverse effects 
Most people with multimorbidity take multiple medications.[379] As well as the 
conditions themselves contributing to mental disorders, the medications, both 
individually and as components of polypharmacy, have psychiatric symptoms as 
adverse effects.[101] Interactions between medicines may also contribute to this 
burden, for example causing delirium.[389] In future work it would be ideal to explore 
each of multimorbidity and polypharmacy while adjusting for the other, to address this 
issue.[379]   
 
7.5 IMPORTANCE AND RELEVANCE 
7.5.1 Contribution to existing evidence 
In this thesis, I have explored the latest methodology of measuring multimorbidity and 
conducted novel analyses of its association with mental and brain health outcomes. 
My systematic review in Chapter 2 provided an updated overview of all available 
multimorbidity indices, along with comprehensive critique of their methods and 
application. This was the first review of its kind since 2012, with an up-to-date search, 
and I expect will be used by multimorbidity researchers from both epidemiological and 
clinical backgrounds.[112] I summarised other methods of measuring multimorbidity, 
and important considerations, in Chapter 3. 
 
In Chapter 4, I corroborated previous findings of associations between the number of 
conditions and clinical depression, and its less often studied relationship with anxiety 
disorder, in a deeply phenotyped mid-life cohort. There has been less research on 
polypharmacy than multimorbidity in relation to mental health, with no existing 
evidence linking medication use and anxiety. My analyses in this area are therefore 
novel. In all of these analyses I complemented self-report with symptom scale scores, 
which is a strength over previous research. 
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In Chapters 4 and 5, I explored multimorbidity and medication use in relation to 
biomarkers linked to cognitive impairment and Alzheimer’s disease. There is limited 
existing research in this area, although some studies found associations between 
multimorbidity and markers of neurodegeneration.[98] My work in Chapter 5 is the first 
to examine multimorbidity and CSF amyloid. The negative findings in Chapter 4, as 
well as the robust inverse association between multimorbidity and CSF amyloid, build 
on other research to suggest that multimorbidity is not linked to known biomarkers for 
neurodegeneration. They challenge previous hypotheses and may pose new 
questions about mechanisms. For example, the co-existence of multimorbidity and 
dementia, which is a multifactorial clinical condition, is likely due to other biological or 
psychosocial pathways. 
 
Previous population-level research has described cross-sectional associations 
between physical multimorbidity and mental disorders.[39] My work on NHS Scotland 
data in Chapter 6 is the largest UK study of polypharmacy to date and the first to 
consider psychiatric outcomes. I found no convincing associations between 
increasing medication use and the psychiatric outcomes, although they had limited 
sensitivity. The fact that psychotropic medication use attenuates associations is 
important, suggesting that pre-existing psychiatric diagnoses are relevant to any 
overlap. This could inform the design of future work, aiming to ensure that temporality 
is considered where possible. 
 
7.5.2 Policy applications 
The part of this thesis with the biggest potential impact on policy is likely to be the 
systematic review of multimorbidity indices in Chapter 2. It will be of practical use 
when choosing between methods of quantifying multimorbidity or illness burden for a 
variety of purposes. It has already been consulted in an ongoing re-evaluation of the 
boundary between general adult and older people’s mental health services in NHS 
Lothian. As well as the direct application of my systematic review, epidemiological 
research provides context for policy interventions.[549] 
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7.5.2.1 Public mental health 
A 2016 King’s Fund report highlighted the importance of integrating physical and 
mental healthcare for people with multimorbidity, suggesting as its top priority that 
mental health should be incorporated into public health programmes.[550] In 2018, 
the Scottish Government published six public health priorities, one of which was “A 
Scotland where we have good mental wellbeing”.[551] My finding that multimorbidity 
is linked to mental health diagnoses and symptoms is relevant to patients. It could be 
used when disseminating related public mental health information, for example that 
people with multiple conditions are at risk of depression and should seek medical help 
early. 
 
Public Health Scotland, the new body sponsored by the Scottish Government and the 
Convention of Scottish Local Authorities, oversees a national set of adult mental 
health indicators.[552] The aim is to use them to monitor public mental health, 
associated risk and protective factors and related inequalities to inform resource 
allocation. The indicators include ‘general health’, disability and chronic conditions as 
contextual factors for mental health and wellbeing. The latest data available for these 
indicators come from the Scottish Health Surveys, a repeated representative sample 
of adults living in private households in Scotland.[553] The response rate has been 
decreasing since the survey’s inception, with the 2018 survey including 4 810 adults, 
with a response rate of 57%.[554] The surveys allow linkage to health records with 
participant consent, but do not include residents of institutions such as care homes, 
and the response rate suggests probable selection bias. In contrast, my results from 
routinely collected data include almost the whole older adult population who use 
healthcare. My findings could therefore beneficially complement these survey data 
when monitoring mental health indicators. Using routinely collected data also 
minimises waste, in line with the former Chief Medical Officer for Scotland’s Realistic 
Medicine agenda.[555] 
  
The findings of no associations between multimorbidity or polypharmacy and 
biomarkers of neurodegeneration in this thesis are also informative. They add 
evidence that multimorbidity and polypharmacy are unlikely to be modifiable targets 
in interventions to prevent dementia. 
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7.5.2.2 Healthcare integration 
Regardless of causality, my cross-sectional results in Chapter 4 showed a co-
existence of multimorbidity, polypharmacy and depression. In the NHS data analysed 
in Chapter 6, the use of psychotropic drugs emerged as important in associations 
between medication use and mental health outcomes. These findings highlight the 
fact that physical-mental multimorbidity is common and involves the careful balancing 
of medication. It has previously been acknowledged that managing co-existing 
physical and mental illnesses poses particular challenges in healthcare.[556,557] My 
findings of associations between multimorbidity, polypharmacy and self-reported 
mental illnesses support previous policies and reports on this topic. For example, the 
Royal College of General Practitioners has recognised the potential for improved 
primary mental healthcare for people with multimorbidity.[558] My research could be 
used to support these calls for healthcare integration, including liaison psychiatry in 
primary care, where patients with multimorbidity receive most of their care.[559] 
 
7.5.3 Multimorbidity interventions 
There are several existing interventions to promote the physical health of people with 
mental disorders. These often involve training for clinical staff and could be applied in 
the other direction, for example integrating geriatric medicine and old age psychiatry 
services [560,561] or increasing mental health nursing input to general practices.[562] 
The Lancet Psychiatry has recently published a Commission emphasising the 
importance of optimising physical healthcare for people with severe mental 
illnesses.[563] This also recommends that physical and mental healthcare be 
integrated, especially in primary care, and suggests multidisciplinary approaches to 
multimorbidity, particularly in addressing potentially modifiable risk factors common to 
poor physical and mental health.[481,563]  
 
There has been recent research interest into interventions for physical-mental 
multimorbidity. For example, a large cluster-randomised trial of the 3D (Dimensions 
of care, Depression and Drugs) approach to integrated care for multimorbidity 
compared 797 patients in an intervention group with 749 patients receiving usual care 
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in GP practices in England and Scotland.[564] The intervention consisted of six-
monthly reviews with a nurse, doctor and pharmacist, as well as training and 
organisational changes at practice level. There was no significant difference in the 
primary outcome of quality of life scores between groups or a secondary outcome of 
Hospital Anxiety and Depression Scale (HADS) scores. However, patients in the 
intervention group rated their care as more patient-centred and reported greater 
satisfaction with their care.[564]  
 
There have been few trials among people with multimorbidity that have mental health 
as a primary outcome. The COINCIDE trial featured input from Psychological 
Wellbeing Practitioners among people with both depression and either diabetes or 
coronary heart disease and included around 190 participants in each arm.[565] The 
results showed an improvement in depression scale scores and quality of life and the 
intervention was found to be cost-effective. The IMPACT randomised controlled trial 
focused on 1 801 adults with depression in the USA.[566] The intervention was a 
depression care manager and outcomes were depression and health-related quality 
of life. The presence of multimorbidity alongside depression did not affect response 
to the intervention.  
 
There have been trials of several interventions which aimed to identify and limit 
polypharmacy where appropriate. A 2016 systematic review of interventions by 
pharmacists found four studies, all of which had a reduction in inappropriate 
prescribing as their outcome. None specifically referred to mental disorders or 
dementia.[567] There is some work into improving care for people with dementia that 
includes both psychological intervention and medication review as part of 
collaborative care.[568] A broader literature exists exploring methods of reducing 
prescribing errors in people with multimorbidity.[569] As polypharmacy most often 
occurs in people with multimorbidity, any interventions improving care for people with 
multimorbidity usually comprise medication considerations.[570] 
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7.5.4 Clinical applications 
The Academy of Medical Sciences’ 2018 report on multimorbidity research asked how 
mental health conditions might be prevented among those with chronic physical 
conditions.[7] My results cannot directly answer this question, but may suggest that 
preventing or managing multimorbidity could promote better mental health. It would 
seem intuitive that people with multimorbidity could benefit from early detection and 
treatment of mental illnesses. The 3D trial’s intervention included screening for 
depression and dementia and did not improve overall mental health symptoms.[564] 
However, the results did not include rates of diagnosis or treatment of these 
conditions; identifying them could have led to benefits to patients that were not 
measured in the trial. 
  
Multimorbidity is known to co-exist with dementia but my results cannot confirm that 
multimorbidity increases the risk of neurodegeneration as measured by 
biomarkers.[39] It may be more important to gain evidence on what constitutes quality 
care for people with dementia that acknowledges their comorbidities than to try to aim 
to reduce dementia incidence by preventing multimorbidity.   
 
Clinical trials have yet to find an intervention that is effective at reducing depressive 
symptoms in people with multimorbidity or polypharmacy. Therefore, at present, it is 
perhaps more pertinent to identify that people with multimorbidity are at higher risk of 
developing mental disorders to allow early diagnosis and support. Epidemiological 
work, especially from population-based studies such as that presented in Chapter 6, 
remains valuable in informing this area. 
 
7.5.5 Application to future research 
The systematic review in Chapter 2 will have direct relevance to forthcoming studies, 
both for choosing a measure of multimorbidity to use as an exposure or covariate and 
when considering designing new indices. The previous major similar reviews have 
been cited over 400 times each, suggesting they are widely used.[112,113,116] Given 
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the continued publication of new multimorbidity indices, the review is also likely to be 
updated in future. 
 
The analyses and results from PREVENT Dementia presented in Chapter 4 provide 
some information on the co-existence of chronic conditions, polypharmacy and 
granular depression and anxiety outcomes. The cross-sectional analyses in a small 
dataset did not permit me to draw firm conclusions, but did allow preliminary 
explorations to prepare future work, particularly gaining experience with analysing 
cohort study data. 
 
The inverse association found between multimorbidity and amyloid in the EPAD 
cohort in Chapter 5 did not provide evidence of a lack of causality. However, it may 
steer future research into the explanatory mechanisms between multimorbidity and 
dementia away from the amyloid pathway, if the findings are confirmed on replication 
in a larger or longitudinal study. 
 
Working with these smaller datasets has carried its own lessons for designing my 
future research, acknowledging the limited ability to rely upon results with limited 
statistical power and the understandable difficulty publishing them. These 
experiences emphasised to me the importance of exploiting the opportunities afforded 
by large datasets. 
 
The analyses in NHS Scotland routinely collected data confirm the previously reported 
association between polypharmacy and mortality, in a longitudinal Scottish cohort, for 
the first time. This will inform future research with a specific focus on Scotland. In the 
analyses with mental disorders as outcomes, there was no overt association with 
increasing numbers of medication. The questions the results raised were about the 
importance of the constituents of polypharmacy. This highlights that future large-scale 
pharmaco-epidemiological studies should consider including markers for specific drug 
groups. Assumptions cannot be made about causality or the order of events, 
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diagnoses or prescriptions, even in longitudinal research, and I aim to address this in 
future analyses. This issue of temporality is pertinent to all multimorbidity research, 
especially focusing on physical-mental multimorbidity, as the timing of a specific 
diagnosis may influence its contribution to an individual’s overall disease burden.  
 
If my results were to be included in the evidence review for public health policy 
changes as mentioned above, any intervention using associations between 
multimorbidity and depression or other mental disorders should be tested in a 
research setting first. 
 
7.6 PLANNED FUTURE WORK 
This thesis has addressed important research questions but also opened up further 
topics and avenues for exploration within the same datasets and in others. With the 
increasing attention on multimorbidity, there have been several consensus 
statements developed on priorities for research in this area, namely by the James 
Lind Alliance, Academy of Medical Sciences and The National Institute for Health and 
Care Excellence (NICE).[89–91] When designing future analyses, I will consult this 
guidance and a Lay Contributor or Patient and Public Involvement (PPI) group, 
building on the work presented in Chapter 8. 
 
7.6.1 Further analyses using NHS data  
The considerable size of this dataset is a major strength and its breadth will allow 
several future research questions to be answered. These include: 
1. Additional diagnosis data 
a. Adding diagnoses from both general and psychiatric hospital 
admissions (SMR01 and SMR04) to ask more detailed questions 
about specific mental health outcomes, such as delirium  
b. Using psychiatric outpatient diagnoses (from SMR00) as outcomes as 
these are likely to represent clearer clinical assessment and diagnosis 
than death certificates. For example, dementia diagnoses made in old 
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age psychiatry clinics should be relatively robust, assuming they are 
accurately recorded. 
2. Interrogating the impact of specific classes of drug on mental health outcomes, 





d. Carbonic anhydrase inhibitors 
e. Anti-convulsants  
3. Calculating a weighted index such as the Chronic Disease Score [148] or 
Medication-based Disease Burden Index [147] to infer multimorbidity burden 
from medication data 
4. Tracking the effects on mortality or mental health outcomes of changes in 
medication use over time, for example the addition of specific medication, 
using multi-level modelling 
5. Using clustering or dendrogram techniques to explore the outcomes relating 
to different combinations of drugs. 
 
In the longitudinal analyses in Chapter 6, I took the exposure variable and covariates 
from baseline only. While most of the demographic covariates used (gender, 
deprivation) are unlikely to change over time, patients probably moved between 
groups in the others (care home residence and psychotropic medication use). 
Therefore, using time-varying covariates would be an improvement for future work.  
 
An approach to addressing causation (as discussed in section 7.3.2) would be to use 
target trial emulation, a technique for scrutinising observational data in respect to a 
specific treatment.[471,571] This entails setting eligibility criteria and including the 
participants who meet them, then matching those who received a specific treatment 
with those who did not and comparing their outcomes. The matching can be 
undertaken using propensity scores.[572] However, the quality of outcome and 
covariate data in the NHS dataset, for example the lack of cognitive test scores and 
information on ethnic group, would limit the value of these results.  
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The datasets held by ISD Scotland do not currently capture primary care medical 
records, but collecting data at GP practice level is being piloted in the Scottish Primary 
Care Information Resource (SPIRE), with rollout ongoing.[573] This will generate 
reports for practices on levels of multimorbidity in their patients but will also be open 
to applications from researchers for anonymised data.[574] When its database has 
grown, this could be a potential source of more detailed population-level data on 
chronic conditions to complement my polypharmacy analyses.  
  
7.6.2 PREVENT Dementia 
My analyses were of the pilot phase of PREVENT Dementia, including 210 
participants at one site. Cross-sectional data for 700 participants across five sites will 
become available soon, which would allow replication of my analyses this larger 
cohort. This will address the main limitation of a small sample size. Data from follow-
up visits will also permit longitudinal analyses, for example to investigate whether 
changes in the number of conditions or medications are associated with changes in 
scores on CES-D. Given that the pilot phase contains mid-life participants, changes 
during ageing are of particular note. 
 
7.6.3 EPAD 
I analysed the first 500 EPAD participants; initial data from 1 500 participants has 
recently been released and two-year follow-up of the original ones will soon 
follow.[475] I plan to replicate my analyses both in the larger cohort and on follow-up. 
As highlighted by a peer reviewer of the paper presented in Chapter 5, the observed 
inverse association between multimorbidity and amyloid positivity may disappear as 
these participants age. Longitudinal data will also allow analysis of multimorbidity as 
a dynamic, rather than static, concept, as recommended by a consensus of 
multimorbidity experts.[114] Another strength of future research using this dataset 
would be the addition of cognitive function outcomes, allowing complementary 
analysis of both biomarker status and clinical phenotype.  
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7.6.4 Additional analyses in UK Biobank 
UK Biobank is an ongoing prospective cohort study of over 500 000 volunteers in 
Great Britain. The participants give detailed medical histories and undergo numerous 
biometric measurements.[575] Multimorbidity research within UK Biobank is already 
taking place, for example regarding its prevalence, clusters and associations with 
medication adverse events.[254,278] Physical-mental multimorbidity has been 
explored in UK Biobank in specific, rather than general, contexts, such as chronic 
pain, depression and bipolar affective disorder.[576] Existing research has used 
computational techniques to identify interactions between depression and specific 
diseases (all by self-report).[577] These approaches need to include pragmatic 
clinical oversight, for example identifying that there are apparent comorbidities 
between depression and other psychiatric disorders, whereas these may represent 
aspects of the same underlying diagnosis. Potential future areas of multimorbidity 
research in UK Biobank would be to examine clustering of conditions and whether 
participants move between them. This would fit with the Academy of Medical 
Sciences’ stance on multimorbidity which emphasises that it is not the co-existence 
of a discordant collection of conditions, but that there are meaningful clusters.[7] 
Repeated medical histories and linkage to medical records would allow multimorbidity 
to be treated as dynamic in this cohort. Its large size, both in terms of number of 
participants and data items collected, would mean that analyses where participants 
could move between clusters may require the adoption of machine learning 
techniques, a newer approach to large-scale data analysis.[578] 
 
7.6.5 Multimorbidity measurement  
In my systematic review in Chapter 2, I found and summarised 35 multimorbidity 
indices. With the publication of this paper, I hope to provide guidance for other 
researchers choosing how to measure multimorbidity. One limitation of my work was 
that I did not compare the predictive ability of indices with each other. There has been 
one systematic review that aimed do this, with a search in March 2011 and restricted 
to those that included either the Charlson or Elixhauser indices in the 
comparison.[233] There is scope to update this review, with more specific search 
terms but broader inclusion criteria, and compare the indices in a suitable dataset. 
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7.6.6 Alternative directions 
This thesis has laid the foundations for future epidemiological work but may also 
inform research using alternative methods, such as trials of interventions for 
identifying and improving mental health symptoms in people with multimorbidity. The 
results are also informative to dementia trials, both those of drugs and of preventative 
interventions, suggesting that multimorbidity should be included as a covariate. 
 
7.7 CONCLUSIONS 
Multimorbidity is a multi-faceted and multi-factorial clinical state. It often includes both 
physical and mental illness. There are numerous difficulties to face when attempting 
to measure it and in designing clinically relevant research that addresses unanswered 
questions. These challenges include the specific measurement of multimorbidity itself 
and attention to the dataset’s design and size. My research corroborated previous 
evidence of associations between physical multimorbidity and clinically relevant 
mental illness diagnoses and symptoms. There was no positive relationship between 
multimorbidity and biomarkers of Alzheimer’s disease risk in cross-sectional analyses. 
Population-level data did not support the hypothesis that polypharmacy, accounting 
for psychotropic drug use, would be associated with psychiatric outcomes. Accounting 
for pre-existing mental disorders was a methodological challenge in these analyses. 
My overall findings pose further questions, such as the importance of the order of 
conditions’ development, and will inform future research.  
 
“All scientific work is incomplete – whether it be observational 
or experimental. All scientific work is liable to be upset or 
modified by advancing knowledge. That does not confer upon 
us a freedom to ignore the knowledge we already have, or to 
postpone the action that it appears to demand at a given time.” 
       Sir Austin Bradford Hill, 1965 [470] 
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Chapter 8 A patient’s perspective on living with 
multiple chronic conditions: reflections 
on involving a lay contributor in this PhD 
8.1 BACKGROUND 
Patient and public involvement (PPI) is increasingly recognised as important for 
improving the quality of research and its relevance to patients.[579] Many large trials 
now involve lay representatives, but there is less emphasis on PPI for researchers 
with smaller projects. I enjoyed presenting my proposal for the work presented in 
Chapter 6 to the Farr Institute Scotland Public Panel, both in making the material 
accessible to a lay audience and having the opportunity to discuss it. I was struck that 
the participants identified limitations I had not considered, for example noting that 
continuous positive airways pressure (CPAP) machines, a sign that a patient has a 
serious chronic condition, would not be included in prescribing records. They 
approached my research questions from a different angle, without the preconceptions 
that often accompany a clinical or research background.  
 
I have been supported throughout this PhD by charitable and public funding and 
analysed routinely collected NHS data. It therefore seemed appropriate to consult a 
member of the public with personal experience of the conditions I was researching. I 
aimed to involve a lay contributor in my PhD to relate my epidemiological findings to 
the context of an individual person living with multimorbidity. 
 
8.2 METHODS 
8.2.1 Planning and preparation 
The Alzheimer’s Society and other major charitable research funders have been 
promoting PPI for over 20 years.[580] They require evidence of PPI in grant and PhD 
fellowship applications, and the diversity of PPI research projects is expanding. When 
starting to plan this collaboration, I conducted an online search and found no evidence 
of other students recruiting patients to be involved for the duration of their PhD. 
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I therefore met the University of Edinburgh’s PPI Adviser and together we designed a 
proposal. I initially wrote a short description of my research and the lay involvement I 
envisaged. I found potential contributors through a local ageing research network; 
ethical approval was not required. I approached Mrs Mary Nisbet, who agreed to be 
involved.21 In her initial response, she said she had:  
“no degrees or special qualifications, just the experience of everything that has 
come my way over the last 80 years”.  
She has several chronic conditions and takes multiple medications. At our preliminary 




Mary agreed to meet me for about two hours approximately every two months for the 
remainder of my PhD, in a café that was convenient to her (see Figure 8-1). At most 
of our meetings, I summarised my recent work and results and Mary offered feedback 
including possible explanations and application to her daily life. I prepared relevant 
discussion questions not only on my research but also on recent multimorbidity 
publications or other topical issues. Mary gave her perspectives from her own 
experience both as a patient and as a carer to her two late husbands. She offered 
specific insights into my systematic review (Chapter 2) that I incorporated into the 
manuscript, and helped prepare a lay summary of it. 
 
21 Mrs Nisbet has given written consent to be named, for details of our discussions to be 
summarised, and for her photograph to be used. She has a copy of the original submission of 
this chapter and has approved its contents. 
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8.3.1 Perspectives on multimorbidity and polypharmacy 
We discussed the difficulties of defining multimorbidity; that counting conditions does 
not reflect each one’s severity or contribution to a person’s overall health and daily 
independence. Mary used the phrase “old age doesn’t come alone”, meaning that as 
she has aged, several health problems have occurred simultaneously and one 
seemed to lead to another. She pointed out that people with an existing health 
condition are more likely to visit their GP and perhaps consequently attract more 
diagnoses. I elaborated on this idea in section 7.4.7 and explained during our 
discussions that epidemiology is in general limited to observing population outcomes 
rather than individual behaviour. 
 
Mobility and memory were two key areas that Mary mentioned were concerns for her 
and her peers. These are reflected in an ethnographic study of people with multiple 
conditions, highlighting the fact that symptoms or independence can be more 
important to individuals than firm clinical diagnoses.[501] This report also identified 
that the biggest impact for a patient is not the number of conditions they have, but 
how they are supported and cared for. This moderates the impact of having 
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multimorbidity. As well as promoting mobility, the report recommends that patients be 
encouraged to take an active role in their care and to identify achievable goals. I 
described the dementia prevention studies analysed in this thesis and that their aims 
were to identify modifiable causes of cognitive decline to prevent it occurring. Mobility 
was not included in my work but I appreciated its importance and links with functioning 
and independence. 
 
Mary observed that when defining conditions as chronic, this can negate important 
illnesses that are considered to be resolved or acute. For example, cancer that has 
been treated and is in remission might be a source of worry for patients, and a major 
life event for older people, such as a hip fracture requiring surgical repair, would not 
be counted in many multimorbidity measures. We also discussed the limitations of 
observational studies and epidemiology. Mary thought my findings from large-scale 
data analysis would be less applicable to GPs, as their clinical decisions had to 
account for all the factors relating to the individual patient in front of them. My 
response was that looking at patterns in data from large numbers of people helped 
inform guidelines under which individuals would be treated. 
 
The term ‘multimorbidity’ did not appeal to Mary; she said she associated ‘morbid’ 
with death and that it sounded bleak. This is in keeping with a 2018 commentary 
written by a multimorbidity researcher who highlighted patients’ discomfort with the 
term. He and his PPI group advised either avoiding the term or reserving its use for 
communicating with clinicians or researchers.[21] As outlined in section 1.2.3, I chose 
to use the term multimorbidity in this thesis as a technical shorthand but was careful 
not to conflate it with chronic condition count. I also avoid using it in lay 
communications where possible.  
 
Mary said that taking multiple medications made her feel she “didn’t have long left”. 
When discussing my investigations into polypharmacy and mental health, she 
suggested a causative explanation – that people might feel depressed or 
disheartened by the notion of needing to take numerous medicines as it implies 
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“you’re serious”. She also raised the possibility that people worry about the 
medications themselves, and whether they “mix”. I explained the self-report symptom 
scales CES-D and STAI and that these capture individuals’ experience of mental 
health symptoms but not their explanations for or understanding of them. 
 
8.3.2 Attitudes and communication 
Our discussions often turned to the difference in attitudes to health and fitness among 
Mary’s peers. For example, she believes that staying active is the best way to avoid 
physical decline and “getting stuck in your armchair”. Despite feeling tired, she 
practises yoga, walks uphill most days and swims once a week. She tries to 
encourage her friends to do the same but some say, “I can’t”. She also reflected on a 
family member who had frequently complained about her health, whether or not she 
seemed to be ill. Relating these issues to specific aspects of my research, we agreed 
that personality and experiences significantly affect people’s perceptions of illness 
burden. This could influence their responses to self-report surveys (both when 
reporting diseases and answering symptom scales) and their approaches to engaging 
with medical care. 
 
Qualitative research has explored perceptions of living with multimorbidity, both from 
patients’ and doctors’ perspectives. A meta-synthesis of studies on this topic found 
that both patients and doctors had feelings of vulnerability and uncertainty when 
managing multiple chronic conditions, but that there was little evidence that parties 
discussed these shared challenges.[581] There is research interest in interventions 
to improve patients’ involvement in decision-making about their care. A 2019 
Cochrane review of trials of these interventions found three studies with a cumulative 
total of 1 879 participants.[582] The interventions included coaching, workshops and 
goal-focused nurse reviews aiming to empower patients to express what was 
important to them at healthcare appointments. The systematic review concluded that 
specific interventions may help patients receive care tailored to their own priorities, 
but it found limited evidence on other outcomes and suggested that more attention 
was needed to this topic. 
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Communication was another recurring topic of our PPI discussions. Mary values 
healthcare professionals being clear and honest, and prefers direct contact such as 
receiving copies of relevant letters. She loses faith in doctors when she hears different 
advice from specialists and her GP, and said, “you wonder who’s wrong”. She 
believes that NHS care could be better integrated. I drew on my clinical experience to 
share practical limitations, for example that in our area, GPs and hospitals have 
different computer systems. I suggested that teams being able to access each other’s 
health records more easily could improve continuity of care. 
 
8.3.3 Priorities for research 
The James Lind Alliance is an organisation that aims to bring patients and clinicians 
together to identify priorities for research.[583] During our collaboration, they held an 
online survey for their Priority Setting Partnership for Multiple Conditions in Later Life. 
Mary and I both participated in the survey and discussed this process. The partnership 
published its top ten priorities for research in May 2018, as shown in Box 8-8-1.[90] 
The Academy of Medical Sciences and National Institute for Health and Care 
Excellence (NICE) have also published research priorities for multimorbidity.[7,91] A 
recent publication summarising the James Lind Alliance findings compares the three 
sets of recommendations according to categories.[584] Each of the organisations has 
a different background and priorities. Mary and I read this overview paper together 
and reflected that the psychosocial category contained only James Lind Alliance 
recommendations and that NICE was interested in life expectancy as well as clinical 
care issues.[91] Mortality was not mentioned in the James Lind Alliance 
recommendations. Mary assigns more importance to quality of life than predicting 
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8.3.4 PPI in other PhDs 
Since my collaboration with Mary began, other examples of PPI in PhDs have 
emerged. For example, a ‘patient buddy’ system has been established for non-clinical 
PhD students in rheumatoid arthritis research at the University of Birmingham.[585] 
Basic science dementia researchers, including PhD students, at the University of 
Edinburgh have met people with dementia and their carers for tours of the laboratories 
1. How can current health, social care and voluntary sectors in the UK be 
optimised to more effectively meet the needs of older people living with 
multiple conditions? 
2. What are the most effective, cost effective and acceptable ways to reduce 
social isolation in older people with multiple conditions? 
3. What are the most effective, cost effective and acceptable strategies for 
the prevention of multiple conditions in later life? 
4. In what ways can carers of older people with multiple conditions be 
supported to maintain their own physical and psychological wellbeing? 
5. What is the most effective, cost effective and acceptable form of exercise 
therapy in different health and social care settings with older people with 
multiple conditions? How does exercise therapy affect outcomes in this 
population? 
6. How can the recognition and management of frailty be improved in older 
people with multiple conditions? Would this lead to an increase in 
perceived quality of life? 
7. How can Comprehensive Geriatric Assessment be optimally delivered in 
different patient populations experiencing multiple conditions in older age? 
8. What are the most effective, cost effective and acceptable interventions to 
improve the psychological wellbeing of older people with multiple 
conditions? 
9. How can independent living be most effectively and acceptably enabled in 
older people with multiple conditions in the UK? 
10. How do older people with multiple conditions perceive and manage their 
risk of falls? How can fear of falling be effectively addressed?  
Box 8-8-1: Top Ten priorities for research from the James Lind Alliance Priority Setting 
Partnership for Multiple Conditions in Later Life [90] 
 
 
Chapter 8: Reflections on working with a lay contributor             316 
and to share experiences.[586] A PhD student at Keele University studied self-harm 
in older adults in a project designed with patient input from the outset.[587] Three PPI 
participants met for four workshops to discuss plans for a systematic review and 
qualitative study. This approach was more formal and thorough than mine, but having 
a single contributor for the duration of my PhD had its own advantages, in that I was 
able to develop a working relationship with Mary and she felt personally invested in 
my work.  
 
A researcher from the University of Bristol included two PPI contributors throughout 
her PhD, the topic of which was lay people’s attitudes to PPI in research.[588] A 2019 
paper from researchers at the University of Bradford outlined diverse PPI methods 
within four doctoral research projects, with most recruiting groups of participants and 
one using online engagement.[589] A paper published in 2020 by two researchers at 
the University of Manchester described their experiences of incorporating PPI into 
their doctoral research.[590] One of these included involving two ‘research buddies’ 
throughout the duration of the project. The paper also highlighted that although PPI 
in PhD projects does take place, it is rarely reported in the literature. It provides 
recommendations for PPI at various stages of the PhD process. These recent 
developments suggest an increasing interest and use of PPI in doctoral research, 
even since the beginning of my PhD.  
 
8.4 LIMITATIONS AND CHALLENGES 
Patients and lay representatives should ideally be involved from the start of a research 
project. I was unaware that this was possible when preparing my PhD proposal. 
However, when I did hear about opportunities for PPI, I designed the role at the 
beginning of the second year of my PhD. This has motivated me to involve patients 
early in future research planning.  
 
As there was no evidence of best practice for involving a lay contributor in a PhD, I 
had to consult generic PPI guidance and develop my own style and plan for meetings. 
Mary and I had a relatively informal style for our meetings. This suited our one-to-one 
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approach and my aim to hear Mary’s general views and experiences, but a more 
structured meeting with an agenda could be more tangibly productive, particularly in 
a group of PPI participants. 
 
A limitation of PPI is that the views of the contributor do not represent those of all 
patients. However, this is not qualitative research, rather the aim is to include the 
perspectives of one patient, acknowledging that they, like all other patients, bring their 
own history and complex background. 
 
8.5 REFLECTIONS AND CONCLUSION 
Mary reported enjoying her involvement in research. Although she sometimes found 
it difficult to see the overall goal of her contribution, she was pleased that a researcher 
was interested in a patient’s experience, and felt she was doing something worthwhile 
to repay many years of healthcare she has received. 
 
It was not expensive or difficult to involve Mary in my work; she volunteered her time 
and costs were limited to refreshments and a round trip in a taxi to meet my 
supervisors. I have valued Mary’s input. I was able to see my research through the 
eyes of a potential study participant and possible future beneficiary. She has helped 
me clarify my research findings as I prepared to explain them to her. This was useful 
not only for consolidating my ideas but in planning for future public engagement. 
Perhaps most importantly, she has reminded me that research is only clinically 
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Appendix 1: Center for Epidemiologic Studies 
Depression Scale 
Radloff 1977 [300]22 
The following items refer to how you felt last week 
Scores: Rarely or none of the time (<1 day) = 0 
Some or a little of the time (1-2 days) = 1 
Occasionally (3-4 days) = 2 
Most of the time (5-7 days) = 3 
 
 
22 Adapted with wording as written in PREVENT case report form. Permission granted by 
SAGE Publications for gratis reuse in doctoral thesis, 27 July 2018. 
I was bothered by things that don’t usually bother me  
I did not feel like eating; my appetite was poor  
I felt that I could not shake off the blues even with the help of 
my family or friends 
 
I felt that I was just as good as other people Scoring inverted  
I had trouble keeping my mind on what I was doing  
I felt depressed  
I felt everything I did was an effort  
I felt hopeful about the future Scoring inverted 
I thought my life had been a failure  
I felt fearful  
My sleep was restless  
I was happy Scoring inverted 
I talked less than usual  
I felt lonely  
People were unfriendly  
I enjoyed life Scoring inverted 
I had crying spells  
I felt sad  
I felt that people disliked me  




Appendix 2: Paper published in Journal of Comorbidity  360 
Introduction
Multimorbidity (the coexistence of multiple chronic dis
eases) and polypharmacy (taking many different medica
tions) are complex areas attracting increasing research and
policy attention.1 Although often linked with older age,
multimorbidity and polypharmacy are becoming more pre
valent in midlife.2,3 Existing research shows that multimor
bidity including both physical and mental illness is
common and associations between physical and mental
health are likely to be bidirectional.2,4
The evidence regarding the interplay between multimor
bidity and depression or anxiety in midlife is limited. For
example, regarding depression, a recent systematic review
revealed that adults with multimorbidity had a three times
greater risk of depression than people with no chronic phys
ical conditions.5 However, only one of the 40 studies
included in that review investigated a midlife cohort (aged
45 64 years), with 26 studies on older people and 13 on
adults of all ages, reflecting the fact that research on multi
morbidity and polypharmacy tends to focus on older age
groups.6 With regard to anxiety, cross sectional studies have
shown that multimorbidity and anxiety coexist.7,8 There is
some evidence that increasing numbers of medication are
associated with more depressive symptoms, but this area is
less well understood.9 Furthermore, there is little research
into associations between polypharmacy and anxiety.
Midlife cohorts are increasingly studied in relation to the
early manifestations of neurodegenerative diseases that
may later lead to dementia. Identifying risk disease inter
actions may contribute to reducing incidence via risk mod
ification strategies.10 Depression and anxiety in midlife
have been identified as risk factors for dementia,11,12
although the direction of the association remains uncer
tain.13 Therefore, understanding the interplay between mul
timorbidity and polypharmacy with depression and anxiety
is crucial, given the fact that all four have been associated
with poor brain health and dementia.
PREVENT Dementia is an ongoing cohort study
designed to investigate midlife risk factors for neurodegen
erative diseases.14 It offers opportunities to explore the
associations between multimorbidity, polypharmacy,
depression and anxiety in midlife and to allow better under
standing both of this age group and of future brain health.
Objective
We aimed to investigate whether increasing numbers of
chronic conditions and medications were associated with
depression and anxiety in this cross sectional midlife cohort.
Methods
Participants
This is an observational cross sectional study of a conve
nience sample of volunteers in the first phase of PREVENT
Dementia (a dementia prevention study) in London, UK.
Volunteers were eligible to participate in PREVENT
Dementia if they were aged 40 59 years at baseline and
were fluent in English. Potential participants who reported
having cognitive impairment or dementia were excluded,
as were those with known contraindication to magnetic
resonance imaging (MRI). Recruitment took place through
a local database (DemReg),15 the UK wide Join Dementia
Research database (JDR),16 via publicity online and at pub
lic presentations. The DemReg and JDR databases are both
open to anyone aged 18 years and over who consent to be
contacted about research. Recruitment to DemReg was
facilitated via memory clinics, meaning those in the age
group of interest for this study were likely attending the
clinic as a family member of a patient. JDR is an online
database and, therefore, is available to anyone with Inter
net access. These databases were selected as the major
recruitment tools for the study as they contained contact
details of volunteers meeting inclusion criteria who were
motivated to participate in research studies. The study
team aimed to recruit half of the participants with a family
history of dementia and half without. All participants gave
written informed consent and approval for the study was
given by the NHS Research Ethics Committee, Camber
well St Giles. Participants underwent in depth physical
and cognitive testing, comprehensive medical, lifestyle
and mental health questionnaires, brain MRI and fMRI
and provided neurodegenerative disease biomarkers.17
The study protocol is published in detail elsewhere,
including justification of the predefined minimum sample
size of 150 participants.14
Depression measures
Depressive symptoms were measured using the Center for
Epidemiologic Studies Depression (CES D) scale.18 The
CES D is a validated self administered scale containing
20 questions about depressive symptoms and scored out
of 60. The questions cover mood, cognitive and somatic
symptoms of depressive disorder, and participants rate how
often they have experienced them in the past week (0 less
than 1 day, 1 1 2 days, 2 3 4 days and 3 5 7 days).
Although a cut off of "16 is generally used to identify
people with depression, the participant’s rating for each
item measures frequency of each reported symptom, so any
increase may be of clinical interest.19 In addition, even low
levels of psychological distress have been associated with
negative outcomes including mortality.20 We anticipated
that only a small proportion of this cohort of volunteers
would be classified as depressed so chose to analyse raw
scores as a pseudo continuous variable. Participants’ self
report of an active, current diagnosis of depression came
from the medical history, which was taken at interview by a
qualified doctor.
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Anxiety measures
Anxiety symptoms were measured using the Spielberger
State and Trait Anxiety Inventory (STAI) state subtest.21
It consists of 20 questions on symptoms of anxiety, scored
from one to four based on participants’ reported severity
(not at all, somewhat, moderately so and very much so)
resulting in a score between 20 and 80. A cut off of !40
for clinically significant anxiety is frequently used,
although higher cut offs have been shown to have higher
accuracy at detecting clinical anxiety disorders in older
people.22 As the STAI was originally designed as a contin
uous scale and we were interested in symptoms, we again
used the overall score as a pseudo continuous variable.
Participants’ self report of current anxiety disorder was
taken from the medical history.
Chronic conditions
The PREVENT Dementia case report medical history
includes a list of medical conditions. Participants were
asked whether they had ever had each condition and
whether it was currently active. They also had the oppor
tunity to report other conditions, which were recorded as
free text by the interviewing doctor. We reviewed all poten
tial conditions and defined them as chronic if they were
likely to be present for at least six months, have an impact
on quality of life and have a pattern of recurrence or dete
rioration. This definition was based on a combination of
definitions from the International Classification of Primary
Care, version 2 and from the NHS National Services Scot
land Information Services Division.23,24 Depending on the
nature of each condition, some were included if they had
ever been diagnosed and others only if they were active.
We excluded psychiatric disorders due to their overlap with
our outcomes. This left 55 possible chronic physical con
ditions, which are listed, with their duration definitions, in
Appendix 1. Multimorbidity is commonly defined as the
coexistence of two or more conditions and many studies
use dichotomous variables (e.g. 0 1 versus 2 conditions).
However, this approach does not capture the full distribu
tion of conditions, particularly at the higher extremes.25
We, therefore, used continuous counts of conditions as
exposure variables for analyses.
Medication history
At the research interview, study doctors collected informa
tion on current medication use according to participant
self report. This included drug name, dose, frequency and
indication. The reported medications were then coded
according to the World Health Organization’s (WHO) Ana
tomical Therapeutic Chemical (ATC) classification sys
tem.26 Over the counter vitamins or health supplements
were excluded, as were entries with insufficient informa
tion to generate an ATC code. Due to the likely effect of
antidepressant use on both depression and anxiety out
comes, we excluded antidepressants from the total count
of medications. We aimed to account for anxiolytic medi
cations but included them in the overall count. We used this
adjusted medication count as an exposure variable in
regression models.
Additional variables
Participants reported their age and gender, which we
included in all regression models as these are clinically
relevant factors influencing depression and anxiety symp
toms. Use of antidepressants was both clinically relevant
and statistically significant in preparatory analyses. Con
sidering that antidepressants are used for several indica
tions, we reviewed the free text records on medication
indication and generated a variable for antidepressant use
for any psychiatric indication. We included this variable in
a separate adjusted model and tested for interaction effects
between chronic conditions and antidepressant use. We
conducted sensitivity analyses in a sample excluding parti
cipants who took antidepressants for psychiatric indica
tions. We also created a variable for using ATC coded
anxiolytic medications.
Statistical analysis
All analyses were run in R version 3.4.3.27 We used Stu
dent’s t test to compare the mean age, chronic conditions
and medications between people with and without self
reported depression and anxiety disorder. Linear regres
sion models were used for the continuous outcome
variables (CES D and STAI scores) and logistic regres
sion for binary outcomes, namely, the presence of self
reported depression and anxiety disorder. Owing to the
disproportionate gender split, we performed additional
analyses stratified by gender.
Results
Description of the sample
The sample, from the pilot phase of PREVENT Dementia
in London, UK, consisted of 210 individuals, 148 (70.5%)
of whom were women. The mean age was 52.0 (SD 5.5)
years and median 53 years. Self reported race was Cauca
sian for 89.5% of participants with the next largest groups
being Black (n 7, 3.3%) and Indian subcontinent (n 7,
3.3%). Almost half (103, 49.0%) of the participants had a
first degree relative with dementia; 10 (4.8%) were current
smokers, 80 (38.1%) were ex smokers and 120 (57.1%) had
never smoked. The mean weekly alcohol intake was 11.5
units (SD 12.4), and the mean body mass index was 27.7
kg/m2 (SD 5.3). The principal demographic details are
listed in Table 1. The mean number of chronic physical
conditions was 2.2 (SD 1.9), with a range of 0 9. The
mean number of medications reported was 1.7 (SD 2.2)
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and range 0 12. After excluding antidepressants, the
mean number of medications was 1.5 (SD 2.0). Only
one participant (0.5%) was taking an anxiolytic medica
tion so due to low prevalence, this variable was not
included in further analyses. Appendix 1 lists all the
included conditions with their prevalence in this sample.
There were no missing data for any of the variables
included.
For participants with at least one chronic condition, the
mean number of medications per condition was 0.7 (SD
0.9). Among all participants, 119 (56.7%) had two or more
conditions and 48 (22.9%) people took three or more med
ications (39 (18.6%) excluding antidepressants). There
was a statistically significant difference between the mean
number of chronic physical conditions among people with
and without self reported depression (m1 3.6, m2 2.1;
p 0.025) but not number of medications or age (Table 2).
For people with and without self reported anxiety disor
der, there was a difference in the mean number of chronic
conditions (m1 4.2, m2 2.0; p < 0.001) but not the
number of medications or age. Figure 1 shows box plots
of these distributions.
We found that 26 (12.4%) participants were taking anti
depressants, of whom 18 (8.6%) were doing so for psychia
tric indications. Within this group, 13 (72.2%) participants
reported a diagnosis of depression and 12 (66.7%) reported
anxiety disorder. We tested for interaction effects between
chronic conditions and antidepressant use and found no
statistically significant interaction. Table 3 presents the
characteristics of participants according to their antidepres
sant status; there was a significantly higher rate of self
reported depression and anxiety disorder among those
taking antidepressants for a psychiatric indication. People
taking antidepressants also had significantly higher mean
CES D scores (m1 14.3, m2 8.7; p 0.021) and mean
chronic conditions (m1 3.7, m2 1.4; p 0.006).
Depression outcomes
On the CES D, 35 (16.7%) participants scored 16 or over,
which is the accepted cut off for depression. The mean
CES D score was 9.2 (SD 8.1). Sixteen people (7.6%)
reported a diagnosis of depression in their medical history,
and of these, seven (44.0%) scored above the 16 cut off
point on the CES D. Nine (4.3%) participants reported both
depression and an anxiety disorder.
With each additional physical condition, the CES D
score increased by 0.72 units (95% CI 0.11 1.33; p
0.020) after adjustment for age and gender. However, the
estimate dropped below conventional significance levels
when we additionally adjusted for antidepressant use
(b 0.56, 95% CI 0.06 1.18; p 0.078) and in a
Table 1. Sample characteristics in whole sample (n ! 210).
Variable n (%) Mean (SD)
Gender (female) 148 (70.5)
Race (Caucasian) 188 (89.5)
Current depression (self-report) 16 (7.6)
Current anxiety disorder (self-report) 21 (10.0)
Taking antidepressant for any indication 26 (12.4)
Taking anxiolytic medication 1 (0.5)
Age (years) 52.0 (5.5)
Education (years) 15.9 (3.4)
CES-D Total (possible range 0 60) 9.2 (8.2)
STAI Total (possible range 20 80) 30.4 (9.4)
Number of chronic physical conditions 2.2 (1.9)
Number of current medications including antidepressants 1.7 (2.2)
Number of current medications excluding antidepressants 1.5 (2.0)
SD: standard deviation; CES-D: Center for Epidemiologic Studies Depression; STAI: State-Trait Anxiety Inventory.














Mean age in years (SD) 52.0 (5.4) 51.3 (6.3) 0.642 52.0 (5.4) 51.4 (6.3) 0.656
Mean number of chronic physical
conditions (SD)
2.1 (1.8) 3.6 (2.5) 0.025 2.0 (1.6) 4.2 (2.4) <0.001
Mean number of medications taken
(excluding antidepressants) (SD)
1.4 (1.8) 2.7 (3.2) 0.140 1.4 (1.9) 2.2 (2.5) 0.174
SD: standard deviation; CES-D: Center for Epidemiologic Studies Depression; STAI: State-Trait Anxiety Inventory.
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subsample of participants who did not take antidepressants
for psychiatric indications (b 0.43, 95% CI 0.23 1.08;
p 0.199).
Similarly, although each additional medication emerged
as associated with higher CES D scores (b 0.88, 95% CI
0.32 1.44; p 0.002, adjusted for age and gender), even
when including antidepressant use as a covariate (b 0.74,
95% CI 0.18 1.31; p 0.011), testing the association in a
subsample of those not taking antidepressants rendered it
non significant (b 0.53, 95% CI 0.09 1.16; p 0.094).
The odds ratio (OR) for self reported depression with
the number of chronic physical conditions, adjusted for age
and gender, was 1.41 (95% CI 1.11 1.80; p 0.004).
Additionally adjusting for antidepressant use reduced the
OR to 1.26 (0.83 1.90; p 0.273). The OR adjusted for
age and gender per unit increase in number of medications
Figure 1. Box plots of age, chronic conditions and medication for self-reported outcomes in whole sample (n ! 210).









Variable n (%) Mean (SD) n (%) Mean (SD)
p for difference
(Student’s t-test or !2 test)
Gender (female) 132 (68.8) 16 (88.9) 0.128
Race (Caucasian) 172 (89.6) 16 (88.9) 1
Current depression (self-report) 3 (1.6) 13 (72.2) <0.001
Current anxiety disorder (self-report) 9 (4.7) 12 (66.7) <0.001
Age (years) 51.9 (5.5) 52.1 (5.8) 0.907
Education (years) 15.9 (3.3) 16.5 (4.6) 0.575
CES-D Total (possible range 0 60) 8.7 (7.9) 14.3 (9.1) 0.021
STAI Total (possible range 20 80) 30.0 (9.4) 34.0 (9.1) 0.090
Number of chronic physical conditions 2.0 (1.8) 3.7 (2.2) 0.006
Number of current medications excluding antidepressants 1.4 (1.8) 2.9 (3.) 0.052
SD: standard deviation; CES-D: Center for Epidemiologic Studies Depression; STAI: State-Trait Anxiety Inventory.
Bold figure indicates p < 0.05.
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for self reported depression was 1.35 (1.08 1.71; p
0.008). This OR reduced to 1.13 (0.79 1.70; p 0.545)
when additionally adjusting for antidepressant use with
psychiatric indication.
Both increasing number of medications and increasing
chronic conditions were associated with increasing CES D
score and self reported depression. These associations were
attenuated when accounting for antidepressant use for psy
chiatric indications and became no longer statistically sig
nificant at conventional levels. All regression analysis
results are summarized in Table 4.
Anxiety outcomes
The mean score on the STAI was 30.4 (SD 9.4). Twenty
one participants (10%) reported a diagnosis of anxiety dis
order in their medical history; of these, 7 (33.3%) scored
above the cut off of 40 on the STAI and 18 had"2 physical
conditions.
There were no significant associations between an
increasing number of chronic conditions and the STAI state
score in a model adjusted for age and gender (b 0.14,
95% CI 0.57 0.85; p 0.704). This remained non
significant when additionally adjusting for antidepressant
use (b 0.01, 95% CI 0.72 0.73; p 0.986). The regres
sion coefficient for the effect of each additional medication
on the STAI score was b 0.27 (95% CI 0.39 0.92;
p 0.425) and this remained non significant when adding
antidepressant use as a covariate (b 0.16, 95% CI 0.51
0.83; p 0.637). In the subsample of participants who did
not take antidepressants for a psychiatric indication, the
associations between both chronic conditions and medica
tion with STAI did not meet conventional significance lev
els (presented as model 3 in Table 4).
The OR (95% CI) adjusted for age and gender for self
reported anxiety disorder with number of chronic condi
tions was 1.70 (1.35 2.19; p < 0.001). Additionally
adjusting for antidepressant use increased the OR to 1.73
(1.30 2.37; p < 0.001). The OR (95% CI) adjusted for age
and gender per unit increase in number of medications for self
reported anxiety disorder was 1.23 (0.99 1.51; p 0.045).
This OR remained non significant at 1.04 (0.78 1.36;
p 0.800) when additionally adjusting for antidepressant use.
Analyses stratified by gender
The results of regression analyses stratified by gender are
presented in Appendix 2. Table 2A shows that in women,
there were associations between chronic physical condi
tions and medications with CES D scores and self
reported depression. There were also associations between
conditions, but not medications, and self reported anxiety
disorder. Additionally adjusting for antidepressant use ren
dered the associations non significant, apart from the
model including chronic conditions and self reported anxi
ety disorder. By contrast, in men, the only significant asso
ciation was between increasing medication use and
increasing CES D scores. Depression was reported by one
Table 4. Summary of regression analysis results.
Exposure
Outcome Model
Chronic physical conditions Medications excluding antidepressants
Coefficient
(95% CI) ORa (95% CI) p Value
Coefficient




CES-D Model 1 0.72 (0.11, 1.33) 0.020 0.88 (0.32, 1.44) 0.002
Model 2 0.56 ( 0.06, 1.18) 0.078 0.74 (0.18, 1.31) 0.011
Model 3b 0.43 ( 0.23, 1.08) 0.199 0.53 ( 0.09, 1.16) 0.094
Self-reported depression Model 1 1.41 (1.11, 1.80) 0.004 1.35 (1.08, 1.71) 0.008
Model 2 1.26 (0.83, 1.90) 0.273 1.13 (0.79, 1.70) 0.545
Model 3b NA NA
Anxiety
STAI Model 1 0.14 ( 0.57, 0.85) 0.704 0.27 ( 0.39, 0.92) 0.425
Model 2 0.01 ( 0.72, 0.73) 0.986 0.16 ( 0.51, 0.83) 0.637
Model 3b 0.06 ( 0.71, 0.84) 0.871 0.20 ( 0.54, 0.95) 0.588
Self-reported anxiety
disorder
Model 1 1.70 (1.35, 2.19) <0.001 1.23 (0.99, 1.51) 0.045
Model 2 1.73 (1.30, 2.37) <0.001 1.04 (0.78, 1.36) 0.800
Model 3b NA NA
OR: odds ratio; CI: confidence interval; CES-D: Center for Epidemiologic Studies Depression; STAI: State-Trait Anxiety Inventory.
aOR per unit increase in number of chronic conditions or medications.
bN.B. smaller sample size, as below: model 1: whole sample (n 210), adjusted for age and gender; model 2: whole sample (n 210), adjusted for age,
gender and use of antidepressants for psychiatric indication; model 3: sample excluding participants taking antidepressants for psychiatric indication (n
192), adjusted for age and gender (not calculated for self-reported diagnoses of depression and anxiety disorder due to high proportion of people with
diagnoses taking medication).
Bold figure indicates p < 0.05.
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(1.6%) male participant and anxiety disorder by two
(3.2%) male participants, so we did not conduct analyses
with self reported depression or anxiety disorder as out
comes in men.
Figures 2 and 3 show the OR and 95% CI for self
reported depression and anxiety per unit increase in chronic
conditions and medications, respectively.
In summary, no clear association between increasing
medication use and anxiety measures emerged. Chronic
conditions were associated with self reported anxiety dis
order but not increasing STAI scores.
Discussion
Key results
We found associations between increasing chronic condi
tions and self reported depression, increasing CES D
scores and self reported anxiety disorder, but not STAI
score. There were associations between increasing numbers
of medication with both self reported depression and
increasing CES D scores. There was no association
between increasing medication count and anxiety, either
self reported or according to the STAI. The findings no
longer met conventional significance levels when adjusting
for antidepressant use, suggesting that a preexisting diag
nosis with partial treatment may explain the observed
associations.
Comparison to existing literature
Participants in the initial wave of the PREVENT Dementia
study had a mean of 2.2 chronic physical conditions.
Recent publications in similar age groups found figures
of 0.8 chronic conditions in an English primary care cohort
and 1.2 chronic conditions in Scottish data.2,28 The appar
ently above average prevalence of multimorbidity in PRE
VENT Dementia participants may reflect the self report
method of gathering medical history.
The majority of PREVENT Dementia participants were
taking at least one medication and among those, the mean
number of medications taken was 2.6 (SD 2.2). In contrast,
a population level analysis in one region of Scotland found
that among adults (mean age 50.1 years) prescribed any
medication, the mean was 4.4 prescribed medications.29
The PREVENT Dementia cohort reported more than would
be expected in terms of medical conditions but were receiv
ing less than would be expected in terms of medication.
This could imply a population that is very observant of their
own health but reporting conditions not severe enough to
require treatment. This discrepancy is, therefore, likely due
to the use of volunteers in PREVENT Dementia.
It is difficult to compare multimorbidity studies when
there is disparity between the number of possible condi
tions listed in each of them. Previous studies reviewing
prevalence estimates of multimorbidity using disease
counts have recommended using a list of at least 12
Figure 2. OR (95% CI) of self-reported outcomes with each additional chronic physical condition: whole sample (n ! 210). OR: odds
ratio; CI: confidence interval.
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conditions30 and between 25 and 75 conditions.31 Our list
of 55 conditions is likely to have been more sensitive than
those in previous similar studies, with the consequent risk
of over estimation of multimorbidity.
We found an association between increasing number of
medications (excluding antidepressants) and scores on the
CES D and self reported depression. The only similar
study using this measure was published in 1989 and found
a similar association but did not account for antidepressant
use.9 There has also been an increase in the prevalence of
polypharmacy since then.3 There is little in the literature
about medication use and specific anxiety outcomes, so our
analyses are novel in this area.
A systematic review and meta analysis of 40 articles
found an OR of 1.45 (95% CI 1.28 1.64; p < 0.001) for
depression with each additional condition, which our
analyses of self reported depression support. All of the
articles reviewed used either a depression rating scale or
clinical diagnosis; none considered both.5 A very large
cross sectional study of primary care patients with
depression and controls found that people with depres
sion were more likely to have multimorbidity and that
this association was stronger in people with socioeco
nomic deprivation.32 This was a representative sample
from primary care, but used routinely collected diagnos
tic information from health records and symptom mea
sures were not available. Our research builds on this
evidence by assessing both self reported diagnoses and
symptom scales as outcomes.
There have been two cross sectional studies specifically
exploring the link between multimorbidity and anxiety,
both of which found statistically significant associations.
One was a large international study of adults aged over 18
years, which measured multimorbidity from a list of nine
conditions and anxiety with a single question answered on a
5 point scale.7 The other measured anxiety according to the
Beck Anxiety Inventory and multimorbidity from a list of
seven conditions, in participants aged over 65 years.8
Again, there is strength in our research using both self
reported diagnosis and symptom scales; we found a similar
association between increasing chronic conditions and
anxiety disorder but not symptoms as reported on STAI.
This difference between reported diagnosis and objective
measurement may reflect the fact that those who report a
diagnosis are likely to be receiving treatment and, there
fore, report fewer active symptoms.
Strengths and limitations of this study
The complementary outcomes we examined include not
only validated rating scales but also participant reported
clinical diagnoses. This selection of measures, therefore,
adds breadth compared to previous research in this area.
Furthermore, there is limited published work on multimor
bidity and polypharmacy in midlife, so this work fills an
important gap.
The data available were collected in the baseline pilot
phase of PREVENT Dementia, only permitting exploratory
Figure 3. OR (95% CI) of self-reported outcomes with each additional medication: whole sample (n ! 210). OR: odds ratio; CI:
confidence interval.
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cross sectional analyses of 210 participants. The cohort
was designed as a longitudinal study and follow up data
collections are ongoing. Cross sectional analysis leaves
questions about direction of causality unclear. It is known,
for example, that all mental disorders are associated with
later physical health consequences, so the findings from
this study may reflect reverse causality in that people who
were originally depressed experienced physical health
deterioration.33 The recruitment of volunteers who are
likely to have an interest in dementia research limits the
generalizability of our results. The sample is 89.5% Cau
casian which is close to the UK proportion of 87.2% but
less diverse than the population of London where 59.8% of
people are white.34
Although the STAI and CES D feature some questions
on somatic symptoms of anxiety and depression, the major
ity are cognitive symptoms so this is unlikely to capture
physical symptoms of physical conditions. However, peo
ple with anxiety and depression, particularly older people,
can report physical symptoms as the primary com
plaint.35,36 This may lead to seeking medical attention and,
therefore, receiving more diagnoses of physical conditions.
The self report nature of the PREVENT Dementia medical
history and the overlap between the clinical presentations
of depression and anxiety disorder meant that a number of
participants reported both conditions. The questions in the
screening tests mean that CES D includes symptoms of
generalized anxiety disorder and STAI, symptoms of
depression.22,37 In addition, there is an overlap between
multimorbidity and polypharmacy and we did not adjust
for either when assessing each exposure.38
With such a sample size, groups within the data set can
be small, for example, only 26 participants reported current
use of antidepressant medication. There are also more
women (148, 70.5%) than men in the sample, so when
groups are subdivided by gender, they can become very
small for example, only seven men took antidepressants.
It is important to recognize the role of chance in analyses
on these numbers, and effect size could be over estimated.
In addition, we adjusted for covariates that were clinically
relevant and statistically significant in preparatory analyses
but there may be residual confounding from unmeasured
factors. These exploratory analyses will inform future
research in a larger sample from this cohort.
The nature of the PREVENT Dementia initial visit is
that all the medical history and medications are self
reported. This can lead to several types of bias including
recall bias and social desirability bias.39 Self reported
depression may be more sensitive than CES D for identi
fying people with a clinical diagnosis who have received
treatment and, therefore, perform better on testing than
they might have done untreated. However, participants
may also report depression that has not been clinically
diagnosed, more so perhaps than a physical condition.
Previous studies comparing self report with diagnostic
or screening tests for depression have remarked upon this
complex relationship.40 Self reported antidepressant use
in cohort studies, however, has been found to correlate
strongly with prescription records.41
In all but one analysis, an apparent association between
exposure and outcomes ceased when including antidepres
sant use as a covariate. This implies that taking antidepres
sants, perhaps as a marker for mental disorders (fully or
partially treated), is an important explanation in the path
way between chronic conditions, medication use and anxi
ety and depression. The overlap between physical and
mental illness is complex and difficult to capture but we
attempted to understand it by approaching it from several
different angles. This is a strength over previous research,
which has not attempted to account for the treatment of
depression or anxiety.5,7 9 In addition, antidepressant use
suggests a preexisting diagnosis of mental illness, but
detailed temporality of mental and physical diagnoses can
not be ascertained in cross sectional data. Future waves of
the PREVENT Dementia study will allow longitudinal
exploration of this issue.
Implications
The presence of associations between increasing chronic
conditions, medications and depression supports the
important interaction of physical health and resulting
medication burden with mental health, even in midlife.
The modest nature of these results in a small sample size
limits the certainty with which conclusions can be drawn
but reinforces the need to corroborate them in larger data
sets. A particular strength of completing this work in a
pilot wave of an ongoing longitudinal study is the oppor
tunity to revisit the analyses when data from future waves
are available. In these cross sectional analyses, we were
unable to evaluate the implications for participants’ future
development of dementia, but follow up may allow this.
The focus on midlife individuals may also inform strate
gies to improve health in later life. For example, if midlife
physical health can be optimized, this may reduce later
anxiety and depression.
Conclusions
In this cross sectional study of a middle aged cohort of
volunteers, we found associations between increasing
chronic conditions and self reported depression, depressive
symptoms and self reported anxiety disorder but not anxi
ety symptoms. In addition, there were associations between
increasing number of medications and depression (both
self reported and according to a screening scale) but not
anxiety. The use of antidepressants, as a marker for preex
isting mental illness, attenuated the associations found.
This work adds to understanding of physical and mental
health multimorbidity.
Stirland et al. 9
 
Appendix 2: Paper published in Journal of Comorbidity  368 
Acknowledgements
We thank the PREVENT Dementia study participants. This
study has been undertaken with assistance from the Join Demen-
tia Research service, run in partnership between the National
Institute for Health Research, Alzheimer Scotland, Alzheimer’s
Research UK and the Alzheimer’s Society, and the authors
would like to thank the service’s volunteers for making this
research possible.
Data availability
The data sets analysed during this study are available from PRE-
VENT Dementia and can be accessed by application via the fol-
lowing URL: https://preventdementia.co.uk/for-researchers/
Declaration of conflicting interests
The author(s) declared no potential conflicts of interest with respect
to the research, authorship, and/or publication of this article.
Funding
The author(s) disclosed receipt of the following financial support
for the research, authorship, and/or publication of this article: The
PREVENT Dementia study is supported by the Alzheimer’s Soci-
ety [Grant Numbers 178 and 264]; Alzheimer’s Association [Grant
Number TriBEKa-17-519007] and philanthropic donations. Lucy
Stirland is funded by the Medical Research Foundation and Med-
ical Research Council through the PsySTAR, Psychiatry: Scottish
Training in Academic Research programme [Grant Number MR/
J000914/1]. Tom Russ is a member of the Alzheimer Scotland
Dementia Research Centre supported by Alzheimer Scotland.
ORCID iD
Lucy E Stirland https://orcid.org/0000-0002-5678-4583
Supplemental material
Supplemental material for this article is available online.
References
1. The Academy of Medical Sciences. Multimorbidity: a prior-
ity for global health research, https://acmedsci.ac.uk/file-
download/39787360 (2018, accessed 11 April 2020).
2. Barnett K, Mercer SW, Norbury M, et al. Epidemiology of
multimorbidity and implications for health care, research, and
medical education: a cross-sectional study. Lancet 2012; 380:
37 43.
3. Guthrie B, Makubate B, Hernandez-Santiago V, et al. The
rising tide of polypharmacy and drug-drug interactions: pop-
ulation database analysis 1995-2010. BMC Med 2015; 13: 74.
4. Prince M, Patel V, Saxena S, et al. No health without mental
health. Lancet 2007; 370: 859 877.
5. Read JR, Sharpe L, Modini M, et al. Multimorbidity and
depression: a systematic review and meta-analysis. J Affect
Disord 2017; 221: 36 46.
6. Wong CKM, Liang J, Chan ML, et al. Prevalence and psy-
chosocial correlates of depressive symptoms in urban Chi-
nese women during midlife. PLoS One 2014; 9: e110877.
7. Vancampfort D, Koyanagi A, Hallgren M, et al. The relation-
ship between chronic physical conditions, multimorbidity and
anxiety in the general population: a global perspective across
42 countries. Gen Hosp Psychiatry 2017; 45: 1 6.
8. Gould CE, O’Hara R, Goldstein MK, et al. Multimorbidity is
associated with anxiety in older adults in the Health and
Retirement Study. Int J Geriatr Psychiatry 2016; 31:
1105 1115.
9. Magaziner J, Cadigan D, Fedder DO, et al. Medication use
and functional decline among community-dwelling older
women. J Aging Health 1989; 1: 470 484.
10. Livingston G, Sommerlad A, Orgeta V, et al. Dementia pre-
vention, intervention, and care. Lancet 2017; 390(10113):
2673 2734.
11. Gimson A, Schlosser M, Huntley JD, et al. Support for mid-
life anxiety diagnosis as an independent risk factor for
dementia: a systematic review. BMJ Open 2018; 8: 19399.
12. Barnes DE, Yaffe K, Byers AL, et al. Midlife vs late-life
depressive symptoms and risk of dementia. Arch Gen Psy-
chiatry 2012; 69: 493.
13. Bennett S and Thomas AJ. Depression and dementia: Cause,
consequence or coincidence? Maturitas 2014; 79: 184 190.
14. Ritchie CW and Ritchie K. The PREVENT study: a prospec-
tive cohort study to identify mid-life biomarkers of late-onset
Alzheimer’s disease. BMJ Open 2012; 2: e001893.
15. Iliffe S, Curry L, Kharicha K, et al. Developing a dementia
research registry: a descriptive case study from North Thames
DeNDRoN and the EVIDEM programme. BMC Med Res
Methodol 2011; 11: 9.
16. NHS National Institute for Health Research. Join Dementia
Research, https://www.joindementiaresearch.nihr.ac.uk/
(2018, accessed 11 April 2020).
17. Ritchie CW, Wells K and Ritchie K. The PREVENT research
programme a novel research programme to identify and
manage midlife risk for dementia: the conceptual framework.
Int Rev Psychiatry 2013; 25: 748 754.
18. Radloff LS. The CES-D scale: a self-report depression scale
for research in the general population. Appl Psychol Meas
1977; 1: 385 401.
19. Siddaway AP, Wood AM and Taylor PJ. The Center for
Epidemiologic Studies-Depression (CES-D) scale measures
a continuum from well-being to depression: testing two key
predictions of positive clinical psychology. J Affect Disord
2017; 213: 180 186.
20. Russ TC, Stamatakis E, Hamer M, et al. Association between
psychological distress and mortality: individual participant
pooled analysis of 10 prospective cohort studies. BMJ
2012; 345: e4933.
21. Spielberger C, Gorsuch R, Lushene R, et al. Manual for the
State-Trait Anxiety Inventory (STAI). Palo Alto, CA: Consult-
ing Psychologists Press, 1983.
22. Kvaal K, Ulstein I, Nordhus IH, et al. The Spielberger State-
Trait Anxiety Inventory (STAI): the state scale in detecting
mental disorders in geriatric patients. Int J Geriatr Psychiatry
2005; 20: 629 634.
23. O’Halloran J, Miller GC and Britt H. Defining chronic con-
ditions for primary care with ICPC-2. Fam Pract 2004; 21:
381 386.
10 Journal of Comorbidity
 
Appendix 2: Paper published in Journal of Comorbidity  369 
24. NHS National Services Scotland Information Services Divi-
sion. Measuring long-term conditions in Scotland, https://
www.isdscotland.org/Health-Topics/Hospital-Care/Diag
noses/2008 08 14 LTC full report.pdf (2008, accessed 11
April 2020).
25. Wister AV, Levasseur M, Griffith LE, et al. Estimating mul-
tiple morbidity disease burden among older persons: a con-
vergent construct validity study to discriminate among six
chronic illness measures, CCHS 2008/09. BMC Geriatr
2015; 15: 12.
26. WHO Collaborating Centre for Drug Statistics Methodology.
WHO Anatomical Therapeutic Chemical (ATC) classifica-
tion system, https://www.whocc.no/ (2018, accessed 4 May
2018).
27. R Core Team. R: a language and environment for statistical
computing. R Foundation for Statistical Computing, Vienna,
Austria, 2017, https://www.R-project.org/.
28. Cassell A, Edwards D, Harshfield A, et al. The epidemiology
of multimorbidity in primary care: a retrospective cohort
study. Br J Gen Pract 2018; 68: e245 e251.
29. Guthrie B, Makubate B, Hernandez-Santiago V, et al. The
rising tide of polypharmacy and potentially serious drug
interactions 1995 2010: repeated cross sectional analysis of
dispensed prescribing in one region. Prim Heal Care Res
Devel 2012; 13: S1:Supp 45.
30. Fortin M, Stewart M, Poitras M-E, et al. A systematic review
of prevalence studies on multimorbidity: toward a more uni-
form methodology. Ann Fam Med 2012; 10: 142 151.
31. Holzer BM, Siebenhuener K, Bopp M, et al. Evidence-based
design recommendations for prevalence studies on multimor-
bidity: improving comparability of estimates. Popul Health
Metr 2017; 15: 9.
32. Smith DJ, McLean G, Martin D, et al. Depression and multi-
morbidity: a cross-sectional study of 1,751,841 patients in
primary care. J Clin Psychiatry 2014; 75: 1202 1208.
33. Scott KM, Lim C, Al-Hamzawi A, et al. Association of men-
tal disorders with subsequent chronic physical conditions.
JAMA Psychiatry 2016; 73: 150.
34. Office for National Statistics. 2011 Census: key statistics and





accessed 20 November 2018).
35. Wetherell JL, Ayers CR, Nuevo R, et al. Medical conditions
and depressive, anxiety, and somatic symptoms in older
adults with and without generalized anxiety disorder. Aging
Ment Health 2010; 14: 764 768.
36. Hegeman JM, Kok RM, van der Mast RC, et al. Phenomen-
ology of depression in older compared with younger adults:
meta-analysis. Br J Psychiatry 2012; 200: 275 281.
37. Naughton MJ and Wiklund I. A critical review of dimension-
specific measures of health-related quality of life in cross-
cultural research. Qual Life Res 1993; 2: 397 432.
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Appendix 1
Table 1A. List of included chronic physical conditions with prevalence in PREVENT Dementia baseline phase.
Condition Definition Prevalence, n (%)
Eye disease Currently active 113 (53.8)
Asthma Currently active 28 (13.3)
Migraine Currently active 27 (12.9)
Sleep disorder Currently active 25 (11.9)
Gastro-oesophageal reflux disease Currently active 23 (11.0)
Hypertension Currently active 22 (10.5)
Irritable bowel syndrome Currently active 17 (8.1)
Other musculoskeletal condition (each free text entry checked for relevance) Currently active or ever
recorded
17 (8.1)
Cardiac arrhythmia Currently active 14 (6.7)
Cancer Ever diagnosed 14 (6.7)
Osteoarthritis Currently active 26 (12.4)
(continued)
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Table 1A. (continued)
Condition Definition Prevalence, n (%)
Degenerative disc disease Currently active 13 (6.2)
Anaemia Currently active 12 (5.7)
Chronic constipation Currently active 12 (5.7)
Hypothyroidism Currently active 11 (5.2)
Diabetes Currently active 7 (3.3)
Peripheral vascular disease venous Currently active 6 (2.9)
Other gastrointestinal disorder (each free text entry checked for relevance) Currently active or ever
recorded
5 (2.4)
Inflammatory bowel disease Ever recorded 4 (1.9)
Other genitourinary/reproductive disorder (each free text entry checked for
relevance)
Currently active or ever
recorded
4 (1.9)
Other haematological disorder (each free text entry checked for relevance) Currently active or ever
recorded
3 (1.4)
Cholelithiasis Currently active 3 (1.4)
Diverticulitis Currently active 3 (1.4)
Peripheral nerve disorder Currently active 3 (1.4)
Angina Currently active 2 (1.0)
Other cardiovascular disease (each free text entry checked for relevance) Currently active or ever
recorded
2 (1.0)
Peptic ulcer disease Currently active 2 (1.0)
Liver disease (excluding hepatitis) Currently active 2 (1.0)
Other eye disease (each free text entry checked for relevance) Currently active or ever
recorded
2 (1.0)
Gout Currently active 2 (1.0)
Stroke Ever diagnosed 2 (1.0)
Other neurological disorder (each free text entry checked for relevance) Currently active or ever
recorded
2 (1.0)
Valvular heart disease Currently active 1 (0.5)
Coronary artery disease Ever diagnosed 1 (0.5)
Gastrointestinal bleed Currently active 1 (0.5)
Benign prostatic hyperplasia Currently active 1 (0.5)
Nephrolithiasis Currently active 1 (0.5)
Hyperthyroidism Currently active 1 (0.5)
Other metabolic (each free text entry checked for relevance) Currently active or ever
recorded
1 (0.5)
Immune deficiency Currently active 1 (0.5)
Other immunological condition (each free text entry checked for relevance) Currently active or ever
recorded
1 (0.5)
Aortic aneurysm Ever diagnosed 0
Cholecystitis Currently active 0
Chronic obstructive pulmonary disease Ever diagnosed 0
Collagen vascular disease Currently active 0
Congenital heart disease Currently active 0
Congestive heart failure Ever diagnosed 0
Hepatitis Currently active 0
Kidney disorder Currently active 0
Pacemaker Ever reported 0
Pancreatitis Currently active 0
Parkinson’s disease Ever diagnosed 0
Peripheral vascular disease arterial Currently active 0
Seizure/convulsion disorder Currently active 0
Tuberculosis Currently active 0
12 Journal of Comorbidity
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Appendix 2
Results of supplementary analyses stratified by gender
Table 2B. Men only.a
Exposure
Outcome Model
Chronic physical conditions Medications excluding antidepressants
Coefficient (95% CI) p Value Coefficient (95% CI) p Value
Depression
CES-D Model 1 0.37 ( 1.01, 1.75) 0.592 1.10 0.22, 1.97) 0.015
Model 2 0.36 ( 1.09, 1.80) 0.622 1.10 (0.21, 2.00) 0.016
Anxiety
STAI Model 1 0.59 2.03, 0.84) 0.412 0.55 ( 0.41, 1.50) 0.256
Model 2 0.52 ( 2.02, 0.99) 0.492 0.60 ( 0.37, 1.57) 0.221
CI: confidence interval; CES-D: Centre for Epidemiologic Studies Depression; STAI: State-Trait Anxiety Inventory; model 1: men only (n 62), adjusted
for age; model 2: men only (n 62), adjusted for age and use of antidepressants for psychiatric indication.
aSelf-reported depression and anxiety disorder not included owing to small number of male participants reporting these diagnoses.
Table 2A. Women only.
Exposure
Outcome Model
Chronic physical conditions Medications excluding antidepressants
Coefficient
(95% CI) ORa (95% CI) p Value
Coefficient




CES-D Model 1 0.81 (0.12, 1.51) 0.021 0.74 (0.01, 1.48) 0.048
Model 2 0.62 ( 0.09, 1.32) 0.085 0.50 ( 0.25, 1.25) 0.190
Self-reported
depression
Model 1 1.43 (1.12, 1.84) 0.005 1.44 (1.12, 1.90) 0.005
Model 2 1.33 (0.88, 2.05) 0.177 1.25 (0.84, 2.06) 0.329
Anxiety
STAI Model 1 0.33 ( 0.50, 1.16) 0.436 0.10 ( 0.79, 0.98) 0.828
Model 2 0.16 ( 0.69, 1.02) 0.707 0.12 ( 1.03, 0.79) 0.795
Self-reported anxiety
disorder
Model 1 1.71 (1.34, 2.25) <0.001 1.25 (0.98, 1.58) 0.061
Model 2 1.72 (1.29, 2.40) <0.001 1.05 (0.79, 1.42) 0.732
OR: odds ratio; CI: confidence interval; CES-D: Center for Epidemiologic Studies Depression; STAI: State-Trait Anxiety Inventory.
aOR per unit increase in number of chronic conditions or medications: model 1: women only (n 148), adjusted for age; model 2: women only (n 148),
adjusted for age and use of antidepressants for psychiatric indication.
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 ☐  Patient Care ☒  Research 
 ☐  Audit ☐  Performance 
Monitoring/Management 
 ☐  Service 
Planning/Improvement 
☐  Health/Social Care Administration 
 ☐  Systems 
Implementation/Testing 
☐  Training/Education 
 ☐  Quality (Clinical, Educational, 
etc) 
 
 If other clearly defined purpose, please give details: 
 
3.1.05 Does the proposal require the use of 
information which can identify or 
potentially identify individuals?  
For linkage only – researchers 
will not have access to this. 
 
3.1.06 Access is being requested to data from which sources? (tick as many as 
are relevant) 
 ☐    A single NHS Scotland Board (excluding NSS)  
☒    NHS National Services Scotland  
☐    More than one NHS Scotland Board 
☐    A national NHS Scotland system/database 
☐    More than one NHS Scotland system/database 
☒    Community Health Index (CHI) database 
☐   NHS Central Registry 
 
 If other, please give details: 
3.1.07 Provide a full, clear concise outline of the proposal background – describe 
why it is needed, aims and objectives and envisaged benefits to the public 
and/or patients: 
 
It is common for people to have more than one health problem at a time, 
particularly as they get older.  Recent research in Scotland has shown that 
people with multiple physical conditions are more likely to have mental 
health problems.  In addition, older people are more likely to be prescribed 
multiple medications (known as polypharmacy).  I aim to find out if there are 
links between polypharmacy and mental ill health in older age.   
 
Information about prescriptions in Scotland is routinely recorded.  Every 
person registered with a GP in Scotland has a unique number, the 
Community Health Index (CHI) which appears on all their prescriptions and 
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contacts with health services.  I will request anonymised prescription data 
for all Scottish residents who were aged over 50 in 2009, namely the 
number and types of medication they were given.  Using the CHI, this 
information can be matched to any subsequent mental health diagnoses 
recorded in psychiatric or general hospital contacts and on death 
certificates.  I will look at the commonest and most important mental health 
problems that can arise in older people, including depression, dementia and 
delirium (a temporary state of confusion that can occur at times of physical 
illness).   
 
I will group people by the number of medications they receive (for example, 
no medication, less than three medications, four or more medications) and 
compare the subsequent mental health diagnoses of these groups.  I will 
ensure that I match the groups for other relevant factors such as age and 
socioeconomic status.  I expect to be able to calculate the risk of developing 
certain mental health problems in relation to the number of medications 
people take.  I will also examine whether the breakdown of these 
medications into different types of drugs affects the association between 
numerous prescriptions and mental health.  I will also look at particular 
combinations of certain individual medications (for example, the inclusion 
of antihistamines or sedatives such as diazepam) to see if these are linked 
to mental health problems.   
 
Using people’s anonymised routinely collected data offers a unique 
opportunity to examine an important question at a population level and 
produce findings that will be relevant for these same people’s future 
healthcare.  My research will deepen our understanding of links between 
physical and mental health, for example, helping to answer questions about 
who is most likely to develop mental health problems.  If I find a link between 
polypharmacy and mental illness, this may be useful for doctors to identify 
people at higher risk of developing mental health problems early.  It may 
also influence prescribing decisions for people who are already taking 
multiple medications, for example encouraging doctors to prescribe the 
minimum number of medications necessary. 
 
I will publish my findings in academic journals and will present at 
conferences.  I will give public talks where the opportunity arises and will be 
active on social media.  My aim is to share my results with a wide audience 
so that clinicians can apply my findings when caring for their patients and 
ultimately the public will benefit from my use of these data. 
3.1.08 Provide a full, clear and concise outline of the proposal design, listing: 
data sources; sample size; inclusion/exclusion criteria (eg involvement in 
trial/survey; health event, etc); relevant date range; need for identifiable or 
potentially identifiable data; requirement for a matched control cohort etc. 
 
My proposed project will examine the links between the number of 
prescriptions a person receives and their subsequent mental health 
diagnoses.  My principal data sources for this project are held by the 
Information Services Division of NHS National Services Scotland (ISD).  
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They will be: prescription details from the Prescribing Information System 
(PIS), outpatient hospital data (SMR00), general inpatient hospital data 
(SMR01), mental health inpatient hospital data (SMR04), and National 
Records of Scotland (NRS) death certificate data.  From 2009 onwards, the 
PIS is linked to the other databases using the Community Health Index 
(CHI) number.  Therefore my date range will be from the date in 2009 when 
linkage was first available to the most recent data available at the time of 
extraction.  I will also request information from the CHI database, including 
postcodes to allow the eDRIS analyst to determine Scottish Index of 
Multiple Deprivation (SIMD) deciles (researchers will not receive the full 
postcode) and a flag for care home residency. 
 
I will include all people living in Scotland who were aged 50 or over on the 
date that PIS linkage first began in 2009.  From National Records of 
Scotland population estimates for 2009 I calculate this to include 
approximately 1.87 million people.  The age cut-off of 50 will allow me to 
focus my research on the older and ageing population in whom I am most 
interested due to their increased likelihood of having multiple physical 
conditions, subsequent polypharmacy, and concurrent mental health 
disorders.   
 
I will request prescribing information on all people in my age range in 
Scotland, regardless of the number of medications they receive.  I will then 
group people by the number of medications they receive (including those 
on no medication) and compare the mental health outcomes of these 
groups.  In addition to overall numbers of prescriptions, I will request a 
breakdown of these prescriptions by British National Formulary (BNF) 
chapter to examine whether different classes of medication carry different 
associations.  I will also request information on individual medications in 
order to further analyse these links.  Most research into polypharmacy 
focuses on counts of medication alone, so including classes of drug and 
specific medications in such a large cohort will produce novel and 
enlightening results. 
 
Due to the large size of my proposed sample, I will request quarterly 
extracts from 2009 onwards, which will allow me to follow people’s 
medication history, including seasonal trends, across a period long enough 
that means my outcomes of interest are likely to occur. 
 
Please see the appended data flow diagram for the steps which will require 
linkage and anonymization.  I will not require access to any identifiable 
patient data; these data will already have been anonymised by the eDRIS 
analyst by the time I receive them.  I will not share the data I receive with 
any other researchers except for the data custodian named above.  When 
I have generated findings from my research I will publish these in scientific 
journals but due to the large population-level numbers involved, and the fact 
I will have been dealing with anonymised data, I consider the risk of 
inadvertent identification to be negligible. 
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3.1.09 Does the proposal have implications for, or target, sensitive groups or 
vulnerable populations? Please give details 
 Mental health is an integral part of my research question and as such I will 
be requesting data regarding psychiatric hospital admissions, mental health 
diagnoses in other hospital records and on death certificates.   My aim is to 
produce research that will eventually lead to better healthcare for people 
with complex health problems, particularly those with mental ill health.  
 
I would also need access to ethnicity information in order to properly 
account for the impact of this on outcomes. I will ask for information on 
broad categories of ethnic group only (for example, white, white European 
and non-white).  In addition, because I am requesting data for a very large 
number of people, it is very unlikely that a particular ethnicity category will 
make an individual identifiable.  I will also take other steps to minimise the 
risk of inadvertent identification, for example, requesting Scottish Index of 
Multiple Deprivation (SIMD) deciles derived by eDRIS analysts instead of 
personally accessing postcodes.  
3.1.10 Does the proposal seek to use information exclusively about deceased 
persons? Please give details 
 No  
3.1.11 Have any members of the public/lay representatives been involved in the 
proposal design? Please give details 
 A summary of the proposal was reviewed by the Farr Institute Scotland’s 
Public Panel and written feedback received on 3rd February 2017.  
Comments included:  
“The study design’s good – the researcher has avoided trying to prove too 
many aspects relating to the hypothesis”;  
“This type of study is long overdue”;  
“From life-experience with 'the elderly', 'Polypharmacy' does require proper 
study for, all too often, it is chance encounter with a third party that 
discovers 'innocent errors'.” 
3.1.12 Has any peer review of the proposal been undertaken? Please give 
details (for example formal review by a peer organisation or funding body, 
informal internal review, review by a third party) 
 This project formed part of my proposal to study for a PhD in the PsySTAR 
(Psychiatry: Scottish Training in Academic Research) programme, funded 
by the Medical Research Foundation and MRC.  I had to defend my 
proposal at an interview with Professors of Psychiatry who make up the 
PsySTAR board, and have made approved amendments following this.  
 
In addition, my three PhD supervisors Dr Graciela Muniz Terrera, Prof Craig 
Ritchie and Dr Tom Russ have ongoing contributions to my project and 
have reviewed this application. 
3.1.13 Is there any commercial aspect or dimension to the proposal or its 
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Section 6 – Declaration 
• I DECLARE THAT this application is accurate, and that, should it be successful, 
any health data made accessible will be used for no other purpose, and in no other 
way, than as described above.  
• I UNDERTAKE TO notify the Public Benefit and Privacy Panel of any future 
changes to the purpose or manner in which data is processed in accordance with 
this application. 
• I UNDERSTAND THAT any future applications by me, or my employing or 
sponsoring organisation, may be refused should any health data made accessible 
be used for any other purpose or in any other way than that described above.   
• I CERTIFY THAT all those who have access to health data in this proposal are 
aware of the requirements of confidentiality and understand that any breach (eg 
disclosure of confidential information to a person not authorised to receive it) will 
be reported to the data controller, and in the case of NHS Scotland originated data 
to Scottish Government eHealth division. 
• I GUARANTEE THAT no publication will appear in any form in which an individual 
may be identified without the written permission of that individual, and that I will 
apply appropriate disclosure control when planning publications involving the data 
requested. 
• I UNDERSTAND THAT the Data Controller, and agents acting on its behalf, 
reserves the right to inspect the data on the sites where it is being processed. 
 
To be signified by the APPLICANT 
Name (in Capitals): LUCY STIRLAND Date: 11/05/2017 
 
• I DECLARE THAT (the applicant named above) is a bona fide worker engaged in 
a reputable project and that the data she asks for can be entrusted to her in the 
knowledge that she will conscientiously discharge her obligations, including in 
regard to confidentiality of the data, as stated in the declaration above. 
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To be signified by the INFORMATION CUSTODIAN named in Section 1.3 above 
(where the Information Custodian is not the applicant). 
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(ii) the data controller cannot reasonably be expected to obtain 
the consent of the data subject, or 
(b) in order to protect the vital interests of another person, in a case where 
consent by or on behalf of the data subject has been unreasonably 
withheld 
4. The processing— 
(a) is carried out in the course of its legitimate activities by any body or 
association which— 
(i) is not established or conducted for profit, and 
(ii) exists for political, philosophical, religious or trade-union 
purposes, 
(b) is carried out with appropriate safeguards for the rights and freedoms of 
data subjects, 
(c) relates only to individuals who either are members of the body or 
association or have regular contact with it in connection with its purposes, 
and 
(d) does not involve disclosure of the personal data to a third party without 
the consent of the data subject 
5. The information contained in the personal data has been made public as a result 
of steps deliberately taken by the data subject 
6. The processing— 
(a) is necessary for the purpose of, or in connection with, any legal 
proceedings (including prospective legal proceedings), 
(b) is necessary for the purpose of obtaining legal advice, or 
(c) is otherwise necessary for the purposes of establishing, exercising or 
defending legal rights 
7. (1) The processing is necessary— 
(a) for the administration of justice, 
(aa) for the exercise of any functions of either House of Parliament, 
(b) for the exercise of any functions conferred on any person by or under 
an enactment, or 
(c) for the exercise of any functions of the Crown, a Minister of the Crown 
or a government department 
(2)The Secretary of State may by order— 
(a) exclude the application of sub-paragraph (1) in such cases as may be 
specified, or 
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(b) provide that, in such cases as may be specified, the condition in sub-
paragraph (1) is not to be regarded as satisfied unless such further 
conditions as may be specified in the order are also satisfied 
7A.  (1) The processing— 
(a) is either— 
(i) the disclosure of sensitive personal data by a person as a 
member of an anti-fraud organisation or otherwise in accordance 
with any arrangements made by such an organisation; or 
(ii) any other processing by that person or another person of 
sensitive personal data so disclosed; and 
(b) is necessary for the purposes of preventing fraud or a particular kind of 
fraud 
(2) In this paragraph “an anti-fraud organisation” means any unincorporated 
association, body corporate or other person which enables or facilitates any 
sharing of information to prevent fraud or a particular kind of fraud or which has any 
of these functions as its purpose or one of its purposes 
8. (1) The processing is necessary for medical purposes and is undertaken by— 
(a) a health professional, or 
(b) a person who in the circumstances owes a duty of confidentiality which 
is equivalent to that which would arise if that person were a health 
professional 
(2) In this paragraph “medical purposes” includes the purposes of preventative 
medicine, medical diagnosis, medical research, the provision of care and treatment 
and the management of healthcare services 
9. (1) The processing— 
(a) is of sensitive personal data consisting of information as to racial or 
ethnic origin, 
(b) is necessary for the purpose of identifying or keeping under review the 
existence or absence of equality of opportunity or treatment between 
persons of different racial or ethnic origins, with a view to enabling such 
equality to be promoted or maintained, and 
(c) is carried out with appropriate safeguards for the rights and freedoms of 
data subjects 
(2) The Secretary of State may by order specify circumstances in which processing 
falling within sub-paragraph (1)(a) and (b) is, or is not, to be taken for the purposes 
of sub-paragraph (1)(c) to be carried out with appropriate safeguards for the rights 
and freedoms of data subjects 
10. The personal data are processed in circumstances specified in an order made 
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